subject,predicate,object,subject_name,object_name,KG_type,relation,category,classifier,auc_roc,log_odds_ratio,log_odds_ratio_95_ci_lower,log_odds_ratio_95_ci_upper,log_odds_ratio_95_ci,adjusted_p_value,positive_patient_count,negative_patient_count,total_sample_size,positive_patient_text,negative_patient_text,all_patient_text,,primary_knowledge_source,knowledge_level,agent_type
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005298,zoledronic acid,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.8033,0.781,0.826,"[0.781,0.826]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0019369,zoledronic acid,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.641,0.615,0.667,"[0.615,0.667]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0008399,zoledronic acid,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.6246,0.599,0.65,"[0.599,0.65]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005392,zoledronic acid,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.4599,0.397,0.523,"[0.397,0.523]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0007186,zoledronic acid,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.3514,0.328,0.375,"[0.328,0.375]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005178,zoledronic acid,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.3487,0.327,0.37,"[0.327,0.37]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0000424,zoledronic acid,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.2221,0.196,0.248,"[0.196,0.248]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0043693,zoledronic acid,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.1791,0.156,0.202,"[0.156,0.202]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0021187,zoledronic acid,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.1137,0.091,0.136,"[0.091,0.136]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0004609,zoledronic acid,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.1095,0.04,0.179,"[0.04,0.179]",0.002,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005101,zoledronic acid,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0976,0.067,0.128,"[0.067,0.128]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0004952,zoledronic acid,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0939,0.005,0.183,"[0.005,0.183]",0.038,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0004648,zoledronic acid,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0705,0.05,0.091,"[0.05,0.091]",1.00E-04,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0007915,zoledronic acid,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0528,-0.078,0.184,"[-0.078,0.184]",0.429,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0002869,zoledronic acid,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0319,-0.134,0.198,"[-0.134,0.198]",0.706,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0008383,zoledronic acid,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0259,-0.156,0.208,"[-0.156,0.208]",0.78,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0007027,zoledronic acid,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0253,0.003,0.047,"[0.003,0.047]",0.024,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005146,zoledronic acid,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0193,-0.069,0.108,"[-0.069,0.108]",0.67,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0004979,zoledronic acid,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0139,-0.24,0.268,"[-0.24,0.268]",0.915,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0002046,zoledronic acid,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0048,-0.376,0.386,"[-0.376,0.386]",0.98,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005010,zoledronic acid,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,0.0032,-0.142,0.149,"[-0.142,0.149]",0.965,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:121586,biolink:associated_with_increased_likelihood_of,MONDO:0005002,zoledronic acid,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944420187,6.00E-04,-0.325,0.326,"[-0.325,0.326]",0.997,126400,21717700,21844100,"Sample size with zoledronic acid, approximately: 126400","Sample size without zoledronic acid, approximately: 21717700",All patients number is approximately: 21844100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0021187,ziprasidone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.6264,0.612,0.641,"[0.612,0.641]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005546,ziprasidone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.4784,0.465,0.492,"[0.465,0.492]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005002,ziprasidone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.3814,0.366,0.397,"[0.366,0.397]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ziprasidone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.3427,0.324,0.361,"[0.324,0.361]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ziprasidone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.29,0.275,0.305,"[0.275,0.305]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0018177,ziprasidone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.2864,0.271,0.302,"[0.271,0.302]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ziprasidone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.2306,0.198,0.263,"[0.198,0.263]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005393,ziprasidone,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.1169,0.102,0.132,"[0.102,0.132]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005180,ziprasidone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.1095,0.083,0.136,"[0.083,0.136]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0004975,ziprasidone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.1055,0.036,0.176,"[0.036,0.176]",0.003,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0007947,ziprasidone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0972,0.065,0.129,"[0.065,0.129]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0004952,ziprasidone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.078,0.035,0.121,"[0.035,0.121]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0002316,ziprasidone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0421,-0.008,0.092,"[-0.008,0.092]",0.099,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0010602,ziprasidone,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.033,0.017,0.049,"[0.017,0.049]",1.00E-04,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005101,ziprasidone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0211,-0.116,0.158,"[-0.116,0.158]",0.763,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,ziprasidone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0189,-0.021,0.058,"[-0.021,0.058]",0.348,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,ziprasidone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0168,-0.206,0.24,"[-0.206,0.24]",0.883,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005392,ziprasidone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0167,-0.032,0.066,"[-0.032,0.066]",0.507,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ziprasidone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0157,-0.146,0.177,"[-0.146,0.177]",0.849,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005404,ziprasidone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0087,-0.2,0.218,"[-0.2,0.218]",0.935,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005364,ziprasidone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0083,-0.096,0.113,"[-0.096,0.113]",0.877,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0004425,ziprasidone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0066,-0.154,0.167,"[-0.154,0.167]",0.936,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0007739,ziprasidone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.004,-0.215,0.224,"[-0.215,0.224]",0.971,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ziprasidone,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0039,-0.269,0.277,"[-0.269,0.277]",0.978,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0002277,ziprasidone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,0.0028,-0.235,0.24,"[-0.235,0.24]",0.982,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60854,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ziprasidone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.931089431,5.00E-04,-1.638,1.639,"[-1.638,1.639]",1,260100,21662700,21922800,"Sample size with ziprasidone, approximately: 260100","Sample size without ziprasidone, approximately: 21662700",All patients number is approximately: 21922800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:35370,biolink:associated_with_increased_likelihood_of,MONDO:0005178,zidovudine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994875411,0.0383,-0.812,0.889,"[-0.812,0.889]",0.93,4400,21789700,21794100,"Sample size with zidovudine, approximately: 4400","Sample size without zidovudine, approximately: 21789700",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:35370,biolink:associated_with_increased_likelihood_of,MONDO:0007186,zidovudine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994875411,0.0089,-147.849,147.866,"[-147.849,147.866]",1,4400,21789700,21794100,"Sample size with zidovudine, approximately: 4400","Sample size without zidovudine, approximately: 21789700",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0007186,zafirlukast,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,1.1987,1.147,1.25,"[1.147,1.25]",1.00E-04,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0005146,zafirlukast,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.5024,0.389,0.616,"[0.389,0.616]",1.00E-04,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0002046,zafirlukast,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.1159,-0.265,0.497,"[-0.265,0.497]",0.551,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0005302,zafirlukast,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.1025,0.051,0.154,"[0.051,0.154]",1.00E-04,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0005002,zafirlukast,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.1004,-0.027,0.228,"[-0.027,0.228]",0.124,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0005392,zafirlukast,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.0135,-0.27,0.297,"[-0.27,0.297]",0.926,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,zafirlukast,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.0119,-0.556,0.58,"[-0.556,0.58]",0.967,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5717,biolink:associated_with_increased_likelihood_of,MONDO:0004981,zafirlukast,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918906957,0.0069,-1.1,1.114,"[-1.1,1.114]",0.99,14800,21784200,21799000,"Sample size with zafirlukast, approximately: 14800","Sample size without zafirlukast, approximately: 21784200",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005010,vortioxetine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.7396,0.691,0.788,"[0.691,0.788]",1.00E-04,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0004648,vortioxetine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.7122,0.68,0.744,"[0.68,0.744]",1.00E-04,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005147,vortioxetine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.1772,0.103,0.251,"[0.103,0.251]",1.00E-04,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,vortioxetine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.1606,0.125,0.196,"[0.125,0.196]",1.00E-04,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0007027,vortioxetine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0956,0.015,0.176,"[0.015,0.176]",0.02,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0007186,vortioxetine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0877,0.009,0.166,"[0.009,0.166]",0.029,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0021187,vortioxetine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0863,0.036,0.137,"[0.036,0.137]",0.001,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005392,vortioxetine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0852,-0.019,0.189,"[-0.019,0.189]",0.109,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005180,vortioxetine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0848,0.028,0.142,"[0.028,0.142]",0.003,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0004981,vortioxetine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0738,-0.32,0.468,"[-0.32,0.468]",0.714,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005133,vortioxetine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0735,0.002,0.145,"[0.002,0.145]",0.044,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0002406,vortioxetine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.07,-0.282,0.422,"[-0.282,0.422]",0.697,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005404,vortioxetine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0697,-0.062,0.202,"[-0.062,0.202]",0.301,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0002277,vortioxetine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0494,-0.075,0.174,"[-0.075,0.174]",0.438,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0011786,vortioxetine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0429,-0.124,0.21,"[-0.124,0.21]",0.614,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005146,vortioxetine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0429,-0.117,0.203,"[-0.117,0.203]",0.599,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,vortioxetine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0266,-0.41,0.464,"[-0.41,0.464]",0.905,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0002046,vortioxetine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0251,-0.091,0.142,"[-0.091,0.142]",0.673,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0003620,vortioxetine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0197,-0.621,0.661,"[-0.621,0.661]",0.952,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0008399,vortioxetine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0171,-0.12,0.154,"[-0.12,0.154]",0.807,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0004979,vortioxetine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0152,-0.093,0.123,"[-0.093,0.123]",0.783,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005364,vortioxetine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0147,-0.484,0.513,"[-0.484,0.513]",0.954,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0004975,vortioxetine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0124,-0.922,0.947,"[-0.922,0.947]",0.979,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0019369,vortioxetine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0054,-0.081,0.092,"[-0.081,0.092]",0.902,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005300,vortioxetine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0031,-0.591,0.597,"[-0.591,0.597]",0.992,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,MONDO:0005302,vortioxetine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0023,-1.33,1.334,"[-1.33,1.334]",0.997,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259875,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,vortioxetine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.873560223,0.0012,-0.478,0.48,"[-0.478,0.48]",0.996,51100,21765100,21816200,"Sample size with vortioxetine, approximately: 51100","Sample size without vortioxetine, approximately: 21765100",All patients number is approximately: 21816200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0008599,vilazodone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.5626,0.521,0.604,"[0.521,0.604]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0000424,vilazodone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.4249,0.349,0.501,"[0.349,0.501]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0043693,vilazodone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.3381,0.271,0.406,"[0.271,0.406]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005364,vilazodone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.2041,0.121,0.287,"[0.121,0.287]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,vilazodone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.1714,0.126,0.217,"[0.126,0.217]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005178,vilazodone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.125,0.07,0.181,"[0.07,0.181]",1.00E-04,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0004979,vilazodone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.1058,-0.268,0.479,"[-0.268,0.479]",0.579,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0002406,vilazodone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0909,0.027,0.155,"[0.027,0.155]",0.005,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,vilazodone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0578,-0.124,0.239,"[-0.124,0.239]",0.533,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0004975,vilazodone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0486,-0.174,0.271,"[-0.174,0.271]",0.668,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0002909,vilazodone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.045,-0.178,0.268,"[-0.178,0.268]",0.693,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005392,vilazodone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0394,-1.255,1.334,"[-1.255,1.334]",0.952,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0008487,vilazodone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0319,-0.055,0.119,"[-0.055,0.119]",0.471,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0007186,vilazodone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0284,-0.102,0.159,"[-0.102,0.159]",0.67,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005298,vilazodone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0252,-0.169,0.219,"[-0.169,0.219]",0.798,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005404,vilazodone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.022,-1.349,1.393,"[-1.349,1.393]",0.975,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0003620,vilazodone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0187,-0.762,0.799,"[-0.762,0.799]",0.963,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0002277,vilazodone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0105,-0.357,0.378,"[-0.357,0.378]",0.955,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005101,vilazodone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0056,-0.414,0.425,"[-0.414,0.425]",0.979,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,vilazodone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0055,-0.15,0.161,"[-0.15,0.161]",0.945,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0005302,vilazodone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.0034,-1.197,1.204,"[-1.197,1.204]",0.996,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6918314,biolink:associated_with_increased_likelihood_of,MONDO:0004981,vilazodone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877515021,0.003,-1.579,1.585,"[-1.579,1.585]",0.997,39300,21770700,21810000,"Sample size with vilazodone, approximately: 39300","Sample size without vilazodone, approximately: 21770700",All patients number is approximately: 21810000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0002277,vilanterol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,4.294,4.283,4.305,"[4.283,4.305]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005393,vilanterol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.377,0.358,0.396,"[0.358,0.396]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005178,vilanterol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.3626,0.343,0.382,"[0.343,0.382]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0013282,vilanterol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.3136,0.293,0.334,"[0.293,0.334]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005364,vilanterol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.2572,0.243,0.271,"[0.243,0.271]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0000424,vilanterol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.2206,0.201,0.24,"[0.201,0.24]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005148,vilanterol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.2057,0.184,0.228,"[0.184,0.228]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0004975,vilanterol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1991,0.145,0.253,"[0.145,0.253]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0019118,vilanterol,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1533,0.125,0.182,"[0.125,0.182]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0004648,vilanterol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1252,0.111,0.139,"[0.111,0.139]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005011,vilanterol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1194,0.085,0.154,"[0.085,0.154]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0021107,vilanterol,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1133,0.092,0.134,"[0.092,0.134]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0010602,vilanterol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1096,0.088,0.131,"[0.088,0.131]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005130,vilanterol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.1091,0.09,0.128,"[0.09,0.128]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005301,vilanterol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0943,0.047,0.142,"[0.047,0.142]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0021187,vilanterol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0778,0.006,0.15,"[0.006,0.15]",0.034,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0004981,vilanterol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.077,0.039,0.115,"[0.039,0.115]",1.00E-04,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,vilanterol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0712,0.002,0.14,"[0.002,0.14]",0.043,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005146,vilanterol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0414,-0.096,0.178,"[-0.096,0.178]",0.554,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0019180,vilanterol,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0412,-0.042,0.124,"[-0.042,0.124]",0.331,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005101,vilanterol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0366,-0.054,0.128,"[-0.054,0.128]",0.431,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,vilanterol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0307,-0.002,0.064,"[-0.002,0.064]",0.068,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005546,vilanterol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0231,-0.009,0.055,"[-0.009,0.055]",0.159,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0007027,vilanterol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.023,-0.028,0.074,"[-0.028,0.074]",0.374,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0004609,vilanterol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0186,-0.062,0.1,"[-0.062,0.1]",0.653,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,vilanterol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0173,-0.087,0.122,"[-0.087,0.122]",0.745,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0005300,vilanterol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0132,-0.149,0.175,"[-0.149,0.175]",0.873,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0002046,vilanterol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0053,-0.575,0.586,"[-0.575,0.586]",0.986,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0002869,vilanterol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0023,-0.169,0.173,"[-0.169,0.173]",0.979,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0002406,vilanterol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0018,-0.294,0.298,"[-0.294,0.298]",0.99,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0008487,vilanterol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0014,-1.388,1.391,"[-1.388,1.391]",0.998,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0019369,vilanterol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,0.0014,-0.752,0.755,"[-0.752,0.755]",0.997,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0015924,vilanterol,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,7.00E-04,-0.139,0.141,"[-0.139,0.141]",0.992,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259805,biolink:associated_with_increased_likelihood_of,MONDO:0018882,vilanterol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997317679,7.00E-04,-772.169,772.17,"[-772.169,772.17]",1,551200,21526600,22077800,"Sample size with vilanterol, approximately: 551200","Sample size without vilanterol, approximately: 21526600",All patients number is approximately: 22077800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304849,biolink:associated_with_increased_likelihood_of,MONDO:0005002,vericiguat,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984884183,0.1704,0.007,0.334,"[0.007,0.334]",0.041,3000,21790200,21793200,"Sample size with vericiguat, approximately: 3000","Sample size without vericiguat, approximately: 21790200",All patients number is approximately: 21793200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304849,biolink:associated_with_increased_likelihood_of,MONDO:0005178,vericiguat,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984884183,0.0515,-0.294,0.397,"[-0.294,0.397]",0.77,3000,21790200,21793200,"Sample size with vericiguat, approximately: 3000","Sample size without vericiguat, approximately: 21790200",All patients number is approximately: 21793200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304849,biolink:associated_with_increased_likelihood_of,MONDO:0003620,vericiguat,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984884183,0.04,-0.319,0.399,"[-0.319,0.399]",0.827,3000,21790200,21793200,"Sample size with vericiguat, approximately: 3000","Sample size without vericiguat, approximately: 21790200",All patients number is approximately: 21793200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304849,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,vericiguat,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984884183,0.0059,-3.698,3.71,"[-3.698,3.71]",0.998,3000,21790200,21793200,"Sample size with vericiguat, approximately: 3000","Sample size without vericiguat, approximately: 21790200",All patients number is approximately: 21793200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0004609,verapamil,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.6419,0.627,0.657,"[0.627,0.657]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005180,verapamil,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.4152,0.408,0.422,"[0.408,0.422]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0011429,verapamil,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.4038,0.381,0.426,"[0.381,0.426]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0010602,verapamil,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.387,0.378,0.396,"[0.378,0.396]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0018177,verapamil,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.359,0.351,0.367,"[0.351,0.367]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0008383,verapamil,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.3438,0.337,0.35,"[0.337,0.35]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0019499,verapamil,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.3378,0.33,0.346,"[0.33,0.346]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005178,verapamil,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.3254,0.317,0.334,"[0.317,0.334]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0007864,verapamil,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.2914,0.261,0.321,"[0.261,0.321]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005404,verapamil,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.2054,0.182,0.228,"[0.182,0.228]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005130,verapamil,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.2012,0.193,0.209,"[0.193,0.209]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005393,verapamil,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.1913,0.179,0.203,"[0.179,0.203]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0000153,verapamil,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.1808,0.173,0.189,"[0.173,0.189]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0002406,verapamil,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.1703,0.162,0.178,"[0.162,0.178]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0009693,verapamil,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.1132,0.102,0.125,"[0.102,0.125]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0019180,verapamil,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0715,0.057,0.086,"[0.057,0.086]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0008599,verapamil,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0414,0.034,0.049,"[0.034,0.049]",1.00E-04,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005147,verapamil,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0352,0.013,0.057,"[0.013,0.057]",0.002,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0021187,verapamil,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0275,-0.011,0.066,"[-0.011,0.066]",0.166,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005083,verapamil,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0213,-0.014,0.057,"[-0.014,0.057]",0.24,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0008487,verapamil,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0205,-0.021,0.062,"[-0.021,0.062]",0.337,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0019369,verapamil,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.018,-0.033,0.069,"[-0.033,0.069]",0.488,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,verapamil,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0174,-0.126,0.161,"[-0.126,0.161]",0.813,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,verapamil,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0133,-0.026,0.052,"[-0.026,0.052]",0.503,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0004979,verapamil,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.011,-0.09,0.112,"[-0.09,0.112]",0.832,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0004952,verapamil,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0093,-0.047,0.065,"[-0.047,0.065]",0.747,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005298,verapamil,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0048,-0.109,0.118,"[-0.109,0.118]",0.934,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005011,verapamil,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0039,-0.111,0.119,"[-0.111,0.119]",0.946,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005146,verapamil,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0026,-0.192,0.197,"[-0.192,0.197]",0.979,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0007947,verapamil,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0022,-0.04,0.044,"[-0.04,0.044]",0.919,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0016218,verapamil,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0019,-0.15,0.154,"[-0.15,0.154]",0.981,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0015564,verapamil,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.0018,-0.296,0.3,"[-0.296,0.3]",0.99,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0004648,verapamil,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,0.001,-0.337,0.339,"[-0.337,0.339]",0.995,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0005546,verapamil,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,9.00E-04,-0.292,0.294,"[-0.292,0.294]",0.995,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0007827,verapamil,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,5.00E-04,-0.277,0.278,"[-0.277,0.278]",0.997,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0015924,verapamil,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,4.00E-04,-0.747,0.748,"[-0.747,0.748]",0.999,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0007818,verapamil,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,3.00E-04,-0.583,0.583,"[-0.583,0.583]",0.999,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2520,biolink:associated_with_increased_likelihood_of,MONDO:0004425,verapamil,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.968115099,2.00E-04,-1.081,1.081,"[-1.081,1.081]",1,2003600,21180200,23183800,"Sample size with verapamil, approximately: 2003600","Sample size without verapamil, approximately: 21180200",All patients number is approximately: 23183800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0007947,venlafaxine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.7821,0.775,0.79,"[0.775,0.79]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005364,venlafaxine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.5264,0.51,0.543,"[0.51,0.543]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004975,venlafaxine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.3909,0.378,0.404,"[0.378,0.404]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0007972,venlafaxine,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.3233,0.312,0.334,"[0.312,0.334]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0010602,venlafaxine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.2944,0.284,0.305,"[0.284,0.305]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0019118,venlafaxine,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.2768,0.265,0.289,"[0.265,0.289]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0019499,venlafaxine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.2428,0.233,0.253,"[0.233,0.253]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005148,venlafaxine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.2098,0.2,0.219,"[0.2,0.219]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0003620,venlafaxine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1988,0.184,0.213,"[0.184,0.213]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0008399,venlafaxine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1972,0.187,0.208,"[0.187,0.208]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004952,venlafaxine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1873,0.17,0.204,"[0.17,0.204]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004648,venlafaxine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1862,0.178,0.195,"[0.178,0.195]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005147,venlafaxine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1837,0.17,0.198,"[0.17,0.198]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005133,venlafaxine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1785,0.167,0.19,"[0.167,0.19]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005546,venlafaxine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1747,0.157,0.192,"[0.157,0.192]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0018882,venlafaxine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1615,0.142,0.181,"[0.142,0.181]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,venlafaxine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1571,0.137,0.178,"[0.137,0.178]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005149,venlafaxine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1498,0.131,0.169,"[0.131,0.169]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004981,venlafaxine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1394,0.113,0.166,"[0.113,0.166]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0002277,venlafaxine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1167,0.091,0.142,"[0.091,0.142]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0011429,venlafaxine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1084,0.091,0.126,"[0.091,0.126]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005404,venlafaxine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.1019,0.078,0.126,"[0.078,0.126]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0006694,venlafaxine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0974,0.077,0.118,"[0.077,0.118]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0002316,venlafaxine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0894,0.053,0.126,"[0.053,0.126]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0009891,venlafaxine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0776,0.067,0.088,"[0.067,0.088]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005083,venlafaxine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0762,0.04,0.113,"[0.04,0.113]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005002,venlafaxine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0718,0.044,0.099,"[0.044,0.099]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005146,venlafaxine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.07,0.033,0.107,"[0.033,0.107]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0008487,venlafaxine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0599,0.019,0.101,"[0.019,0.101]",0.004,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0019350,venlafaxine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0575,0.011,0.104,"[0.011,0.104]",0.015,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0000424,venlafaxine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0571,0.026,0.088,"[0.026,0.088]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0011849,venlafaxine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.056,0.031,0.081,"[0.031,0.081]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0013282,venlafaxine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0559,0.03,0.082,"[0.03,0.082]",1.00E-04,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0043693,venlafaxine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0205,-0.06,0.101,"[-0.06,0.101]",0.619,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0019565,venlafaxine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0135,-0.127,0.154,"[-0.127,0.154]",0.851,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005009,venlafaxine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.012,-0.095,0.119,"[-0.095,0.119]",0.825,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0002869,venlafaxine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0117,-0.063,0.086,"[-0.063,0.086]",0.757,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005011,venlafaxine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0111,-0.094,0.117,"[-0.094,0.117]",0.836,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,venlafaxine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0087,-0.185,0.202,"[-0.185,0.202]",0.93,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0021187,venlafaxine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0086,-0.071,0.088,"[-0.071,0.088]",0.833,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005010,venlafaxine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0059,-35.804,35.815,"[-35.804,35.815]",1,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0007739,venlafaxine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0059,-0.14,0.152,"[-0.14,0.152]",0.937,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005101,venlafaxine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0057,-0.099,0.11,"[-0.099,0.11]",0.915,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004979,venlafaxine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0053,-0.24,0.25,"[-0.24,0.25]",0.966,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0007186,venlafaxine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0052,-0.113,0.124,"[-0.113,0.124]",0.932,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005301,venlafaxine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.005,-0.02,0.03,"[-0.02,0.03]",0.695,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0004425,venlafaxine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0045,-0.123,0.132,"[-0.123,0.132]",0.945,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,venlafaxine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0039,-0.148,0.156,"[-0.148,0.156]",0.96,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0002909,venlafaxine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0038,-0.182,0.189,"[-0.182,0.189]",0.968,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0016218,venlafaxine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0019,-0.15,0.153,"[-0.15,0.153]",0.981,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0010526,venlafaxine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,0.0013,-0.342,0.344,"[-0.342,0.344]",0.994,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0019369,venlafaxine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,6.00E-04,-0.082,0.083,"[-0.082,0.083]",0.989,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0021107,venlafaxine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,6.00E-04,-0.59,0.591,"[-0.59,0.591]",0.999,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,MONDO:0005294,venlafaxine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,5.00E-04,-0.145,0.146,"[-0.145,0.146]",0.995,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5656,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,venlafaxine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.84524631,1.00E-04,-0.438,0.439,"[-0.438,0.439]",1,844700,21334100,22178800,"Sample size with venlafaxine, approximately: 844700","Sample size without venlafaxine, approximately: 21334100",All patients number is approximately: 22178800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,MONDO:0005178,velpatasvir,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,4.2762,4.144,4.409,"[4.144,4.409]",1.00E-04,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,MONDO:0002909,velpatasvir,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,0.2659,-0.195,0.727,"[-0.195,0.727]",0.259,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,MONDO:0004981,velpatasvir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,0.1661,-0.181,0.513,"[-0.181,0.513]",0.349,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,MONDO:0007186,velpatasvir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,0.077,-0.189,0.343,"[-0.189,0.343]",0.571,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,velpatasvir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,0.0528,-0.563,0.669,"[-0.563,0.669]",0.866,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259778,biolink:associated_with_increased_likelihood_of,MONDO:0005298,velpatasvir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.99977501,0.0344,-0.306,0.375,"[-0.306,0.375]",0.843,10000,21785400,21795400,"Sample size with velpatasvir, approximately: 10000","Sample size without velpatasvir, approximately: 21785400",All patients number is approximately: 21795400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005392,varenicline,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,1.9036,1.884,1.923,"[1.884,1.923]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005180,varenicline,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.4581,0.433,0.483,"[0.433,0.483]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005306,varenicline,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.231,0.21,0.252,"[0.21,0.252]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005133,varenicline,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.2272,0.202,0.252,"[0.202,0.252]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0013282,varenicline,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.1371,0.112,0.162,"[0.112,0.162]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0004981,varenicline,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0768,0.034,0.119,"[0.034,0.119]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0004648,varenicline,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0731,0.044,0.103,"[0.044,0.103]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0011122,varenicline,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0685,0.038,0.099,"[0.038,0.099]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0002406,varenicline,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0644,-0.025,0.154,"[-0.025,0.154]",0.157,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0008599,varenicline,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0589,0.034,0.084,"[0.034,0.084]",1.00E-04,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0004425,varenicline,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0557,0.018,0.094,"[0.018,0.094]",0.004,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005404,varenicline,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0534,-0.035,0.142,"[-0.035,0.142]",0.238,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005147,varenicline,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.048,0.01,0.086,"[0.01,0.086]",0.014,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0009693,varenicline,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0323,0.004,0.061,"[0.004,0.061]",0.025,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0008383,varenicline,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.028,-0.074,0.129,"[-0.074,0.129]",0.589,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005393,varenicline,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0123,-0.056,0.081,"[-0.056,0.081]",0.726,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0007186,varenicline,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0096,-127.039,127.058,"[-127.039,127.058]",1,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,varenicline,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0096,-0.259,0.278,"[-0.259,0.278]",0.944,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005146,varenicline,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.009,-0.353,0.371,"[-0.353,0.371]",0.961,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0011786,varenicline,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0054,-0.236,0.247,"[-0.236,0.247]",0.965,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0018882,varenicline,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.005,-0.232,0.242,"[-0.232,0.242]",0.967,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,varenicline,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.005,-0.511,0.521,"[-0.511,0.521]",0.985,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0003620,varenicline,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0044,-0.308,0.317,"[-0.308,0.317]",0.978,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0002316,varenicline,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0036,-0.144,0.151,"[-0.144,0.151]",0.962,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005364,varenicline,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0034,-0.121,0.127,"[-0.121,0.127]",0.957,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0019369,varenicline,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0024,-0.577,0.581,"[-0.577,0.581]",0.994,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:170361,biolink:associated_with_increased_likelihood_of,MONDO:0005302,varenicline,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.838704249,0.0016,-0.415,0.418,"[-0.415,0.418]",0.994,222700,21650300,21873000,"Sample size with varenicline, approximately: 222700","Sample size without varenicline, approximately: 21650300",All patients number is approximately: 21873000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0008394,valsartan,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.6593,0.643,0.676,"[0.643,0.676]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0019369,valsartan,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.6229,0.615,0.631,"[0.615,0.631]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0010383,valsartan,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.4208,0.412,0.429,"[0.412,0.429]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005010,valsartan,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.4048,0.396,0.414,"[0.396,0.414]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0019499,valsartan,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.3376,0.316,0.359,"[0.316,0.359]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005101,valsartan,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.3352,0.32,0.35,"[0.32,0.35]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005002,valsartan,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.3243,0.304,0.344,"[0.304,0.344]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0009693,valsartan,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.2558,0.248,0.264,"[0.248,0.264]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,valsartan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.2437,0.232,0.256,"[0.232,0.256]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005302,valsartan,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.177,0.167,0.187,"[0.167,0.187]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0004975,valsartan,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.1596,0.127,0.192,"[0.127,0.192]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0000424,valsartan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0793,0.069,0.09,"[0.069,0.09]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0004609,valsartan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0725,0.031,0.114,"[0.031,0.114]",0.001,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0000153,valsartan,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0719,0.048,0.096,"[0.048,0.096]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0021107,valsartan,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0708,0.009,0.132,"[0.009,0.132]",0.024,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0007739,valsartan,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.069,0.033,0.105,"[0.033,0.105]",1.00E-04,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005298,valsartan,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0451,-0.004,0.095,"[-0.004,0.095]",0.074,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0002277,valsartan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0389,-0.046,0.124,"[-0.046,0.124]",0.37,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0011786,valsartan,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0335,-0.036,0.103,"[-0.036,0.103]",0.343,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005392,valsartan,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0284,-0.047,0.104,"[-0.047,0.104]",0.462,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0019180,valsartan,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0263,-0.035,0.088,"[-0.035,0.088]",0.403,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0004648,valsartan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0225,-0.004,0.049,"[-0.004,0.049]",0.098,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0004952,valsartan,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0204,-0.02,0.061,"[-0.02,0.061]",0.324,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0008487,valsartan,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0199,-0.159,0.198,"[-0.159,0.198]",0.827,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,valsartan,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0175,-0.051,0.086,"[-0.051,0.086]",0.618,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0003620,valsartan,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0163,-0.111,0.144,"[-0.111,0.144]",0.802,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0021187,valsartan,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0157,-0.086,0.117,"[-0.086,0.117]",0.761,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005364,valsartan,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0122,-0.115,0.139,"[-0.115,0.139]",0.85,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005133,valsartan,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.01,-0.096,0.116,"[-0.096,0.116]",0.853,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0007186,valsartan,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0068,-0.196,0.209,"[-0.196,0.209]",0.948,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0004981,valsartan,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0049,-0.15,0.16,"[-0.15,0.16]",0.951,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0002869,valsartan,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0039,-0.064,0.072,"[-0.064,0.072]",0.91,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0013282,valsartan,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.003,-0.112,0.118,"[-0.112,0.118]",0.959,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,valsartan,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0018,-0.34,0.343,"[-0.34,0.343]",0.992,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0011508,valsartan,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0014,-0.09,0.093,"[-0.09,0.093]",0.977,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0002316,valsartan,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.0012,-0.455,0.458,"[-0.455,0.458]",0.996,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,valsartan,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,0.001,-0.368,0.37,"[-0.368,0.37]",0.996,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60846,biolink:associated_with_increased_likelihood_of,MONDO:0005300,valsartan,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950534997,1.00E-04,-0.108,0.109,"[-0.108,0.109]",0.998,1193300,21239900,22433200,"Sample size with valsartan, approximately: 1193300","Sample size without valsartan, approximately: 21239900",All patients number is approximately: 22433200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0007186,ustekinumab,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.3841,0.278,0.49,"[0.278,0.49]",1.00E-04,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ustekinumab,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.3311,0.27,0.392,"[0.27,0.392]",1.00E-04,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ustekinumab,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.2931,0.226,0.36,"[0.226,0.36]",1.00E-04,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005301,ustekinumab,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.2376,-0.078,0.553,"[-0.078,0.553]",0.14,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ustekinumab,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0854,-0.104,0.275,"[-0.104,0.275]",0.378,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ustekinumab,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0803,-0.106,0.267,"[-0.106,0.267]",0.399,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005083,ustekinumab,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0299,-0.485,0.545,"[-0.485,0.545]",0.909,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0002046,ustekinumab,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0254,-0.489,0.54,"[-0.489,0.54]",0.923,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0004975,ustekinumab,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.021,-0.632,0.674,"[-0.632,0.674]",0.95,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0002277,ustekinumab,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0185,-0.847,0.884,"[-0.847,0.884]",0.967,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0005546,ustekinumab,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0156,-0.146,0.177,"[-0.146,0.177]",0.85,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ustekinumab,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0123,-0.269,0.293,"[-0.269,0.293]",0.932,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0004609,ustekinumab,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,0.0066,-1.348,1.361,"[-1.348,1.361]",0.992,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201835,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ustekinumab,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.878883371,5.00E-04,-0.705,0.705,"[-0.705,0.705]",0.999,23800,21777900,21801700,"Sample size with ustekinumab, approximately: 23800","Sample size without ustekinumab, approximately: 21777900",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259708,biolink:associated_with_increased_likelihood_of,MONDO:0005146,upadacitinib,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913190467,0.0707,-0.652,0.793,"[-0.652,0.793]",0.848,12900,21784000,21796900,"Sample size with upadacitinib, approximately: 12900","Sample size without upadacitinib, approximately: 21784000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259708,biolink:associated_with_increased_likelihood_of,MONDO:0002277,upadacitinib,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913190467,0.0613,-0.122,0.245,"[-0.122,0.245]",0.512,12900,21784000,21796900,"Sample size with upadacitinib, approximately: 12900","Sample size without upadacitinib, approximately: 21784000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259708,biolink:associated_with_increased_likelihood_of,MONDO:0005149,upadacitinib,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913190467,0.0276,-1.488,1.543,"[-1.488,1.543]",0.972,12900,21784000,21796900,"Sample size with upadacitinib, approximately: 12900","Sample size without upadacitinib, approximately: 21784000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259708,biolink:associated_with_increased_likelihood_of,MONDO:0005298,upadacitinib,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913190467,0.0099,-0.881,0.901,"[-0.881,0.901]",0.983,12900,21784000,21796900,"Sample size with upadacitinib, approximately: 12900","Sample size without upadacitinib, approximately: 21784000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0002909,umeclidinium,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.751,0.73,0.772,"[0.73,0.772]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005364,umeclidinium,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.6914,0.673,0.71,"[0.673,0.71]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0011786,umeclidinium,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.3922,0.359,0.426,"[0.359,0.426]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0013282,umeclidinium,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.3661,0.341,0.391,"[0.341,0.391]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0010602,umeclidinium,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.3241,0.299,0.349,"[0.299,0.349]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0002277,umeclidinium,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.2795,0.264,0.295,"[0.264,0.295]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0004648,umeclidinium,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.2378,0.219,0.257,"[0.219,0.257]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0009693,umeclidinium,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.2308,0.202,0.26,"[0.202,0.26]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0011508,umeclidinium,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.209,0.185,0.233,"[0.185,0.233]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0004609,umeclidinium,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1884,0.166,0.211,"[0.166,0.211]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0018177,umeclidinium,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1797,0.155,0.205,"[0.155,0.205]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0004975,umeclidinium,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.177,0.109,0.245,"[0.109,0.245]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005393,umeclidinium,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1442,0.082,0.207,"[0.082,0.207]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0002406,umeclidinium,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1364,0.093,0.179,"[0.093,0.179]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005392,umeclidinium,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1327,0.076,0.19,"[0.076,0.19]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0003620,umeclidinium,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1223,0.101,0.143,"[0.101,0.143]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0008599,umeclidinium,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1221,0.099,0.145,"[0.099,0.145]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0004981,umeclidinium,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.1135,0.057,0.17,"[0.057,0.17]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0009061,umeclidinium,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0767,0.045,0.109,"[0.045,0.109]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,umeclidinium,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0538,-0.037,0.145,"[-0.037,0.145]",0.248,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0000424,umeclidinium,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0537,0.032,0.075,"[0.032,0.075]",1.00E-04,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0008383,umeclidinium,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0493,-0.053,0.151,"[-0.053,0.151]",0.343,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005146,umeclidinium,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0429,-0.107,0.193,"[-0.107,0.193]",0.574,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005002,umeclidinium,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0334,-0.201,0.268,"[-0.201,0.268]",0.78,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005009,umeclidinium,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0274,-0.145,0.2,"[-0.145,0.2]",0.755,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005101,umeclidinium,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0246,-0.107,0.156,"[-0.107,0.156]",0.715,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0002316,umeclidinium,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0232,-0.112,0.159,"[-0.112,0.159]",0.736,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0043693,umeclidinium,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.02,-0.01,0.049,"[-0.01,0.049]",0.185,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0011849,umeclidinium,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0151,-0.145,0.175,"[-0.145,0.175]",0.853,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0000477,umeclidinium,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0145,-0.125,0.154,"[-0.125,0.154]",0.839,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0008487,umeclidinium,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0125,-0.21,0.234,"[-0.21,0.234]",0.912,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005294,umeclidinium,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0064,-0.433,0.446,"[-0.433,0.446]",0.977,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005302,umeclidinium,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0034,-0.585,0.592,"[-0.585,0.592]",0.991,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0004425,umeclidinium,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.002,-0.424,0.428,"[-0.424,0.428]",0.993,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0019369,umeclidinium,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0019,-0.544,0.548,"[-0.544,0.548]",0.995,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005404,umeclidinium,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,0.0013,-0.453,0.456,"[-0.453,0.456]",0.996,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,umeclidinium,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,8.00E-04,-0.202,0.204,"[-0.202,0.204]",0.994,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:79041,biolink:associated_with_increased_likelihood_of,MONDO:0005011,umeclidinium,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990577562,5.00E-04,-0.3,0.301,"[-0.3,0.301]",0.997,433600,21587900,22021500,"Sample size with umeclidinium, approximately: 433600","Sample size without umeclidinium, approximately: 21587900",All patients number is approximately: 22021500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tryptophan,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.7017,0.678,0.725,"[0.678,0.725]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tryptophan,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.655,0.636,0.674,"[0.636,0.674]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tryptophan,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.6017,0.579,0.625,"[0.579,0.625]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0007027,tryptophan,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.4681,0.447,0.489,"[0.447,0.489]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0008399,tryptophan,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.3852,0.362,0.408,"[0.362,0.408]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tryptophan,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.3238,0.302,0.345,"[0.302,0.345]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tryptophan,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.3072,0.285,0.33,"[0.285,0.33]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0004952,tryptophan,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1709,0.144,0.198,"[0.144,0.198]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0003620,tryptophan,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1474,0.127,0.168,"[0.127,0.168]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0006694,tryptophan,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1385,0.118,0.159,"[0.118,0.159]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0043693,tryptophan,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1192,0.095,0.143,"[0.095,0.143]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tryptophan,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1151,0.034,0.196,"[0.034,0.196]",0.005,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,tryptophan,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.1137,0.093,0.135,"[0.093,0.135]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0011849,tryptophan,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0882,0.042,0.135,"[0.042,0.135]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0000424,tryptophan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0772,0.049,0.106,"[0.049,0.106]",1.00E-04,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005404,tryptophan,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0728,0.007,0.138,"[0.007,0.138]",0.029,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005392,tryptophan,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0532,-0.009,0.115,"[-0.009,0.115]",0.092,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005146,tryptophan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0473,-0.033,0.127,"[-0.033,0.127]",0.247,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005180,tryptophan,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0379,0.008,0.068,"[0.008,0.068]",0.013,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0004979,tryptophan,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.033,-0.053,0.118,"[-0.053,0.118]",0.45,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005301,tryptophan,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0287,-0.034,0.091,"[-0.034,0.091]",0.367,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0004609,tryptophan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0241,-0.03,0.078,"[-0.03,0.078]",0.383,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tryptophan,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.015,-0.131,0.161,"[-0.131,0.161]",0.841,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0009891,tryptophan,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0129,-0.014,0.04,"[-0.014,0.04]",0.356,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0004648,tryptophan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0124,-0.097,0.121,"[-0.097,0.121]",0.823,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0002909,tryptophan,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0066,-0.136,0.149,"[-0.136,0.149]",0.928,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,tryptophan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0053,-0.187,0.198,"[-0.187,0.198]",0.957,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tryptophan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0045,-0.295,0.304,"[-0.295,0.304]",0.976,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0005388,tryptophan,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.0024,-7.547,7.552,"[-7.547,7.552]",0.999,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1148,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tryptophan,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.970289721,0.001,-0.542,0.544,"[-0.542,0.544]",0.997,78700,21765100,21843800,"Sample size with tryptophan, approximately: 78700","Sample size without tryptophan, approximately: 21765100",All patients number is approximately: 21843800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0019369,triamterene,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.762,0.747,0.777,"[0.747,0.777]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005404,triamterene,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.334,0.313,0.355,"[0.313,0.355]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0007972,triamterene,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.3143,0.297,0.332,"[0.297,0.332]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,triamterene,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.3141,0.296,0.332,"[0.296,0.332]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0009693,triamterene,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.2974,0.277,0.317,"[0.277,0.317]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0008383,triamterene,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.2257,0.213,0.238,"[0.213,0.238]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0018177,triamterene,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.1397,0.111,0.169,"[0.111,0.169]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005178,triamterene,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0801,0.038,0.122,"[0.038,0.122]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0008487,triamterene,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0653,0.035,0.096,"[0.035,0.096]",1.00E-04,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0008399,triamterene,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0495,0.001,0.098,"[0.001,0.098]",0.044,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005148,triamterene,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0338,0,0.067,"[0,0.067]",0.048,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005002,triamterene,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0275,-0.038,0.093,"[-0.038,0.093]",0.412,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0019180,triamterene,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0267,-0.058,0.111,"[-0.058,0.111]",0.535,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005101,triamterene,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0257,-0.048,0.099,"[-0.048,0.099]",0.495,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005298,triamterene,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0239,-0.049,0.096,"[-0.049,0.096]",0.518,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0021187,triamterene,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0234,-0.078,0.125,"[-0.078,0.125]",0.65,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005392,triamterene,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0165,-0.092,0.125,"[-0.092,0.125]",0.766,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005146,triamterene,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0109,-0.07,0.092,"[-0.07,0.092]",0.791,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0011786,triamterene,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.006,-0.344,0.356,"[-0.344,0.356]",0.973,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0003620,triamterene,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0052,-0.191,0.201,"[-0.191,0.201]",0.959,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0004425,triamterene,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0043,-0.217,0.225,"[-0.217,0.225]",0.97,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005010,triamterene,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0036,-0.199,0.206,"[-0.199,0.206]",0.972,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0000477,triamterene,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0028,-0.104,0.11,"[-0.104,0.11]",0.96,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0004975,triamterene,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0025,-0.063,0.068,"[-0.063,0.068]",0.939,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005009,triamterene,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0025,-0.226,0.231,"[-0.226,0.231]",0.983,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0007027,triamterene,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,0.0018,-0.029,0.032,"[-0.029,0.032]",0.91,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005302,triamterene,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,9.00E-04,-0.31,0.312,"[-0.31,0.312]",0.995,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0015924,triamterene,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,8.00E-04,-0.519,0.52,"[-0.519,0.52]",0.998,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0007186,triamterene,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,7.00E-04,-0.694,0.695,"[-0.694,0.695]",0.998,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0004979,triamterene,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,7.00E-04,-0.26,0.261,"[-0.26,0.261]",0.996,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,triamterene,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,6.00E-04,-0.42,0.421,"[-0.42,0.421]",0.998,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0008542,triamterene,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,5.00E-04,-0.937,0.938,"[-0.937,0.938]",0.999,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0005306,triamterene,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,4.00E-04,-0.545,0.546,"[-0.545,0.546]",0.999,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5546,biolink:associated_with_increased_likelihood_of,MONDO:0002046,triamterene,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985253728,3.00E-04,-0.324,0.325,"[-0.324,0.325]",0.999,377000,21564200,21941200,"Sample size with triamterene, approximately: 377000","Sample size without triamterene, approximately: 21564200",All patients number is approximately: 21941200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0002316,triamcinolone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.4602,0.451,0.469,"[0.451,0.469]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019499,triamcinolone,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.3267,0.319,0.334,"[0.319,0.334]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0006694,triamcinolone,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.3183,0.31,0.326,"[0.31,0.326]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0000153,triamcinolone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.2348,0.221,0.249,"[0.221,0.249]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019180,triamcinolone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.2215,0.202,0.241,"[0.202,0.241]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0020066,triamcinolone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1965,0.188,0.205,"[0.188,0.205]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005133,triamcinolone,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.196,0.178,0.214,"[0.178,0.214]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019080,triamcinolone,alopecia totalis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1685,0.162,0.175,"[0.162,0.175]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0004952,triamcinolone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1604,0.151,0.17,"[0.151,0.17]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0008599,triamcinolone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1589,0.152,0.166,"[0.152,0.166]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0004425,triamcinolone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1492,0.125,0.174,"[0.125,0.174]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,triamcinolone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1391,0.134,0.145,"[0.134,0.145]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005388,triamcinolone,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1333,0.128,0.139,"[0.128,0.139]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0011122,triamcinolone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.131,0.119,0.143,"[0.119,0.143]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005302,triamcinolone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1223,0.109,0.136,"[0.109,0.136]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0000477,triamcinolone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.1195,0.081,0.158,"[0.081,0.158]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0015614,triamcinolone,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.098,0.089,0.107,"[0.089,0.107]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005072,triamcinolone,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0925,0.088,0.097,"[0.088,0.097]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0008399,triamcinolone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0881,0.075,0.102,"[0.075,0.102]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005083,triamcinolone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0853,0.06,0.111,"[0.06,0.111]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005404,triamcinolone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0826,0.057,0.108,"[0.057,0.108]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005009,triamcinolone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0826,0.049,0.116,"[0.049,0.116]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005364,triamcinolone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0793,0.044,0.115,"[0.044,0.115]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0007186,triamcinolone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0645,0.047,0.082,"[0.047,0.082]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0018177,triamcinolone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0627,0.056,0.069,"[0.056,0.069]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0011429,triamcinolone,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0548,0.04,0.07,"[0.04,0.07]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005711,triamcinolone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0542,0.024,0.085,"[0.024,0.085]",0.001,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0007739,triamcinolone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0509,-0.002,0.104,"[-0.002,0.104]",0.059,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0004979,triamcinolone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0497,0.013,0.086,"[0.013,0.086]",0.008,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005002,triamcinolone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0458,0.027,0.065,"[0.027,0.065]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,triamcinolone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0351,0.008,0.062,"[0.008,0.062]",0.01,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005301,triamcinolone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0311,-0.001,0.063,"[-0.001,0.063]",0.056,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005010,triamcinolone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0229,-0.064,0.109,"[-0.064,0.109]",0.604,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0043693,triamcinolone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0216,-0.002,0.045,"[-0.002,0.045]",0.074,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0002277,triamcinolone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0202,0.011,0.03,"[0.011,0.03]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0004609,triamcinolone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0197,-0.092,0.131,"[-0.092,0.131]",0.729,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0000424,triamcinolone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0195,0.012,0.026,"[0.012,0.026]",1.00E-04,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019369,triamcinolone,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0186,-0.013,0.05,"[-0.013,0.05]",0.248,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0002909,triamcinolone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0179,-0.042,0.078,"[-0.042,0.078]",0.558,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005011,triamcinolone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0175,-0.041,0.076,"[-0.041,0.076]",0.555,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,triamcinolone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0141,-0.093,0.121,"[-0.093,0.121]",0.796,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0003620,triamcinolone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0126,-0.119,0.144,"[-0.119,0.144]",0.851,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0008300,triamcinolone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0109,-0.203,0.224,"[-0.203,0.224]",0.921,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0008642,triamcinolone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0062,-0.149,0.161,"[-0.149,0.161]",0.938,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0001516,triamcinolone,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0059,-0.002,0.014,"[-0.002,0.014]",0.167,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0004975,triamcinolone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0058,-0.07,0.082,"[-0.07,0.082]",0.882,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005306,triamcinolone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0056,-0.103,0.114,"[-0.103,0.114]",0.919,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0008487,triamcinolone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0056,-0.077,0.088,"[-0.077,0.088]",0.895,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0021187,triamcinolone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.005,-0.098,0.108,"[-0.098,0.108]",0.924,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005148,triamcinolone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0047,-0.037,0.046,"[-0.037,0.046]",0.825,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019118,triamcinolone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0033,-0.064,0.071,"[-0.064,0.071]",0.924,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0007947,triamcinolone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0016,-14.647,14.65,"[-14.647,14.65]",1,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019565,triamcinolone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0014,-0.015,0.018,"[-0.015,0.018]",0.868,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005294,triamcinolone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0014,-0.053,0.055,"[-0.053,0.055]",0.959,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0005392,triamcinolone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0013,-0.161,0.164,"[-0.161,0.164]",0.987,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0002406,triamcinolone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0013,-0.193,0.196,"[-0.193,0.196]",0.989,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0800026,triamcinolone,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0013,-0.388,0.391,"[-0.388,0.391]",0.995,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0011786,triamcinolone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.0012,-0.297,0.3,"[-0.297,0.3]",0.994,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0013282,triamcinolone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,0.001,-0.147,0.149,"[-0.147,0.149]",0.99,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:31307,biolink:associated_with_increased_likelihood_of,MONDO:0019350,triamcinolone,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.764982108,3.00E-04,-0.351,0.351,"[-0.351,0.351]",0.999,2590500,19988200,22578700,"Sample size with triamcinolone, approximately: 2590500","Sample size without triamcinolone, approximately: 19988200",All patients number is approximately: 22578700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002277,trazodone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.8472,0.84,0.854,"[0.84,0.854]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0018882,trazodone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.6411,0.634,0.648,"[0.634,0.648]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002046,trazodone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.6116,0.598,0.626,"[0.598,0.626]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005302,trazodone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.564,0.56,0.568,"[0.56,0.568]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0007540,trazodone,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.4578,0.454,0.462,"[0.454,0.462]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0019118,trazodone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.45,0.443,0.457,"[0.443,0.457]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008300,trazodone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.4006,0.393,0.408,"[0.393,0.408]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0021187,trazodone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.3817,0.373,0.39,"[0.373,0.39]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005083,trazodone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.3262,0.315,0.338,"[0.315,0.338]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005711,trazodone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.3086,0.305,0.312,"[0.305,0.312]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005392,trazodone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.213,0.188,0.238,"[0.188,0.238]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0007186,trazodone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1546,0.138,0.171,"[0.138,0.171]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0019565,trazodone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1498,0.134,0.165,"[0.134,0.165]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005147,trazodone,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1456,0.142,0.149,"[0.142,0.149]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0007864,trazodone,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1395,0.134,0.145,"[0.134,0.145]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0004425,trazodone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.126,0.109,0.143,"[0.109,0.143]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002869,trazodone,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1245,0.117,0.132,"[0.117,0.132]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008383,trazodone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1134,0.108,0.119,"[0.108,0.119]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008006,trazodone,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1118,0.081,0.143,"[0.081,0.143]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0009693,trazodone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1063,0.102,0.111,"[0.102,0.111]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0004975,trazodone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1026,0.082,0.123,"[0.082,0.123]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005404,trazodone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.1011,0.066,0.137,"[0.066,0.137]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0004952,trazodone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0981,0.094,0.102,"[0.094,0.102]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005011,trazodone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0958,0.084,0.108,"[0.084,0.108]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0006694,trazodone,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0896,0.084,0.095,"[0.084,0.095]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005180,trazodone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0811,0.075,0.088,"[0.075,0.088]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005294,trazodone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0808,0.064,0.098,"[0.064,0.098]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005178,trazodone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.067,0.062,0.072,"[0.062,0.072]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0019080,trazodone,alopecia totalis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0598,0.039,0.08,"[0.039,0.08]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008642,trazodone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0573,0.035,0.079,"[0.035,0.079]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0007947,trazodone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0526,0.013,0.092,"[0.013,0.092]",0.01,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0011122,trazodone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0473,0.039,0.056,"[0.039,0.056]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002406,trazodone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0417,0.025,0.058,"[0.025,0.058]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0020066,trazodone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0404,0.013,0.068,"[0.013,0.068]",0.004,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005148,trazodone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0363,0.016,0.057,"[0.016,0.057]",0.001,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005009,trazodone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0353,-0.013,0.083,"[-0.013,0.083]",0.149,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0003620,trazodone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0339,0.011,0.056,"[0.011,0.056]",0.003,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0013282,trazodone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.031,0.002,0.06,"[0.002,0.06]",0.036,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,trazodone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0281,-0.021,0.077,"[-0.021,0.077]",0.257,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005300,trazodone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0276,-0.001,0.056,"[-0.001,0.056]",0.058,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005002,trazodone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0261,0.017,0.035,"[0.017,0.035]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005146,trazodone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0226,0.003,0.042,"[0.003,0.042]",0.022,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,trazodone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0223,-0.058,0.102,"[-0.058,0.102]",0.585,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0010383,trazodone,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.019,-0.05,0.088,"[-0.05,0.088]",0.588,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,trazodone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0121,-0.078,0.102,"[-0.078,0.102]",0.791,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0001516,trazodone,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0117,0.007,0.016,"[0.007,0.016]",1.00E-04,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005298,trazodone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0101,-0.087,0.108,"[-0.087,0.108]",0.839,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005010,trazodone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0085,-0.041,0.058,"[-0.041,0.058]",0.736,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,trazodone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0081,-0.032,0.048,"[-0.032,0.048]",0.688,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0043693,trazodone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0073,-0.074,0.088,"[-0.074,0.088]",0.86,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0004979,trazodone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0073,-0.079,0.094,"[-0.079,0.094]",0.868,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005101,trazodone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0059,-0.114,0.126,"[-0.114,0.126]",0.923,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005393,trazodone,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.005,-0.006,0.016,"[-0.006,0.016]",0.369,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005546,trazodone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.002,-0.365,0.369,"[-0.365,0.369]",0.992,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0004609,trazodone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0019,-0.08,0.083,"[-0.08,0.083]",0.963,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002909,trazodone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0016,-0.167,0.17,"[-0.167,0.17]",0.985,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0005388,trazodone,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0015,-0.175,0.178,"[-0.175,0.178]",0.986,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008542,trazodone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0015,-1.541,1.544,"[-1.541,1.544]",0.998,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0008678,trazodone,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0014,-0.012,0.015,"[-0.012,0.015]",0.832,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0015564,trazodone,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.0011,-0.221,0.223,"[-0.221,0.223]",0.992,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0015924,trazodone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,0.001,-0.362,0.364,"[-0.362,0.364]",0.995,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0002316,trazodone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,6.00E-04,-0.268,0.27,"[-0.268,0.27]",0.996,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0011786,trazodone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,5.00E-04,-0.21,0.211,"[-0.21,0.211]",0.996,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5533,biolink:associated_with_increased_likelihood_of,MONDO:0007160,trazodone,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903142252,4.00E-04,-0.064,0.065,"[-0.064,0.065]",0.991,5645100,19538600,25183700,"Sample size with trazodone, approximately: 5645100","Sample size without trazodone, approximately: 19538600",All patients number is approximately: 25183700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5484727,biolink:associated_with_increased_likelihood_of,MONDO:0002869,trandolapril,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94265326,0.0479,-0.231,0.326,"[-0.231,0.326]",0.736,7500,21787800,21795300,"Sample size with trandolapril, approximately: 7500","Sample size without trandolapril, approximately: 21787800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005146,torsemide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.4872,0.475,0.5,"[0.475,0.5]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0009891,torsemide,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.4498,0.442,0.458,"[0.442,0.458]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0008383,torsemide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.4437,0.436,0.452,"[0.436,0.452]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0010602,torsemide,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.3816,0.372,0.391,"[0.372,0.391]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005072,torsemide,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.3616,0.35,0.373,"[0.35,0.373]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0004979,torsemide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2676,0.254,0.281,"[0.254,0.281]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0002316,torsemide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2619,0.248,0.275,"[0.248,0.275]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0002869,torsemide,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2589,0.246,0.272,"[0.246,0.272]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0002909,torsemide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2431,0.227,0.259,"[0.227,0.259]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005147,torsemide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2358,0.223,0.249,"[0.223,0.249]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005302,torsemide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2316,0.216,0.247,"[0.216,0.247]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005393,torsemide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.2146,0.207,0.222,"[0.207,0.222]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0008487,torsemide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.1675,0.153,0.181,"[0.153,0.181]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0019180,torsemide,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.1446,0.13,0.159,"[0.13,0.159]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,torsemide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.1416,0.133,0.151,"[0.133,0.151]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005404,torsemide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.126,0.097,0.155,"[0.097,0.155]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005298,torsemide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.124,0.094,0.154,"[0.094,0.154]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0008542,torsemide,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.084,0.066,0.102,"[0.066,0.102]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0011849,torsemide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0547,0.034,0.075,"[0.034,0.075]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0007540,torsemide,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0479,0.008,0.088,"[0.008,0.088]",0.019,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005301,torsemide,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0467,-0.01,0.104,"[-0.01,0.104]",0.109,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0008599,torsemide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0268,0.019,0.035,"[0.019,0.035]",1.00E-04,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005546,torsemide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0229,-0.036,0.082,"[-0.036,0.082]",0.444,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0004952,torsemide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.019,-0.033,0.071,"[-0.033,0.071]",0.474,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0013282,torsemide,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0153,-0.028,0.058,"[-0.028,0.058]",0.486,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0004981,torsemide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.012,-0.109,0.133,"[-0.109,0.133]",0.846,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0011429,torsemide,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0107,0,0.022,"[0,0.022]",0.06,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0021187,torsemide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0061,-0.051,0.063,"[-0.051,0.063]",0.833,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005364,torsemide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0051,-0.119,0.129,"[-0.119,0.129]",0.936,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0000153,torsemide,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.003,-0.138,0.144,"[-0.138,0.144]",0.967,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0011508,torsemide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0023,-0.123,0.128,"[-0.123,0.128]",0.972,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0000424,torsemide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.002,-0.049,0.054,"[-0.049,0.054]",0.938,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0002406,torsemide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0015,-0.171,0.174,"[-0.171,0.174]",0.986,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,torsemide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,0.0014,-0.356,0.359,"[-0.356,0.359]",0.994,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005010,torsemide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,6.00E-04,-0.301,0.302,"[-0.301,0.302]",0.997,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41781,biolink:associated_with_increased_likelihood_of,MONDO:0005388,torsemide,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.964225451,5.18E-05,-0.054,0.054,"[-0.054,0.054]",0.998,1148500,21425100,22573600,"Sample size with torsemide, approximately: 1148500","Sample size without torsemide, approximately: 21425100",All patients number is approximately: 22573600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0004981,topiramate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.7647,0.752,0.778,"[0.752,0.778]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0021187,topiramate,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.6746,0.657,0.692,"[0.657,0.692]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0019369,topiramate,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.593,0.582,0.604,"[0.582,0.604]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005306,topiramate,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.5837,0.572,0.596,"[0.572,0.596]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005364,topiramate,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.5477,0.525,0.57,"[0.525,0.57]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,topiramate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.3898,0.372,0.407,"[0.372,0.407]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0000914,topiramate,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.3446,0.329,0.36,"[0.329,0.36]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005101,topiramate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.2737,0.249,0.298,"[0.249,0.298]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0002046,topiramate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.245,0.219,0.271,"[0.219,0.271]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0008399,topiramate,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.2086,0.192,0.226,"[0.192,0.226]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0004648,topiramate,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.1632,0.139,0.187,"[0.139,0.187]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0018882,topiramate,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.1531,0.137,0.169,"[0.137,0.169]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005147,topiramate,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.1518,0.133,0.171,"[0.133,0.171]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0002406,topiramate,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.1331,0.101,0.166,"[0.101,0.166]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005546,topiramate,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.1242,0.11,0.138,"[0.11,0.138]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0021107,topiramate,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0856,0.069,0.102,"[0.069,0.102]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005002,topiramate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0672,-0.03,0.165,"[-0.03,0.165]",0.177,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0002316,topiramate,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0515,-0.146,0.249,"[-0.146,0.249]",0.608,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0011122,topiramate,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.051,0.008,0.094,"[0.008,0.094]",0.021,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0011849,topiramate,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.051,0.019,0.083,"[0.019,0.083]",0.002,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0008300,topiramate,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0493,0.001,0.097,"[0.001,0.097]",0.044,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0002909,topiramate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0463,0.015,0.078,"[0.015,0.078]",0.004,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0008487,topiramate,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0397,0,0.079,"[0,0.079]",0.049,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005148,topiramate,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0337,0.019,0.048,"[0.019,0.048]",1.00E-04,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0007160,topiramate,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0239,0.002,0.046,"[0.002,0.046]",0.035,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0009891,topiramate,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.023,-0.026,0.072,"[-0.026,0.072]",0.353,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0007739,topiramate,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0222,-0.095,0.139,"[-0.095,0.139]",0.71,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0007186,topiramate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0207,-0.122,0.163,"[-0.122,0.163]",0.777,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0004609,topiramate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0188,-0.167,0.205,"[-0.167,0.205]",0.843,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0019565,topiramate,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0174,-0.06,0.095,"[-0.06,0.095]",0.661,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005300,topiramate,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0154,-0.156,0.187,"[-0.156,0.187]",0.86,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005392,topiramate,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0142,-0.015,0.043,"[-0.015,0.043]",0.344,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,topiramate,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.01,-0.221,0.241,"[-0.221,0.241]",0.932,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005146,topiramate,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0091,-0.175,0.193,"[-0.175,0.193]",0.923,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0000477,topiramate,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0089,-0.334,0.351,"[-0.334,0.351]",0.959,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0011429,topiramate,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0069,-0.147,0.161,"[-0.147,0.161]",0.93,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0019350,topiramate,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0037,-0.178,0.186,"[-0.178,0.186]",0.968,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005298,topiramate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0027,-0.112,0.118,"[-0.112,0.118]",0.963,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,topiramate,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.002,-0.256,0.26,"[-0.256,0.26]",0.988,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0004425,topiramate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0019,-0.301,0.304,"[-0.301,0.304]",0.99,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005388,topiramate,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0017,-0.286,0.29,"[-0.286,0.29]",0.991,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0004975,topiramate,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0014,-0.267,0.269,"[-0.267,0.269]",0.992,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0002277,topiramate,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0014,-0.751,0.754,"[-0.751,0.754]",0.997,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0010383,topiramate,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0014,-0.248,0.251,"[-0.248,0.251]",0.991,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0000153,topiramate,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0013,-73.3,73.302,"[-73.3,73.302]",1,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0011786,topiramate,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,0.0013,-0.578,0.58,"[-0.578,0.58]",0.997,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0043693,topiramate,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,9.00E-04,-0.09,0.092,"[-0.09,0.092]",0.984,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005133,topiramate,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,9.00E-04,-0.111,0.112,"[-0.111,0.112]",0.987,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0007947,topiramate,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,6.00E-04,-0.34,0.341,"[-0.34,0.341]",0.997,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,MONDO:0005302,topiramate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,4.00E-04,-0.506,0.507,"[-0.506,0.507]",0.999,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284627,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,topiramate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846518809,3.00E-04,-0.466,0.466,"[-0.466,0.466]",0.999,466300,21518500,21984800,"Sample size with topiramate, approximately: 466300","Sample size without topiramate, approximately: 21518500",All patients number is approximately: 21984800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tofacitinib,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.4051,0.301,0.51,"[0.301,0.51]",1.00E-04,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tofacitinib,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.2757,0.234,0.318,"[0.234,0.318]",1.00E-04,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005180,tofacitinib,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.2563,0.193,0.32,"[0.193,0.32]",1.00E-04,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tofacitinib,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.2158,0.027,0.405,"[0.027,0.405]",0.025,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0021187,tofacitinib,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.2137,0.13,0.298,"[0.13,0.298]",1.00E-04,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tofacitinib,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.1436,-0.054,0.341,"[-0.054,0.341]",0.155,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005147,tofacitinib,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.13,-0.08,0.34,"[-0.08,0.34]",0.224,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tofacitinib,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.127,-0.022,0.276,"[-0.022,0.276]",0.096,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0004648,tofacitinib,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0721,-0.246,0.39,"[-0.246,0.39]",0.656,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0000424,tofacitinib,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0259,-0.536,0.588,"[-0.536,0.588]",0.928,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0002046,tofacitinib,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0225,-1.02,1.065,"[-1.02,1.065]",0.966,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0011786,tofacitinib,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0195,-0.413,0.452,"[-0.413,0.452]",0.93,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0011429,tofacitinib,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0182,-0.352,0.388,"[-0.352,0.388]",0.923,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,tofacitinib,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.014,-0.95,0.978,"[-0.95,0.978]",0.977,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0003620,tofacitinib,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.007,-0.278,0.292,"[-0.278,0.292]",0.962,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0004975,tofacitinib,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0066,-1.274,1.287,"[-1.274,1.287]",0.992,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tofacitinib,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.002,-0.662,0.666,"[-0.662,0.666]",0.995,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0005002,tofacitinib,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0017,-0.686,0.689,"[-0.686,0.689]",0.996,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9926791,biolink:associated_with_increased_likelihood_of,MONDO:0002869,tofacitinib,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924283888,0.0016,-0.194,0.197,"[-0.194,0.197]",0.987,23900,21778700,21802600,"Sample size with tofacitinib, approximately: 23900","Sample size without tofacitinib, approximately: 21778700",All patients number is approximately: 21802600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tocilizumab,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,1.21,1.183,1.237,"[1.183,1.237]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0008487,tocilizumab,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,1.0298,1.005,1.055,"[1.005,1.055]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005180,tocilizumab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.8166,0.787,0.846,"[0.787,0.846]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tocilizumab,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.7791,0.751,0.808,"[0.751,0.808]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0018882,tocilizumab,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.5608,0.534,0.588,"[0.534,0.588]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tocilizumab,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.3634,0.337,0.39,"[0.337,0.39]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0001516,tocilizumab,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.2454,0.222,0.269,"[0.222,0.269]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005101,tocilizumab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.1526,0.12,0.185,"[0.12,0.185]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0021187,tocilizumab,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.1249,0.091,0.159,"[0.091,0.159]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0011849,tocilizumab,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.1137,0.073,0.155,"[0.073,0.155]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005147,tocilizumab,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0618,0.037,0.087,"[0.037,0.087]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tocilizumab,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0528,0.026,0.08,"[0.026,0.08]",1.00E-04,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005306,tocilizumab,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0386,-0.042,0.119,"[-0.042,0.119]",0.346,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0002909,tocilizumab,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0309,-0.172,0.234,"[-0.172,0.234]",0.765,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0002869,tocilizumab,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0267,-0.157,0.21,"[-0.157,0.21]",0.775,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0008599,tocilizumab,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0123,-0.023,0.047,"[-0.023,0.047]",0.491,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0004975,tocilizumab,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0064,-0.131,0.144,"[-0.131,0.144]",0.927,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005002,tocilizumab,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0055,-0.495,0.506,"[-0.495,0.506]",0.983,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tocilizumab,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0024,-0.336,0.341,"[-0.336,0.341]",0.989,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0005010,tocilizumab,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0019,-3.086,3.09,"[-3.086,3.09]",0.999,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1237022,biolink:associated_with_increased_likelihood_of,MONDO:0011429,tocilizumab,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976157173,0.0011,-0.558,0.56,"[-0.558,0.56]",0.997,86200,21755900,21842100,"Sample size with tocilizumab, approximately: 86200","Sample size without tocilizumab, approximately: 21755900",All patients number is approximately: 21842100,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0005146,tirzepatide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.4848,0.431,0.539,"[0.431,0.539]",1.00E-04,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tirzepatide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.4069,0.324,0.49,"[0.324,0.49]",1.00E-04,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0005393,tirzepatide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.24,0.104,0.376,"[0.104,0.376]",0.001,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0007027,tirzepatide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.1938,-0.034,0.421,"[-0.034,0.421]",0.095,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0019369,tirzepatide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0784,-0.047,0.204,"[-0.047,0.204]",0.222,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0011786,tirzepatide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0488,-0.032,0.13,"[-0.032,0.13]",0.238,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0020066,tirzepatide,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0365,-0.09,0.163,"[-0.09,0.163]",0.571,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0005133,tirzepatide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0363,-0.256,0.329,"[-0.256,0.329]",0.808,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tirzepatide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0236,-0.001,0.048,"[-0.001,0.048]",0.063,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tirzepatide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0066,-0.378,0.391,"[-0.378,0.391]",0.973,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tirzepatide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0022,-0.33,0.334,"[-0.33,0.334]",0.989,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tirzepatide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0016,-0.439,0.443,"[-0.439,0.443]",0.994,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:11429,biolink:associated_with_increased_likelihood_of,MONDO:0004979,tirzepatide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89423004,0.0012,-0.384,0.386,"[-0.384,0.386]",0.995,86500,21737300,21823800,"Sample size with tirzepatide, approximately: 86500","Sample size without tirzepatide, approximately: 21737300",All patients number is approximately: 21823800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL183041,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tipranavir,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997192048,0.0088,-0.807,0.824,"[-0.807,0.824]",0.983,100,21792200,21792300,"Sample size with tipranavir, approximately: 100","Sample size without tipranavir, approximately: 21792200",All patients number is approximately: 21792300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0008487,tiotropium,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.463,0.438,0.488,"[0.438,0.488]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0019369,tiotropium,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.3476,0.34,0.355,"[0.34,0.355]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005392,tiotropium,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.3322,0.321,0.343,"[0.321,0.343]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tiotropium,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.3148,0.306,0.324,"[0.306,0.324]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tiotropium,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.2638,0.256,0.272,"[0.256,0.272]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005101,tiotropium,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.2361,0.222,0.25,"[0.222,0.25]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0009891,tiotropium,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.1911,0.182,0.2,"[0.182,0.2]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005147,tiotropium,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.1389,0.113,0.165,"[0.113,0.165]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0019350,tiotropium,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.1365,0.096,0.177,"[0.096,0.177]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tiotropium,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.1088,0.084,0.133,"[0.084,0.133]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005011,tiotropium,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.1026,0.086,0.119,"[0.086,0.119]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0015263,tiotropium,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0955,0.087,0.104,"[0.087,0.104]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tiotropium,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0854,0.049,0.121,"[0.049,0.121]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0002046,tiotropium,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0792,0.027,0.131,"[0.027,0.131]",0.003,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005302,tiotropium,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0752,0.063,0.087,"[0.063,0.087]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0004648,tiotropium,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0635,0.056,0.071,"[0.056,0.071]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0002909,tiotropium,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.049,0.039,0.059,"[0.039,0.059]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0011849,tiotropium,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0387,0.014,0.064,"[0.014,0.064]",0.002,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0002316,tiotropium,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0359,-0.028,0.1,"[-0.028,0.1]",0.274,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005130,tiotropium,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0352,0.026,0.044,"[0.026,0.044]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tiotropium,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0345,-0.045,0.114,"[-0.045,0.114]",0.395,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005364,tiotropium,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0331,0.01,0.056,"[0.01,0.056]",0.006,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tiotropium,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0311,0.023,0.04,"[0.023,0.04]",1.00E-04,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tiotropium,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0302,-0.014,0.074,"[-0.014,0.074]",0.179,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0043693,tiotropium,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0215,-0.02,0.063,"[-0.02,0.063]",0.311,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0004609,tiotropium,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0143,-0.043,0.071,"[-0.043,0.071]",0.624,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tiotropium,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0117,-0.179,0.202,"[-0.179,0.202]",0.904,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0007739,tiotropium,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0081,-0.151,0.167,"[-0.151,0.167]",0.92,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0019180,tiotropium,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0079,-0.128,0.143,"[-0.128,0.143]",0.909,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tiotropium,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0049,-0.055,0.064,"[-0.055,0.064]",0.872,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0003620,tiotropium,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0049,-0.104,0.114,"[-0.104,0.114]",0.929,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005133,tiotropium,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0046,-0.25,0.259,"[-0.25,0.259]",0.972,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0004952,tiotropium,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0027,-0.137,0.142,"[-0.137,0.142]",0.97,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0011786,tiotropium,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0024,-0.171,0.176,"[-0.171,0.176]",0.978,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0021187,tiotropium,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,0.0011,-0.097,0.1,"[-0.097,0.1]",0.983,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0010526,tiotropium,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,8.00E-04,-0.084,0.085,"[-0.084,0.085]",0.985,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,tiotropium,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,8.00E-04,-0.211,0.212,"[-0.211,0.212]",0.994,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tiotropium,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,5.00E-04,-0.322,0.323,"[-0.322,0.323]",0.997,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005306,tiotropium,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,4.00E-04,-0.249,0.25,"[-0.249,0.25]",0.998,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0004425,tiotropium,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,1.00E-04,-0.137,0.138,"[-0.137,0.138]",0.998,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1182657,biolink:associated_with_increased_likelihood_of,MONDO:0005546,tiotropium,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96951811,1.82E-05,-0.46,0.46,"[-0.46,0.46]",1,1219900,21272100,22492000,"Sample size with tiotropium, approximately: 1219900","Sample size without tiotropium, approximately: 21272100",All patients number is approximately: 22492000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005010,timolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.3294,0.32,0.339,"[0.32,0.339]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005178,timolol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.2736,0.264,0.283,"[0.264,0.283]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005393,timolol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.2503,0.24,0.261,"[0.24,0.261]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0004425,timolol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.2352,0.226,0.245,"[0.226,0.245]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0019369,timolol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.1721,0.163,0.181,"[0.163,0.181]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0010602,timolol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.1591,0.148,0.17,"[0.148,0.17]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005011,timolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.1053,0.088,0.123,"[0.088,0.123]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0019565,timolol,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.1052,0.068,0.143,"[0.068,0.143]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005301,timolol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.1015,0.087,0.116,"[0.087,0.116]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0008399,timolol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0974,0.087,0.107,"[0.087,0.107]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005146,timolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0853,0.066,0.105,"[0.066,0.105]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0019118,timolol,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0764,0.066,0.087,"[0.066,0.087]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005101,timolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0741,0.026,0.122,"[0.026,0.122]",0.003,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005180,timolol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0603,0.048,0.072,"[0.048,0.072]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005130,timolol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0559,0.046,0.066,"[0.046,0.066]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005009,timolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0549,0.041,0.068,"[0.041,0.068]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005002,timolol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0544,0.044,0.065,"[0.044,0.065]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0008383,timolol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.052,0.011,0.093,"[0.011,0.093]",0.014,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0011849,timolol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0291,-0.035,0.094,"[-0.035,0.094]",0.376,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0008599,timolol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0234,0.013,0.034,"[0.013,0.034]",1.00E-04,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0016532,timolol,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0229,-0.014,0.06,"[-0.014,0.06]",0.223,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0004975,timolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0227,-0.018,0.063,"[-0.018,0.063]",0.27,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0013282,timolol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0093,-0.11,0.129,"[-0.11,0.129]",0.879,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0011786,timolol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0081,-0.276,0.292,"[-0.276,0.292]",0.955,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0003620,timolol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0081,-0.098,0.114,"[-0.098,0.114]",0.881,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005298,timolol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.007,-0.097,0.111,"[-0.097,0.111]",0.895,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0021107,timolol,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0057,-0.061,0.073,"[-0.061,0.073]",0.867,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005546,timolol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0043,-0.176,0.185,"[-0.176,0.185]",0.963,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,timolol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0038,-0.019,0.026,"[-0.019,0.026]",0.741,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0011429,timolol,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0036,-0.114,0.121,"[-0.114,0.121]",0.952,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,timolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0032,-0.313,0.32,"[-0.313,0.32]",0.984,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005364,timolol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.003,-0.131,0.137,"[-0.131,0.137]",0.965,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0002277,timolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0027,-0.085,0.09,"[-0.085,0.09]",0.952,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0004981,timolol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0023,-0.15,0.155,"[-0.15,0.155]",0.976,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0007186,timolol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,0.0013,-0.232,0.235,"[-0.232,0.235]",0.991,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0008487,timolol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,5.00E-04,-0.908,0.909,"[-0.908,0.909]",0.999,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005302,timolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,5.00E-04,-0.163,0.163,"[-0.163,0.163]",0.996,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0005388,timolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,5.00E-04,-0.266,0.267,"[-0.266,0.267]",0.997,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0015924,timolol,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,4.00E-04,-0.66,0.661,"[-0.66,0.661]",0.999,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:33624,biolink:associated_with_increased_likelihood_of,MONDO:0009891,timolol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877859367,2.00E-04,-0.775,0.775,"[-0.775,0.775]",1,558200,21527000,22085200,"Sample size with timolol, approximately: 558200","Sample size without timolol, approximately: 21527000",All patients number is approximately: 22085200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:229387,biolink:associated_with_increased_likelihood_of,MONDO:0004975,thiothixene,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962081861,0.0274,-1.26,1.315,"[-1.26,1.315]",0.967,5200,21788900,21794100,"Sample size with thiothixene, approximately: 5200","Sample size without thiothixene, approximately: 21788900",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5452,biolink:associated_with_increased_likelihood_of,MONDO:0013282,thioridazine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926861967,0.0028,-0.957,0.963,"[-0.957,0.963]",0.995,1800,21791200,21793000,"Sample size with thioridazine, approximately: 1800","Sample size without thioridazine, approximately: 21791200",All patients number is approximately: 21793000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304895,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,tezacaftor,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999997776,0.0057,-0.875,0.886,"[-0.875,0.886]",0.99,1600,21791300,21792900,"Sample size with tezacaftor, approximately: 1600","Sample size without tezacaftor, approximately: 21791300",All patients number is approximately: 21792900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005306,teriparatide,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.7769,0.702,0.851,"[0.702,0.851]",1.00E-04,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0002909,teriparatide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.2071,0.13,0.284,"[0.13,0.284]",1.00E-04,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,teriparatide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.2045,0.124,0.285,"[0.124,0.285]",1.00E-04,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005300,teriparatide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.2004,0.088,0.312,"[0.088,0.312]",1.00E-04,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0002277,teriparatide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.1721,0.052,0.292,"[0.052,0.292]",0.005,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005147,teriparatide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.1265,-0.027,0.28,"[-0.027,0.28]",0.106,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005149,teriparatide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.079,-0.099,0.257,"[-0.099,0.257]",0.385,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0019369,teriparatide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0744,-0.131,0.28,"[-0.131,0.28]",0.478,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005002,teriparatide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0222,-1.094,1.138,"[-1.094,1.138]",0.969,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0010787,teriparatide,kearns sayre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0122,-1.247,1.271,"[-1.247,1.271]",0.985,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0004979,teriparatide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0107,-0.43,0.451,"[-0.43,0.451]",0.962,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0004648,teriparatide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0074,-0.596,0.611,"[-0.596,0.611]",0.981,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005101,teriparatide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0031,-0.347,0.353,"[-0.347,0.353]",0.986,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0018882,teriparatide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0024,-0.577,0.582,"[-0.577,0.582]",0.994,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16133850,biolink:associated_with_increased_likelihood_of,MONDO:0005009,teriparatide,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.932367138,0.0012,-0.316,0.318,"[-0.316,0.318]",0.994,22300,21779300,21801600,"Sample size with teriparatide, approximately: 22300","Sample size without teriparatide, approximately: 21779300",All patients number is approximately: 21801600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258832,biolink:associated_with_increased_likelihood_of,MONDO:0004979,teriflunomide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924474827,0.0168,-0.53,0.563,"[-0.53,0.563]",0.952,6200,21788800,21795000,"Sample size with teriflunomide, approximately: 6200","Sample size without teriflunomide, approximately: 21788800",All patients number is approximately: 21795000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258832,biolink:associated_with_increased_likelihood_of,MONDO:0005149,teriflunomide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924474827,4.00E-04,-1.243,1.244,"[-1.243,1.244]",0.999,6200,21788800,21795000,"Sample size with teriflunomide, approximately: 6200","Sample size without teriflunomide, approximately: 21788800",All patients number is approximately: 21795000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0002909,terbutaline,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,2.8605,2.849,2.872,"[2.849,2.872]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0008738,terbutaline,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,2.2764,2.264,2.289,"[2.264,2.289]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0007186,terbutaline,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,1.2224,1.208,1.237,"[1.208,1.237]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0009061,terbutaline,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.8336,0.819,0.848,"[0.819,0.848]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005711,terbutaline,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.5657,0.547,0.584,"[0.547,0.584]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005298,terbutaline,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.548,0.525,0.571,"[0.525,0.571]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0008487,terbutaline,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.2412,0.218,0.265,"[0.218,0.265]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005180,terbutaline,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.2108,0.174,0.247,"[0.174,0.247]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0002277,terbutaline,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.2028,0.158,0.247,"[0.158,0.247]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005002,terbutaline,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.1584,0.012,0.305,"[0.012,0.305]",0.034,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0002869,terbutaline,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0973,0.043,0.151,"[0.043,0.151]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005546,terbutaline,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0818,0.052,0.111,"[0.052,0.111]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0007027,terbutaline,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0693,0.042,0.097,"[0.042,0.097]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0008542,terbutaline,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0534,0.006,0.101,"[0.006,0.101]",0.029,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005101,terbutaline,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0486,-0.048,0.145,"[-0.048,0.145]",0.324,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005130,terbutaline,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0449,0.022,0.068,"[0.022,0.068]",1.00E-04,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0011122,terbutaline,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0382,0.009,0.067,"[0.009,0.067]",0.009,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0011849,terbutaline,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0276,-0.127,0.183,"[-0.127,0.183]",0.727,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005392,terbutaline,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0103,-0.152,0.172,"[-0.152,0.172]",0.901,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0004609,terbutaline,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.01,-0.158,0.178,"[-0.158,0.178]",0.907,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0003620,terbutaline,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0092,-0.337,0.355,"[-0.337,0.355]",0.958,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0008383,terbutaline,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0041,-0.245,0.253,"[-0.245,0.253]",0.974,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5403,biolink:associated_with_increased_likelihood_of,MONDO:0005300,terbutaline,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991761481,0.0037,-0.332,0.339,"[-0.332,0.339]",0.983,1013100,21230800,22243900,"Sample size with terbutaline, approximately: 1013100","Sample size without terbutaline, approximately: 21230800",All patients number is approximately: 22243900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0000424,terazosin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.7017,0.686,0.717,"[0.686,0.717]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005546,terazosin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.6308,0.619,0.642,"[0.619,0.642]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005180,terazosin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.4854,0.472,0.499,"[0.472,0.499]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,terazosin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.4401,0.429,0.452,"[0.429,0.452]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,terazosin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.3425,0.329,0.356,"[0.329,0.356]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0019565,terazosin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.214,0.2,0.228,"[0.2,0.228]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0008383,terazosin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.196,0.177,0.215,"[0.177,0.215]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0021187,terazosin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.173,0.16,0.186,"[0.16,0.186]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005010,terazosin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.1622,0.147,0.178,"[0.147,0.178]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0011849,terazosin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0548,0.029,0.081,"[0.029,0.081]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,terazosin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0445,0.007,0.082,"[0.007,0.082]",0.021,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005146,terazosin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0411,-0.013,0.095,"[-0.013,0.095]",0.136,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005147,terazosin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0404,0.025,0.056,"[0.025,0.056]",1.00E-04,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005101,terazosin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0338,-0.004,0.072,"[-0.004,0.072]",0.079,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005364,terazosin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0315,-0.034,0.097,"[-0.034,0.097]",0.343,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0015924,terazosin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0286,-0.035,0.092,"[-0.035,0.092]",0.379,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0018882,terazosin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0252,-0.041,0.092,"[-0.041,0.092]",0.458,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0007915,terazosin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0198,-0.07,0.109,"[-0.07,0.109]",0.664,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005294,terazosin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0169,-0.121,0.155,"[-0.121,0.155]",0.81,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0004975,terazosin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0157,-0.045,0.076,"[-0.045,0.076]",0.611,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0004425,terazosin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0134,-0.058,0.085,"[-0.058,0.085]",0.714,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0002046,terazosin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0081,-0.044,0.06,"[-0.044,0.06]",0.762,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0003620,terazosin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0056,-0.17,0.181,"[-0.17,0.181]",0.95,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0005302,terazosin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0052,-0.326,0.336,"[-0.326,0.336]",0.975,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0007027,terazosin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.005,-0.034,0.044,"[-0.034,0.044]",0.803,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0007827,terazosin,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.0042,-0.153,0.162,"[-0.153,0.162]",0.959,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0002277,terazosin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,0.001,-0.373,0.375,"[-0.373,0.375]",0.996,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0004952,terazosin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,5.00E-04,-0.096,0.097,"[-0.096,0.097]",0.992,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5401,biolink:associated_with_increased_likelihood_of,MONDO:0011786,terazosin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926331831,1.00E-04,-0.293,0.293,"[-0.293,0.293]",0.999,229900,21668600,21898500,"Sample size with terazosin, approximately: 229900","Sample size without terazosin, approximately: 21668600",All patients number is approximately: 21898500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tenofovir disoproxil,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,1.0213,0.976,1.067,"[0.976,1.067]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0018882,tenofovir disoproxil,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.9538,0.894,1.014,"[0.894,1.014]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005133,tenofovir disoproxil,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.6286,0.573,0.684,"[0.573,0.684]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tenofovir disoproxil,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.5727,0.504,0.641,"[0.504,0.641]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005180,tenofovir disoproxil,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.5201,0.417,0.623,"[0.417,0.623]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005393,tenofovir disoproxil,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.497,0.433,0.561,"[0.433,0.561]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0043693,tenofovir disoproxil,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.3989,0.345,0.453,"[0.345,0.453]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0008399,tenofovir disoproxil,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.3028,0.23,0.376,"[0.23,0.376]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0004609,tenofovir disoproxil,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.1664,0.122,0.211,"[0.122,0.211]",1.00E-04,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tenofovir disoproxil,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0564,-0.029,0.141,"[-0.029,0.141]",0.193,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tenofovir disoproxil,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0559,-0.379,0.491,"[-0.379,0.491]",0.801,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005083,tenofovir disoproxil,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0355,-0.093,0.164,"[-0.093,0.164]",0.587,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,tenofovir disoproxil,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0216,-0.619,0.662,"[-0.619,0.662]",0.947,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tenofovir disoproxil,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0164,-0.038,0.07,"[-0.038,0.07]",0.553,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0004975,tenofovir disoproxil,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.011,-7.129,7.151,"[-7.129,7.151]",0.998,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005009,tenofovir disoproxil,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0106,-0.442,0.463,"[-0.442,0.463]",0.964,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005010,tenofovir disoproxil,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0102,-2.775,2.796,"[-2.775,2.796]",0.994,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tenofovir disoproxil,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0102,-5.148,5.168,"[-5.148,5.168]",0.997,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005364,tenofovir disoproxil,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0091,-0.115,0.133,"[-0.115,0.133]",0.885,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0002869,tenofovir disoproxil,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0077,-0.194,0.209,"[-0.194,0.209]",0.94,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,tenofovir disoproxil,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0044,-0.897,0.906,"[-0.897,0.906]",0.992,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tenofovir disoproxil,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0043,-0.759,0.768,"[-0.759,0.768]",0.991,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0005392,tenofovir disoproxil,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0028,-2546.71,2546.716,"[-2546.71,2546.716]",1,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247572,biolink:associated_with_increased_likelihood_of,MONDO:0004979,tenofovir disoproxil,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.981007882,0.0013,-0.717,0.72,"[-0.717,0.72]",0.997,81900,21733600,21815500,"Sample size with tenofovir disoproxil, approximately: 81900","Sample size without tenofovir disoproxil, approximately: 21733600",All patients number is approximately: 21815500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,tenofovir alafenamide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,12.0664,12.017,12.116,"[12.017,12.116]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005393,tenofovir alafenamide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,1.2911,1.24,1.342,"[1.24,1.342]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tenofovir alafenamide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,1.2893,1.252,1.327,"[1.252,1.327]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0000424,tenofovir alafenamide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,1.0396,0.991,1.088,"[0.991,1.088]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tenofovir alafenamide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.8839,0.839,0.929,"[0.839,0.929]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tenofovir alafenamide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.8489,0.808,0.89,"[0.808,0.89]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,tenofovir alafenamide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.8169,0.781,0.853,"[0.781,0.853]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tenofovir alafenamide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.7958,0.754,0.837,"[0.754,0.837]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005147,tenofovir alafenamide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.7947,0.748,0.842,"[0.748,0.842]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0011508,tenofovir alafenamide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.5905,0.536,0.645,"[0.536,0.645]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0002046,tenofovir alafenamide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.5521,0.515,0.589,"[0.515,0.589]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tenofovir alafenamide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.5115,0.445,0.578,"[0.445,0.578]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0006694,tenofovir alafenamide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.507,0.469,0.545,"[0.469,0.545]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005083,tenofovir alafenamide,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.2526,0.128,0.377,"[0.128,0.377]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tenofovir alafenamide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.2515,0.164,0.339,"[0.164,0.339]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0004648,tenofovir alafenamide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.1362,0.07,0.203,"[0.07,0.203]",1.00E-04,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005146,tenofovir alafenamide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0749,-0.255,0.405,"[-0.255,0.405]",0.656,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005301,tenofovir alafenamide,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0186,-0.279,0.316,"[-0.279,0.316]",0.903,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005302,tenofovir alafenamide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0101,-0.174,0.194,"[-0.174,0.194]",0.915,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005101,tenofovir alafenamide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0066,-0.256,0.27,"[-0.256,0.27]",0.961,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tenofovir alafenamide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0049,-0.751,0.761,"[-0.751,0.761]",0.99,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tenofovir alafenamide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0029,-1.038,1.043,"[-1.038,1.043]",0.996,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0015564,tenofovir alafenamide,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,0.0023,-1.01,1.014,"[-1.01,1.014]",0.996,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251727,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tenofovir alafenamide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.988973917,2.00E-04,-0.337,0.337,"[-0.337,0.337]",0.999,59400,21755500,21814900,"Sample size with tenofovir alafenamide, approximately: 59400","Sample size without tenofovir alafenamide, approximately: 21755500",All patients number is approximately: 21814900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0002909,tenecteplase,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,2.7877,2.762,2.814,"[2.762,2.814]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0018882,tenecteplase,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.5585,0.535,0.582,"[0.535,0.582]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0003620,tenecteplase,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.4418,0.418,0.465,"[0.418,0.465]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0011122,tenecteplase,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.2976,0.269,0.326,"[0.269,0.326]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0008399,tenecteplase,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.2453,0.213,0.278,"[0.213,0.278]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tenecteplase,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.1689,0.104,0.234,"[0.104,0.234]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0005009,tenecteplase,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.1452,0.114,0.177,"[0.114,0.177]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tenecteplase,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.1395,0.114,0.166,"[0.114,0.166]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tenecteplase,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0892,0.066,0.112,"[0.066,0.112]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0019499,tenecteplase,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0626,0.037,0.088,"[0.037,0.088]",1.00E-04,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0000424,tenecteplase,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0568,-0.057,0.17,"[-0.057,0.17]",0.327,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0021187,tenecteplase,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0439,-0.034,0.122,"[-0.034,0.122]",0.268,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0005083,tenecteplase,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0307,-0.064,0.125,"[-0.064,0.125]",0.526,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0007915,tenecteplase,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0153,-0.138,0.169,"[-0.138,0.169]",0.845,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108791,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tenecteplase,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984514769,0.0023,-0.123,0.127,"[-0.123,0.127]",0.971,81700,21760200,21841900,"Sample size with tenecteplase, approximately: 81700","Sample size without tenecteplase, approximately: 21760200",All patients number is approximately: 21841900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005546,telmisartan,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.5682,0.552,0.585,"[0.552,0.585]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005133,telmisartan,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.4966,0.471,0.522,"[0.471,0.522]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005010,telmisartan,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.4506,0.428,0.473,"[0.428,0.473]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0006694,telmisartan,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.2073,0.173,0.242,"[0.173,0.242]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,telmisartan,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.2003,0.183,0.218,"[0.183,0.218]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005148,telmisartan,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.1345,0.11,0.159,"[0.11,0.159]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0004648,telmisartan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.131,0.102,0.16,"[0.102,0.16]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005178,telmisartan,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.1221,0.087,0.157,"[0.087,0.157]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0007027,telmisartan,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0971,0.063,0.131,"[0.063,0.131]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0011122,telmisartan,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0944,0.066,0.123,"[0.066,0.123]",1.00E-04,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0004425,telmisartan,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0301,-0.089,0.149,"[-0.089,0.149]",0.62,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0008383,telmisartan,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0296,-0.065,0.124,"[-0.065,0.124]",0.541,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0018882,telmisartan,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0293,-0.018,0.077,"[-0.018,0.077]",0.226,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005101,telmisartan,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0293,-0.031,0.089,"[-0.031,0.089]",0.339,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005404,telmisartan,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0234,-0.014,0.061,"[-0.014,0.061]",0.218,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0011786,telmisartan,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0198,-0.037,0.077,"[-0.037,0.077]",0.498,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0004979,telmisartan,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0121,-0.118,0.142,"[-0.118,0.142]",0.855,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0002316,telmisartan,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0096,-0.153,0.172,"[-0.153,0.172]",0.908,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0003620,telmisartan,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.009,-0.297,0.315,"[-0.297,0.315]",0.954,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005149,telmisartan,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0062,-0.195,0.207,"[-0.195,0.207]",0.952,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0002909,telmisartan,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0059,-0.051,0.063,"[-0.051,0.063]",0.839,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005364,telmisartan,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0057,-0.139,0.15,"[-0.139,0.15]",0.939,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005002,telmisartan,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0049,-0.119,0.129,"[-0.119,0.129]",0.939,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0015924,telmisartan,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0015,-0.191,0.194,"[-0.191,0.194]",0.988,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005294,telmisartan,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,0.0012,-0.576,0.579,"[-0.576,0.579]",0.997,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0007186,telmisartan,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,7.00E-04,-0.09,0.091,"[-0.09,0.091]",0.989,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005146,telmisartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,6.00E-04,-0.304,0.305,"[-0.304,0.305]",0.997,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005301,telmisartan,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,4.00E-04,-0.374,0.375,"[-0.374,0.375]",0.998,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65999,biolink:associated_with_increased_likelihood_of,MONDO:0005009,telmisartan,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892877499,4.00E-04,-0.417,0.418,"[-0.417,0.418]",0.998,140000,21699800,21839800,"Sample size with telmisartan, approximately: 140000","Sample size without telmisartan, approximately: 21699800",All patients number is approximately: 21839800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5381,biolink:associated_with_increased_likelihood_of,MONDO:0002869,tazarotene,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.839285714,0.01,-0.343,0.364,"[-0.343,0.364]",0.956,15700,21780600,21796300,"Sample size with tazarotene, approximately: 15700","Sample size without tazarotene, approximately: 21780600",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5381,biolink:associated_with_increased_likelihood_of,MONDO:0002046,tazarotene,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.839285714,2.38E-05,-0.612,0.612,"[-0.612,0.612]",1,15700,21780600,21796300,"Sample size with tazarotene, approximately: 15700","Sample size without tazarotene, approximately: 21780600",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6439522,biolink:associated_with_increased_likelihood_of,MONDO:0011786,tapinarof,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.920520661,0.0205,-0.633,0.674,"[-0.633,0.674]",0.951,1400,21791400,21792800,"Sample size with tapinarof, approximately: 1400","Sample size without tapinarof, approximately: 21791400",All patients number is approximately: 21792800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0004648,tamoxifen,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.8668,0.843,0.89,"[0.843,0.89]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0021187,tamoxifen,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.6279,0.59,0.666,"[0.59,0.666]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tamoxifen,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.2658,0.234,0.298,"[0.234,0.298]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0007027,tamoxifen,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.2438,0.213,0.275,"[0.213,0.275]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0005364,tamoxifen,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.201,0.176,0.226,"[0.176,0.226]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tamoxifen,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.178,0.105,0.251,"[0.105,0.251]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0008399,tamoxifen,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.1589,0.112,0.206,"[0.112,0.206]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0007186,tamoxifen,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.1419,0.093,0.191,"[0.093,0.191]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0008599,tamoxifen,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.1024,0.06,0.145,"[0.06,0.145]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0019180,tamoxifen,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0819,0.018,0.146,"[0.018,0.146]",0.012,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0005302,tamoxifen,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0758,0.047,0.105,"[0.047,0.105]",1.00E-04,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0004979,tamoxifen,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0379,-0.186,0.262,"[-0.186,0.262]",0.74,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0019369,tamoxifen,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0278,-0.049,0.104,"[-0.049,0.104]",0.477,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tamoxifen,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0247,-0.145,0.195,"[-0.145,0.195]",0.776,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0013282,tamoxifen,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0175,-0.159,0.194,"[-0.159,0.194]",0.846,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,tamoxifen,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0137,-0.037,0.064,"[-0.037,0.064]",0.595,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0018882,tamoxifen,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0083,-0.202,0.218,"[-0.202,0.218]",0.938,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0005083,tamoxifen,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0071,-0.215,0.229,"[-0.215,0.229]",0.95,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,tamoxifen,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0028,-0.289,0.295,"[-0.289,0.295]",0.985,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0019565,tamoxifen,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0024,-0.309,0.314,"[-0.309,0.314]",0.988,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2733526,biolink:associated_with_increased_likelihood_of,MONDO:0004609,tamoxifen,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.860360989,0.0017,-0.54,0.543,"[-0.54,0.543]",0.995,76700,21740700,21817400,"Sample size with tamoxifen, approximately: 76700","Sample size without tamoxifen, approximately: 21740700",All patients number is approximately: 21817400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005148,tacrolimus,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.475,0.457,0.493,"[0.457,0.493]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0019180,tacrolimus,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.4569,0.437,0.476,"[0.437,0.476]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005393,tacrolimus,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.4282,0.41,0.447,"[0.41,0.447]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005178,tacrolimus,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.3918,0.372,0.411,"[0.372,0.411]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0004979,tacrolimus,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.345,0.313,0.377,"[0.313,0.377]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0002909,tacrolimus,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.2128,0.18,0.245,"[0.18,0.245]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005388,tacrolimus,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.1588,0.136,0.181,"[0.136,0.181]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0007739,tacrolimus,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.1154,0.069,0.161,"[0.069,0.161]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0009891,tacrolimus,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.1054,0.085,0.126,"[0.085,0.126]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005298,tacrolimus,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0956,0.021,0.17,"[0.021,0.17]",0.012,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005101,tacrolimus,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.09,-0.079,0.259,"[-0.079,0.259]",0.297,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0011122,tacrolimus,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0692,0.046,0.092,"[0.046,0.092]",1.00E-04,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005083,tacrolimus,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0523,-0.016,0.12,"[-0.016,0.12]",0.132,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0004975,tacrolimus,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0416,0.016,0.067,"[0.016,0.067]",0.001,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005149,tacrolimus,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0404,-0.007,0.088,"[-0.007,0.088]",0.095,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005404,tacrolimus,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0343,-0.058,0.126,"[-0.058,0.126]",0.466,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0007027,tacrolimus,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0311,-0.007,0.069,"[-0.007,0.069]",0.107,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0008383,tacrolimus,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0234,-0.064,0.11,"[-0.064,0.11]",0.598,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0008399,tacrolimus,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0228,0.005,0.041,"[0.005,0.041]",0.014,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0004981,tacrolimus,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0213,-0.124,0.166,"[-0.124,0.166]",0.774,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005294,tacrolimus,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0187,-0.084,0.121,"[-0.084,0.121]",0.72,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005302,tacrolimus,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0177,-0.002,0.037,"[-0.002,0.037]",0.074,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005364,tacrolimus,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0157,-0.202,0.233,"[-0.202,0.233]",0.888,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0019350,tacrolimus,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0141,-0.1,0.128,"[-0.1,0.128]",0.809,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0013282,tacrolimus,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0104,-0.049,0.07,"[-0.049,0.07]",0.732,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005306,tacrolimus,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0085,-0.134,0.151,"[-0.134,0.151]",0.907,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0020066,tacrolimus,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0083,-0.082,0.099,"[-0.082,0.099]",0.857,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005002,tacrolimus,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0081,-0.063,0.079,"[-0.063,0.079]",0.824,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0004609,tacrolimus,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0075,-0.089,0.105,"[-0.089,0.105]",0.879,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,tacrolimus,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.005,-0.222,0.232,"[-0.222,0.232]",0.966,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0002277,tacrolimus,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0045,-0.202,0.211,"[-0.202,0.211]",0.966,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0002046,tacrolimus,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0029,-1.054,1.059,"[-1.054,1.059]",0.996,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,tacrolimus,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0021,-1.221,1.225,"[-1.221,1.225]",0.997,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0005300,tacrolimus,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0014,-0.273,0.275,"[-0.273,0.275]",0.992,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,tacrolimus,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0011,-1.266,1.269,"[-1.266,1.269]",0.999,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0003620,tacrolimus,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,0.0011,-0.334,0.336,"[-0.334,0.336]",0.995,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242348,biolink:associated_with_increased_likelihood_of,MONDO:0002406,tacrolimus,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.881500044,5.00E-04,-0.253,0.254,"[-0.253,0.254]",0.997,229200,21665900,21895100,"Sample size with tacrolimus, approximately: 229200","Sample size without tacrolimus, approximately: 21665900",All patients number is approximately: 21895100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0002869,sulfasalazine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,1.1844,1.136,1.233,"[1.136,1.233]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005010,sulfasalazine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.5141,0.485,0.543,"[0.485,0.543]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005178,sulfasalazine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.448,0.415,0.481,"[0.415,0.481]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005147,sulfasalazine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.4013,0.373,0.429,"[0.373,0.429]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005546,sulfasalazine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.2701,0.242,0.298,"[0.242,0.298]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0007027,sulfasalazine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.2604,0.22,0.301,"[0.22,0.301]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0007739,sulfasalazine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.2044,0.163,0.246,"[0.163,0.246]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sulfasalazine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.2003,0.145,0.256,"[0.145,0.256]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,sulfasalazine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.1593,0.136,0.183,"[0.136,0.183]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005149,sulfasalazine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.1451,-0.038,0.328,"[-0.038,0.328]",0.119,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005133,sulfasalazine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.11,0.068,0.152,"[0.068,0.152]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0004609,sulfasalazine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.1065,0.062,0.151,"[0.062,0.151]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0008399,sulfasalazine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0995,0.05,0.149,"[0.05,0.149]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005009,sulfasalazine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0904,0.056,0.125,"[0.056,0.125]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0009693,sulfasalazine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.086,0.021,0.151,"[0.021,0.151]",0.01,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,sulfasalazine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.085,0.035,0.135,"[0.035,0.135]",0.001,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005393,sulfasalazine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0847,0.043,0.127,"[0.043,0.127]",1.00E-04,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005364,sulfasalazine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0788,-0.046,0.203,"[-0.046,0.203]",0.214,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0004425,sulfasalazine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0626,0.015,0.111,"[0.015,0.111]",0.01,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0004648,sulfasalazine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0604,0.02,0.101,"[0.02,0.101]",0.003,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005294,sulfasalazine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0292,-0.238,0.297,"[-0.238,0.297]",0.831,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0002046,sulfasalazine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0242,-0.01,0.059,"[-0.01,0.059]",0.169,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,sulfasalazine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0212,-0.111,0.153,"[-0.111,0.153]",0.752,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0018882,sulfasalazine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0156,-0.379,0.41,"[-0.379,0.41]",0.938,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005388,sulfasalazine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0119,-0.209,0.233,"[-0.209,0.233]",0.916,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005101,sulfasalazine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0106,-0.066,0.087,"[-0.066,0.087]",0.787,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005404,sulfasalazine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0084,-0.108,0.125,"[-0.108,0.125]",0.887,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005002,sulfasalazine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0056,-0.173,0.184,"[-0.173,0.184]",0.951,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0004981,sulfasalazine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0034,-0.183,0.19,"[-0.183,0.19]",0.971,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0011786,sulfasalazine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.0011,-0.954,0.956,"[-0.954,0.956]",0.998,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0011508,sulfasalazine,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,0.001,-0.357,0.359,"[-0.357,0.359]",0.996,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0004979,sulfasalazine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,8.00E-04,-1.123,1.124,"[-1.123,1.124]",0.999,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5339,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sulfasalazine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898956882,7.00E-04,-0.832,0.833,"[-0.832,0.833]",0.999,95400,21740200,21835600,"Sample size with sulfasalazine, approximately: 95400","Sample size without sulfasalazine, approximately: 21740200",All patients number is approximately: 21835600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008542,spironolactone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,1.654,1.644,1.663,"[1.644,1.663]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008644,spironolactone,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.576,0.57,0.582,"[0.57,0.582]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0002277,spironolactone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.5447,0.53,0.559,"[0.53,0.559]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005083,spironolactone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.3963,0.382,0.411,"[0.382,0.411]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008300,spironolactone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.3676,0.36,0.376,"[0.36,0.376]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0015263,spironolactone,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.318,0.311,0.325,"[0.311,0.325]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0018975,spironolactone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.2921,0.275,0.31,"[0.275,0.31]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0001516,spironolactone,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.2347,0.228,0.242,"[0.228,0.242]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,spironolactone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.2214,0.214,0.228,"[0.214,0.228]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0000424,spironolactone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1976,0.192,0.204,"[0.192,0.204]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007843,spironolactone,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1952,0.188,0.202,"[0.188,0.202]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005130,spironolactone,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1851,0.172,0.198,"[0.172,0.198]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005392,spironolactone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.146,0.13,0.162,"[0.13,0.162]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0019565,spironolactone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.138,0.112,0.164,"[0.112,0.164]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0000477,spironolactone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1231,0.112,0.135,"[0.112,0.135]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008399,spironolactone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1171,0.11,0.125,"[0.11,0.125]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0006694,spironolactone,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.1076,0.101,0.114,"[0.101,0.114]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007915,spironolactone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0799,0.07,0.09,"[0.07,0.09]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0043693,spironolactone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0634,0.036,0.091,"[0.036,0.091]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0018177,spironolactone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0524,0.045,0.059,"[0.045,0.059]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0010602,spironolactone,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0521,0.032,0.073,"[0.032,0.073]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0011508,spironolactone,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0509,0.045,0.057,"[0.045,0.057]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007827,spironolactone,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0425,-0.044,0.129,"[-0.044,0.129]",0.336,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007186,spironolactone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0295,-0.03,0.089,"[-0.03,0.089]",0.333,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0018882,spironolactone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0261,-0.031,0.083,"[-0.031,0.083]",0.367,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005298,spironolactone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0231,-0.069,0.115,"[-0.069,0.115]",0.623,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008383,spironolactone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0212,0.015,0.027,"[0.015,0.027]",1.00E-04,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0011849,spironolactone,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0209,0.006,0.035,"[0.006,0.035]",0.005,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0004979,spironolactone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0194,-0.105,0.143,"[-0.105,0.143]",0.759,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0004975,spironolactone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0175,-0.007,0.042,"[-0.007,0.042]",0.162,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005300,spironolactone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0144,-0.033,0.061,"[-0.033,0.061]",0.549,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0002046,spironolactone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0136,-0.136,0.163,"[-0.136,0.163]",0.858,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005011,spironolactone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0085,-0.126,0.143,"[-0.126,0.143]",0.901,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005010,spironolactone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0082,-0.01,0.027,"[-0.01,0.027]",0.383,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0008487,spironolactone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0068,-0.132,0.145,"[-0.132,0.145]",0.924,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0002406,spironolactone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0056,-0.047,0.059,"[-0.047,0.059]",0.835,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007739,spironolactone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0053,-0.115,0.126,"[-0.115,0.126]",0.932,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005301,spironolactone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0032,-0.176,0.183,"[-0.176,0.183]",0.972,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,spironolactone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0032,-0.283,0.289,"[-0.283,0.289]",0.983,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0000153,spironolactone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0031,-0.083,0.089,"[-0.083,0.089]",0.944,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0011786,spironolactone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0028,-0.291,0.297,"[-0.291,0.297]",0.985,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0004952,spironolactone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0025,-0.194,0.198,"[-0.194,0.198]",0.98,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007540,spironolactone,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0017,-0.17,0.173,"[-0.17,0.173]",0.985,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0007947,spironolactone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0015,-0.094,0.097,"[-0.094,0.097]",0.975,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0009476,spironolactone,congenital atresia of small intestine,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,0.0013,-0.357,0.359,"[-0.357,0.359]",0.994,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0002316,spironolactone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,6.00E-04,-0.547,0.548,"[-0.547,0.548]",0.998,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5833,biolink:associated_with_increased_likelihood_of,MONDO:0005404,spironolactone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.925231151,5.00E-04,-0.67,0.671,"[-0.67,0.671]",0.999,2445000,20773000,23218000,"Sample size with spironolactone, approximately: 2445000","Sample size without spironolactone, approximately: 20773000",All patients number is approximately: 23218000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005130,sotalol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,1.8233,1.807,1.839,"[1.807,1.839]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0006694,sotalol,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.4854,0.47,0.501,"[0.47,0.501]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005393,sotalol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.4448,0.427,0.463,"[0.427,0.463]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005010,sotalol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.4102,0.393,0.428,"[0.393,0.428]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005009,sotalol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.2504,0.232,0.268,"[0.232,0.268]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sotalol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.24,0.224,0.256,"[0.224,0.256]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0004981,sotalol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.2344,0.194,0.274,"[0.194,0.274]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005180,sotalol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.2056,0.175,0.236,"[0.175,0.236]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005148,sotalol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.2022,0.186,0.219,"[0.186,0.219]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0004609,sotalol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.1799,0.16,0.199,"[0.16,0.199]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005101,sotalol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.1219,0.103,0.141,"[0.103,0.141]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005146,sotalol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.1173,0.027,0.208,"[0.027,0.208]",0.011,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,sotalol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0979,0.066,0.13,"[0.066,0.13]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0018177,sotalol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0865,0.036,0.137,"[0.036,0.137]",0.001,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0018882,sotalol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0751,0.04,0.11,"[0.04,0.11]",1.00E-04,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0007915,sotalol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0683,0.022,0.115,"[0.022,0.115]",0.004,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0008383,sotalol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0439,-0.036,0.124,"[-0.036,0.124]",0.283,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0007947,sotalol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.033,-0.009,0.075,"[-0.009,0.075]",0.12,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0011849,sotalol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0308,-0.067,0.129,"[-0.067,0.129]",0.538,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005011,sotalol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.022,-0.011,0.055,"[-0.011,0.055]",0.193,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0020066,sotalol,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0092,-0.112,0.131,"[-0.112,0.131]",0.883,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0003620,sotalol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0076,-0.104,0.119,"[-0.104,0.119]",0.894,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0016218,sotalol,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0029,-0.247,0.253,"[-0.247,0.253]",0.982,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0000424,sotalol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0024,-0.021,0.025,"[-0.021,0.025]",0.841,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0004979,sotalol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0018,-0.137,0.141,"[-0.137,0.141]",0.979,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0004425,sotalol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,0.0016,-2.16,2.163,"[-2.16,2.163]",0.999,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0002909,sotalol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,3.00E-04,-0.139,0.139,"[-0.139,0.139]",0.997,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0019180,sotalol,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,3.00E-04,-0.3,0.3,"[-0.3,0.3]",0.998,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5253,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sotalol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927184753,3.00E-04,-0.517,0.518,"[-0.517,0.518]",0.999,164300,21717200,21881500,"Sample size with sotalol, approximately: 164300","Sample size without sotalol, approximately: 21717200",All patients number is approximately: 21881500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0018882,sofosbuvir,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,2.9064,2.774,3.039,"[2.774,3.039]",1.00E-04,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sofosbuvir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,1.1795,1.095,1.264,"[1.095,1.264]",1.00E-04,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0002406,sofosbuvir,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.8245,0.773,0.876,"[0.773,0.876]",1.00E-04,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005147,sofosbuvir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.5455,0.443,0.648,"[0.443,0.648]",1.00E-04,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0011122,sofosbuvir,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1359,0.01,0.262,"[0.01,0.262]",0.034,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0016218,sofosbuvir,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1351,-0.121,0.392,"[-0.121,0.392]",0.302,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005546,sofosbuvir,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1303,-22800,22800,"[-22800,22800]",1,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,sofosbuvir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1303,-22800,22800,"[-22800,22800]",1,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0004648,sofosbuvir,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.129,0.031,0.227,"[0.031,0.227]",0.01,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,sofosbuvir,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1262,-0.075,0.327,"[-0.075,0.327]",0.219,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005146,sofosbuvir,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.1179,-0.045,0.281,"[-0.045,0.281]",0.157,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005148,sofosbuvir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.088,-0.034,0.21,"[-0.034,0.21]",0.156,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sofosbuvir,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0848,-0.274,0.444,"[-0.274,0.444]",0.643,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0002277,sofosbuvir,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0831,-0.159,0.326,"[-0.159,0.326]",0.502,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0003620,sofosbuvir,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0693,-0.131,0.27,"[-0.131,0.27]",0.498,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0005393,sofosbuvir,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0346,-0.065,0.134,"[-0.065,0.134]",0.495,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0011786,sofosbuvir,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0334,-0.574,0.641,"[-0.574,0.641]",0.914,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0002869,sofosbuvir,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0081,-0.196,0.213,"[-0.196,0.213]",0.938,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0004609,sofosbuvir,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0059,-0.791,0.803,"[-0.791,0.803]",0.988,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0009693,sofosbuvir,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.0026,-0.143,0.148,"[-0.143,0.148]",0.972,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0004979,sofosbuvir,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,0.001,-3.626,3.628,"[-3.626,3.628]",1,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45375808,biolink:associated_with_increased_likelihood_of,MONDO:0002046,sofosbuvir,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994316263,2.00E-04,-0.663,0.663,"[-0.663,0.663]",1,22600,21776600,21799200,"Sample size with sofosbuvir, approximately: 22600","Sample size without sofosbuvir, approximately: 21776600",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002909,sitagliptin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,1.5837,1.572,1.596,"[1.572,1.596]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005180,sitagliptin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.3251,0.312,0.338,"[0.312,0.338]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005147,sitagliptin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.3205,0.309,0.332,"[0.309,0.332]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0009693,sitagliptin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.3166,0.303,0.33,"[0.303,0.33]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0003620,sitagliptin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.2623,0.246,0.279,"[0.246,0.279]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0006694,sitagliptin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.191,0.169,0.213,"[0.169,0.213]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,sitagliptin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1664,0.152,0.181,"[0.152,0.181]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0010602,sitagliptin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1553,0.122,0.188,"[0.122,0.188]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0018177,sitagliptin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1529,0.14,0.166,"[0.14,0.166]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005178,sitagliptin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1227,0.106,0.139,"[0.106,0.139]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005133,sitagliptin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1196,0.102,0.137,"[0.102,0.137]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005002,sitagliptin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.117,0.087,0.147,"[0.087,0.147]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005148,sitagliptin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1137,0.102,0.126,"[0.102,0.126]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002316,sitagliptin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1134,0.071,0.156,"[0.071,0.156]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0007915,sitagliptin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1096,0.091,0.128,"[0.091,0.128]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0007947,sitagliptin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.1034,0.093,0.114,"[0.093,0.114]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0019565,sitagliptin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0794,0.041,0.117,"[0.041,0.117]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0004981,sitagliptin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0554,0.027,0.084,"[0.027,0.084]",1.00E-04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0000424,sitagliptin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0452,-0.017,0.108,"[-0.017,0.108]",0.157,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sitagliptin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0449,0.002,0.088,"[0.002,0.088]",0.04,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005306,sitagliptin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0433,0.017,0.069,"[0.017,0.069]",0.001,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0004609,sitagliptin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0366,0.002,0.071,"[0.002,0.071]",0.039,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002406,sitagliptin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0182,-0.038,0.074,"[-0.038,0.074]",0.525,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0019180,sitagliptin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0143,-0.04,0.069,"[-0.04,0.069]",0.607,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002046,sitagliptin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0136,-0.019,0.047,"[-0.019,0.047]",0.416,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005101,sitagliptin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0134,-0.005,0.032,"[-0.005,0.032]",0.156,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sitagliptin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0103,-0.055,0.076,"[-0.055,0.076]",0.757,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005404,sitagliptin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0102,-0.169,0.19,"[-0.169,0.19]",0.911,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002869,sitagliptin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0102,-0.068,0.088,"[-0.068,0.088]",0.798,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0008006,sitagliptin,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0094,-0.154,0.173,"[-0.154,0.173]",0.91,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0002277,sitagliptin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0062,-0.303,0.315,"[-0.303,0.315]",0.969,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005300,sitagliptin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0061,-0.173,0.185,"[-0.173,0.185]",0.947,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0004952,sitagliptin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0038,-0.151,0.159,"[-0.151,0.159]",0.961,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005294,sitagliptin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0037,-0.249,0.256,"[-0.249,0.256]",0.977,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,sitagliptin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0037,-0.157,0.164,"[-0.157,0.164]",0.964,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005392,sitagliptin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0029,-0.076,0.082,"[-0.076,0.082]",0.944,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0004648,sitagliptin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0027,-0.11,0.115,"[-0.11,0.115]",0.962,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0008542,sitagliptin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0027,-0.065,0.071,"[-0.065,0.071]",0.938,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0004425,sitagliptin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0019,-0.238,0.242,"[-0.238,0.242]",0.988,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0021107,sitagliptin,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0016,-0.154,0.158,"[-0.154,0.158]",0.984,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0008300,sitagliptin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0015,-0.137,0.14,"[-0.137,0.14]",0.983,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0007186,sitagliptin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.0015,-0.398,0.401,"[-0.398,0.401]",0.994,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005009,sitagliptin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,0.001,-0.29,0.292,"[-0.29,0.292]",0.995,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257085,biolink:associated_with_increased_likelihood_of,MONDO:0005010,sitagliptin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687708,5.00E-04,-0.145,0.146,"[-0.145,0.146]",0.995,587000,21498000,22085000,"Sample size with sitagliptin, approximately: 587000","Sample size without sitagliptin, approximately: 21498000",All patients number is approximately: 22085000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005133,simvastatin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.6188,0.613,0.625,"[0.613,0.625]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0000914,simvastatin,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.4599,0.453,0.467,"[0.453,0.467]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0007947,simvastatin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.3062,0.291,0.321,"[0.291,0.321]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0018882,simvastatin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2773,0.261,0.293,"[0.261,0.293]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005711,simvastatin,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2565,0.246,0.267,"[0.246,0.267]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0004425,simvastatin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2522,0.239,0.265,"[0.239,0.265]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,simvastatin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2456,0.238,0.253,"[0.238,0.253]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0019499,simvastatin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2365,0.222,0.251,"[0.222,0.251]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0015263,simvastatin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.2356,0.229,0.242,"[0.229,0.242]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005010,simvastatin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.1857,0.178,0.193,"[0.178,0.193]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0004609,simvastatin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.1185,0.101,0.136,"[0.101,0.136]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0004979,simvastatin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.1012,0.072,0.13,"[0.072,0.13]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0018177,simvastatin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0987,0.091,0.107,"[0.091,0.107]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0002406,simvastatin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0779,0.062,0.094,"[0.062,0.094]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0019118,simvastatin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0669,0.034,0.1,"[0.034,0.1]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005180,simvastatin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0611,0.03,0.092,"[0.03,0.092]",1.00E-04,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0021187,simvastatin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0584,0.02,0.097,"[0.02,0.097]",0.003,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005546,simvastatin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0425,0.008,0.077,"[0.008,0.077]",0.015,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0011786,simvastatin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0382,0.013,0.063,"[0.013,0.063]",0.003,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0019565,simvastatin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0364,-0.007,0.08,"[-0.007,0.08]",0.099,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0002277,simvastatin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0338,0.002,0.065,"[0.002,0.065]",0.036,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0004648,simvastatin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0175,-0.043,0.078,"[-0.043,0.078]",0.573,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005298,simvastatin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0127,-0.048,0.073,"[-0.048,0.073]",0.682,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0011429,simvastatin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0116,-0.049,0.072,"[-0.049,0.072]",0.707,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005009,simvastatin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0111,-0.089,0.111,"[-0.089,0.111]",0.827,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,simvastatin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0104,-0.095,0.116,"[-0.095,0.116]",0.847,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0009693,simvastatin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0102,-0.004,0.024,"[-0.004,0.024]",0.146,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005404,simvastatin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.01,-0.043,0.063,"[-0.043,0.063]",0.711,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0019180,simvastatin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0088,-0.085,0.103,"[-0.085,0.103]",0.855,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005147,simvastatin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0058,-0.003,0.015,"[-0.003,0.015]",0.196,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005300,simvastatin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0052,-0.104,0.115,"[-0.104,0.115]",0.926,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0019369,simvastatin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0046,-0.145,0.154,"[-0.145,0.154]",0.952,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0010526,simvastatin,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0041,-0.093,0.101,"[-0.093,0.101]",0.934,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0002316,simvastatin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0031,-0.166,0.173,"[-0.166,0.173]",0.971,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,simvastatin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0028,-0.128,0.133,"[-0.128,0.133]",0.967,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005101,simvastatin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0024,-0.431,0.436,"[-0.431,0.436]",0.991,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0000477,simvastatin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0022,-0.061,0.065,"[-0.061,0.065]",0.946,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0011508,simvastatin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0022,-0.341,0.346,"[-0.341,0.346]",0.99,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005364,simvastatin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0019,-0.079,0.083,"[-0.079,0.083]",0.963,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005302,simvastatin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0017,-0.075,0.078,"[-0.075,0.078]",0.965,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0005146,simvastatin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,0.0014,-0.141,0.144,"[-0.141,0.144]",0.985,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0002909,simvastatin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,9.00E-04,-0.513,0.515,"[-0.513,0.515]",0.997,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,simvastatin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,8.00E-04,-0.501,0.502,"[-0.501,0.502]",0.997,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54454,biolink:associated_with_increased_likelihood_of,MONDO:0021107,simvastatin,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892260152,2.04E-05,-0.492,0.492,"[-0.492,0.492]",1,1791600,20613100,22404700,"Sample size with simvastatin, approximately: 1791600","Sample size without simvastatin, approximately: 20613100",All patients number is approximately: 22404700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0011786,sertraline,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.5752,0.56,0.591,"[0.56,0.591]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0019499,sertraline,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.3796,0.372,0.387,"[0.372,0.387]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005146,sertraline,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.371,0.362,0.38,"[0.362,0.38]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0004952,sertraline,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.3041,0.299,0.309,"[0.299,0.309]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0019565,sertraline,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.2881,0.28,0.296,"[0.28,0.296]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0008644,sertraline,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.2365,0.23,0.243,"[0.23,0.243]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005711,sertraline,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.2071,0.18,0.234,"[0.18,0.234]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0007473,sertraline,duane syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1838,0.177,0.191,"[0.177,0.191]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0019180,sertraline,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1707,0.159,0.182,"[0.159,0.182]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0006694,sertraline,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1415,0.135,0.148,"[0.135,0.148]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005083,sertraline,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1392,0.117,0.162,"[0.117,0.162]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0009891,sertraline,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1223,0.114,0.131,"[0.114,0.131]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0002869,sertraline,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1209,0.096,0.146,"[0.096,0.146]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005133,sertraline,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1195,0.112,0.127,"[0.112,0.127]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0018882,sertraline,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1161,0.088,0.144,"[0.088,0.144]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0002316,sertraline,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.1144,0.088,0.141,"[0.088,0.141]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0009061,sertraline,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0901,0.076,0.104,"[0.076,0.104]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0001516,sertraline,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0889,0.082,0.096,"[0.082,0.096]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0009693,sertraline,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0886,0.067,0.11,"[0.067,0.11]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005101,sertraline,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0615,0.024,0.099,"[0.024,0.099]",0.001,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0021187,sertraline,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0501,0.035,0.065,"[0.035,0.065]",1.00E-04,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,sertraline,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0476,0.018,0.077,"[0.018,0.077]",0.001,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0010526,sertraline,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0442,-0.044,0.133,"[-0.044,0.133]",0.328,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0008642,sertraline,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0396,0.012,0.067,"[0.012,0.067]",0.004,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sertraline,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0384,-0.01,0.087,"[-0.01,0.087]",0.123,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0007947,sertraline,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0318,-0.043,0.106,"[-0.043,0.106]",0.402,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005546,sertraline,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0211,-0.025,0.067,"[-0.025,0.067]",0.366,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,sertraline,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0185,-0.01,0.047,"[-0.01,0.047]",0.202,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0000477,sertraline,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0177,-0.034,0.069,"[-0.034,0.069]",0.504,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005148,sertraline,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0169,-0.032,0.065,"[-0.032,0.065]",0.495,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0011849,sertraline,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0162,0.006,0.027,"[0.006,0.027]",0.003,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005364,sertraline,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.007,-0.091,0.105,"[-0.091,0.105]",0.888,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0011122,sertraline,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0049,-0.007,0.017,"[-0.007,0.017]",0.424,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0004975,sertraline,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0039,-0.12,0.127,"[-0.12,0.127]",0.951,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005011,sertraline,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0031,-0.067,0.073,"[-0.067,0.073]",0.93,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0016218,sertraline,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0028,-0.097,0.102,"[-0.097,0.102]",0.957,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0004609,sertraline,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0025,-0.489,0.494,"[-0.489,0.494]",0.992,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0002046,sertraline,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0024,-0.15,0.155,"[-0.15,0.155]",0.976,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0800026,sertraline,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0024,-0.236,0.24,"[-0.236,0.24]",0.984,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0004425,sertraline,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0024,-1.26,1.265,"[-1.26,1.265]",0.997,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,sertraline,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0016,-0.282,0.286,"[-0.282,0.286]",0.991,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0007186,sertraline,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.0014,-0.236,0.239,"[-0.236,0.239]",0.991,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005010,sertraline,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,0.001,-0.075,0.077,"[-0.075,0.077]",0.979,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005392,sertraline,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,8.00E-04,-0.146,0.148,"[-0.146,0.148]",0.992,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005002,sertraline,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,8.00E-04,-0.105,0.107,"[-0.105,0.107]",0.989,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0004648,sertraline,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,6.00E-04,-0.193,0.194,"[-0.193,0.194]",0.995,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0008542,sertraline,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,6.00E-04,-0.167,0.168,"[-0.167,0.168]",0.995,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0015564,sertraline,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,4.00E-04,-0.542,0.543,"[-0.542,0.543]",0.999,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005149,sertraline,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,4.00E-04,-0.613,0.614,"[-0.613,0.614]",0.999,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:68617,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sertraline,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.819780766,1.00E-04,-0.36,0.36,"[-0.36,0.36]",0.999,2128100,20599800,22727900,"Sample size with sertraline, approximately: 2128100","Sample size without sertraline, approximately: 20599800",All patients number is approximately: 22727900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0015924,semaglutide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,1.315,1.305,1.325,"[1.305,1.325]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005546,semaglutide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,1.0344,1.024,1.045,"[1.024,1.045]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0004609,semaglutide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.476,0.464,0.488,"[0.464,0.488]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0008599,semaglutide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.3039,0.287,0.321,"[0.287,0.321]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0002909,semaglutide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.2332,0.217,0.25,"[0.217,0.25]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,semaglutide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1971,0.16,0.234,"[0.16,0.234]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0018177,semaglutide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1961,0.171,0.221,"[0.171,0.221]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005302,semaglutide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1724,0.142,0.202,"[0.142,0.202]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0043693,semaglutide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1662,0.147,0.186,"[0.147,0.186]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005393,semaglutide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1555,0.137,0.174,"[0.137,0.174]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,semaglutide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1419,0.13,0.154,"[0.13,0.154]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0002406,semaglutide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1403,0.113,0.168,"[0.113,0.168]",1.00E-04,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005002,semaglutide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.1108,0.026,0.195,"[0.026,0.195]",0.01,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0004425,semaglutide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0789,0.008,0.149,"[0.008,0.149]",0.028,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0019180,semaglutide,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0741,0.024,0.124,"[0.024,0.124]",0.004,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005404,semaglutide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0628,-0.03,0.155,"[-0.03,0.155]",0.184,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0003620,semaglutide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0538,0.021,0.086,"[0.021,0.086]",0.001,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005298,semaglutide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0461,-0.127,0.219,"[-0.127,0.219]",0.603,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0021187,semaglutide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0417,-0.083,0.166,"[-0.083,0.166]",0.511,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005147,semaglutide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0388,0.001,0.077,"[0.001,0.077]",0.045,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005306,semaglutide,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0369,-0.014,0.088,"[-0.014,0.088]",0.156,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,semaglutide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0338,-0.012,0.079,"[-0.012,0.079]",0.146,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005388,semaglutide,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0195,-0.071,0.11,"[-0.071,0.11]",0.671,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005149,semaglutide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0177,-0.074,0.11,"[-0.074,0.11]",0.707,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0011849,semaglutide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0146,-0.104,0.133,"[-0.104,0.133]",0.81,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005146,semaglutide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0133,-0.188,0.214,"[-0.188,0.214]",0.897,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0004981,semaglutide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0125,-0.125,0.15,"[-0.125,0.15]",0.858,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005300,semaglutide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0113,-0.166,0.188,"[-0.166,0.188]",0.9,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0008487,semaglutide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0086,-0.135,0.153,"[-0.135,0.153]",0.907,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0007827,semaglutide,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0057,-0.329,0.341,"[-0.329,0.341]",0.973,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005392,semaglutide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0048,-0.026,0.035,"[-0.026,0.035]",0.758,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0004975,semaglutide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0035,-0.21,0.217,"[-0.21,0.217]",0.974,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005364,semaglutide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0033,-0.095,0.102,"[-0.095,0.102]",0.948,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0005133,semaglutide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0032,-0.16,0.166,"[-0.16,0.166]",0.969,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0016218,semaglutide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0027,-0.141,0.146,"[-0.141,0.146]",0.971,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0000477,semaglutide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0024,-0.051,0.055,"[-0.051,0.055]",0.93,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0007186,semaglutide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.0015,-82.475,82.478,"[-82.475,82.478]",1,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0002316,semaglutide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,0.001,-0.924,0.926,"[-0.924,0.926]",0.998,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0258219,biolink:associated_with_increased_likelihood_of,MONDO:0008300,semaglutide,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893665693,6.00E-04,-0.547,0.549,"[-0.547,0.549]",0.998,471800,21518200,21990000,"Sample size with semaglutide, approximately: 471800","Sample size without semaglutide, approximately: 21518200",All patients number is approximately: 21990000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0005180,secukinumab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.1231,-0.156,0.403,"[-0.156,0.403]",0.388,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0005300,secukinumab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.1026,-0.296,0.501,"[-0.296,0.501]",0.613,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0011786,secukinumab,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0326,-0.239,0.305,"[-0.239,0.305]",0.814,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0008487,secukinumab,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0132,-1.379,1.405,"[-1.379,1.405]",0.985,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0005302,secukinumab,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0127,-0.722,0.747,"[-0.722,0.747]",0.973,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0005101,secukinumab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0055,-0.579,0.59,"[-0.579,0.59]",0.985,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0007915,secukinumab,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0045,-0.518,0.527,"[-0.518,0.527]",0.986,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743068,biolink:associated_with_increased_likelihood_of,MONDO:0002046,secukinumab,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883622461,0.0016,-0.423,0.426,"[-0.423,0.426]",0.994,22000,21779200,21801200,"Sample size with secukinumab, approximately: 22000","Sample size without secukinumab, approximately: 21779200",All patients number is approximately: 21801200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005300,saxagliptin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,1.0845,1.05,1.119,"[1.05,1.119]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005010,saxagliptin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.8728,0.83,0.915,"[0.83,0.915]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0008487,saxagliptin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.5219,0.477,0.567,"[0.477,0.567]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0002277,saxagliptin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.4414,0.39,0.493,"[0.39,0.493]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0008599,saxagliptin,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.2533,0.187,0.32,"[0.187,0.32]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0011122,saxagliptin,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.1471,0.085,0.209,"[0.085,0.209]",1.00E-04,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005178,saxagliptin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.1145,0.018,0.211,"[0.018,0.211]",0.02,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005298,saxagliptin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0853,-0.06,0.231,"[-0.06,0.231]",0.25,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0002406,saxagliptin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0587,0.017,0.1,"[0.017,0.1]",0.006,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005294,saxagliptin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0365,-0.41,0.483,"[-0.41,0.483]",0.873,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,saxagliptin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0244,-0.199,0.248,"[-0.199,0.248]",0.83,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005101,saxagliptin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0074,-0.435,0.45,"[-0.435,0.45]",0.974,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0004981,saxagliptin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0051,-0.605,0.615,"[-0.605,0.615]",0.987,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0000424,saxagliptin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0031,-0.095,0.101,"[-0.095,0.101]",0.951,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0005146,saxagliptin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,0.0015,-0.577,0.581,"[-0.577,0.581]",0.996,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11235729,biolink:associated_with_increased_likelihood_of,MONDO:0008383,saxagliptin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951251472,6.00E-04,-0.241,0.242,"[-0.241,0.242]",0.996,28200,21775900,21804100,"Sample size with saxagliptin, approximately: 28200","Sample size without saxagliptin, approximately: 21775900",All patients number is approximately: 21804100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108730,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,sarilumab,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979754686,0.4542,0.048,0.861,"[0.048,0.861]",0.029,3700,21790400,21794100,"Sample size with sarilumab, approximately: 3700","Sample size without sarilumab, approximately: 21790400",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108730,biolink:associated_with_increased_likelihood_of,MONDO:0004979,sarilumab,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979754686,0.2424,0.082,0.403,"[0.082,0.403]",0.003,3700,21790400,21794100,"Sample size with sarilumab, approximately: 3700","Sample size without sarilumab, approximately: 21790400",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108730,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sarilumab,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979754686,0.1115,-0.107,0.33,"[-0.107,0.33]",0.318,3700,21790400,21794100,"Sample size with sarilumab, approximately: 3700","Sample size without sarilumab, approximately: 21790400",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108730,biolink:associated_with_increased_likelihood_of,MONDO:0005300,sarilumab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979754686,0.0546,-0.071,0.18,"[-0.071,0.18]",0.393,3700,21790400,21794100,"Sample size with sarilumab, approximately: 3700","Sample size without sarilumab, approximately: 21790400",All patients number is approximately: 21794100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0000153,salmeterol,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.2961,0.285,0.307,"[0.285,0.307]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0010602,salmeterol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.2472,0.234,0.26,"[0.234,0.26]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005392,salmeterol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.2121,0.202,0.222,"[0.202,0.222]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0009061,salmeterol,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.1408,0.122,0.159,"[0.122,0.159]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005404,salmeterol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.1325,0.115,0.15,"[0.115,0.15]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005011,salmeterol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.1136,0.089,0.138,"[0.089,0.138]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0004979,salmeterol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.1014,0.062,0.141,"[0.062,0.141]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0004609,salmeterol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.09,0.064,0.116,"[0.064,0.116]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0008599,salmeterol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0753,0.064,0.087,"[0.064,0.087]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0019180,salmeterol,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.061,0.024,0.098,"[0.024,0.098]",0.001,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0013282,salmeterol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0607,0.023,0.098,"[0.023,0.098]",0.001,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0000424,salmeterol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0518,0.017,0.087,"[0.017,0.087]",0.004,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005178,salmeterol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0433,0.03,0.056,"[0.03,0.056]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0002316,salmeterol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0425,0.012,0.073,"[0.012,0.073]",0.007,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005302,salmeterol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0391,0.008,0.07,"[0.008,0.07]",0.015,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0004981,salmeterol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0355,0.02,0.051,"[0.02,0.051]",1.00E-04,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0007915,salmeterol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0336,0,0.067,"[0,0.067]",0.049,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0007947,salmeterol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0295,-0.029,0.088,"[-0.029,0.088]",0.32,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0800026,salmeterol,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0236,-0.01,0.057,"[-0.01,0.057]",0.173,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,salmeterol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0221,-0.075,0.119,"[-0.075,0.119]",0.656,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0011849,salmeterol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0173,-0.054,0.089,"[-0.054,0.089]",0.635,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0008377,salmeterol,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0125,-0.002,0.027,"[-0.002,0.027]",0.085,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0018975,salmeterol,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0096,-0.01,0.029,"[-0.01,0.029]",0.335,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0018882,salmeterol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.007,-0.082,0.096,"[-0.082,0.096]",0.879,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0007864,salmeterol,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0055,-0.122,0.134,"[-0.122,0.134]",0.933,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0021107,salmeterol,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.004,-0.084,0.092,"[-0.084,0.092]",0.93,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0002277,salmeterol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0037,-0.166,0.174,"[-0.166,0.174]",0.966,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0019350,salmeterol,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0033,-0.59,0.596,"[-0.59,0.596]",0.991,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005101,salmeterol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0022,-0.15,0.155,"[-0.15,0.155]",0.977,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005298,salmeterol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0019,-0.395,0.399,"[-0.395,0.399]",0.992,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0019118,salmeterol,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0013,-0.35,0.352,"[-0.35,0.352]",0.994,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0003620,salmeterol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,0.0011,-0.643,0.645,"[-0.643,0.645]",0.997,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0011429,salmeterol,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,8.00E-04,-0.351,0.352,"[-0.351,0.352]",0.996,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,salmeterol,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,8.00E-04,-0.302,0.303,"[-0.302,0.303]",0.996,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005146,salmeterol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,7.00E-04,-0.599,0.6,"[-0.599,0.6]",0.998,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005546,salmeterol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,6.00E-04,-0.282,0.283,"[-0.282,0.283]",0.997,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0005301,salmeterol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,5.00E-04,-0.756,0.757,"[-0.756,0.757]",0.999,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0011786,salmeterol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,5.00E-04,-0.737,0.738,"[-0.737,0.738]",0.999,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0015924,salmeterol,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,2.00E-04,-0.66,0.66,"[-0.66,0.66]",0.999,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5152,biolink:associated_with_increased_likelihood_of,MONDO:0004975,salmeterol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990622825,1.00E-04,-0.186,0.187,"[-0.186,0.187]",0.999,1302600,21117200,22419800,"Sample size with salmeterol, approximately: 1302600","Sample size without salmeterol, approximately: 21117200",All patients number is approximately: 22419800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0004425,sacubitril,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,14.3482,14.295,14.401,"[14.295,14.401]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0000424,sacubitril,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,1.579,1.549,1.609,"[1.549,1.609]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0007947,sacubitril,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.996,0.969,1.023,"[0.969,1.023]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005101,sacubitril,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.8867,0.849,0.924,"[0.849,0.924]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0008377,sacubitril,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.6283,0.6,0.656,"[0.6,0.656]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005302,sacubitril,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.4795,0.452,0.507,"[0.452,0.507]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0011786,sacubitril,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.3677,0.331,0.404,"[0.331,0.404]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0003620,sacubitril,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.3517,0.301,0.402,"[0.301,0.402]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0009693,sacubitril,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.3496,0.315,0.384,"[0.315,0.384]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005011,sacubitril,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.312,0.255,0.369,"[0.255,0.369]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0007186,sacubitril,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.3102,0.25,0.37,"[0.25,0.37]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005002,sacubitril,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.1608,0.092,0.23,"[0.092,0.23]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0043693,sacubitril,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0711,0.04,0.102,"[0.04,0.102]",1.00E-04,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005178,sacubitril,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0607,0.008,0.114,"[0.008,0.114]",0.024,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005298,sacubitril,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0425,-0.134,0.219,"[-0.134,0.219]",0.637,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0006694,sacubitril,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0284,-0.013,0.069,"[-0.013,0.069]",0.174,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0004952,sacubitril,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0066,-0.111,0.124,"[-0.111,0.124]",0.912,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0002277,sacubitril,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0041,-1.146,1.154,"[-1.146,1.154]",0.994,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0008678,sacubitril,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0035,-1.168,1.175,"[-1.168,1.175]",0.995,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005392,sacubitril,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0025,-0.8,0.805,"[-0.8,0.805]",0.995,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257439,biolink:associated_with_increased_likelihood_of,MONDO:0005301,sacubitril,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999496366,0.0017,-1.713,1.717,"[-1.713,1.717]",0.998,519500,21598000,22117500,"Sample size with sacubitril, approximately: 519500","Sample size without sacubitril, approximately: 21598000",All patients number is approximately: 22117500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,rosuvastatin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.7853,0.779,0.792,"[0.779,0.792]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005002,rosuvastatin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.6558,0.648,0.664,"[0.648,0.664]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0002316,rosuvastatin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.5284,0.514,0.543,"[0.514,0.543]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005147,rosuvastatin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.4954,0.488,0.503,"[0.488,0.503]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005364,rosuvastatin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.4891,0.483,0.495,"[0.483,0.495]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004609,rosuvastatin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.4539,0.439,0.468,"[0.439,0.468]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0021187,rosuvastatin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.4082,0.396,0.42,"[0.396,0.42]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0000424,rosuvastatin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.3145,0.306,0.323,"[0.306,0.323]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0007540,rosuvastatin,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.2865,0.279,0.294,"[0.279,0.294]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005302,rosuvastatin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.278,0.264,0.292,"[0.264,0.292]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0008377,rosuvastatin,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.2688,0.259,0.279,"[0.259,0.279]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005101,rosuvastatin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.2331,0.221,0.245,"[0.221,0.245]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004979,rosuvastatin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.1724,0.142,0.203,"[0.142,0.203]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0020066,rosuvastatin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.1658,0.155,0.176,"[0.155,0.176]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005546,rosuvastatin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.153,0.124,0.182,"[0.124,0.182]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004425,rosuvastatin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.1182,0.104,0.132,"[0.104,0.132]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0015263,rosuvastatin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0912,0.083,0.099,"[0.083,0.099]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0002277,rosuvastatin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0727,0.044,0.101,"[0.044,0.101]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0019180,rosuvastatin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0544,0.004,0.105,"[0.004,0.105]",0.035,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,rosuvastatin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0509,0.043,0.059,"[0.043,0.059]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005133,rosuvastatin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0435,0.019,0.068,"[0.019,0.068]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0003620,rosuvastatin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.042,0.023,0.06,"[0.023,0.06]",1.00E-04,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0011429,rosuvastatin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0417,-0.01,0.093,"[-0.01,0.093]",0.11,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0011508,rosuvastatin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0382,-0.019,0.096,"[-0.019,0.096]",0.193,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,rosuvastatin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0366,-0.015,0.088,"[-0.015,0.088]",0.165,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0019565,rosuvastatin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0354,-0.012,0.083,"[-0.012,0.083]",0.146,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005146,rosuvastatin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0252,-0.073,0.123,"[-0.073,0.123]",0.614,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0021107,rosuvastatin,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0235,-0.021,0.068,"[-0.021,0.068]",0.297,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004975,rosuvastatin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0204,-0.089,0.13,"[-0.089,0.13]",0.714,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0007739,rosuvastatin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.015,-0.058,0.088,"[-0.058,0.088]",0.688,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0008300,rosuvastatin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0127,-0.049,0.075,"[-0.049,0.075]",0.686,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004981,rosuvastatin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0122,-0.064,0.088,"[-0.064,0.088]",0.753,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0000153,rosuvastatin,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0104,-0.074,0.095,"[-0.074,0.095]",0.81,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0008487,rosuvastatin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0094,-0.013,0.032,"[-0.013,0.032]",0.404,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0018882,rosuvastatin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0078,-0.096,0.111,"[-0.096,0.111]",0.883,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004648,rosuvastatin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0075,-0.08,0.095,"[-0.08,0.095]",0.867,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0002406,rosuvastatin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0067,-0.139,0.153,"[-0.139,0.153]",0.928,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0004952,rosuvastatin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0051,-0.141,0.151,"[-0.141,0.151]",0.945,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0002909,rosuvastatin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0046,-0.259,0.269,"[-0.259,0.269]",0.972,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005149,rosuvastatin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0041,-0.108,0.116,"[-0.108,0.116]",0.943,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005392,rosuvastatin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0031,-0.334,0.34,"[-0.334,0.34]",0.986,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005298,rosuvastatin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.003,-0.065,0.071,"[-0.065,0.071]",0.931,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0019350,rosuvastatin,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0027,-0.124,0.13,"[-0.124,0.13]",0.966,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0800026,rosuvastatin,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0024,-0.278,0.283,"[-0.278,0.283]",0.987,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0019118,rosuvastatin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0022,-0.148,0.152,"[-0.148,0.152]",0.977,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005300,rosuvastatin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0021,-0.116,0.12,"[-0.116,0.12]",0.972,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,rosuvastatin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0017,-0.322,0.326,"[-0.322,0.326]",0.992,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0002046,rosuvastatin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0015,-0.169,0.172,"[-0.169,0.172]",0.986,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005404,rosuvastatin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.0013,-0.249,0.251,"[-0.249,0.251]",0.992,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005083,rosuvastatin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,0.001,-0.216,0.218,"[-0.216,0.218]",0.993,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0043693,rosuvastatin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,8.00E-04,-0.05,0.052,"[-0.05,0.052]",0.976,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0005388,rosuvastatin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,6.00E-04,-0.519,0.52,"[-0.519,0.52]",0.998,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:446157,biolink:associated_with_increased_likelihood_of,MONDO:0013282,rosuvastatin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894265777,5.00E-04,-0.499,0.5,"[-0.499,0.5]",0.998,1672700,20901300,22574000,"Sample size with rosuvastatin, approximately: 1672700","Sample size without rosuvastatin, approximately: 20901300",All patients number is approximately: 22574000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:127054492,biolink:associated_with_increased_likelihood_of,MONDO:0005148,rosiglitazone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973126816,0.0266,-0.669,0.722,"[-0.669,0.722]",0.94,4900,21788600,21793500,"Sample size with rosiglitazone, approximately: 4900","Sample size without rosiglitazone, approximately: 21788600",All patients number is approximately: 21793500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:127054492,biolink:associated_with_increased_likelihood_of,MONDO:0005178,rosiglitazone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973126816,0.0125,-0.34,0.365,"[-0.34,0.365]",0.944,4900,21788600,21793500,"Sample size with rosiglitazone, approximately: 4900","Sample size without rosiglitazone, approximately: 21788600",All patients number is approximately: 21793500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0011786,roflumilast,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.9128,0.87,0.955,"[0.87,0.955]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0021187,roflumilast,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.7939,0.751,0.837,"[0.751,0.837]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0007186,roflumilast,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.679,0.636,0.722,"[0.636,0.722]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0005178,roflumilast,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.526,0.494,0.558,"[0.494,0.558]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0018882,roflumilast,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.3325,0.285,0.38,"[0.285,0.38]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0002909,roflumilast,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.2752,0.242,0.309,"[0.242,0.309]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0000424,roflumilast,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.2151,0.159,0.271,"[0.159,0.271]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0003620,roflumilast,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.1887,0.155,0.222,"[0.155,0.222]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0008399,roflumilast,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.1789,0.134,0.224,"[0.134,0.224]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0002277,roflumilast,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.1221,0.078,0.166,"[0.078,0.166]",1.00E-04,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0002869,roflumilast,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0779,0.015,0.141,"[0.015,0.141]",0.015,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0005010,roflumilast,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0498,-0.054,0.154,"[-0.054,0.154]",0.349,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0004609,roflumilast,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0277,-0.093,0.149,"[-0.093,0.149]",0.654,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0007915,roflumilast,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.026,-0.242,0.294,"[-0.242,0.294]",0.849,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0005101,roflumilast,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0099,-0.158,0.178,"[-0.158,0.178]",0.908,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,roflumilast,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0058,-0.592,0.604,"[-0.592,0.604]",0.985,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,roflumilast,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.002,-0.726,0.729,"[-0.726,0.729]",0.996,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0257288,biolink:associated_with_increased_likelihood_of,MONDO:0005002,roflumilast,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973071601,0.0019,-0.207,0.211,"[-0.207,0.211]",0.986,34300,21774600,21808900,"Sample size with roflumilast, approximately: 34300","Sample size without roflumilast, approximately: 21774600",All patients number is approximately: 21808900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0018882,rivastigmine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,1.3445,1.319,1.37,"[1.319,1.37]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005300,rivastigmine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,1.0882,1.067,1.109,"[1.067,1.109]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0008599,rivastigmine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.4834,0.456,0.511,"[0.456,0.511]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0000424,rivastigmine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.4641,0.439,0.489,"[0.439,0.489]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0006694,rivastigmine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.4316,0.41,0.453,"[0.41,0.453]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0009693,rivastigmine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.3575,0.334,0.381,"[0.334,0.381]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005298,rivastigmine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.3563,0.332,0.381,"[0.332,0.381]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0043693,rivastigmine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.2945,0.273,0.316,"[0.273,0.316]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005393,rivastigmine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.1533,0.1,0.207,"[0.1,0.207]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0004648,rivastigmine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.1252,0.078,0.172,"[0.078,0.172]",1.00E-04,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005101,rivastigmine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0903,-0.036,0.217,"[-0.036,0.217]",0.162,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0002046,rivastigmine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0412,-0.015,0.098,"[-0.015,0.098]",0.154,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005364,rivastigmine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0395,-0.081,0.16,"[-0.081,0.16]",0.522,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0004979,rivastigmine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0267,-0.092,0.146,"[-0.092,0.146]",0.66,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0005294,rivastigmine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.012,-0.034,0.058,"[-0.034,0.058]",0.611,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0004975,rivastigmine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0108,-0.156,0.178,"[-0.156,0.178]",0.899,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:77991,biolink:associated_with_increased_likelihood_of,MONDO:0011508,rivastigmine,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956733346,0.0092,-0.017,0.036,"[-0.017,0.036]",0.496,84400,21750400,21834800,"Sample size with rivastigmine, approximately: 84400","Sample size without rivastigmine, approximately: 21750400",All patients number is approximately: 21834800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005180,rituximab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,1.7032,1.674,1.732,"[1.674,1.732]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0019118,rituximab,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,1.1177,1.094,1.142,"[1.094,1.142]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0004425,rituximab,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.877,0.849,0.905,"[0.849,0.905]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0008399,rituximab,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.7171,0.689,0.745,"[0.689,0.745]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,rituximab,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.6655,0.637,0.694,"[0.637,0.694]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0043693,rituximab,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.6289,0.602,0.656,"[0.602,0.656]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0010602,rituximab,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.2526,0.227,0.278,"[0.227,0.278]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0015924,rituximab,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.181,0.145,0.217,"[0.145,0.217]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005178,rituximab,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1778,0.154,0.202,"[0.154,0.202]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005010,rituximab,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1677,0.137,0.198,"[0.137,0.198]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005101,rituximab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1629,0.058,0.268,"[0.058,0.268]",0.002,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0007027,rituximab,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1278,0.102,0.154,"[0.102,0.154]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0021187,rituximab,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1192,0.041,0.198,"[0.041,0.198]",0.003,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0004975,rituximab,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.1126,0.078,0.147,"[0.078,0.147]",1.00E-04,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0007915,rituximab,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.0949,0.038,0.151,"[0.038,0.151]",0.001,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0011849,rituximab,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.0557,-0.061,0.173,"[-0.061,0.173]",0.351,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0004979,rituximab,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.0331,-0.064,0.13,"[-0.064,0.13]",0.503,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005302,rituximab,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.0283,-0.183,0.24,"[-0.183,0.24]",0.793,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005388,rituximab,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.0254,-0.168,0.219,"[-0.168,0.219]",0.797,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,rituximab,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,0.004,-0.168,0.176,"[-0.168,0.176]",0.963,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201576,biolink:associated_with_increased_likelihood_of,MONDO:0005300,rituximab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.982014383,1.00E-04,-0.617,0.617,"[-0.617,0.617]",1,103900,21744000,21847900,"Sample size with rituximab, approximately: 103900","Sample size without rituximab, approximately: 21744000",All patients number is approximately: 21847900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ritonavir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.4384,0.409,0.468,"[0.409,0.468]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ritonavir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.3166,0.292,0.341,"[0.292,0.341]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ritonavir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.2517,0.221,0.283,"[0.221,0.283]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005294,ritonavir,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.2209,-0.025,0.467,"[-0.025,0.467]",0.079,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0004952,ritonavir,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.1612,0.121,0.202,"[0.121,0.202]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ritonavir,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.1593,0.134,0.184,"[0.134,0.184]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ritonavir,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.1015,0.069,0.134,"[0.069,0.134]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0004648,ritonavir,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.1001,0.093,0.108,"[0.093,0.108]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005302,ritonavir,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0926,0.052,0.133,"[0.052,0.133]",1.00E-04,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0004981,ritonavir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0867,0.009,0.165,"[0.009,0.165]",0.029,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0002406,ritonavir,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0738,-0.397,0.545,"[-0.397,0.545]",0.759,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,ritonavir,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0557,0.014,0.097,"[0.014,0.097]",0.008,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0006694,ritonavir,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0534,0.023,0.084,"[0.023,0.084]",0.001,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0008599,ritonavir,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0488,-0.017,0.115,"[-0.017,0.115]",0.147,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ritonavir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0485,-0.007,0.104,"[-0.007,0.104]",0.088,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ritonavir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0397,-0.159,0.239,"[-0.159,0.239]",0.696,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0007186,ritonavir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0369,-0.842,0.915,"[-0.842,0.915]",0.934,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,ritonavir,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0366,-0.016,0.089,"[-0.016,0.089]",0.174,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005392,ritonavir,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0284,-0.002,0.058,"[-0.002,0.058]",0.064,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0004975,ritonavir,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0212,-0.013,0.055,"[-0.013,0.055]",0.224,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005546,ritonavir,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0199,-0.045,0.085,"[-0.045,0.085]",0.55,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0007915,ritonavir,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0121,-0.172,0.196,"[-0.172,0.196]",0.897,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0015924,ritonavir,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0098,-0.139,0.159,"[-0.139,0.159]",0.897,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0005146,ritonavir,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0025,-0.073,0.078,"[-0.073,0.078]",0.949,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:392622,biolink:associated_with_increased_likelihood_of,MONDO:0015564,ritonavir,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.874848582,0.0011,-0.675,0.677,"[-0.675,0.677]",0.998,270200,21541700,21811900,"Sample size with ritonavir, approximately: 270200","Sample size without ritonavir, approximately: 21541700",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005302,risperidone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.3899,0.379,0.4,"[0.379,0.4]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0013282,risperidone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.2859,0.272,0.3,"[0.272,0.3]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008599,risperidone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.2564,0.247,0.266,"[0.247,0.266]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008377,risperidone,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.2359,0.221,0.25,"[0.221,0.25]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008644,risperidone,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.2141,0.204,0.224,"[0.204,0.224]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0010602,risperidone,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.1751,0.164,0.186,"[0.164,0.186]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,risperidone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.1678,0.154,0.182,"[0.154,0.182]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0002869,risperidone,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.1303,0.109,0.152,"[0.109,0.152]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0002909,risperidone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0815,0.057,0.105,"[0.057,0.105]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005180,risperidone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0719,0.061,0.083,"[0.061,0.083]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0011849,risperidone,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0676,0.019,0.117,"[0.019,0.117]",0.007,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008383,risperidone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.063,0.054,0.072,"[0.054,0.072]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0007915,risperidone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0511,0.027,0.075,"[0.027,0.075]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005146,risperidone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0492,0.008,0.091,"[0.008,0.091]",0.02,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005083,risperidone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0482,0.017,0.079,"[0.017,0.079]",0.002,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0007186,risperidone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0458,-0.028,0.12,"[-0.028,0.12]",0.226,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0006694,risperidone,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0419,0.029,0.055,"[0.029,0.055]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005392,risperidone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0324,-0.011,0.076,"[-0.011,0.076]",0.148,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005178,risperidone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0254,0.016,0.035,"[0.016,0.035]",1.00E-04,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0007947,risperidone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0177,-0.014,0.049,"[-0.014,0.049]",0.27,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0009693,risperidone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0174,0.003,0.032,"[0.003,0.032]",0.018,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0019565,risperidone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0169,-0.107,0.141,"[-0.107,0.141]",0.789,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0011122,risperidone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0081,-0.069,0.085,"[-0.069,0.085]",0.837,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0020066,risperidone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0079,-0.099,0.115,"[-0.099,0.115]",0.885,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008487,risperidone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0059,-0.06,0.072,"[-0.06,0.072]",0.861,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,risperidone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0044,-0.176,0.184,"[-0.176,0.184]",0.962,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005011,risperidone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0043,-0.122,0.13,"[-0.122,0.13]",0.946,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0004609,risperidone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0033,-0.257,0.264,"[-0.257,0.264]",0.98,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005404,risperidone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.003,-0.209,0.215,"[-0.209,0.215]",0.978,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0002406,risperidone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0027,-0.223,0.229,"[-0.223,0.229]",0.981,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0008300,risperidone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0019,-5.645,5.648,"[-5.645,5.648]",0.999,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0021187,risperidone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0016,-0.307,0.311,"[-0.307,0.311]",0.992,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0005010,risperidone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0015,-3.56,3.563,"[-3.56,3.563]",0.999,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0002316,risperidone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,0.0012,-0.082,0.084,"[-0.082,0.084]",0.977,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5073,biolink:associated_with_increased_likelihood_of,MONDO:0004975,risperidone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91836859,1.00E-04,-0.17,0.171,"[-0.17,0.171]",0.999,708500,21474600,22183100,"Sample size with risperidone, approximately: 708500","Sample size without risperidone, approximately: 21474600",All patients number is approximately: 22183100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5245,biolink:associated_with_increased_likelihood_of,MONDO:0007186,risedronic acid,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955733334,0.012,-0.522,0.546,"[-0.522,0.546]",0.965,6500,21787100,21793600,"Sample size with risedronic acid, approximately: 6500","Sample size without risedronic acid, approximately: 21787100",All patients number is approximately: 21793600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5245,biolink:associated_with_increased_likelihood_of,MONDO:0011786,risedronic acid,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955733334,2.00E-04,-0.423,0.424,"[-0.423,0.424]",0.999,6500,21787100,21793600,"Sample size with risedronic acid, approximately: 6500","Sample size without risedronic acid, approximately: 21787100",All patients number is approximately: 21793600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C4078397,biolink:associated_with_increased_likelihood_of,MONDO:0043693,risankizumab,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.871478295,0.0242,-0.373,0.421,"[-0.373,0.421]",0.905,11100,21785500,21796600,"Sample size with risankizumab, approximately: 11100","Sample size without risankizumab, approximately: 21785500",All patients number is approximately: 21796600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C4078397,biolink:associated_with_increased_likelihood_of,MONDO:0005147,risankizumab,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.871478295,0.02,-2.604,2.644,"[-2.604,2.644]",0.988,11100,21785500,21796600,"Sample size with risankizumab, approximately: 11100","Sample size without risankizumab, approximately: 21785500",All patients number is approximately: 21796600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C4078397,biolink:associated_with_increased_likelihood_of,MONDO:0011786,risankizumab,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.871478295,0.0134,-0.675,0.702,"[-0.675,0.702]",0.969,11100,21785500,21796600,"Sample size with risankizumab, approximately: 11100","Sample size without risankizumab, approximately: 21785500",All patients number is approximately: 21796600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C4078397,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,risankizumab,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.871478295,0.0045,-0.809,0.818,"[-0.809,0.818]",0.991,11100,21785500,21796600,"Sample size with risankizumab, approximately: 11100","Sample size without risankizumab, approximately: 21785500",All patients number is approximately: 21796600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0002046,revefenacin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.2833,0.213,0.353,"[0.213,0.353]",1.00E-04,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0006694,revefenacin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.2217,0.064,0.38,"[0.064,0.38]",0.006,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0020066,revefenacin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.0965,-3.022,3.215,"[-3.022,3.215]",0.952,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0021187,revefenacin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.0707,-0.114,0.255,"[-0.114,0.255]",0.453,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0007915,revefenacin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.0394,-0.256,0.334,"[-0.256,0.334]",0.794,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0304897,biolink:associated_with_increased_likelihood_of,MONDO:0003620,revefenacin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979112189,0.0045,-0.396,0.405,"[-0.396,0.405]",0.983,7700,21788000,21795700,"Sample size with revefenacin, approximately: 7700","Sample size without revefenacin, approximately: 21788000",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005010,repaglinide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.8778,0.846,0.909,"[0.846,0.909]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0011122,repaglinide,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.2778,0.244,0.311,"[0.244,0.311]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0006694,repaglinide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.2643,0.222,0.307,"[0.222,0.307]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0011786,repaglinide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.2475,0.192,0.303,"[0.192,0.303]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0009693,repaglinide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.1483,0.112,0.185,"[0.112,0.185]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005180,repaglinide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.1244,0.084,0.165,"[0.084,0.165]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005002,repaglinide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.1094,0.061,0.158,"[0.061,0.158]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0004648,repaglinide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0944,0.045,0.144,"[0.045,0.144]",1.00E-04,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0015924,repaglinide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0849,0.006,0.164,"[0.006,0.164]",0.034,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0002316,repaglinide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0619,-0.015,0.139,"[-0.015,0.139]",0.114,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0002046,repaglinide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0407,-0.133,0.214,"[-0.133,0.214]",0.646,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0002909,repaglinide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.035,0.006,0.064,"[0.006,0.064]",0.017,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0002277,repaglinide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0304,-0.104,0.165,"[-0.104,0.165]",0.658,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005101,repaglinide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0119,-0.282,0.306,"[-0.282,0.306]",0.937,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005294,repaglinide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0115,-0.44,0.463,"[-0.44,0.463]",0.96,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,repaglinide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.011,-0.347,0.369,"[-0.347,0.369]",0.952,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0005300,repaglinide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0055,-0.538,0.549,"[-0.538,0.549]",0.984,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0004981,repaglinide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0045,-0.416,0.424,"[-0.416,0.424]",0.983,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0007915,repaglinide,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0027,-0.27,0.275,"[-0.27,0.275]",0.985,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0004975,repaglinide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0025,-0.553,0.558,"[-0.553,0.558]",0.993,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65981,biolink:associated_with_increased_likelihood_of,MONDO:0000424,repaglinide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950598541,0.0024,-0.039,0.044,"[-0.039,0.044]",0.912,44800,21767800,21812600,"Sample size with repaglinide, approximately: 44800","Sample size without repaglinide, approximately: 21767800",All patients number is approximately: 21812600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0004648,ramipril,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,1.4071,1.391,1.423,"[1.391,1.423]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005364,ramipril,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.9175,0.901,0.933,"[0.901,0.933]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,ramipril,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.706,0.687,0.725,"[0.687,0.725]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0011786,ramipril,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.6393,0.613,0.666,"[0.613,0.666]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ramipril,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.513,0.496,0.53,"[0.496,0.53]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005180,ramipril,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.4126,0.388,0.437,"[0.388,0.437]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0008383,ramipril,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.3174,0.299,0.335,"[0.299,0.335]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0009891,ramipril,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.2889,0.263,0.315,"[0.263,0.315]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ramipril,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.2522,0.224,0.28,"[0.224,0.28]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ramipril,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.2042,0.175,0.233,"[0.175,0.233]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0002046,ramipril,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.1971,0.154,0.24,"[0.154,0.24]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0002277,ramipril,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.1931,0.142,0.244,"[0.142,0.244]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0021187,ramipril,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.1909,0.167,0.215,"[0.167,0.215]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0004981,ramipril,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.1161,0.045,0.188,"[0.045,0.188]",0.001,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005011,ramipril,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0981,0.061,0.136,"[0.061,0.136]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0006694,ramipril,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0808,0.046,0.116,"[0.046,0.116]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005146,ramipril,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.062,-0.015,0.139,"[-0.015,0.139]",0.114,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ramipril,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0486,0.025,0.072,"[0.025,0.072]",1.00E-04,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005404,ramipril,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0436,-0.012,0.099,"[-0.012,0.099]",0.122,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0011849,ramipril,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0348,-0.184,0.253,"[-0.184,0.253]",0.755,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005002,ramipril,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0184,-0.117,0.154,"[-0.117,0.154]",0.79,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ramipril,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0151,-0.012,0.042,"[-0.012,0.042]",0.271,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0018882,ramipril,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0069,-0.088,0.102,"[-0.088,0.102]",0.887,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0043693,ramipril,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0055,-0.024,0.035,"[-0.024,0.035]",0.716,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ramipril,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0036,-0.269,0.276,"[-0.269,0.276]",0.979,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005306,ramipril,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0033,-0.056,0.062,"[-0.056,0.062]",0.913,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0002869,ramipril,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.003,-0.193,0.199,"[-0.193,0.199]",0.976,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005294,ramipril,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0023,-0.547,0.551,"[-0.547,0.551]",0.994,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005009,ramipril,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,0.0016,-0.501,0.504,"[-0.501,0.504]",0.995,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0004609,ramipril,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,9.00E-04,-0.102,0.104,"[-0.102,0.104]",0.987,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,MONDO:0005302,ramipril,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,8.00E-04,-0.447,0.449,"[-0.447,0.449]",0.997,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362129,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,ramipril,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895484035,7.00E-04,-0.234,0.235,"[-0.234,0.235]",0.995,123300,21711100,21834400,"Sample size with ramipril, approximately: 123300","Sample size without ramipril, approximately: 21711100",All patients number is approximately: 21834400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0005010,raltegravir,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.9411,0.573,1.309,"[0.573,1.309]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0002406,raltegravir,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.9059,0.847,0.965,"[0.847,0.965]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0002277,raltegravir,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.6372,0.524,0.751,"[0.524,0.751]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0005178,raltegravir,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.5631,0.484,0.643,"[0.484,0.643]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0018882,raltegravir,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.3313,0.197,0.466,"[0.197,0.466]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0005147,raltegravir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.2676,0.168,0.367,"[0.168,0.367]",1.00E-04,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0005146,raltegravir,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.0452,-0.831,0.922,"[-0.831,0.922]",0.92,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54671008,biolink:associated_with_increased_likelihood_of,MONDO:0015564,raltegravir,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98834248,0.0097,-4.344,4.363,"[-4.344,4.363]",0.997,21400,21776600,21798000,"Sample size with raltegravir, approximately: 21400","Sample size without raltegravir, approximately: 21776600",All patients number is approximately: 21798000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0009891,raloxifene,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.6995,0.663,0.736,"[0.663,0.736]",1.00E-04,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005133,raloxifene,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.6197,0.58,0.66,"[0.58,0.66]",1.00E-04,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0021187,raloxifene,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.4464,0.411,0.482,"[0.411,0.482]",1.00E-04,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0008599,raloxifene,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.1514,0.099,0.204,"[0.099,0.204]",1.00E-04,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0000424,raloxifene,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.1075,0.031,0.184,"[0.031,0.184]",0.006,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0011122,raloxifene,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.103,0.053,0.153,"[0.053,0.153]",1.00E-04,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0002046,raloxifene,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0769,-0.019,0.173,"[-0.019,0.173]",0.118,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005002,raloxifene,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0532,-0.081,0.188,"[-0.081,0.188]",0.438,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0004648,raloxifene,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0494,-0.02,0.119,"[-0.02,0.119]",0.162,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0009693,raloxifene,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0482,-0.016,0.112,"[-0.016,0.112]",0.142,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005010,raloxifene,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.045,-0.062,0.152,"[-0.062,0.152]",0.409,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005298,raloxifene,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0331,-0.174,0.24,"[-0.174,0.24]",0.754,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005178,raloxifene,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0239,-0.016,0.064,"[-0.016,0.064]",0.239,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005146,raloxifene,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0082,-0.287,0.304,"[-0.287,0.304]",0.956,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,raloxifene,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0048,-0.378,0.387,"[-0.378,0.387]",0.981,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0005294,raloxifene,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0018,-0.541,0.544,"[-0.541,0.544]",0.995,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0004981,raloxifene,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,0.0016,-0.666,0.669,"[-0.666,0.669]",0.996,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5035,biolink:associated_with_increased_likelihood_of,MONDO:0002277,raloxifene,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945215495,5.00E-04,-0.421,0.422,"[-0.421,0.422]",0.998,48400,21762200,21810600,"Sample size with raloxifene, approximately: 48400","Sample size without raloxifene, approximately: 21762200",All patients number is approximately: 21810600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,quinapril,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.8013,0.773,0.83,"[0.773,0.83]",1.00E-04,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005300,quinapril,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.4262,0.396,0.456,"[0.396,0.456]",1.00E-04,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005302,quinapril,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.4045,0.372,0.437,"[0.372,0.437]",1.00E-04,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005009,quinapril,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.1929,0.145,0.241,"[0.145,0.241]",1.00E-04,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005147,quinapril,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.1433,0.074,0.212,"[0.074,0.212]",1.00E-04,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005010,quinapril,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0771,-0.014,0.168,"[-0.014,0.168]",0.097,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0002277,quinapril,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0532,-0.092,0.198,"[-0.092,0.198]",0.472,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005364,quinapril,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0248,-0.073,0.122,"[-0.073,0.122]",0.618,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005146,quinapril,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0213,-0.19,0.232,"[-0.19,0.232]",0.843,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0002909,quinapril,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.018,-0.069,0.105,"[-0.069,0.105]",0.685,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005101,quinapril,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0111,-0.455,0.477,"[-0.455,0.477]",0.963,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0005546,quinapril,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.009,-0.36,0.377,"[-0.36,0.377]",0.962,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54892,biolink:associated_with_increased_likelihood_of,MONDO:0004975,quinapril,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.910310262,0.0056,-0.641,0.652,"[-0.641,0.652]",0.987,44100,21763600,21807700,"Sample size with quinapril, approximately: 44100","Sample size without quinapril, approximately: 21763600",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0013282,propranolol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.6863,0.676,0.697,"[0.676,0.697]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0002046,propranolol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.3905,0.375,0.406,"[0.375,0.406]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005364,propranolol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.3654,0.346,0.385,"[0.346,0.385]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,propranolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.3429,0.333,0.353,"[0.333,0.353]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005083,propranolol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.2978,0.279,0.317,"[0.279,0.317]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005010,propranolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.2505,0.23,0.271,"[0.23,0.271]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0011849,propranolol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.227,0.207,0.247,"[0.207,0.247]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0008399,propranolol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.2154,0.205,0.226,"[0.205,0.226]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,propranolol,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.2104,0.176,0.245,"[0.176,0.245]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0019369,propranolol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1995,0.189,0.21,"[0.189,0.21]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0000424,propranolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1728,0.163,0.182,"[0.163,0.182]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0000914,propranolol,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1678,0.154,0.181,"[0.154,0.181]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004648,propranolol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1338,0.119,0.148,"[0.119,0.148]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005101,propranolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1319,0.114,0.15,"[0.114,0.15]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005146,propranolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1261,0.098,0.154,"[0.098,0.154]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0002909,propranolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1077,0.096,0.119,"[0.096,0.119]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0009693,propranolol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.1047,0.097,0.112,"[0.097,0.112]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0002406,propranolol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0928,0.072,0.114,"[0.072,0.114]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005302,propranolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0866,0.074,0.1,"[0.074,0.1]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005149,propranolol,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0608,0.013,0.108,"[0.013,0.108]",0.012,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005392,propranolol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0511,0.036,0.066,"[0.036,0.066]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0007915,propranolol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.051,0.035,0.067,"[0.035,0.067]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0015263,propranolol,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0507,0.041,0.06,"[0.041,0.06]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005546,propranolol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0504,0.04,0.061,"[0.04,0.061]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0007739,propranolol,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0456,0.007,0.085,"[0.007,0.085]",0.022,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005180,propranolol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0386,0.028,0.049,"[0.028,0.049]",1.00E-04,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0007186,propranolol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0209,-0.057,0.098,"[-0.057,0.098]",0.597,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0011122,propranolol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0204,-0.006,0.046,"[-0.006,0.046]",0.124,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0007947,propranolol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0165,-0.042,0.075,"[-0.042,0.075]",0.578,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0008487,propranolol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0163,-0.015,0.048,"[-0.015,0.048]",0.314,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005393,propranolol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0114,2.72E-05,0.023,"[0.0000272,0.023]",0.049,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0002316,propranolol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0113,-0.116,0.139,"[-0.116,0.139]",0.862,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004425,propranolol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0112,-0.138,0.161,"[-0.138,0.161]",0.883,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0007027,propranolol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0085,-0.002,0.019,"[-0.002,0.019]",0.103,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0020066,propranolol,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0081,-0.111,0.127,"[-0.111,0.127]",0.894,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004975,propranolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0065,-0.146,0.159,"[-0.146,0.159]",0.933,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0011429,propranolol,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0056,-0.105,0.116,"[-0.105,0.116]",0.921,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0021107,propranolol,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0041,-0.098,0.107,"[-0.098,0.107]",0.937,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0021187,propranolol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.004,-0.541,0.549,"[-0.541,0.549]",0.989,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004981,propranolol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0039,-0.097,0.105,"[-0.097,0.105]",0.94,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0008383,propranolol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0038,-0.349,0.356,"[-0.349,0.356]",0.983,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005300,propranolol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0035,-0.189,0.196,"[-0.189,0.196]",0.972,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0019180,propranolol,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0034,-0.082,0.089,"[-0.082,0.089]",0.938,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005133,propranolol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0029,-0.091,0.097,"[-0.091,0.097]",0.952,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004979,propranolol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0015,-0.065,0.068,"[-0.065,0.068]",0.966,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005388,propranolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.0012,-0.17,0.173,"[-0.17,0.173]",0.989,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0004952,propranolol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.001,-0.291,0.293,"[-0.291,0.293]",0.995,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005298,propranolol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,0.001,-0.448,0.45,"[-0.448,0.45]",0.996,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0000153,propranolol,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,7.00E-04,-0.144,0.145,"[-0.144,0.145]",0.993,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0005009,propranolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,7.00E-04,-0.503,0.505,"[-0.503,0.505]",0.998,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0011786,propranolol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,5.00E-04,-0.524,0.525,"[-0.524,0.525]",0.999,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0000477,propranolol,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,5.00E-04,-0.535,0.536,"[-0.535,0.536]",0.999,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4946,biolink:associated_with_increased_likelihood_of,MONDO:0002277,propranolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.817347573,4.00E-04,-0.179,0.18,"[-0.179,0.18]",0.996,824200,21325000,22149200,"Sample size with propranolol, approximately: 824200","Sample size without propranolol, approximately: 21325000",All patients number is approximately: 22149200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0002909,prochlorperazine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,1.7632,1.76,1.767,"[1.76,1.767]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005072,prochlorperazine,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.9319,0.928,0.935,"[0.928,0.935]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,prochlorperazine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.5651,0.56,0.57,"[0.56,0.57]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005147,prochlorperazine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.4738,0.47,0.478,"[0.47,0.478]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0021187,prochlorperazine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.3935,0.384,0.403,"[0.384,0.403]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005149,prochlorperazine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.2543,0.231,0.277,"[0.231,0.277]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008399,prochlorperazine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.2477,0.243,0.252,"[0.243,0.252]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005009,prochlorperazine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.211,0.203,0.219,"[0.203,0.219]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0018975,prochlorperazine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.2098,0.205,0.215,"[0.205,0.215]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0015924,prochlorperazine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.2059,0.2,0.211,"[0.2,0.211]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008678,prochlorperazine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1445,0.136,0.153,"[0.136,0.153]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005083,prochlorperazine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1441,0.128,0.16,"[0.128,0.16]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005711,prochlorperazine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1387,0.131,0.147,"[0.131,0.147]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0002046,prochlorperazine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1353,0.13,0.141,"[0.13,0.141]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005393,prochlorperazine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1334,0.122,0.145,"[0.122,0.145]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0000424,prochlorperazine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1289,0.109,0.149,"[0.109,0.149]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007915,prochlorperazine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1258,0.121,0.13,"[0.121,0.13]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0010526,prochlorperazine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.1234,0.115,0.132,"[0.115,0.132]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005130,prochlorperazine,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.087,0.082,0.092,"[0.082,0.092]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0018177,prochlorperazine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0589,0.029,0.089,"[0.029,0.089]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007903,prochlorperazine,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0488,0.016,0.082,"[0.016,0.082]",0.004,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008377,prochlorperazine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0477,0.041,0.054,"[0.041,0.054]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0001044,prochlorperazine,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0431,0.014,0.073,"[0.014,0.073]",0.004,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0019350,prochlorperazine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0431,0.031,0.055,"[0.031,0.055]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005133,prochlorperazine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0359,0.005,0.067,"[0.005,0.067]",0.024,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0001516,prochlorperazine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0333,0.028,0.038,"[0.028,0.038]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0002406,prochlorperazine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0326,-0.027,0.092,"[-0.027,0.092]",0.282,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0002316,prochlorperazine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0297,-0.029,0.088,"[-0.029,0.088]",0.32,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0013282,prochlorperazine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0205,-0.01,0.051,"[-0.01,0.051]",0.188,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0018882,prochlorperazine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0167,-0.05,0.083,"[-0.05,0.083]",0.621,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0004952,prochlorperazine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0159,0.011,0.02,"[0.011,0.02]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008383,prochlorperazine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0157,0.01,0.022,"[0.01,0.022]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008599,prochlorperazine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0128,0.007,0.019,"[0.007,0.019]",1.00E-04,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005011,prochlorperazine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0094,-0.048,0.066,"[-0.048,0.066]",0.747,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007160,prochlorperazine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0084,-0.049,0.065,"[-0.049,0.065]",0.773,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005010,prochlorperazine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0081,-0.027,0.043,"[-0.027,0.043]",0.651,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005101,prochlorperazine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0079,-0.093,0.109,"[-0.093,0.109]",0.878,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005146,prochlorperazine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0057,-0.072,0.084,"[-0.072,0.084]",0.887,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007827,prochlorperazine,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0057,-0.05,0.061,"[-0.05,0.061]",0.839,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0021107,prochlorperazine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0048,-0.048,0.058,"[-0.048,0.058]",0.859,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007186,prochlorperazine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0041,-0.144,0.152,"[-0.144,0.152]",0.957,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008487,prochlorperazine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0031,-0.716,0.723,"[-0.716,0.723]",0.993,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0019369,prochlorperazine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0031,-0.067,0.074,"[-0.067,0.074]",0.931,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0009889,prochlorperazine,polycystic kidney disease infantile type,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0021,-0.004,0.008,"[-0.004,0.008]",0.475,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0043693,prochlorperazine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.002,-0.103,0.107,"[-0.103,0.107]",0.97,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0004425,prochlorperazine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,0.0012,-0.039,0.042,"[-0.039,0.042]",0.953,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005306,prochlorperazine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,6.00E-04,-0.446,0.448,"[-0.446,0.448]",0.998,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0008300,prochlorperazine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,3.00E-04,-0.257,0.258,"[-0.257,0.258]",0.998,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0002277,prochlorperazine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,3.00E-04,-0.557,0.557,"[-0.557,0.557]",0.999,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0007947,prochlorperazine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,1.00E-04,-0.283,0.283,"[-0.283,0.283]",0.999,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4917,biolink:associated_with_increased_likelihood_of,MONDO:0005404,prochlorperazine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939431634,1.00E-04,-0.072,0.072,"[-0.072,0.072]",0.997,5880500,19462900,25343400,"Sample size with prochlorperazine, approximately: 5880500","Sample size without prochlorperazine, approximately: 19462900",All patients number is approximately: 25343400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005392,prednisone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,1.8743,1.87,1.879,"[1.87,1.879]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0000477,prednisone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.8421,0.826,0.858,"[0.826,0.858]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004952,prednisone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.6557,0.651,0.66,"[0.651,0.66]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0016532,prednisone,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.596,0.59,0.602,"[0.59,0.602]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005404,prednisone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.4461,0.438,0.454,"[0.438,0.454]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004609,prednisone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.3848,0.374,0.396,"[0.374,0.396]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0007818,prednisone,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.3411,0.314,0.368,"[0.314,0.368]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005294,prednisone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.3344,0.308,0.36,"[0.308,0.36]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004975,prednisone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.3254,0.306,0.344,"[0.306,0.344]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005306,prednisone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.2778,0.254,0.301,"[0.254,0.301]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005711,prednisone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.26,0.252,0.268,"[0.252,0.268]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0015263,prednisone,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.2319,0.226,0.237,"[0.226,0.237]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005180,prednisone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.2136,0.205,0.222,"[0.205,0.222]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0043693,prednisone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1974,0.177,0.218,"[0.177,0.218]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0018975,prednisone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1879,0.171,0.205,"[0.171,0.205]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0003620,prednisone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1848,0.155,0.214,"[0.155,0.214]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0021187,prednisone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1662,0.143,0.189,"[0.143,0.189]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0009061,prednisone,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1511,0.14,0.162,"[0.14,0.162]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0013282,prednisone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1336,0.125,0.143,"[0.125,0.143]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005002,prednisone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1283,0.101,0.155,"[0.101,0.155]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0019080,prednisone,alopecia totalis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1143,0.109,0.12,"[0.109,0.12]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0008300,prednisone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.1124,0.089,0.136,"[0.089,0.136]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005298,prednisone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0993,0.058,0.141,"[0.058,0.141]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005011,prednisone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0898,0.079,0.101,"[0.079,0.101]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004979,prednisone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0812,0.074,0.088,"[0.074,0.088]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0002277,prednisone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0712,0.05,0.093,"[0.05,0.093]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004981,prednisone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0645,0.056,0.073,"[0.056,0.073]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,prednisone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0626,0.044,0.081,"[0.044,0.081]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0008487,prednisone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0541,-0.007,0.115,"[-0.007,0.115]",0.08,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0009693,prednisone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0522,0.039,0.065,"[0.039,0.065]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0006694,prednisone,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0353,0.03,0.041,"[0.03,0.041]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0011122,prednisone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0302,0.014,0.046,"[0.014,0.046]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0008642,prednisone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0291,0.024,0.035,"[0.024,0.035]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0019499,prednisone,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0216,0.014,0.029,"[0.014,0.029]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0010526,prednisone,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0211,0.013,0.03,"[0.013,0.03]",1.00E-04,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0019180,prednisone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0181,-0.036,0.073,"[-0.036,0.073]",0.515,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005149,prednisone,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0079,-0.007,0.022,"[-0.007,0.022]",0.288,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0015614,prednisone,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0072,0.001,0.014,"[0.001,0.014]",0.03,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005364,prednisone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0044,-0.074,0.083,"[-0.074,0.083]",0.913,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0002046,prednisone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0029,-0.044,0.049,"[-0.044,0.049]",0.901,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0007827,prednisone,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0023,-0.269,0.273,"[-0.269,0.273]",0.986,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005010,prednisone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0023,-0.144,0.149,"[-0.144,0.149]",0.975,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0019350,prednisone,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0023,-0.283,0.287,"[-0.283,0.287]",0.987,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0000153,prednisone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0022,-0.071,0.075,"[-0.071,0.075]",0.954,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0011786,prednisone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0021,-0.31,0.315,"[-0.31,0.315]",0.99,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0004648,prednisone,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0019,-0.208,0.212,"[-0.208,0.212]",0.986,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005009,prednisone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0017,-0.127,0.13,"[-0.127,0.13]",0.979,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0007186,prednisone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,0.0013,-0.159,0.161,"[-0.159,0.161]",0.988,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0019565,prednisone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,5.00E-04,-0.594,0.594,"[-0.594,0.594]",0.999,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,prednisone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,4.00E-04,-0.565,0.566,"[-0.565,0.566]",0.999,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0002406,prednisone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,3.00E-04,-0.492,0.493,"[-0.492,0.493]",0.999,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5865,biolink:associated_with_increased_likelihood_of,MONDO:0005146,prednisone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.87362428,2.80E-05,-0.277,0.277,"[-0.277,0.277]",1,4883800,19045000,23928800,"Sample size with prednisone, approximately: 4883800","Sample size without prednisone, approximately: 19045000",All patients number is approximately: 23928800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0002046,prazosin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.7619,0.75,0.774,"[0.75,0.774]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,prazosin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.4638,0.452,0.475,"[0.452,0.475]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0009693,prazosin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.3968,0.378,0.415,"[0.378,0.415]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0018975,prazosin,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.3805,0.366,0.395,"[0.366,0.395]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005298,prazosin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.3554,0.34,0.371,"[0.34,0.371]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0010602,prazosin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.3106,0.295,0.326,"[0.295,0.326]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0008300,prazosin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.2735,0.257,0.29,"[0.257,0.29]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0018177,prazosin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.2335,0.217,0.25,"[0.217,0.25]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,prazosin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1746,0.148,0.201,"[0.148,0.201]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005404,prazosin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1644,0.117,0.212,"[0.117,0.212]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0004952,prazosin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1461,0.118,0.175,"[0.118,0.175]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0013282,prazosin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1232,0.065,0.182,"[0.065,0.182]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005133,prazosin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1209,0.093,0.148,"[0.093,0.148]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005083,prazosin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1159,0.069,0.163,"[0.069,0.163]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0002406,prazosin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.1069,0.071,0.143,"[0.071,0.143]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005148,prazosin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0991,0.083,0.115,"[0.083,0.115]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0004609,prazosin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0982,0.084,0.113,"[0.084,0.113]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005101,prazosin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0955,0.059,0.132,"[0.059,0.132]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005546,prazosin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0945,0.052,0.137,"[0.052,0.137]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0021107,prazosin,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0921,0.075,0.11,"[0.075,0.11]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0007739,prazosin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0774,0.033,0.122,"[0.033,0.122]",0.001,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0006694,prazosin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0742,0.052,0.096,"[0.052,0.096]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005180,prazosin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0697,0.051,0.088,"[0.051,0.088]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005178,prazosin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0584,0.03,0.087,"[0.03,0.087]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0008542,prazosin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.056,0.03,0.082,"[0.03,0.082]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0009891,prazosin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0537,0.038,0.069,"[0.038,0.069]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0009061,prazosin,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0536,0.035,0.072,"[0.035,0.072]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0008599,prazosin,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0533,0.038,0.068,"[0.038,0.068]",1.00E-04,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0008487,prazosin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0429,-0.019,0.105,"[-0.019,0.105]",0.172,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0007186,prazosin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0424,-0.022,0.107,"[-0.022,0.107]",0.2,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0008383,prazosin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0407,-0.027,0.109,"[-0.027,0.109]",0.241,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005146,prazosin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0398,0.005,0.075,"[0.005,0.075]",0.025,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0002909,prazosin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0386,0.003,0.074,"[0.003,0.074]",0.035,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005294,prazosin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0382,-0.053,0.13,"[-0.053,0.13]",0.413,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0007915,prazosin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0358,-0.045,0.116,"[-0.045,0.116]",0.383,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0000477,prazosin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0348,-0.037,0.106,"[-0.037,0.106]",0.339,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005364,prazosin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0321,-0.103,0.168,"[-0.103,0.168]",0.642,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0007160,prazosin,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.032,-0.047,0.111,"[-0.047,0.111]",0.425,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0004648,prazosin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.025,-0.13,0.18,"[-0.13,0.18]",0.751,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0019369,prazosin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0193,-0.104,0.142,"[-0.104,0.142]",0.759,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0021187,prazosin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0162,-0.072,0.105,"[-0.072,0.105]",0.72,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0003620,prazosin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.014,-0.008,0.036,"[-0.008,0.036]",0.206,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,prazosin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0138,-0.024,0.051,"[-0.024,0.051]",0.47,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0005011,prazosin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0125,-0.142,0.167,"[-0.142,0.167]",0.875,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0002277,prazosin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0122,-0.131,0.155,"[-0.131,0.155]",0.867,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0018882,prazosin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0108,-0.235,0.256,"[-0.235,0.256]",0.932,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0002316,prazosin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0066,-0.675,0.688,"[-0.675,0.688]",0.985,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0011429,prazosin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,0.0043,-0.083,0.092,"[-0.083,0.092]",0.923,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0019499,prazosin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,7.00E-04,-0.102,0.104,"[-0.102,0.104]",0.989,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4893,biolink:associated_with_increased_likelihood_of,MONDO:0019565,prazosin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.912110207,4.39E-05,-0.359,0.359,"[-0.359,0.359]",1,399800,21597400,21997200,"Sample size with prazosin, approximately: 399800","Sample size without prazosin, approximately: 21597400",All patients number is approximately: 21997200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004648,pravastatin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,1.277,1.271,1.283,"[1.271,1.283]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0002909,pravastatin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.5565,0.548,0.565,"[0.548,0.565]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0003620,pravastatin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.497,0.49,0.504,"[0.49,0.504]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005364,pravastatin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.3824,0.371,0.394,"[0.371,0.394]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0007947,pravastatin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.3279,0.319,0.336,"[0.319,0.336]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0002277,pravastatin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.2581,0.238,0.278,"[0.238,0.278]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0019499,pravastatin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.2472,0.229,0.265,"[0.229,0.265]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004975,pravastatin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.2069,0.197,0.217,"[0.197,0.217]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0007739,pravastatin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.2045,0.191,0.218,"[0.191,0.218]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005133,pravastatin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.1811,0.166,0.197,"[0.166,0.197]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005002,pravastatin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.1605,0.147,0.174,"[0.147,0.174]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005011,pravastatin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.1591,0.145,0.173,"[0.145,0.173]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005393,pravastatin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.1333,0.12,0.146,"[0.12,0.146]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005180,pravastatin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0945,0.082,0.107,"[0.082,0.107]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0008383,pravastatin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0925,0.081,0.103,"[0.081,0.103]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0011849,pravastatin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0887,0.066,0.111,"[0.066,0.111]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0008487,pravastatin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0874,0.07,0.105,"[0.07,0.105]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005178,pravastatin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0767,0.067,0.086,"[0.067,0.086]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004609,pravastatin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0502,0.013,0.087,"[0.013,0.087]",0.008,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0010602,pravastatin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0457,0.017,0.074,"[0.017,0.074]",0.002,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pravastatin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0388,0.029,0.048,"[0.029,0.048]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005306,pravastatin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0361,0.024,0.048,"[0.024,0.048]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0011122,pravastatin,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0354,0.024,0.047,"[0.024,0.047]",1.00E-04,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0016218,pravastatin,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0312,-0.034,0.097,"[-0.034,0.097]",0.35,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005404,pravastatin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0221,-0.019,0.063,"[-0.019,0.063]",0.293,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0019565,pravastatin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0156,-0.111,0.142,"[-0.111,0.142]",0.808,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004425,pravastatin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.015,-0.012,0.042,"[-0.012,0.042]",0.28,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0007186,pravastatin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0111,-0.081,0.103,"[-0.081,0.103]",0.812,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,pravastatin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0098,-0.052,0.071,"[-0.052,0.071]",0.755,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004952,pravastatin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.007,-0.08,0.094,"[-0.08,0.094]",0.875,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0002316,pravastatin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0068,-0.067,0.081,"[-0.067,0.081]",0.856,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005101,pravastatin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0064,-0.058,0.071,"[-0.058,0.071]",0.846,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0011786,pravastatin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0062,-0.059,0.071,"[-0.059,0.071]",0.853,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0008542,pravastatin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0059,-0.142,0.154,"[-0.142,0.154]",0.937,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005300,pravastatin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0053,-0.236,0.247,"[-0.236,0.247]",0.966,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005010,pravastatin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0042,-0.142,0.15,"[-0.142,0.15]",0.955,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0000477,pravastatin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0034,-0.061,0.068,"[-0.061,0.068]",0.916,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,pravastatin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0023,-0.503,0.508,"[-0.503,0.508]",0.993,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0002406,pravastatin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0015,-0.28,0.283,"[-0.28,0.283]",0.992,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0004979,pravastatin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0014,-0.311,0.314,"[-0.311,0.314]",0.993,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0018882,pravastatin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0012,-0.504,0.507,"[-0.504,0.507]",0.996,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,pravastatin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,0.0011,-0.302,0.305,"[-0.302,0.305]",0.994,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005294,pravastatin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,9.00E-04,-0.141,0.142,"[-0.141,0.142]",0.991,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0021187,pravastatin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,6.00E-04,-0.099,0.1,"[-0.099,0.1]",0.991,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,pravastatin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,2.00E-04,-0.095,0.096,"[-0.095,0.096]",0.997,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:24849132,biolink:associated_with_increased_likelihood_of,MONDO:0005302,pravastatin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89368827,1.57E-05,-0.356,0.356,"[-0.356,0.356]",1,1021300,21255600,22276900,"Sample size with pravastatin, approximately: 1021300","Sample size without pravastatin, approximately: 21255600",All patients number is approximately: 22276900,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:7482,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pramlintide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972596248,0.0033,-1.249,1.255,"[-1.249,1.255]",0.996,2400,21791200,21793600,"Sample size with pramlintide, approximately: 2400","Sample size without pramlintide, approximately: 21791200",All patients number is approximately: 21793600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005546,pioglitazone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,1.9992,1.989,2.009,"[1.989,2.009]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005010,pioglitazone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,1.2362,1.223,1.249,"[1.223,1.249]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0018882,pioglitazone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.526,0.512,0.54,"[0.512,0.54]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005364,pioglitazone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.4204,0.41,0.431,"[0.41,0.431]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0007540,pioglitazone,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.4034,0.391,0.416,"[0.391,0.416]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0002909,pioglitazone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.3435,0.327,0.36,"[0.327,0.36]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0002046,pioglitazone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.3339,0.317,0.35,"[0.317,0.35]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005133,pioglitazone,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.2485,0.222,0.275,"[0.222,0.275]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0009693,pioglitazone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.217,0.197,0.237,"[0.197,0.237]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,pioglitazone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.1498,0.104,0.195,"[0.104,0.195]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0018177,pioglitazone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.148,0.132,0.164,"[0.132,0.164]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0003620,pioglitazone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.1478,0.114,0.182,"[0.114,0.182]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,pioglitazone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.1282,0.117,0.14,"[0.117,0.14]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005404,pioglitazone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.119,0.056,0.182,"[0.056,0.182]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0008383,pioglitazone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.1183,0.102,0.134,"[0.102,0.134]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0009891,pioglitazone,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.1106,0.094,0.127,"[0.094,0.127]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0004975,pioglitazone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0746,0.05,0.1,"[0.05,0.1]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0019499,pioglitazone,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0571,0.042,0.073,"[0.042,0.073]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005306,pioglitazone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0381,0.02,0.056,"[0.02,0.056]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pioglitazone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0377,0.024,0.052,"[0.024,0.052]",1.00E-04,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0004425,pioglitazone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0215,-0.056,0.099,"[-0.056,0.099]",0.588,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0002277,pioglitazone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0191,-0.128,0.166,"[-0.128,0.166]",0.8,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0007915,pioglitazone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0141,-0.028,0.056,"[-0.028,0.056]",0.506,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0011786,pioglitazone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0112,-0.273,0.296,"[-0.273,0.296]",0.938,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0004609,pioglitazone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0095,-0.136,0.155,"[-0.136,0.155]",0.898,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0004981,pioglitazone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0066,-0.1,0.114,"[-0.1,0.114]",0.903,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0008487,pioglitazone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0061,-0.136,0.148,"[-0.136,0.148]",0.933,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0011849,pioglitazone,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0038,-0.108,0.116,"[-0.108,0.116]",0.946,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0015924,pioglitazone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0033,-0.084,0.091,"[-0.084,0.091]",0.941,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0004648,pioglitazone,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0014,-0.584,0.587,"[-0.584,0.587]",0.996,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005300,pioglitazone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,0.0014,-0.213,0.216,"[-0.213,0.216]",0.99,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005146,pioglitazone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,9.00E-04,-0.369,0.371,"[-0.369,0.371]",0.996,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005392,pioglitazone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,9.00E-04,-0.495,0.497,"[-0.495,0.497]",0.997,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0007186,pioglitazone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,8.00E-04,-0.185,0.186,"[-0.185,0.186]",0.993,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005302,pioglitazone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,8.00E-04,-0.4,0.402,"[-0.4,0.402]",0.997,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4829,biolink:associated_with_increased_likelihood_of,MONDO:0005101,pioglitazone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942083351,3.00E-04,-0.325,0.325,"[-0.325,0.325]",0.999,342300,21600400,21942700,"Sample size with pioglitazone, approximately: 342300","Sample size without pioglitazone, approximately: 21600400",All patients number is approximately: 21942700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0005101,pimecrolimus,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0951,-0.178,0.368,"[-0.178,0.368]",0.494,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0004981,pimecrolimus,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0226,-0.213,0.258,"[-0.213,0.258]",0.851,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,pimecrolimus,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.013,-0.162,0.188,"[-0.162,0.188]",0.885,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0002277,pimecrolimus,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0124,-0.173,0.198,"[-0.173,0.198]",0.896,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0004648,pimecrolimus,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0117,-0.408,0.431,"[-0.408,0.431]",0.956,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0019499,pimecrolimus,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0112,-0.217,0.239,"[-0.217,0.239]",0.923,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0011786,pimecrolimus,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0064,-0.237,0.25,"[-0.237,0.25]",0.959,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0019565,pimecrolimus,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0048,-0.339,0.349,"[-0.339,0.349]",0.978,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0005300,pimecrolimus,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.002,-1.069,1.073,"[-1.069,1.073]",0.997,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0005392,pimecrolimus,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0016,-0.378,0.381,"[-0.378,0.381]",0.993,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0005298,pimecrolimus,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0012,-0.407,0.409,"[-0.407,0.409]",0.996,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0007186,pimecrolimus,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,0.0011,-0.654,0.656,"[-0.654,0.656]",0.997,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0003620,pimecrolimus,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,9.00E-04,-0.78,0.782,"[-0.78,0.782]",0.998,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0005133,pimecrolimus,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,5.00E-04,-0.574,0.575,"[-0.574,0.575]",0.999,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,pimecrolimus,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,4.00E-04,-0.395,0.396,"[-0.395,0.396]",0.998,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:17753757,biolink:associated_with_increased_likelihood_of,MONDO:0011508,pimecrolimus,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849974557,1.88E-05,-0.335,0.335,"[-0.335,0.335]",1,51200,21756500,21807700,"Sample size with pimecrolimus, approximately: 51200","Sample size without pimecrolimus, approximately: 21756500",All patients number is approximately: 21807700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0005298,pimavanserin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.3589,0.227,0.491,"[0.227,0.491]",1.00E-04,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0002909,pimavanserin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.08,-0.37,0.53,"[-0.37,0.53]",0.727,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pimavanserin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.0551,-0.142,0.252,"[-0.142,0.252]",0.583,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0005180,pimavanserin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.0211,-1.042,1.085,"[-1.042,1.085]",0.969,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0005148,pimavanserin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.0067,-1.583,1.597,"[-1.583,1.597]",0.993,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0007186,pimavanserin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.0066,-0.714,0.727,"[-0.714,0.727]",0.986,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,pimavanserin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.005,-0.312,0.322,"[-0.312,0.322]",0.975,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256551,biolink:associated_with_increased_likelihood_of,MONDO:0002277,pimavanserin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.971001532,0.001,-1.084,1.086,"[-1.084,1.086]",0.999,6800,21788900,21795700,"Sample size with pimavanserin, approximately: 6800","Sample size without pimavanserin, approximately: 21788900",All patients number is approximately: 21795700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0002909,pibrentasvir,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.761,0.548,0.974,"[0.548,0.974]",1.00E-04,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005300,pibrentasvir,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.3581,0.266,0.45,"[0.266,0.45]",1.00E-04,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005294,pibrentasvir,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.3047,0.226,0.384,"[0.226,0.384]",1.00E-04,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005011,pibrentasvir,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.2471,-0.047,0.542,"[-0.047,0.542]",0.1,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005009,pibrentasvir,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.2422,0.058,0.426,"[0.058,0.426]",0.01,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0002046,pibrentasvir,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.2414,0.155,0.328,"[0.155,0.328]",1.00E-04,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0002869,pibrentasvir,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.2343,-0.035,0.503,"[-0.035,0.503]",0.088,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005147,pibrentasvir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.217,-1.511,1.945,"[-1.511,1.945]",0.806,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0004981,pibrentasvir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.1404,-0.283,0.564,"[-0.283,0.564]",0.516,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0007186,pibrentasvir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.0918,-0.031,0.215,"[-0.031,0.215]",0.143,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0005302,pibrentasvir,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.0635,-0.007,0.134,"[-0.007,0.134]",0.077,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0003620,pibrentasvir,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.0359,-0.094,0.166,"[-0.094,0.166]",0.588,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0256528,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pibrentasvir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999820469,0.0062,-1.192,1.205,"[-1.192,1.205]",0.992,13300,21781800,21795100,"Sample size with pibrentasvir, approximately: 13300","Sample size without pibrentasvir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005306,phentermine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,2.3177,2.305,2.331,"[2.305,2.331]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0002909,phentermine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.4947,0.46,0.529,"[0.46,0.529]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005146,phentermine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.4098,0.378,0.441,"[0.378,0.441]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0019369,phentermine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.393,0.358,0.428,"[0.358,0.428]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0011786,phentermine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.3356,0.3,0.371,"[0.3,0.371]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0007027,phentermine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.2038,0.112,0.296,"[0.112,0.296]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005364,phentermine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.186,0.164,0.208,"[0.164,0.208]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005010,phentermine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.1705,0.147,0.194,"[0.147,0.194]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005393,phentermine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.1454,0.079,0.212,"[0.079,0.212]",1.00E-04,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0007186,phentermine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.1069,-0.301,0.515,"[-0.301,0.515]",0.608,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005298,phentermine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0815,0.008,0.155,"[0.008,0.155]",0.03,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0021107,phentermine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.079,0.018,0.14,"[0.018,0.14]",0.012,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0004981,phentermine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0616,-0.136,0.26,"[-0.136,0.26]",0.542,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0002277,phentermine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0263,-0.137,0.19,"[-0.137,0.19]",0.753,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0004425,phentermine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0229,-0.158,0.204,"[-0.158,0.204]",0.803,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005149,phentermine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0162,-0.038,0.07,"[-0.038,0.07]",0.558,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,phentermine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0117,-0.259,0.282,"[-0.259,0.282]",0.932,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0000477,phentermine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0062,-0.115,0.127,"[-0.115,0.127]",0.919,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0004979,phentermine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.005,-0.286,0.296,"[-0.286,0.296]",0.973,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005302,phentermine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0045,-0.15,0.159,"[-0.15,0.159]",0.955,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,phentermine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0038,-0.32,0.328,"[-0.32,0.328]",0.982,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005404,phentermine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0029,-0.167,0.173,"[-0.167,0.173]",0.973,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005101,phentermine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0023,-0.205,0.21,"[-0.205,0.21]",0.983,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005294,phentermine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0019,-0.772,0.776,"[-0.772,0.776]",0.996,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005133,phentermine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0018,-0.097,0.101,"[-0.097,0.101]",0.972,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4771,biolink:associated_with_increased_likelihood_of,MONDO:0005002,phentermine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894099665,0.0017,-0.151,0.155,"[-0.151,0.155]",0.982,177100,21677600,21854700,"Sample size with phentermine, approximately: 177100","Sample size without phentermine, approximately: 21677600",All patients number is approximately: 21854700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0005546,perphenazine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,1.2946,1.231,1.358,"[1.231,1.358]",1.00E-04,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0000424,perphenazine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.4716,0.446,0.497,"[0.446,0.497]",1.00E-04,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0043693,perphenazine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.3124,0.22,0.405,"[0.22,0.405]",1.00E-04,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0005147,perphenazine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.0826,-0.042,0.207,"[-0.042,0.207]",0.193,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0002046,perphenazine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.0745,-0.002,0.151,"[-0.002,0.151]",0.057,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0007186,perphenazine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.0742,-0.217,0.365,"[-0.217,0.365]",0.617,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0002869,perphenazine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.0455,-0.035,0.126,"[-0.035,0.126]",0.266,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,MONDO:0002406,perphenazine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.034,-0.017,0.085,"[-0.017,0.085]",0.194,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4748,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,perphenazine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941412695,0.0253,-0.509,0.559,"[-0.509,0.559]",0.926,23200,21781100,21804300,"Sample size with perphenazine, approximately: 23200","Sample size without perphenazine, approximately: 21781100",All patients number is approximately: 21804300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201560,biolink:associated_with_increased_likelihood_of,MONDO:0005002,peginterferon alfa 2a,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913273469,0.005,-8.226,8.236,"[-8.226,8.236]",0.999,1500,21791100,21792600,"Sample size with peginterferon alfa 2a, approximately: 1500","Sample size without peginterferon alfa 2a, approximately: 21791100",All patients number is approximately: 21792600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0007947,paroxetine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.4892,0.479,0.499,"[0.479,0.499]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005364,paroxetine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.4078,0.399,0.417,"[0.399,0.417]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0007186,paroxetine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.3724,0.361,0.384,"[0.361,0.384]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0018975,paroxetine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.267,0.255,0.279,"[0.255,0.279]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,paroxetine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.2496,0.232,0.267,"[0.232,0.267]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0018177,paroxetine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.2354,0.223,0.248,"[0.223,0.248]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005180,paroxetine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.2304,0.214,0.247,"[0.214,0.247]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0000424,paroxetine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.2127,0.202,0.224,"[0.202,0.224]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004609,paroxetine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.2061,0.194,0.218,"[0.194,0.218]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005116,paroxetine,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.1814,0.154,0.209,"[0.154,0.209]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0009891,paroxetine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.1753,0.162,0.189,"[0.162,0.189]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0007739,paroxetine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.1454,0.127,0.164,"[0.127,0.164]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004648,paroxetine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.1298,0.105,0.155,"[0.105,0.155]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005393,paroxetine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.127,0.104,0.15,"[0.104,0.15]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0003620,paroxetine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.121,0.094,0.148,"[0.094,0.148]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004952,paroxetine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0937,0.057,0.131,"[0.057,0.131]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0002909,paroxetine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0892,0.074,0.105,"[0.074,0.105]",1.00E-04,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005546,paroxetine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0444,0.01,0.079,"[0.01,0.079]",0.012,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,paroxetine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.043,0.002,0.084,"[0.002,0.084]",0.041,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,paroxetine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0388,0.003,0.075,"[0.003,0.075]",0.034,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0011849,paroxetine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0342,0.014,0.055,"[0.014,0.055]",0.001,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005101,paroxetine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.03,-0.003,0.063,"[-0.003,0.063]",0.071,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005388,paroxetine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0297,-0.029,0.088,"[-0.029,0.088]",0.317,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005133,paroxetine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0271,-0.001,0.055,"[-0.001,0.055]",0.058,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004425,paroxetine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0269,-0.046,0.1,"[-0.046,0.1]",0.468,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0013282,paroxetine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0072,-0.061,0.076,"[-0.061,0.076]",0.837,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0019499,paroxetine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0048,-0.233,0.242,"[-0.233,0.242]",0.968,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005711,paroxetine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0038,-0.542,0.549,"[-0.542,0.549]",0.989,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005404,paroxetine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0033,-0.089,0.095,"[-0.089,0.095]",0.945,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0002316,paroxetine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0029,-0.726,0.732,"[-0.726,0.732]",0.994,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0008487,paroxetine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0028,-0.111,0.117,"[-0.111,0.117]",0.962,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004979,paroxetine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0023,-0.164,0.169,"[-0.164,0.169]",0.978,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0019369,paroxetine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0021,-0.097,0.101,"[-0.097,0.101]",0.966,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0008542,paroxetine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0021,-0.105,0.11,"[-0.105,0.11]",0.969,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005149,paroxetine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0019,-0.099,0.102,"[-0.099,0.102]",0.97,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0004975,paroxetine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0012,-0.229,0.232,"[-0.229,0.232]",0.992,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005298,paroxetine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,0.0012,-0.332,0.335,"[-0.332,0.335]",0.994,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005300,paroxetine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,9.00E-04,-0.512,0.514,"[-0.512,0.514]",0.997,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0011429,paroxetine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,7.00E-04,-0.771,0.772,"[-0.771,0.772]",0.999,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005010,paroxetine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,5.00E-04,-62.379,62.38,"[-62.379,62.38]",1,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:43815,biolink:associated_with_increased_likelihood_of,MONDO:0005002,paroxetine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829046781,1.81E-05,-0.198,0.198,"[-0.198,0.198]",1,458300,21532600,21990900,"Sample size with paroxetine, approximately: 458300","Sample size without paroxetine, approximately: 21532600",All patients number is approximately: 21990900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0021187,pamidronate,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,3.245,3.223,3.267,"[3.223,3.267]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0000424,pamidronate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,1.0433,1.015,1.071,"[1.015,1.071]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005148,pamidronate,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.9071,0.877,0.937,"[0.877,0.937]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005392,pamidronate,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.4331,0.407,0.459,"[0.407,0.459]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005010,pamidronate,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.3872,0.356,0.418,"[0.356,0.418]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005393,pamidronate,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.3749,0.333,0.417,"[0.333,0.417]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005388,pamidronate,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.3467,0.262,0.431,"[0.262,0.431]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005180,pamidronate,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.3364,0.313,0.36,"[0.313,0.36]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005294,pamidronate,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.3355,0.306,0.365,"[0.306,0.365]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0004981,pamidronate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.2929,0.264,0.322,"[0.264,0.322]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005300,pamidronate,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.2515,0.228,0.275,"[0.228,0.275]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0007915,pamidronate,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.2282,0.193,0.264,"[0.193,0.264]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005546,pamidronate,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.1453,0.098,0.193,"[0.098,0.193]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0002406,pamidronate,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.1109,0.087,0.135,"[0.087,0.135]",1.00E-04,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0002046,pamidronate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.0513,-0.047,0.15,"[-0.047,0.15]",0.309,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005002,pamidronate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.023,-0.024,0.07,"[-0.024,0.07]",0.335,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0004952,pamidronate,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.0096,-0.141,0.16,"[-0.141,0.16]",0.901,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005146,pamidronate,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.0077,-0.078,0.094,"[-0.078,0.094]",0.861,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0005306,pamidronate,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.007,-0.696,0.71,"[-0.696,0.71]",0.984,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0004975,pamidronate,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.0057,-0.21,0.222,"[-0.21,0.222]",0.959,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0004609,pamidronate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,0.0017,-0.164,0.167,"[-0.164,0.167]",0.984,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4674,biolink:associated_with_increased_likelihood_of,MONDO:0002909,pamidronate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992131566,1.00E-04,-1.091,1.092,"[-1.091,1.092]",1,72800,21770400,21843200,"Sample size with pamidronate, approximately: 72800","Sample size without pamidronate, approximately: 21770400",All patients number is approximately: 21843200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0004425,paliperidone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.6955,0.664,0.727,"[0.664,0.727]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0043693,paliperidone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.3354,0.296,0.374,"[0.296,0.374]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0004981,paliperidone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.2083,0.175,0.241,"[0.175,0.241]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005146,paliperidone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.1443,0.014,0.275,"[0.014,0.275]",0.03,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005364,paliperidone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.1395,0.066,0.213,"[0.066,0.213]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0002277,paliperidone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.1354,0.075,0.195,"[0.075,0.195]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,paliperidone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.1091,0.037,0.182,"[0.037,0.182]",0.003,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0004979,paliperidone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.1047,0.064,0.145,"[0.064,0.145]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0002406,paliperidone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.094,0.045,0.143,"[0.045,0.143]",1.00E-04,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005148,paliperidone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0791,0.009,0.149,"[0.009,0.149]",0.027,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005083,paliperidone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0579,-0.103,0.219,"[-0.103,0.219]",0.481,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0021187,paliperidone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0408,0.01,0.071,"[0.01,0.071]",0.009,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005294,paliperidone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0326,-0.028,0.093,"[-0.028,0.093]",0.289,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0005300,paliperidone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0326,-0.19,0.255,"[-0.19,0.255]",0.774,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0002909,paliperidone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0279,-0.324,0.38,"[-0.324,0.38]",0.876,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0004975,paliperidone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0218,-0.159,0.203,"[-0.159,0.203]",0.813,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0019369,paliperidone,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0114,-0.609,0.632,"[-0.609,0.632]",0.971,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0002046,paliperidone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.007,-0.497,0.511,"[-0.497,0.511]",0.978,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0247256,biolink:associated_with_increased_likelihood_of,MONDO:0007186,paliperidone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950845811,0.0062,-0.745,0.757,"[-0.745,0.757]",0.987,65100,21761400,21826500,"Sample size with paliperidone, approximately: 65100","Sample size without paliperidone, approximately: 21761400",All patients number is approximately: 21826500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3034010,biolink:associated_with_increased_likelihood_of,MONDO:0005149,orlistat,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908830633,0.0099,-1.191,1.211,"[-1.191,1.211]",0.987,8000,21787500,21795500,"Sample size with orlistat, approximately: 8000","Sample size without orlistat, approximately: 21787500",All patients number is approximately: 21795500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3034010,biolink:associated_with_increased_likelihood_of,MONDO:0004981,orlistat,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908830633,7.00E-04,-0.699,0.7,"[-0.699,0.7]",0.998,8000,21787500,21795500,"Sample size with orlistat, approximately: 8000","Sample size without orlistat, approximately: 21787500",All patients number is approximately: 21795500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,MONDO:0005147,omalizumab,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.3158,0.182,0.45,"[0.182,0.45]",1.00E-04,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,MONDO:0005298,omalizumab,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.2531,0.2,0.306,"[0.2,0.306]",1.00E-04,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,MONDO:0013282,omalizumab,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.0283,-0.724,0.781,"[-0.724,0.781]",0.941,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,MONDO:0005546,omalizumab,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.0241,-0.507,0.555,"[-0.507,0.555]",0.929,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,MONDO:0002277,omalizumab,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.0213,-0.906,0.948,"[-0.906,0.948]",0.964,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201589,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,omalizumab,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906861545,0.0179,-1.681,1.717,"[-1.681,1.717]",0.983,15500,21783500,21799000,"Sample size with omalizumab, approximately: 15500","Sample size without omalizumab, approximately: 21783500",All patients number is approximately: 21799000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0004979,olodaterol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,1.7679,1.695,1.84,"[1.695,1.84]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0003620,olodaterol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,1.1108,1.084,1.137,"[1.084,1.137]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0002277,olodaterol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,1.0912,1.06,1.122,"[1.06,1.122]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005178,olodaterol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.576,0.538,0.614,"[0.538,0.614]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005147,olodaterol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.5426,0.512,0.573,"[0.512,0.573]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0018882,olodaterol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.4765,0.441,0.512,"[0.441,0.512]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0010602,olodaterol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.3739,0.339,0.409,"[0.339,0.409]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0007027,olodaterol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.3699,0.323,0.416,"[0.323,0.416]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0021187,olodaterol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.3151,0.277,0.353,"[0.277,0.353]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0011122,olodaterol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.3054,0.267,0.343,"[0.267,0.343]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0009693,olodaterol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.2246,0.154,0.295,"[0.154,0.295]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0043693,olodaterol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.1945,0.158,0.231,"[0.158,0.231]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0011508,olodaterol,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.1546,0.083,0.226,"[0.083,0.226]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,olodaterol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.1539,0.107,0.201,"[0.107,0.201]",1.00E-04,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0007915,olodaterol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0617,-0.121,0.244,"[-0.121,0.244]",0.508,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0002316,olodaterol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0556,-0.048,0.159,"[-0.048,0.159]",0.294,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005083,olodaterol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0479,-0.048,0.144,"[-0.048,0.144]",0.328,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0004648,olodaterol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0375,-0.148,0.223,"[-0.148,0.223]",0.692,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0000424,olodaterol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0207,-0.178,0.219,"[-0.178,0.219]",0.838,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0002869,olodaterol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0148,-0.29,0.319,"[-0.29,0.319]",0.924,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005300,olodaterol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0114,-0.346,0.369,"[-0.346,0.369]",0.95,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005302,olodaterol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.009,-0.146,0.164,"[-0.146,0.164]",0.909,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005002,olodaterol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0066,-0.497,0.51,"[-0.497,0.51]",0.979,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005101,olodaterol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0055,-0.44,0.451,"[-0.44,0.451]",0.981,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005298,olodaterol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0052,-0.463,0.473,"[-0.463,0.473]",0.983,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005301,olodaterol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0022,-0.522,0.527,"[-0.522,0.527]",0.993,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255957,biolink:associated_with_increased_likelihood_of,MONDO:0005294,olodaterol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993826018,0.0021,-0.299,0.304,"[-0.299,0.304]",0.989,99400,21738100,21837500,"Sample size with olodaterol, approximately: 99400","Sample size without olodaterol, approximately: 21738100",All patients number is approximately: 21837500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0018882,olmesartan,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.5025,0.488,0.517,"[0.488,0.517]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0004648,olmesartan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.3913,0.38,0.403,"[0.38,0.403]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005302,olmesartan,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.3089,0.292,0.326,"[0.292,0.326]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005364,olmesartan,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.3032,0.291,0.315,"[0.291,0.315]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0000424,olmesartan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.2837,0.268,0.299,"[0.268,0.299]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,olmesartan,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.2366,0.22,0.254,"[0.22,0.254]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005180,olmesartan,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.2214,0.2,0.243,"[0.2,0.243]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0002277,olmesartan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.1834,0.147,0.22,"[0.147,0.22]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0002046,olmesartan,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.1807,0.146,0.215,"[0.146,0.215]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005404,olmesartan,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.1152,0.073,0.157,"[0.073,0.157]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0043693,olmesartan,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.11,0.088,0.132,"[0.088,0.132]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0007027,olmesartan,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0911,0.064,0.118,"[0.064,0.118]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005178,olmesartan,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0875,0.05,0.125,"[0.05,0.125]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0008599,olmesartan,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0722,0.024,0.12,"[0.024,0.12]",0.003,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0018177,olmesartan,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0696,0.042,0.097,"[0.042,0.097]",1.00E-04,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0008399,olmesartan,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0629,0.018,0.108,"[0.018,0.108]",0.006,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,olmesartan,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.049,0.008,0.09,"[0.008,0.09]",0.02,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0004975,olmesartan,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0279,0,0.056,"[0,0.056]",0.048,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0004979,olmesartan,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0257,-0.074,0.126,"[-0.074,0.126]",0.614,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0021107,olmesartan,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0181,-0.106,0.143,"[-0.106,0.143]",0.775,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0019369,olmesartan,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0159,-0.086,0.118,"[-0.086,0.118]",0.759,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005002,olmesartan,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.012,-0.099,0.123,"[-0.099,0.123]",0.832,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0019350,olmesartan,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.009,-0.172,0.19,"[-0.172,0.19]",0.923,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005298,olmesartan,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0066,-0.199,0.212,"[-0.199,0.212]",0.949,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,olmesartan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0029,-0.032,0.038,"[-0.032,0.038]",0.869,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0004609,olmesartan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,0.0011,-0.523,0.525,"[-0.523,0.525]",0.997,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C21543,biolink:associated_with_increased_likelihood_of,MONDO:0005146,olmesartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903463798,4.00E-04,-0.435,0.435,"[-0.435,0.435]",0.999,287800,21611800,21899600,"Sample size with olmesartan, approximately: 287800","Sample size without olmesartan, approximately: 21611800",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0011786,olanzapine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.6034,0.591,0.616,"[0.591,0.616]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005147,olanzapine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.526,0.52,0.532,"[0.52,0.532]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0000153,olanzapine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.4712,0.461,0.481,"[0.461,0.481]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0009693,olanzapine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.4543,0.448,0.46,"[0.448,0.46]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008738,olanzapine,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.2702,0.263,0.277,"[0.263,0.277]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0000424,olanzapine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.2668,0.259,0.274,"[0.259,0.274]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,olanzapine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.2612,0.223,0.3,"[0.223,0.3]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0007843,olanzapine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.2274,0.221,0.234,"[0.221,0.234]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0000914,olanzapine,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.2204,0.214,0.227,"[0.214,0.227]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0009891,olanzapine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1926,0.186,0.199,"[0.186,0.199]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0002909,olanzapine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1905,0.184,0.197,"[0.184,0.197]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008383,olanzapine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1861,0.18,0.192,"[0.18,0.192]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,olanzapine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1809,0.173,0.188,"[0.173,0.188]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005146,olanzapine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1668,0.149,0.185,"[0.149,0.185]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008377,olanzapine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1603,0.152,0.169,"[0.152,0.169]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0011122,olanzapine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1491,0.141,0.157,"[0.141,0.157]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0004609,olanzapine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1444,0.137,0.152,"[0.137,0.152]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0002316,olanzapine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1405,0.112,0.169,"[0.112,0.169]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008399,olanzapine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1382,0.132,0.144,"[0.132,0.144]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005083,olanzapine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1287,0.11,0.148,"[0.11,0.148]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008678,olanzapine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1237,0.1,0.148,"[0.1,0.148]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0019180,olanzapine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1205,0.109,0.132,"[0.109,0.132]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0019565,olanzapine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1106,0.087,0.134,"[0.087,0.134]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0009061,olanzapine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.107,0.099,0.115,"[0.099,0.115]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0015564,olanzapine,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.1061,0.046,0.166,"[0.046,0.166]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008006,olanzapine,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0947,0.087,0.103,"[0.087,0.103]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005298,olanzapine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0891,-0.001,0.179,"[-0.001,0.179]",0.052,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005392,olanzapine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0629,0.055,0.071,"[0.055,0.071]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0800026,olanzapine,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0596,0.046,0.073,"[0.046,0.073]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0004952,olanzapine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0514,-0.032,0.135,"[-0.032,0.135]",0.227,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0002406,olanzapine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0361,0.025,0.047,"[0.025,0.047]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005009,olanzapine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.035,0.025,0.045,"[0.025,0.045]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0015924,olanzapine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0349,0.026,0.043,"[0.026,0.043]",1.00E-04,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0010602,olanzapine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.029,0.009,0.049,"[0.009,0.049]",0.005,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0019369,olanzapine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0247,-0.01,0.06,"[-0.01,0.06]",0.167,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0007915,olanzapine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0223,0.009,0.036,"[0.009,0.036]",0.001,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005388,olanzapine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0221,-0.091,0.136,"[-0.091,0.136]",0.703,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0007739,olanzapine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0219,-0.006,0.049,"[-0.006,0.049]",0.121,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005011,olanzapine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0101,-0.069,0.089,"[-0.069,0.089]",0.804,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005364,olanzapine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0073,-0.113,0.128,"[-0.113,0.128]",0.906,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0010383,olanzapine,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0072,-0.127,0.141,"[-0.127,0.141]",0.916,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0021187,olanzapine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0049,-0.515,0.525,"[-0.515,0.525]",0.985,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0004975,olanzapine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0046,-0.139,0.148,"[-0.139,0.148]",0.95,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0020066,olanzapine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.003,-0.351,0.357,"[-0.351,0.357]",0.987,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0043693,olanzapine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0017,-0.15,0.153,"[-0.15,0.153]",0.982,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0019499,olanzapine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0016,-0.458,0.461,"[-0.458,0.461]",0.994,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0018882,olanzapine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0015,-0.276,0.279,"[-0.276,0.279]",0.992,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005404,olanzapine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,0.0011,-0.08,0.082,"[-0.08,0.082]",0.978,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0004425,olanzapine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,8.00E-04,-0.703,0.704,"[-0.703,0.704]",0.998,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0007947,olanzapine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,6.00E-04,-0.353,0.354,"[-0.353,0.354]",0.998,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0005133,olanzapine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,4.00E-04,-4.463,4.463,"[-4.463,4.463]",1,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:94534,biolink:associated_with_increased_likelihood_of,MONDO:0008300,olanzapine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946736854,1.31E-05,-0.152,0.152,"[-0.152,0.152]",1,2269300,20975100,23244400,"Sample size with olanzapine, approximately: 2269300","Sample size without olanzapine, approximately: 20975100",All patients number is approximately: 23244400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:8254,biolink:associated_with_increased_likelihood_of,MONDO:0002869,ofatumumab,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919134806,0.0049,-0.908,0.918,"[-0.908,0.918]",0.992,2500,21790500,21793000,"Sample size with ofatumumab, approximately: 2500","Sample size without ofatumumab, approximately: 21790500",All patients number is approximately: 21793000,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C1882138,biolink:associated_with_increased_likelihood_of,MONDO:0021187,ocrelizumab,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95556459,0.3664,-0.031,0.764,"[-0.031,0.764]",0.071,8200,21786600,21794800,"Sample size with ocrelizumab, approximately: 8200","Sample size without ocrelizumab, approximately: 21786600",All patients number is approximately: 21794800,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C1882138,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ocrelizumab,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95556459,0.003,-0.937,0.943,"[-0.937,0.943]",0.995,8200,21786600,21794800,"Sample size with ocrelizumab, approximately: 8200","Sample size without ocrelizumab, approximately: 21786600",All patients number is approximately: 21794800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0003620,nortriptyline,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.8221,0.803,0.842,"[0.803,0.842]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005364,nortriptyline,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.4783,0.469,0.487,"[0.469,0.487]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nortriptyline,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.4449,0.434,0.456,"[0.434,0.456]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005178,nortriptyline,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.2815,0.269,0.294,"[0.269,0.294]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0018177,nortriptyline,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.208,0.194,0.222,"[0.194,0.222]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0004981,nortriptyline,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.196,0.147,0.245,"[0.147,0.245]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005393,nortriptyline,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1926,0.176,0.209,"[0.176,0.209]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,nortriptyline,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1883,0.171,0.205,"[0.171,0.205]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0004648,nortriptyline,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1611,0.136,0.186,"[0.136,0.186]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0015564,nortriptyline,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1505,0.129,0.172,"[0.129,0.172]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005180,nortriptyline,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1445,0.128,0.161,"[0.128,0.161]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,nortriptyline,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1334,0.111,0.156,"[0.111,0.156]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0010602,nortriptyline,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1323,0.119,0.145,"[0.119,0.145]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005301,nortriptyline,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.1025,0.076,0.13,"[0.076,0.13]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005011,nortriptyline,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0865,0.064,0.109,"[0.064,0.109]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0009891,nortriptyline,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0814,0.069,0.094,"[0.069,0.094]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005306,nortriptyline,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0721,0.055,0.089,"[0.055,0.089]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0019565,nortriptyline,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0697,0.013,0.126,"[0.013,0.126]",0.016,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0002277,nortriptyline,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0689,0.038,0.1,"[0.038,0.1]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0002046,nortriptyline,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.068,0.05,0.086,"[0.05,0.086]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0009693,nortriptyline,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0579,0.044,0.072,"[0.044,0.072]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0008599,nortriptyline,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0532,0.043,0.064,"[0.043,0.064]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nortriptyline,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0509,0.002,0.1,"[0.002,0.1]",0.043,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0004975,nortriptyline,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0502,0.035,0.066,"[0.035,0.066]",1.00E-04,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0002406,nortriptyline,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0408,-0.011,0.092,"[-0.011,0.092]",0.121,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,nortriptyline,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0328,0.002,0.063,"[0.002,0.063]",0.034,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005149,nortriptyline,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0307,0.001,0.06,"[0.001,0.06]",0.042,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005404,nortriptyline,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0307,-0.02,0.081,"[-0.02,0.081]",0.237,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0008542,nortriptyline,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0281,-0.035,0.091,"[-0.035,0.091]",0.38,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0002316,nortriptyline,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0269,-0.022,0.075,"[-0.022,0.075]",0.278,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0000477,nortriptyline,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0139,-0.067,0.095,"[-0.067,0.095]",0.737,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005392,nortriptyline,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0128,-0.05,0.076,"[-0.05,0.076]",0.689,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0002909,nortriptyline,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0096,-0.127,0.146,"[-0.127,0.146]",0.89,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0021107,nortriptyline,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0087,-0.141,0.158,"[-0.141,0.158]",0.909,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0011508,nortriptyline,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0055,-0.174,0.184,"[-0.174,0.184]",0.952,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,nortriptyline,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0053,-0.214,0.224,"[-0.214,0.224]",0.962,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005146,nortriptyline,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.005,-0.259,0.269,"[-0.259,0.269]",0.97,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005302,nortriptyline,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0049,-0.22,0.23,"[-0.22,0.23]",0.966,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0004609,nortriptyline,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0037,-0.355,0.363,"[-0.355,0.363]",0.984,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0011429,nortriptyline,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0013,-0.202,0.205,"[-0.202,0.205]",0.99,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0004425,nortriptyline,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0011,-0.791,0.794,"[-0.791,0.794]",0.998,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005300,nortriptyline,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.0011,-0.467,0.469,"[-0.467,0.469]",0.996,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0007827,nortriptyline,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,0.001,-0.886,0.888,"[-0.886,0.888]",0.998,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005010,nortriptyline,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,8.00E-04,-55.672,55.674,"[-55.672,55.674]",1,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005101,nortriptyline,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,7.00E-04,-0.182,0.183,"[-0.182,0.183]",0.994,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005294,nortriptyline,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,5.00E-04,-0.175,0.176,"[-0.175,0.176]",0.995,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0007947,nortriptyline,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,2.00E-04,-0.013,0.014,"[-0.013,0.014]",0.972,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4543,biolink:associated_with_increased_likelihood_of,MONDO:0005546,nortriptyline,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837111357,3.94E-05,-0.371,0.371,"[-0.371,0.371]",1,469500,21550500,22020000,"Sample size with nortriptyline, approximately: 469500","Sample size without nortriptyline, approximately: 21550500",All patients number is approximately: 22020000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0015924,nitroglycerin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.3473,0.342,0.353,"[0.342,0.353]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0010602,nitroglycerin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.3473,0.342,0.353,"[0.342,0.353]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005009,nitroglycerin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.3413,0.333,0.349,"[0.333,0.349]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004975,nitroglycerin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.3352,0.311,0.36,"[0.311,0.36]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0019180,nitroglycerin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.2245,0.216,0.233,"[0.216,0.233]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,nitroglycerin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.2083,0.202,0.214,"[0.202,0.214]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0009693,nitroglycerin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1883,0.172,0.205,"[0.172,0.205]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0015614,nitroglycerin,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1856,0.181,0.191,"[0.181,0.191]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0000914,nitroglycerin,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1685,0.16,0.177,"[0.16,0.177]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004609,nitroglycerin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1623,0.155,0.169,"[0.155,0.169]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008394,nitroglycerin,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1231,0.113,0.133,"[0.113,0.133]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0000424,nitroglycerin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1211,0.114,0.128,"[0.114,0.128]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0009891,nitroglycerin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.1134,0.106,0.12,"[0.106,0.12]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008377,nitroglycerin,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0922,0.083,0.101,"[0.083,0.101]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nitroglycerin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0669,0.024,0.11,"[0.024,0.11]",0.002,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0021187,nitroglycerin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0607,0.027,0.094,"[0.027,0.094]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008383,nitroglycerin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0567,0.052,0.061,"[0.052,0.061]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0006694,nitroglycerin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0495,0.042,0.057,"[0.042,0.057]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005393,nitroglycerin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.047,0.039,0.055,"[0.039,0.055]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0002277,nitroglycerin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0447,-0.04,0.129,"[-0.04,0.129]",0.3,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0002046,nitroglycerin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0415,0.014,0.069,"[0.014,0.069]",0.003,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008399,nitroglycerin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0387,0.033,0.045,"[0.033,0.045]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004648,nitroglycerin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.031,0.027,0.035,"[0.027,0.035]",1.00E-04,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0019118,nitroglycerin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0295,-0.006,0.065,"[-0.006,0.065]",0.105,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0007739,nitroglycerin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0263,0.002,0.05,"[0.002,0.05]",0.032,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005404,nitroglycerin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0239,0.002,0.046,"[0.002,0.046]",0.033,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0007818,nitroglycerin,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0235,-0.013,0.06,"[-0.013,0.06]",0.202,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005711,nitroglycerin,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0198,0.006,0.034,"[0.006,0.034]",0.005,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,nitroglycerin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0198,-0.041,0.081,"[-0.041,0.081]",0.523,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005010,nitroglycerin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0188,-0.016,0.053,"[-0.016,0.053]",0.288,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004979,nitroglycerin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0173,-0.02,0.055,"[-0.02,0.055]",0.369,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005011,nitroglycerin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.016,-0.044,0.076,"[-0.044,0.076]",0.602,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,nitroglycerin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0159,-0.026,0.058,"[-0.026,0.058]",0.455,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0010789,nitroglycerin,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0054,-0.106,0.117,"[-0.106,0.117]",0.924,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nitroglycerin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0041,-0.078,0.086,"[-0.078,0.086]",0.922,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005146,nitroglycerin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.004,-0.097,0.105,"[-0.097,0.105]",0.939,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004952,nitroglycerin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.004,-0.147,0.155,"[-0.147,0.155]",0.958,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0800026,nitroglycerin,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0036,-0.13,0.138,"[-0.13,0.138]",0.958,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0007827,nitroglycerin,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0031,-0.218,0.224,"[-0.218,0.224]",0.978,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0010383,nitroglycerin,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0026,-0.2,0.205,"[-0.2,0.205]",0.98,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0004425,nitroglycerin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0023,-0.083,0.088,"[-0.083,0.088]",0.958,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0002406,nitroglycerin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0023,-0.088,0.092,"[-0.088,0.092]",0.96,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0018882,nitroglycerin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0022,-0.22,0.224,"[-0.22,0.224]",0.984,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005392,nitroglycerin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0021,-0.214,0.218,"[-0.214,0.218]",0.985,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005364,nitroglycerin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0017,-0.043,0.046,"[-0.043,0.046]",0.94,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0007540,nitroglycerin,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0016,-0.134,0.138,"[-0.134,0.138]",0.981,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0013282,nitroglycerin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0016,-0.143,0.147,"[-0.143,0.147]",0.983,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0015564,nitroglycerin,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.0012,-0.271,0.273,"[-0.271,0.273]",0.993,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008542,nitroglycerin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,0.001,-0.121,0.123,"[-0.121,0.123]",0.987,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0043693,nitroglycerin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,9.00E-04,-0.709,0.71,"[-0.709,0.71]",0.998,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0011429,nitroglycerin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,8.00E-04,-0.143,0.144,"[-0.143,0.144]",0.992,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0008487,nitroglycerin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,8.00E-04,-0.232,0.234,"[-0.232,0.234]",0.994,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005306,nitroglycerin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,7.00E-04,-0.417,0.418,"[-0.417,0.418]",0.998,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0019350,nitroglycerin,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,7.00E-04,-0.165,0.166,"[-0.165,0.166]",0.994,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0002316,nitroglycerin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,7.00E-04,-0.371,0.373,"[-0.371,0.373]",0.997,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0011786,nitroglycerin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,4.00E-04,-0.326,0.327,"[-0.326,0.327]",0.998,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4510,biolink:associated_with_increased_likelihood_of,MONDO:0005294,nitroglycerin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953888443,4.00E-04,-0.484,0.485,"[-0.484,0.485]",0.999,5281200,19762300,25043500,"Sample size with nitroglycerin, approximately: 5281200","Sample size without nitroglycerin, approximately: 19762300",All patients number is approximately: 25043500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0019369,nifedipine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.7595,0.752,0.767,"[0.752,0.767]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005010,nifedipine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.5782,0.569,0.587,"[0.569,0.587]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005546,nifedipine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.3874,0.377,0.397,"[0.377,0.397]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005364,nifedipine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.3872,0.223,0.552,"[0.223,0.552]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0010602,nifedipine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.3452,0.336,0.354,"[0.336,0.354]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005180,nifedipine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.244,0.231,0.257,"[0.231,0.257]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005404,nifedipine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.224,0.202,0.246,"[0.202,0.246]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0007947,nifedipine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.2089,0.198,0.22,"[0.198,0.22]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0009891,nifedipine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.1141,0.103,0.125,"[0.103,0.125]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0008383,nifedipine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.1088,0.076,0.142,"[0.076,0.142]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nifedipine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0757,0.055,0.097,"[0.055,0.097]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005147,nifedipine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0705,0.055,0.086,"[0.055,0.086]",1.00E-04,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0004981,nifedipine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0476,0.001,0.094,"[0.001,0.094]",0.045,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005178,nifedipine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0283,0.003,0.053,"[0.003,0.053]",0.027,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nifedipine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0238,-0.018,0.066,"[-0.018,0.066]",0.269,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0004952,nifedipine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0216,-0.025,0.068,"[-0.025,0.068]",0.36,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005294,nifedipine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0112,-0.114,0.137,"[-0.114,0.137]",0.86,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0003620,nifedipine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0088,-0.081,0.099,"[-0.081,0.099]",0.848,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0015924,nifedipine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0065,-0.053,0.066,"[-0.053,0.066]",0.83,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0008599,nifedipine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0053,-0.003,0.014,"[-0.003,0.014]",0.2,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005388,nifedipine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0053,-0.175,0.186,"[-0.175,0.186]",0.954,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0013282,nifedipine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0043,-0.076,0.085,"[-0.076,0.085]",0.916,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005298,nifedipine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0016,-0.058,0.061,"[-0.058,0.061]",0.957,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,nifedipine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0013,-0.095,0.097,"[-0.095,0.097]",0.98,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0018882,nifedipine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,0.0012,-0.357,0.36,"[-0.357,0.36]",0.995,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0005133,nifedipine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,8.00E-04,-0.549,0.551,"[-0.549,0.551]",0.998,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4485,biolink:associated_with_increased_likelihood_of,MONDO:0019350,nifedipine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919210686,2.00E-04,-0.268,0.268,"[-0.268,0.268]",0.999,872400,21422800,22295200,"Sample size with nifedipine, approximately: 872400","Sample size without nifedipine, approximately: 21422800",All patients number is approximately: 22295200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008487,nicotine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.9623,0.957,0.967,"[0.957,0.967]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008377,nicotine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.55,0.546,0.554,"[0.546,0.554]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005083,nicotine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.5434,0.53,0.556,"[0.53,0.556]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008738,nicotine,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.4294,0.424,0.435,"[0.424,0.435]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008678,nicotine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.4171,0.402,0.432,"[0.402,0.432]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0009891,nicotine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.3066,0.301,0.312,"[0.301,0.312]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005711,nicotine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.2985,0.275,0.322,"[0.275,0.322]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0006694,nicotine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.2034,0.197,0.21,"[0.197,0.21]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005178,nicotine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1715,0.159,0.184,"[0.159,0.184]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0007739,nicotine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1505,0.116,0.185,"[0.116,0.185]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005147,nicotine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1351,0.122,0.148,"[0.122,0.148]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005388,nicotine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1283,0.122,0.135,"[0.122,0.135]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008300,nicotine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1273,0.103,0.152,"[0.103,0.152]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0001516,nicotine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.1058,0.1,0.112,"[0.1,0.112]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0020066,nicotine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0774,0.067,0.088,"[0.067,0.088]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008383,nicotine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0708,0.042,0.1,"[0.042,0.1]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008644,nicotine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0623,0.056,0.068,"[0.056,0.068]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005404,nicotine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0529,0.031,0.075,"[0.031,0.075]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nicotine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0411,0.009,0.073,"[0.009,0.073]",0.011,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0011849,nicotine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0369,0.027,0.047,"[0.027,0.047]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005364,nicotine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.035,0.024,0.046,"[0.024,0.046]",1.00E-04,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005009,nicotine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0301,-0.005,0.065,"[-0.005,0.065]",0.093,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nicotine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0285,0.009,0.048,"[0.009,0.048]",0.004,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0004981,nicotine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0262,-0.03,0.083,"[-0.03,0.083]",0.363,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0013282,nicotine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0189,-0.061,0.098,"[-0.061,0.098]",0.641,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0019369,nicotine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0101,-0.025,0.045,"[-0.025,0.045]",0.569,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005146,nicotine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0097,-0.093,0.112,"[-0.093,0.112]",0.853,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0007160,nicotine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0088,-0.033,0.051,"[-0.033,0.051]",0.682,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0000153,nicotine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0079,-0.129,0.145,"[-0.129,0.145]",0.91,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0021187,nicotine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0068,-0.358,0.371,"[-0.358,0.371]",0.971,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0010602,nicotine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0067,-0.014,0.028,"[-0.014,0.028]",0.531,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0000424,nicotine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0057,-0.002,0.014,"[-0.002,0.014]",0.148,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005011,nicotine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.004,-0.068,0.076,"[-0.068,0.076]",0.914,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0007947,nicotine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0029,-0.1,0.106,"[-0.1,0.106]",0.955,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005298,nicotine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0018,-0.294,0.298,"[-0.294,0.298]",0.991,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0043693,nicotine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0014,-0.424,0.427,"[-0.424,0.427]",0.995,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0002316,nicotine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,0.0012,-4.182,4.185,"[-4.182,4.185]",1,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0008542,nicotine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,7.00E-04,-0.266,0.267,"[-0.266,0.267]",0.996,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,nicotine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,6.00E-04,-1.213,1.214,"[-1.213,1.214]",0.999,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0005301,nicotine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,3.00E-04,-0.441,0.441,"[-0.441,0.441]",0.999,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:89594,biolink:associated_with_increased_likelihood_of,MONDO:0019180,nicotine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93583114,1.00E-04,-0.083,0.083,"[-0.083,0.083]",0.998,2486800,20804700,23291500,"Sample size with nicotine, approximately: 2486800","Sample size without nicotine, approximately: 20804700",All patients number is approximately: 23291500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0018975,nicardipine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.8426,0.834,0.851,"[0.834,0.851]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0013282,nicardipine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.7302,0.723,0.737,"[0.723,0.737]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0010602,nicardipine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.6992,0.69,0.708,"[0.69,0.708]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0000914,nicardipine,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.6482,0.641,0.656,"[0.641,0.656]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0004952,nicardipine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.584,0.577,0.591,"[0.577,0.591]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005101,nicardipine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.5747,0.568,0.582,"[0.568,0.582]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005180,nicardipine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.347,0.328,0.366,"[0.328,0.366]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005130,nicardipine,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.3241,0.31,0.338,"[0.31,0.338]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0006640,nicardipine,adrenal cushing syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.2781,0.269,0.287,"[0.269,0.287]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005147,nicardipine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.2086,0.201,0.217,"[0.201,0.217]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0004979,nicardipine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.1991,0.188,0.21,"[0.188,0.21]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005083,nicardipine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.1678,0.146,0.189,"[0.146,0.189]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0015263,nicardipine,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.1286,0.12,0.138,"[0.12,0.138]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nicardipine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.1192,0.104,0.135,"[0.104,0.135]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0004975,nicardipine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0962,0.063,0.13,"[0.063,0.13]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0008644,nicardipine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0557,0.042,0.069,"[0.042,0.069]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0018177,nicardipine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.038,0.02,0.056,"[0.02,0.056]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0009693,nicardipine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0218,0.01,0.034,"[0.01,0.034]",1.00E-04,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005546,nicardipine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0175,0,0.035,"[0,0.035]",0.047,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0004981,nicardipine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0124,-0.042,0.067,"[-0.042,0.067]",0.657,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0043693,nicardipine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.009,-0.094,0.112,"[-0.094,0.112]",0.864,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nicardipine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0086,-0.105,0.122,"[-0.105,0.122]",0.882,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0002909,nicardipine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0057,-0.038,0.049,"[-0.038,0.049]",0.796,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005148,nicardipine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0055,-0.057,0.068,"[-0.057,0.068]",0.862,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0000477,nicardipine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0048,-0.132,0.142,"[-0.132,0.142]",0.946,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0006058,nicardipine,nephroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0048,-0.008,0.018,"[-0.008,0.018]",0.456,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0002406,nicardipine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0039,-0.041,0.049,"[-0.041,0.049]",0.864,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0001676,nicardipine,erythropoietic protoporphyria,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0028,-0.206,0.212,"[-0.206,0.212]",0.979,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0004648,nicardipine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0026,-0.17,0.175,"[-0.17,0.175]",0.976,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005711,nicardipine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0025,-0.15,0.155,"[-0.15,0.155]",0.974,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0008542,nicardipine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.002,-0.236,0.24,"[-0.236,0.24]",0.987,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0008487,nicardipine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0015,-0.334,0.337,"[-0.334,0.337]",0.993,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005306,nicardipine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.0015,-0.21,0.213,"[-0.21,0.213]",0.989,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0019369,nicardipine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.001,-0.431,0.433,"[-0.431,0.433]",0.996,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0011786,nicardipine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.001,-0.431,0.433,"[-0.431,0.433]",0.996,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0005364,nicardipine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,0.001,-0.174,0.175,"[-0.174,0.175]",0.991,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0020066,nicardipine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,6.00E-04,-0.429,0.43,"[-0.429,0.43]",0.998,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4474,biolink:associated_with_increased_likelihood_of,MONDO:0011429,nicardipine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.984835776,5.00E-04,-0.254,0.255,"[-0.254,0.255]",0.997,1859100,21317100,23176200,"Sample size with nicardipine, approximately: 1859100","Sample size without nicardipine, approximately: 21317100",All patients number is approximately: 23176200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0007947,niacin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.4817,0.473,0.491,"[0.473,0.491]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0002909,niacin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.4775,0.47,0.485,"[0.47,0.485]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005010,niacin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.322,0.298,0.346,"[0.298,0.346]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0007903,niacin,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.2991,0.288,0.31,"[0.288,0.31]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0009891,niacin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.2926,0.282,0.303,"[0.282,0.303]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0015263,niacin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.2901,0.28,0.3,"[0.28,0.3]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005392,niacin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.2419,0.232,0.252,"[0.232,0.252]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005546,niacin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.2382,0.228,0.248,"[0.228,0.248]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0019118,niacin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.1322,0.09,0.175,"[0.09,0.175]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0008383,niacin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.125,0.112,0.138,"[0.112,0.138]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0000914,niacin,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.1113,0.101,0.122,"[0.101,0.122]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0019499,niacin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.1075,0.088,0.127,"[0.088,0.127]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005178,niacin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.1002,0.087,0.114,"[0.087,0.114]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005011,niacin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0964,0.086,0.107,"[0.086,0.107]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005009,niacin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0916,0.078,0.105,"[0.078,0.105]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0008300,niacin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0842,0.071,0.098,"[0.071,0.098]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0008542,niacin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0775,0.06,0.095,"[0.06,0.095]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0002046,niacin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0771,0.029,0.125,"[0.029,0.125]",0.002,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,niacin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0767,0.067,0.087,"[0.067,0.087]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0002316,niacin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0747,0.048,0.101,"[0.048,0.101]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0019350,niacin,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0648,0.037,0.093,"[0.037,0.093]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005147,niacin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0643,0.051,0.078,"[0.051,0.078]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0006694,niacin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0433,0.025,0.061,"[0.025,0.061]",1.00E-04,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0007186,niacin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0312,-0.053,0.115,"[-0.053,0.115]",0.468,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005404,niacin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0268,-0.011,0.065,"[-0.011,0.065]",0.166,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0021187,niacin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0219,0,0.044,"[0,0.044]",0.048,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005294,niacin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0192,-0.046,0.084,"[-0.046,0.084]",0.563,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005301,niacin,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.017,-0.041,0.075,"[-0.041,0.075]",0.564,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0004979,niacin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0152,-0.048,0.078,"[-0.048,0.078]",0.636,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,niacin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0145,-0.084,0.113,"[-0.084,0.113]",0.773,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0007739,niacin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0122,-0.123,0.148,"[-0.123,0.148]",0.86,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005002,niacin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0103,-0.096,0.117,"[-0.096,0.117]",0.85,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0019180,niacin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0078,-0.123,0.139,"[-0.123,0.139]",0.907,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0008487,niacin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0066,-0.204,0.217,"[-0.204,0.217]",0.951,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0011786,niacin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0057,-0.387,0.398,"[-0.387,0.398]",0.977,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0019369,niacin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0054,-0.16,0.171,"[-0.16,0.171]",0.949,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0004425,niacin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0046,-0.314,0.323,"[-0.314,0.323]",0.977,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005083,niacin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0038,-0.232,0.239,"[-0.232,0.239]",0.975,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0018882,niacin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0026,-0.367,0.372,"[-0.367,0.372]",0.989,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005146,niacin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0022,-0.157,0.161,"[-0.157,0.161]",0.978,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0000153,niacin,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0018,-0.108,0.112,"[-0.108,0.112]",0.974,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0020066,niacin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0017,-0.183,0.186,"[-0.183,0.186]",0.985,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0043693,niacin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0014,-0.24,0.242,"[-0.24,0.242]",0.991,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0004648,niacin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.0012,-0.167,0.17,"[-0.167,0.17]",0.989,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005364,niacin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,0.001,-0.264,0.266,"[-0.264,0.266]",0.994,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0011508,niacin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,6.00E-04,-0.101,0.102,"[-0.101,0.102]",0.991,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:936,biolink:associated_with_increased_likelihood_of,MONDO:0005298,niacin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.837843748,2.00E-04,-0.141,0.141,"[-0.141,0.141]",0.997,763000,21403000,22166000,"Sample size with niacin, approximately: 763000","Sample size without niacin, approximately: 21403000",All patients number is approximately: 22166000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4463,biolink:associated_with_increased_likelihood_of,MONDO:0005009,nevirapine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993372347,0.3706,-0.841,1.582,"[-0.841,1.582]",0.549,3500,21790300,21793800,"Sample size with nevirapine, approximately: 3500","Sample size without nevirapine, approximately: 21790300",All patients number is approximately: 21793800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4463,biolink:associated_with_increased_likelihood_of,MONDO:0011786,nevirapine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993372347,0.104,-0.86,1.068,"[-0.86,1.068]",0.832,3500,21790300,21793800,"Sample size with nevirapine, approximately: 3500","Sample size without nevirapine, approximately: 21790300",All patients number is approximately: 21793800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4463,biolink:associated_with_increased_likelihood_of,MONDO:0005298,nevirapine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993372347,0.0129,-1.029,1.055,"[-1.029,1.055]",0.981,3500,21790300,21793800,"Sample size with nevirapine, approximately: 3500","Sample size without nevirapine, approximately: 21790300",All patients number is approximately: 21793800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005101,nebivolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,1.2767,1.257,1.296,"[1.257,1.296]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005010,nebivolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.7828,0.764,0.801,"[0.764,0.801]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,nebivolol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.6727,0.656,0.69,"[0.656,0.69]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0003620,nebivolol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.6414,0.625,0.658,"[0.625,0.658]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005133,nebivolol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.634,0.611,0.657,"[0.611,0.657]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005148,nebivolol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.4209,0.395,0.447,"[0.395,0.447]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0000424,nebivolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.3023,0.278,0.327,"[0.278,0.327]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0006694,nebivolol,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.2173,0.185,0.249,"[0.185,0.249]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0008599,nebivolol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.162,0.133,0.191,"[0.133,0.191]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005298,nebivolol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.1431,0.093,0.194,"[0.093,0.194]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005392,nebivolol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.1244,0.101,0.147,"[0.101,0.147]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0007027,nebivolol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.114,0.084,0.144,"[0.084,0.144]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005011,nebivolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0952,0.07,0.12,"[0.07,0.12]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005546,nebivolol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0874,0.062,0.113,"[0.062,0.113]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005178,nebivolol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0728,0.041,0.104,"[0.041,0.104]",1.00E-04,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,nebivolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0658,0.028,0.103,"[0.028,0.103]",0.001,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0043693,nebivolol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0649,0.023,0.107,"[0.023,0.107]",0.002,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nebivolol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0199,-0.201,0.241,"[-0.201,0.241]",0.86,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0011786,nebivolol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0178,-0.203,0.239,"[-0.203,0.239]",0.874,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0002406,nebivolol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.017,-0.257,0.29,"[-0.257,0.29]",0.903,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0004975,nebivolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0129,-0.105,0.131,"[-0.105,0.131]",0.831,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005302,nebivolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0074,-0.148,0.163,"[-0.148,0.163]",0.925,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0005300,nebivolol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0071,-0.226,0.24,"[-0.226,0.24]",0.952,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0011508,nebivolol,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,0.0018,-0.214,0.218,"[-0.214,0.218]",0.987,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,nebivolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,8.00E-04,-0.824,0.825,"[-0.824,0.825]",0.998,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0007915,nebivolol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,4.00E-04,-0.172,0.172,"[-0.172,0.172]",0.996,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:71301,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nebivolol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895479125,3.00E-04,-0.177,0.178,"[-0.177,0.178]",0.998,127900,21716300,21844200,"Sample size with nebivolol, approximately: 127900","Sample size without nebivolol, approximately: 21716300",All patients number is approximately: 21844200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0021187,nateglinide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.8322,0.79,0.874,"[0.79,0.874]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0008383,nateglinide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.4769,0.437,0.517,"[0.437,0.517]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0004981,nateglinide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.287,0.247,0.327,"[0.247,0.327]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0004648,nateglinide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.2865,0.225,0.348,"[0.225,0.348]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0006694,nateglinide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.264,0.23,0.298,"[0.23,0.298]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0002277,nateglinide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.2467,0.195,0.298,"[0.195,0.298]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005393,nateglinide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.2424,0.207,0.278,"[0.207,0.278]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005148,nateglinide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.2029,0.022,0.384,"[0.022,0.384]",0.028,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0009693,nateglinide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.1281,0.076,0.18,"[0.076,0.18]",1.00E-04,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005146,nateglinide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.1265,0.029,0.224,"[0.029,0.224]",0.011,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005010,nateglinide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0978,0.015,0.181,"[0.015,0.181]",0.02,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005147,nateglinide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.065,-0.026,0.156,"[-0.026,0.156]",0.163,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,nateglinide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0545,-0.023,0.132,"[-0.023,0.132]",0.167,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005298,nateglinide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0172,-0.144,0.178,"[-0.144,0.178]",0.834,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0007915,nateglinide,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0146,-0.295,0.324,"[-0.295,0.324]",0.926,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,nateglinide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0055,-0.423,0.434,"[-0.423,0.434]",0.98,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0002406,nateglinide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0049,-0.114,0.124,"[-0.114,0.124]",0.936,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0011849,nateglinide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0022,-0.061,0.065,"[-0.061,0.065]",0.945,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0005294,nateglinide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,0.0021,-0.631,0.635,"[-0.631,0.635]",0.995,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL783,biolink:associated_with_increased_likelihood_of,MONDO:0007186,nateglinide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961443944,9.00E-04,-0.227,0.229,"[-0.227,0.229]",0.994,32200,21775100,21807300,"Sample size with nateglinide, approximately: 32200","Sample size without nateglinide, approximately: 21775100",All patients number is approximately: 21807300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005149,naproxen,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.8967,0.89,0.903,"[0.89,0.903]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0019118,naproxen,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.6818,0.674,0.69,"[0.674,0.69]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005301,naproxen,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.6479,0.641,0.655,"[0.641,0.655]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0015263,naproxen,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.3164,0.308,0.325,"[0.308,0.325]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005546,naproxen,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.2931,0.288,0.299,"[0.288,0.299]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0008399,naproxen,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.2843,0.276,0.293,"[0.276,0.293]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0000914,naproxen,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.2471,0.24,0.255,"[0.24,0.255]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0010602,naproxen,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.2091,0.202,0.217,"[0.202,0.217]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0013282,naproxen,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.1863,0.177,0.195,"[0.177,0.195]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0020066,naproxen,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.1744,0.138,0.211,"[0.138,0.211]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0002406,naproxen,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.1094,0.093,0.126,"[0.093,0.126]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005404,naproxen,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.1058,0.096,0.116,"[0.096,0.116]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0009891,naproxen,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0929,0.085,0.101,"[0.085,0.101]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0007947,naproxen,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0767,0.065,0.088,"[0.065,0.088]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0021187,naproxen,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0756,0.062,0.089,"[0.062,0.089]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005083,naproxen,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0713,0.043,0.1,"[0.043,0.1]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005392,naproxen,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0627,0.047,0.078,"[0.047,0.078]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0008487,naproxen,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0597,0.041,0.079,"[0.041,0.079]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0008383,naproxen,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0538,0.048,0.06,"[0.048,0.06]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005147,naproxen,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.053,0.044,0.062,"[0.044,0.062]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0043693,naproxen,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0519,0.025,0.078,"[0.025,0.078]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,naproxen,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.051,0.033,0.069,"[0.033,0.069]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004425,naproxen,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0349,0.017,0.053,"[0.017,0.053]",1.00E-04,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005146,naproxen,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0336,0.012,0.056,"[0.012,0.056]",0.003,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0019369,naproxen,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.028,-0.02,0.076,"[-0.02,0.076]",0.253,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005011,naproxen,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0269,-0.033,0.087,"[-0.033,0.087]",0.38,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0007186,naproxen,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0264,-0.048,0.101,"[-0.048,0.101]",0.488,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,naproxen,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0233,-0.014,0.061,"[-0.014,0.061]",0.226,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004979,naproxen,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0189,-0.072,0.11,"[-0.072,0.11]",0.685,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005101,naproxen,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0188,0.005,0.033,"[0.005,0.033]",0.007,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0007864,naproxen,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0141,-0.045,0.073,"[-0.045,0.073]",0.641,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0002046,naproxen,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0137,-0.035,0.063,"[-0.035,0.063]",0.583,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004952,naproxen,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0136,-0.006,0.033,"[-0.006,0.033]",0.175,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004648,naproxen,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0135,-0.057,0.084,"[-0.057,0.084]",0.707,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005002,naproxen,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0106,-0.063,0.084,"[-0.063,0.084]",0.777,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004975,naproxen,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0037,-0.107,0.115,"[-0.107,0.115]",0.948,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005300,naproxen,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0034,-0.088,0.095,"[-0.088,0.095]",0.942,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,naproxen,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0027,-0.147,0.152,"[-0.147,0.152]",0.972,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0019499,naproxen,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0024,-0.27,0.275,"[-0.27,0.275]",0.986,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0004609,naproxen,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0024,-0.119,0.123,"[-0.119,0.123]",0.969,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0002277,naproxen,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0012,-0.274,0.277,"[-0.274,0.277]",0.993,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0011786,naproxen,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0011,-0.313,0.315,"[-0.313,0.315]",0.995,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0015924,naproxen,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,0.0011,-0.528,0.53,"[-0.528,0.53]",0.997,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005009,naproxen,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,8.00E-04,-0.063,0.064,"[-0.063,0.064]",0.979,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,naproxen,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,8.00E-04,-0.204,0.206,"[-0.204,0.206]",0.994,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005302,naproxen,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,4.00E-04,-0.11,0.11,"[-0.11,0.11]",0.994,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1302,biolink:associated_with_increased_likelihood_of,MONDO:0005010,naproxen,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.751307717,2.00E-04,-0.243,0.243,"[-0.243,0.243]",0.999,2244400,20247400,22491800,"Sample size with naproxen, approximately: 2244400","Sample size without naproxen, approximately: 20247400",All patients number is approximately: 22491800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0016218,naltrexone,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.6974,0.684,0.711,"[0.684,0.711]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0009891,naltrexone,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.6303,0.602,0.659,"[0.602,0.659]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005364,naltrexone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.5553,0.538,0.573,"[0.538,0.573]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,naltrexone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.4513,0.432,0.47,"[0.432,0.47]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0008006,naltrexone,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.2584,0.237,0.279,"[0.237,0.279]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0002406,naltrexone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.2568,0.229,0.285,"[0.229,0.285]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0003620,naltrexone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.1822,0.152,0.212,"[0.152,0.212]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005133,naltrexone,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.1452,0.118,0.172,"[0.118,0.172]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0007027,naltrexone,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.1151,0.082,0.148,"[0.082,0.148]",1.00E-04,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005404,naltrexone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.1119,0.039,0.185,"[0.039,0.185]",0.003,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,naltrexone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.076,-0.004,0.156,"[-0.004,0.156]",0.061,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0004975,naltrexone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0518,0.014,0.09,"[0.014,0.09]",0.008,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0010561,naltrexone,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0421,-0.009,0.093,"[-0.009,0.093]",0.105,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005301,naltrexone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0404,0.01,0.071,"[0.01,0.071]",0.009,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005146,naltrexone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.023,-0.034,0.08,"[-0.034,0.08]",0.428,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0008487,naltrexone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0183,-0.127,0.164,"[-0.127,0.164]",0.806,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005294,naltrexone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0163,-0.26,0.293,"[-0.26,0.293]",0.908,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005180,naltrexone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0146,-0.046,0.075,"[-0.046,0.075]",0.636,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0004425,naltrexone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0145,-0.102,0.131,"[-0.102,0.131]",0.806,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005298,naltrexone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0115,-0.113,0.136,"[-0.113,0.136]",0.856,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0015924,naltrexone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0109,-0.149,0.171,"[-0.149,0.171]",0.893,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0000477,naltrexone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0097,-0.082,0.102,"[-0.082,0.102]",0.837,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005002,naltrexone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0071,-0.219,0.234,"[-0.219,0.234]",0.951,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0002316,naltrexone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0053,-0.154,0.165,"[-0.154,0.165]",0.948,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005302,naltrexone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0053,-0.357,0.367,"[-0.357,0.367]",0.977,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0004609,naltrexone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0049,-0.465,0.475,"[-0.465,0.475]",0.984,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005148,naltrexone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0023,-0.479,0.484,"[-0.479,0.484]",0.993,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0008383,naltrexone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0015,-3.759,3.762,"[-3.759,3.762]",0.999,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0002909,naltrexone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.0014,-0.339,0.342,"[-0.339,0.342]",0.993,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0008300,naltrexone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,0.001,-0.532,0.534,"[-0.532,0.534]",0.997,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0004648,naltrexone,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,8.00E-04,-0.686,0.687,"[-0.686,0.687]",0.998,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0005010,naltrexone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,6.00E-04,-0.481,0.483,"[-0.481,0.483]",0.998,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0019180,naltrexone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,6.00E-04,-0.331,0.332,"[-0.331,0.332]",0.997,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5360515,biolink:associated_with_increased_likelihood_of,MONDO:0004979,naltrexone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894848878,3.00E-04,-0.259,0.26,"[-0.259,0.26]",0.998,210200,21671400,21881600,"Sample size with naltrexone, approximately: 210200","Sample size without naltrexone, approximately: 21671400",All patients number is approximately: 21881600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005393,nadolol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.5516,0.527,0.576,"[0.527,0.576]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0018882,nadolol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.4543,0.433,0.475,"[0.433,0.475]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0018177,nadolol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.2981,0.273,0.323,"[0.273,0.323]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0008599,nadolol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.2417,0.215,0.268,"[0.215,0.268]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005147,nadolol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.2353,0.213,0.257,"[0.213,0.257]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005148,nadolol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.1189,0.089,0.149,"[0.089,0.149]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0002046,nadolol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.1054,0.045,0.165,"[0.045,0.165]",0.001,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0009693,nadolol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0929,0.053,0.133,"[0.053,0.133]",1.00E-04,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0013282,nadolol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0553,-0.043,0.154,"[-0.043,0.154]",0.271,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0010789,nadolol,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0435,0.019,0.068,"[0.019,0.068]",0.001,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0011122,nadolol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.032,-0.039,0.103,"[-0.039,0.103]",0.376,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0008383,nadolol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0314,-0.003,0.066,"[-0.003,0.066]",0.076,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0007915,nadolol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0266,-0.112,0.166,"[-0.112,0.166]",0.708,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,nadolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0237,-0.171,0.219,"[-0.171,0.219]",0.811,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005294,nadolol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0102,-0.478,0.498,"[-0.478,0.498]",0.967,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0002909,nadolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0075,-1.022,1.037,"[-1.022,1.037]",0.989,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005009,nadolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0065,-0.373,0.386,"[-0.373,0.386]",0.973,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005178,nadolol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0046,-0.03,0.039,"[-0.03,0.039]",0.795,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005388,nadolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0039,-8.865,8.873,"[-8.865,8.873]",0.999,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0002277,nadolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0017,-0.179,0.183,"[-0.179,0.183]",0.985,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005002,nadolol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.0014,-0.479,0.482,"[-0.479,0.482]",0.995,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0002869,nadolol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.001,-1.389,1.391,"[-1.389,1.391]",0.999,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0005392,nadolol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,0.001,-1.317,1.319,"[-1.317,1.319]",0.999,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248375,biolink:associated_with_increased_likelihood_of,MONDO:0004952,nadolol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.919340821,9.00E-04,-0.117,0.119,"[-0.117,0.119]",0.988,91500,21746800,21838300,"Sample size with nadolol, approximately: 91500","Sample size without nadolol, approximately: 21746800",All patients number is approximately: 21838300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0019499,morphine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,1.5231,1.519,1.527,"[1.519,1.527]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005147,morphine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.5533,0.55,0.557,"[0.55,0.557]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0004975,morphine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.365,0.355,0.375,"[0.355,0.375]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0015924,morphine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.159,0.154,0.164,"[0.154,0.164]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0009693,morphine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1499,0.145,0.155,"[0.145,0.155]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0001044,morphine,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1416,0.132,0.151,"[0.132,0.151]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0001516,morphine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1352,0.13,0.14,"[0.13,0.14]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005180,morphine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1343,0.127,0.141,"[0.127,0.141]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0007160,morphine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1048,0.076,0.134,"[0.076,0.134]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0007972,morphine,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.1047,0.099,0.111,"[0.099,0.111]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0000477,morphine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.078,0.063,0.093,"[0.063,0.093]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0019180,morphine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0729,0.069,0.077,"[0.069,0.077]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0015263,morphine,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0721,0.067,0.077,"[0.067,0.077]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0020066,morphine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.067,0.06,0.075,"[0.06,0.075]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0002277,morphine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0609,0.047,0.075,"[0.047,0.075]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0008678,morphine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0552,0.029,0.081,"[0.029,0.081]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0007027,morphine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0391,0.035,0.044,"[0.035,0.044]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005133,morphine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0377,0.014,0.061,"[0.014,0.061]",0.002,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005101,morphine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0296,0.016,0.043,"[0.016,0.043]",1.00E-04,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0800026,morphine,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0271,-0.016,0.07,"[-0.016,0.07]",0.219,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0002406,morphine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.021,0.003,0.039,"[0.003,0.039]",0.022,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0004425,morphine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0163,-0.017,0.05,"[-0.017,0.05]",0.344,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0021107,morphine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.013,-0.011,0.037,"[-0.011,0.037]",0.285,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0008006,morphine,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0117,-0.061,0.084,"[-0.061,0.084]",0.752,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005009,morphine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0112,-0.045,0.067,"[-0.045,0.067]",0.694,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005149,morphine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0075,-0.02,0.036,"[-0.02,0.036]",0.598,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005302,morphine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0068,-0.035,0.048,"[-0.035,0.048]",0.748,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0009264,morphine,gastroschisis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0029,-0.115,0.121,"[-0.115,0.121]",0.962,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0000153,morphine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0021,-0.051,0.055,"[-0.051,0.055]",0.939,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0002909,morphine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0017,-0.024,0.027,"[-0.024,0.027]",0.895,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005546,morphine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,0.0011,-0.114,0.116,"[-0.114,0.116]",0.985,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005300,morphine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,9.00E-04,-0.431,0.433,"[-0.431,0.433]",0.997,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005116,morphine,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,8.00E-04,-0.273,0.275,"[-0.273,0.275]",0.995,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0016218,morphine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,7.00E-04,-0.286,0.287,"[-0.286,0.287]",0.996,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005404,morphine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,6.00E-04,-0.184,0.185,"[-0.184,0.185]",0.995,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0007843,morphine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,4.00E-04,-0.235,0.236,"[-0.235,0.236]",0.997,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0004609,morphine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,4.00E-04,-0.054,0.054,"[-0.054,0.054]",0.987,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005148,morphine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,4.00E-04,-0.145,0.146,"[-0.145,0.146]",0.996,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0008642,morphine,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,3.00E-04,-0.28,0.281,"[-0.28,0.281]",0.998,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0008542,morphine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,3.00E-04,-0.489,0.489,"[-0.489,0.489]",0.999,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005072,morphine,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,3.00E-04,-0.874,0.875,"[-0.874,0.875]",0.999,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0008383,morphine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,2.00E-04,-0.2,0.201,"[-0.2,0.201]",0.999,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0011786,morphine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,2.00E-04,-0.232,0.232,"[-0.232,0.232]",0.999,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,MONDO:0005130,morphine,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,1.00E-04,-0.083,0.083,"[-0.083,0.083]",0.997,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:23253564,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,morphine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.93294607,7.04E-05,-0.381,0.381,"[-0.381,0.381]",1,10076400,16940000,27016400,"Sample size with morphine, approximately: 10076400","Sample size without morphine, approximately: 16940000",All patients number is approximately: 27016400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005083,montelukast,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,1.0431,1.032,1.054,"[1.032,1.054]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0008300,montelukast,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.4981,0.487,0.509,"[0.487,0.509]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,montelukast,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.4712,0.464,0.479,"[0.464,0.479]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,montelukast,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.336,0.325,0.347,"[0.325,0.347]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005388,montelukast,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.2844,0.277,0.292,"[0.277,0.292]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0004981,montelukast,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.259,0.248,0.27,"[0.248,0.27]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0002406,montelukast,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.2044,0.189,0.22,"[0.189,0.22]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005147,montelukast,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.1985,0.19,0.208,"[0.19,0.208]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0021187,montelukast,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.1632,0.147,0.179,"[0.147,0.179]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005180,montelukast,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.1067,0.092,0.122,"[0.092,0.122]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0021107,montelukast,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.1037,0.077,0.13,"[0.077,0.13]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0008542,montelukast,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.1025,0.092,0.113,"[0.092,0.113]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0018975,montelukast,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0886,0.075,0.102,"[0.075,0.102]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0019180,montelukast,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0798,0.056,0.104,"[0.056,0.104]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0000424,montelukast,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0795,0.068,0.091,"[0.068,0.091]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0010602,montelukast,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0758,0.066,0.086,"[0.066,0.086]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0015263,montelukast,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0731,0.063,0.083,"[0.063,0.083]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0000477,montelukast,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0674,0.041,0.094,"[0.041,0.094]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005404,montelukast,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0665,0.053,0.08,"[0.053,0.08]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0009891,montelukast,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0641,0.054,0.074,"[0.054,0.074]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0002316,montelukast,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0631,0.042,0.084,"[0.042,0.084]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0010526,montelukast,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0557,0.02,0.092,"[0.02,0.092]",0.003,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0008399,montelukast,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0497,0.04,0.06,"[0.04,0.06]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005546,montelukast,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0496,0.014,0.085,"[0.014,0.085]",0.006,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005392,montelukast,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.042,0.028,0.056,"[0.028,0.056]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0002909,montelukast,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0393,0.02,0.058,"[0.02,0.058]",1.00E-04,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0008487,montelukast,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0372,0.013,0.061,"[0.013,0.061]",0.002,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0043693,montelukast,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0271,-0.009,0.064,"[-0.009,0.064]",0.145,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0018882,montelukast,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0252,-0.051,0.102,"[-0.051,0.102]",0.519,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005010,montelukast,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0187,-0.055,0.093,"[-0.055,0.093]",0.62,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0013282,montelukast,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0186,-0.011,0.048,"[-0.011,0.048]",0.211,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0007186,montelukast,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0171,0.005,0.03,"[0.005,0.03]",0.007,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0007739,montelukast,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0158,-0.062,0.094,"[-0.062,0.094]",0.692,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0004979,montelukast,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0147,-0.108,0.137,"[-0.108,0.137]",0.813,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0003620,montelukast,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0119,-0.077,0.101,"[-0.077,0.101]",0.794,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005101,montelukast,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0079,-0.103,0.119,"[-0.103,0.119]",0.889,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0019350,montelukast,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0061,-0.121,0.133,"[-0.121,0.133]",0.925,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0002046,montelukast,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0059,-0.051,0.063,"[-0.051,0.063]",0.839,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,montelukast,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0044,-0.492,0.501,"[-0.492,0.501]",0.986,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005364,montelukast,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0044,-0.09,0.099,"[-0.09,0.099]",0.927,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0002277,montelukast,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0032,-0.134,0.141,"[-0.134,0.141]",0.964,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0004609,montelukast,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0029,-0.007,0.012,"[-0.007,0.012]",0.556,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0004975,montelukast,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0017,-0.148,0.152,"[-0.148,0.152]",0.982,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0000153,montelukast,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0016,-0.119,0.122,"[-0.119,0.122]",0.979,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005711,montelukast,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0015,-0.313,0.316,"[-0.313,0.316]",0.992,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005011,montelukast,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0013,-0.017,0.019,"[-0.017,0.019]",0.889,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005133,montelukast,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,0.0011,-0.452,0.454,"[-0.452,0.454]",0.996,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005298,montelukast,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,9.00E-04,-0.451,0.453,"[-0.451,0.453]",0.997,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0011508,montelukast,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,7.00E-04,-0.411,0.412,"[-0.411,0.412]",0.997,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0007947,montelukast,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,5.00E-04,-0.157,0.158,"[-0.157,0.158]",0.995,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005146,montelukast,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,4.00E-04,-0.56,0.561,"[-0.56,0.561]",0.999,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0015564,montelukast,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,3.00E-04,-0.427,0.427,"[-0.427,0.427]",0.999,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0005300,montelukast,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,3.00E-04,-0.366,0.367,"[-0.366,0.367]",0.999,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0011429,montelukast,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,3.00E-04,-0.256,0.257,"[-0.256,0.257]",0.998,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,MONDO:0007827,montelukast,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,2.00E-04,-0.613,0.613,"[-0.613,0.613]",1,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5281040,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,montelukast,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.885432577,5.50E-05,-0.234,0.235,"[-0.234,0.235]",1,1310500,21098600,22409100,"Sample size with montelukast, approximately: 1310500","Sample size without montelukast, approximately: 21098600",All patients number is approximately: 22409100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005711,mometasone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.8977,0.888,0.908,"[0.888,0.908]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005130,mometasone,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.7932,0.784,0.802,"[0.784,0.802]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0010602,mometasone,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.4384,0.428,0.448,"[0.428,0.448]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,mometasone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.3828,0.373,0.392,"[0.373,0.392]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005101,mometasone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.334,0.327,0.341,"[0.327,0.341]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0004609,mometasone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.3238,0.316,0.332,"[0.316,0.332]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008383,mometasone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.3029,0.295,0.311,"[0.295,0.311]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005146,mometasone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.2729,0.26,0.286,"[0.26,0.286]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008644,mometasone,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.266,0.257,0.275,"[0.257,0.275]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0015614,mometasone,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.216,0.207,0.225,"[0.207,0.225]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0015924,mometasone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.2015,0.193,0.21,"[0.193,0.21]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,mometasone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.1949,0.18,0.21,"[0.18,0.21]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0004425,mometasone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.1135,0.076,0.151,"[0.076,0.151]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008377,mometasone,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.1127,0.105,0.121,"[0.105,0.121]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0007972,mometasone,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0909,0.081,0.101,"[0.081,0.101]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005546,mometasone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0781,0.068,0.088,"[0.068,0.088]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0009693,mometasone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0772,0.066,0.088,"[0.066,0.088]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008487,mometasone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0763,0.052,0.101,"[0.052,0.101]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0015263,mometasone,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0738,0.065,0.082,"[0.065,0.082]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0021107,mometasone,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0691,0.038,0.1,"[0.038,0.1]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0011508,mometasone,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0647,0.055,0.075,"[0.055,0.075]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0018882,mometasone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0557,0.007,0.104,"[0.007,0.104]",0.025,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005083,mometasone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0459,0.008,0.084,"[0.008,0.084]",0.018,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0019118,mometasone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0434,-0.006,0.092,"[-0.006,0.092]",0.083,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008399,mometasone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0416,0.029,0.054,"[0.029,0.054]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005002,mometasone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0377,-0.057,0.133,"[-0.057,0.133]",0.437,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005010,mometasone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0363,-0.049,0.122,"[-0.049,0.122]",0.405,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0019350,mometasone,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.036,0.024,0.048,"[0.024,0.048]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,mometasone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0351,0.001,0.07,"[0.001,0.07]",0.047,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0000424,mometasone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0291,0.017,0.041,"[0.017,0.041]",1.00E-04,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005298,mometasone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0243,-0.044,0.093,"[-0.044,0.093]",0.487,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0002316,mometasone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0191,-0.054,0.092,"[-0.054,0.092]",0.606,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0000477,mometasone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.017,-0.01,0.044,"[-0.01,0.044]",0.215,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0004979,mometasone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0162,-0.043,0.075,"[-0.043,0.075]",0.592,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0007186,mometasone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0143,-0.048,0.077,"[-0.048,0.077]",0.653,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008642,mometasone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0136,-0.037,0.064,"[-0.037,0.064]",0.601,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0020066,mometasone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0128,-0.049,0.075,"[-0.049,0.075]",0.686,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0004981,mometasone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0124,-0.054,0.079,"[-0.054,0.079]",0.716,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0004952,mometasone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0113,-0.164,0.186,"[-0.164,0.186]",0.899,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0043693,mometasone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0076,-0.087,0.102,"[-0.087,0.102]",0.875,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008300,mometasone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0074,-0.131,0.146,"[-0.131,0.146]",0.917,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005302,mometasone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0044,-0.085,0.093,"[-0.085,0.093]",0.922,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005392,mometasone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0033,-0.187,0.194,"[-0.187,0.194]",0.973,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0007947,mometasone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0027,-0.14,0.146,"[-0.14,0.146]",0.97,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0005404,mometasone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0027,-0.168,0.173,"[-0.168,0.173]",0.976,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0008542,mometasone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0026,-0.118,0.123,"[-0.118,0.123]",0.966,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0002046,mometasone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0025,-0.159,0.164,"[-0.159,0.164]",0.976,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0800026,mometasone,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0025,-43.563,43.568,"[-43.563,43.568]",1,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0019369,mometasone,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0025,-43.562,43.567,"[-43.562,43.567]",1,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0011429,mometasone,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0011,-0.237,0.239,"[-0.237,0.239]",0.993,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0021187,mometasone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,0.0011,-0.15,0.152,"[-0.15,0.152]",0.989,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0007864,mometasone,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,6.00E-04,-0.166,0.167,"[-0.166,0.167]",0.994,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0015564,mometasone,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,6.00E-04,-0.325,0.327,"[-0.325,0.327]",0.997,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0007739,mometasone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,5.00E-04,-0.244,0.245,"[-0.244,0.245]",0.997,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0019180,mometasone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,2.00E-04,-0.149,0.15,"[-0.149,0.15]",0.997,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441335,biolink:associated_with_increased_likelihood_of,MONDO:0011786,mometasone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.89356292,1.00E-04,-0.424,0.425,"[-0.424,0.425]",1,859700,21380900,22240600,"Sample size with mometasone, approximately: 859700","Sample size without mometasone, approximately: 21380900",All patients number is approximately: 22240600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0002046,mirtazapine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.4938,0.482,0.506,"[0.482,0.506]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0021187,mirtazapine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.4335,0.421,0.446,"[0.421,0.446]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005147,mirtazapine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.3332,0.327,0.34,"[0.327,0.34]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0002277,mirtazapine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.2889,0.279,0.299,"[0.279,0.299]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0000914,mirtazapine,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.2828,0.276,0.289,"[0.276,0.289]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0002406,mirtazapine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.244,0.232,0.256,"[0.232,0.256]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0015263,mirtazapine,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.2399,0.233,0.247,"[0.233,0.247]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0011786,mirtazapine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.2381,0.23,0.246,"[0.23,0.246]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005009,mirtazapine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.2224,0.213,0.232,"[0.213,0.232]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0000153,mirtazapine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.1912,0.177,0.205,"[0.177,0.205]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0043693,mirtazapine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.1546,0.134,0.175,"[0.134,0.175]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0004425,mirtazapine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.14,0.124,0.156,"[0.124,0.156]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0010602,mirtazapine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.1303,0.123,0.138,"[0.123,0.138]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0009693,mirtazapine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0959,0.09,0.102,"[0.09,0.102]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005011,mirtazapine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0954,0.082,0.109,"[0.082,0.109]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0011849,mirtazapine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0915,0.075,0.108,"[0.075,0.108]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0019350,mirtazapine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0845,0.052,0.117,"[0.052,0.117]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0013282,mirtazapine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0679,0.056,0.08,"[0.056,0.08]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0019499,mirtazapine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0571,0.042,0.072,"[0.042,0.072]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0007739,mirtazapine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0489,-0.004,0.102,"[-0.004,0.102]",0.07,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005146,mirtazapine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0484,-0.037,0.134,"[-0.037,0.134]",0.269,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0016532,mirtazapine,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.045,0.036,0.054,"[0.036,0.054]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005083,mirtazapine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0437,0.022,0.066,"[0.022,0.066]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0018975,mirtazapine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0421,0.034,0.05,"[0.034,0.05]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005002,mirtazapine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0413,0.01,0.073,"[0.01,0.073]",0.01,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005404,mirtazapine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0381,-0.012,0.088,"[-0.012,0.088]",0.133,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0008377,mirtazapine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0296,0.02,0.039,"[0.02,0.039]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005010,mirtazapine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0243,-0.054,0.103,"[-0.054,0.103]",0.542,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0004952,mirtazapine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.023,-0.018,0.064,"[-0.018,0.064]",0.269,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0019565,mirtazapine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0228,-0.024,0.07,"[-0.024,0.07]",0.342,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0015564,mirtazapine,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0213,-0.061,0.104,"[-0.061,0.104]",0.614,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0000424,mirtazapine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0188,0.011,0.027,"[0.011,0.027]",1.00E-04,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005392,mirtazapine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0175,-0.01,0.045,"[-0.01,0.045]",0.211,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005393,mirtazapine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0157,0.005,0.027,"[0.005,0.027]",0.004,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0019180,mirtazapine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.014,-0.072,0.1,"[-0.072,0.1]",0.748,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005300,mirtazapine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0118,-0.02,0.044,"[-0.02,0.044]",0.468,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,mirtazapine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0076,-0.001,0.016,"[-0.001,0.016]",0.078,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0007947,mirtazapine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0042,-0.128,0.136,"[-0.128,0.136]",0.95,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005302,mirtazapine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.004,-0.073,0.081,"[-0.073,0.081]",0.919,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,mirtazapine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0031,-0.109,0.115,"[-0.109,0.115]",0.956,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0008678,mirtazapine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0025,-0.105,0.11,"[-0.105,0.11]",0.964,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005133,mirtazapine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0021,-0.004,0.009,"[-0.004,0.009]",0.526,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0010561,mirtazapine,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0019,-0.158,0.162,"[-0.158,0.162]",0.981,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0007915,mirtazapine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0015,-0.014,0.016,"[-0.014,0.016]",0.848,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005306,mirtazapine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0013,-0.162,0.165,"[-0.162,0.165]",0.988,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,mirtazapine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0012,-0.138,0.141,"[-0.138,0.141]",0.987,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005298,mirtazapine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,0.0011,-0.399,0.401,"[-0.399,0.401]",0.996,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005388,mirtazapine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,9.00E-04,-0.139,0.14,"[-0.139,0.14]",0.99,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0002909,mirtazapine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,7.00E-04,-2.743,2.745,"[-2.743,2.745]",1,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0020066,mirtazapine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,5.00E-04,-0.498,0.499,"[-0.498,0.499]",0.998,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0019118,mirtazapine,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,3.00E-04,-0.308,0.308,"[-0.308,0.308]",0.998,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0002316,mirtazapine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,2.00E-04,-3.64,3.64,"[-3.64,3.64]",1,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4205,biolink:associated_with_increased_likelihood_of,MONDO:0005546,mirtazapine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904921118,2.03E-05,-0.503,0.503,"[-0.503,0.503]",1,1388300,21204100,22592400,"Sample size with mirtazapine, approximately: 1388300","Sample size without mirtazapine, approximately: 21204100",All patients number is approximately: 22592400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005294,milnacipran,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0974,-0.062,0.257,"[-0.062,0.257]",0.23,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005298,milnacipran,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0588,-0.095,0.212,"[-0.095,0.212]",0.453,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005302,milnacipran,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0497,-0.076,0.176,"[-0.076,0.176]",0.439,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0011786,milnacipran,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0232,-0.517,0.564,"[-0.517,0.564]",0.933,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0002046,milnacipran,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0227,-0.515,0.56,"[-0.515,0.56]",0.934,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005301,milnacipran,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0178,-0.26,0.295,"[-0.26,0.295]",0.9,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0019369,milnacipran,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0164,-0.614,0.647,"[-0.614,0.647]",0.959,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,milnacipran,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0158,-2.508,2.539,"[-2.508,2.539]",0.99,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005002,milnacipran,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0119,-0.221,0.244,"[-0.221,0.244]",0.92,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005011,milnacipran,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0092,-0.42,0.439,"[-0.42,0.439]",0.966,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005178,milnacipran,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0067,-0.413,0.427,"[-0.413,0.427]",0.975,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0005404,milnacipran,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0042,-0.641,0.649,"[-0.641,0.649]",0.99,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0015602,biolink:associated_with_increased_likelihood_of,MONDO:0003620,milnacipran,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926184526,0.0038,-0.7,0.707,"[-0.7,0.707]",0.992,16200,21783500,21799700,"Sample size with milnacipran, approximately: 16200","Sample size without milnacipran, approximately: 21783500",All patients number is approximately: 21799700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441314,biolink:associated_with_increased_likelihood_of,MONDO:0007186,miglitol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961104403,0.0144,-3.076,3.105,"[-3.076,3.105]",0.993,1200,21791600,21792800,"Sample size with miglitol, approximately: 1200","Sample size without miglitol, approximately: 21791600",All patients number is approximately: 21792800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:441314,biolink:associated_with_increased_likelihood_of,MONDO:0005178,miglitol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.961104403,0.0089,-87.265,87.282,"[-87.265,87.282]",1,1200,21791600,21792800,"Sample size with miglitol, approximately: 1200","Sample size without miglitol, approximately: 21791600",All patients number is approximately: 21792800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005130,metoprolol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,1.4659,1.461,1.471,"[1.461,1.471]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008006,metoprolol,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,1.0186,1.012,1.025,"[1.012,1.025]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0019369,metoprolol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.7516,0.747,0.756,"[0.747,0.756]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0007027,metoprolol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.2855,0.28,0.291,"[0.28,0.291]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0010561,metoprolol,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.258,0.253,0.263,"[0.253,0.263]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0004975,metoprolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1981,0.172,0.225,"[0.172,0.225]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005711,metoprolol,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1959,0.188,0.204,"[0.188,0.204]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0015614,metoprolol,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1799,0.174,0.186,"[0.174,0.186]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0002277,metoprolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1795,0.167,0.192,"[0.167,0.192]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,metoprolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1631,0.152,0.174,"[0.152,0.174]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008644,metoprolol,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.149,0.142,0.156,"[0.142,0.156]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0002316,metoprolol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1411,0.127,0.155,"[0.127,0.155]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0020066,metoprolol,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.141,0.134,0.148,"[0.134,0.148]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0009693,metoprolol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1368,0.129,0.145,"[0.129,0.145]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0007540,metoprolol,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.124,0.117,0.131,"[0.117,0.131]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008383,metoprolol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.1163,0.11,0.122,"[0.11,0.122]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005302,metoprolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0885,0.072,0.105,"[0.072,0.105]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008542,metoprolol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0757,0.066,0.085,"[0.066,0.085]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005146,metoprolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0756,0.059,0.093,"[0.059,0.093]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0002909,metoprolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0641,0.058,0.071,"[0.058,0.071]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0018177,metoprolol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.054,0.047,0.061,"[0.047,0.061]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008377,metoprolol,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0502,0.037,0.063,"[0.037,0.063]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005388,metoprolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0446,0.014,0.076,"[0.014,0.076]",0.005,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0007739,metoprolol,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0431,0.02,0.066,"[0.02,0.066]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005083,metoprolol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0397,0.024,0.056,"[0.024,0.056]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005294,metoprolol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0391,0.021,0.057,"[0.021,0.057]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005300,metoprolol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0376,0.006,0.069,"[0.006,0.069]",0.018,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005101,metoprolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0334,0.001,0.066,"[0.001,0.066]",0.042,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0011849,metoprolol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0291,0.017,0.041,"[0.017,0.041]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005298,metoprolol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0276,-0.039,0.094,"[-0.039,0.094]",0.419,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005010,metoprolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.027,-0.005,0.059,"[-0.005,0.059]",0.1,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005009,metoprolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0237,-0.009,0.056,"[-0.009,0.056]",0.151,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005404,metoprolol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0214,0.001,0.042,"[0.001,0.042]",0.039,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,metoprolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.019,-0.035,0.073,"[-0.035,0.073]",0.49,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0004425,metoprolol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0189,-0.049,0.086,"[-0.049,0.086]",0.582,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0019118,metoprolol,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0166,0.013,0.02,"[0.013,0.02]",1.00E-04,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0019565,metoprolol,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0157,-0.001,0.032,"[-0.001,0.032]",0.063,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,metoprolol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0139,-0.03,0.057,"[-0.03,0.057]",0.531,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0002046,metoprolol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0125,-0.031,0.057,"[-0.031,0.057]",0.577,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,metoprolol,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0112,-0.074,0.097,"[-0.074,0.097]",0.797,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005011,metoprolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0108,-0.044,0.065,"[-0.044,0.065]",0.699,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0007186,metoprolol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0047,-0.14,0.15,"[-0.14,0.15]",0.95,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0004979,metoprolol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0032,-0.281,0.288,"[-0.281,0.288]",0.983,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0019180,metoprolol,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0027,-0.08,0.086,"[-0.08,0.086]",0.949,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008300,metoprolol,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0026,-0.099,0.105,"[-0.099,0.105]",0.961,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0043693,metoprolol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0018,-0.314,0.318,"[-0.314,0.318]",0.991,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0007843,metoprolol,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0016,-0.126,0.129,"[-0.126,0.129]",0.98,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0004648,metoprolol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0015,-0.136,0.139,"[-0.136,0.139]",0.983,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0015924,metoprolol,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0014,-0.214,0.217,"[-0.214,0.217]",0.99,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005133,metoprolol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,0.0012,-0.112,0.115,"[-0.112,0.115]",0.983,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0003620,metoprolol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,8.00E-04,-0.224,0.226,"[-0.224,0.226]",0.994,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0004952,metoprolol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,7.00E-04,-0.095,0.097,"[-0.095,0.097]",0.988,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0008487,metoprolol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,5.00E-04,-0.594,0.595,"[-0.594,0.595]",0.999,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0005364,metoprolol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,4.00E-04,-0.091,0.092,"[-0.091,0.092]",0.992,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0016218,metoprolol,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,3.00E-04,-0.231,0.231,"[-0.231,0.231]",0.998,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4171,biolink:associated_with_increased_likelihood_of,MONDO:0019350,metoprolol,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.934671409,7.55E-05,-0.88,0.88,"[-0.88,0.88]",1,7658200,18334600,25992800,"Sample size with metoprolol, approximately: 7658200","Sample size without metoprolol, approximately: 18334600",All patients number is approximately: 25992800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0002046,methylprednisolone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,1.9812,1.977,1.986,"[1.977,1.986]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005116,methylprednisolone,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.5591,0.549,0.569,"[0.549,0.569]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005546,methylprednisolone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.5206,0.516,0.525,"[0.516,0.525]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008399,methylprednisolone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.4644,0.456,0.473,"[0.456,0.473]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0018177,methylprednisolone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.3547,0.349,0.36,"[0.349,0.36]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005178,methylprednisolone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.2225,0.218,0.227,"[0.218,0.227]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005404,methylprednisolone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.2114,0.184,0.238,"[0.184,0.238]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008599,methylprednisolone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1911,0.186,0.196,"[0.186,0.196]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0002316,methylprednisolone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1648,0.158,0.172,"[0.158,0.172]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008300,methylprednisolone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1433,0.127,0.159,"[0.127,0.159]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0016532,methylprednisolone,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1172,0.109,0.125,"[0.109,0.125]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005298,methylprednisolone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1148,0.106,0.124,"[0.106,0.124]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0019565,methylprednisolone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1105,0.1,0.121,"[0.1,0.121]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0004981,methylprednisolone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1089,0.104,0.113,"[0.104,0.113]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005083,methylprednisolone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1073,0.089,0.125,"[0.089,0.125]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0000914,methylprednisolone,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.1021,0.096,0.108,"[0.096,0.108]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007027,methylprednisolone,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0922,0.087,0.098,"[0.087,0.098]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0011122,methylprednisolone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0901,0.06,0.12,"[0.06,0.12]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0004609,methylprednisolone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0872,0.073,0.102,"[0.073,0.102]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0010526,methylprednisolone,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0801,0.056,0.105,"[0.056,0.105]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007186,methylprednisolone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0798,0.06,0.1,"[0.06,0.1]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007915,methylprednisolone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.063,0.053,0.073,"[0.053,0.073]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0002406,methylprednisolone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0593,0.039,0.079,"[0.039,0.079]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0004952,methylprednisolone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0586,0.044,0.073,"[0.044,0.073]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0015614,methylprednisolone,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0511,0.045,0.057,"[0.045,0.057]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0015924,methylprednisolone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0483,0.043,0.054,"[0.043,0.054]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005148,methylprednisolone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0471,0.024,0.07,"[0.024,0.07]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005711,methylprednisolone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0461,0.041,0.051,"[0.041,0.051]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0800026,methylprednisolone,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0459,0.007,0.084,"[0.007,0.084]",0.019,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008721,methylprednisolone,medium chain acyl coenzyme a dehydrogenase deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0439,-0.028,0.116,"[-0.028,0.116]",0.233,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005294,methylprednisolone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0395,0.028,0.051,"[0.028,0.051]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007739,methylprednisolone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.036,0.03,0.042,"[0.03,0.042]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005011,methylprednisolone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0329,-0.022,0.088,"[-0.022,0.088]",0.24,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0018975,methylprednisolone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0273,0.019,0.035,"[0.019,0.035]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0043693,methylprednisolone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0249,-0.045,0.095,"[-0.045,0.095]",0.485,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005180,methylprednisolone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0196,0.014,0.025,"[0.014,0.025]",1.00E-04,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0002909,methylprednisolone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0161,-0.017,0.049,"[-0.017,0.049]",0.338,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005364,methylprednisolone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0118,-0.095,0.118,"[-0.095,0.118]",0.828,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,methylprednisolone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0094,0,0.019,"[0,0.019]",0.046,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0000424,methylprednisolone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0089,-0.035,0.053,"[-0.035,0.053]",0.695,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0021187,methylprednisolone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0088,-0.001,0.019,"[-0.001,0.019]",0.089,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007827,methylprednisolone,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0068,-0.056,0.069,"[-0.056,0.069]",0.831,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0007160,methylprednisolone,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0037,-0.116,0.123,"[-0.116,0.123]",0.951,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0011508,methylprednisolone,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0034,-0.073,0.08,"[-0.073,0.08]",0.931,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0015564,methylprednisolone,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0029,-0.236,0.242,"[-0.236,0.242]",0.981,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008006,methylprednisolone,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0019,-0.093,0.097,"[-0.093,0.097]",0.968,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005002,methylprednisolone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0016,-0.091,0.094,"[-0.091,0.094]",0.974,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0001044,methylprednisolone,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,0.0013,-0.008,0.011,"[-0.008,0.011]",0.793,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0000153,methylprednisolone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,9.00E-04,-0.016,0.018,"[-0.016,0.018]",0.911,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0008542,methylprednisolone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,5.00E-04,-0.726,0.728,"[-0.726,0.728]",0.999,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0020066,methylprednisolone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,4.00E-04,-0.387,0.388,"[-0.387,0.388]",0.998,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0004648,methylprednisolone,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,3.00E-04,-0.803,0.804,"[-0.803,0.804]",0.999,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6741,biolink:associated_with_increased_likelihood_of,MONDO:0005306,methylprednisolone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906378999,2.00E-05,-0.513,0.513,"[-0.513,0.513]",1,4931900,19387600,24319500,"Sample size with methylprednisolone, approximately: 4931900","Sample size without methylprednisolone, approximately: 19387600",All patients number is approximately: 24319500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,MONDO:0005294,methyldopa,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.216,0.139,0.293,"[0.139,0.293]",1.00E-04,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,MONDO:0005298,methyldopa,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.1251,-0.848,1.098,"[-0.848,1.098]",0.801,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,methyldopa,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.0848,0.034,0.136,"[0.034,0.136]",0.001,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,MONDO:0002909,methyldopa,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.0549,-0.361,0.47,"[-0.361,0.47]",0.796,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,MONDO:0005148,methyldopa,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.042,-0.262,0.346,"[-0.262,0.346]",0.787,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251525,biolink:associated_with_increased_likelihood_of,MONDO:0005147,methyldopa,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937339724,0.0336,-1.179,1.247,"[-1.179,1.247]",0.957,9100,21787300,21796400,"Sample size with methyldopa, approximately: 9100","Sample size without methyldopa, approximately: 21787300",All patients number is approximately: 21796400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0009891,methotrexate,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.721,0.702,0.74,"[0.702,0.74]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,methotrexate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.5553,0.535,0.576,"[0.535,0.576]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005010,methotrexate,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.5105,0.495,0.526,"[0.495,0.526]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005178,methotrexate,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.4545,0.424,0.485,"[0.424,0.485]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005002,methotrexate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.4161,0.388,0.445,"[0.388,0.445]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005116,methotrexate,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.3638,0.34,0.387,"[0.34,0.387]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005546,methotrexate,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.3482,0.333,0.363,"[0.333,0.363]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004609,methotrexate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.3482,0.295,0.401,"[0.295,0.401]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,methotrexate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.2563,0.227,0.286,"[0.227,0.286]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0006694,methotrexate,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.185,0.144,0.226,"[0.144,0.226]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0000424,methotrexate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1841,0.165,0.203,"[0.165,0.203]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004648,methotrexate,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.169,0.137,0.201,"[0.137,0.201]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0010602,methotrexate,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1618,0.144,0.18,"[0.144,0.18]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005180,methotrexate,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1606,0.139,0.182,"[0.139,0.182]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0008599,methotrexate,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1347,0.088,0.181,"[0.088,0.181]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005302,methotrexate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1328,0.114,0.151,"[0.114,0.151]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004981,methotrexate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1306,0.001,0.26,"[0.001,0.26]",0.048,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005301,methotrexate,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1206,0.102,0.139,"[0.102,0.139]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0007739,methotrexate,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1182,0.07,0.166,"[0.07,0.166]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0009693,methotrexate,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.1016,0.083,0.12,"[0.083,0.12]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005306,methotrexate,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0954,0.063,0.127,"[0.063,0.127]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0008399,methotrexate,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0728,0.033,0.113,"[0.033,0.113]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005364,methotrexate,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0695,-0.096,0.235,"[-0.096,0.235]",0.411,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005711,methotrexate,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0664,0.039,0.094,"[0.039,0.094]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004425,methotrexate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0658,-0.006,0.137,"[-0.006,0.137]",0.071,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004979,methotrexate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0608,0.021,0.101,"[0.021,0.101]",0.003,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0011429,methotrexate,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0512,-0.028,0.131,"[-0.028,0.131]",0.207,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005404,methotrexate,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0506,0.028,0.073,"[0.028,0.073]",1.00E-04,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0002909,methotrexate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0468,0,0.094,"[0,0.094]",0.051,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0011849,methotrexate,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0382,0.006,0.071,"[0.006,0.071]",0.021,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0000477,methotrexate,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0231,-0.059,0.105,"[-0.059,0.105]",0.581,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005101,methotrexate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0215,-0.037,0.08,"[-0.037,0.08]",0.474,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0002406,methotrexate,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0206,-0.013,0.055,"[-0.013,0.055]",0.236,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005388,methotrexate,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0195,-0.132,0.171,"[-0.132,0.171]",0.801,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005146,methotrexate,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0165,-0.039,0.072,"[-0.039,0.072]",0.557,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0004975,methotrexate,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0079,-0.251,0.266,"[-0.251,0.266]",0.952,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0002277,methotrexate,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.006,-0.268,0.28,"[-0.268,0.28]",0.966,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005298,methotrexate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0041,-0.136,0.144,"[-0.136,0.144]",0.954,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,methotrexate,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0032,-0.243,0.249,"[-0.243,0.249]",0.98,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0008487,methotrexate,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0027,-0.239,0.245,"[-0.239,0.245]",0.982,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005294,methotrexate,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,0.0017,-0.374,0.377,"[-0.374,0.377]",0.993,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0005392,methotrexate,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,8.00E-04,-0.184,0.186,"[-0.184,0.186]",0.993,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248287,biolink:associated_with_increased_likelihood_of,MONDO:0003620,methotrexate,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.895914014,4.00E-04,-0.205,0.206,"[-0.205,0.206]",0.997,317700,21611400,21929100,"Sample size with methotrexate, approximately: 317700","Sample size without methotrexate, approximately: 21611400",All patients number is approximately: 21929100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0004975,methadone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.9924,0.981,1.004,"[0.981,1.004]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0004425,methadone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.6556,0.646,0.665,"[0.646,0.665]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0002316,methadone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.5896,0.574,0.605,"[0.574,0.605]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0000153,methadone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.573,0.561,0.585,"[0.561,0.585]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0018975,methadone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.4691,0.453,0.485,"[0.453,0.485]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0018177,methadone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.4681,0.457,0.48,"[0.457,0.48]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005546,methadone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.4191,0.408,0.43,"[0.408,0.43]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0008738,methadone,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.3486,0.337,0.361,"[0.337,0.361]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005298,methadone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.2338,0.198,0.269,"[0.198,0.269]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005711,methadone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.2193,0.199,0.24,"[0.199,0.24]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0009891,methadone,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.2147,0.202,0.227,"[0.202,0.227]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0002046,methadone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.1574,0.131,0.184,"[0.131,0.184]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0011849,methadone,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.1497,0.124,0.176,"[0.124,0.176]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0008487,methadone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.1279,0.107,0.149,"[0.107,0.149]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0020066,methadone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0867,0.042,0.131,"[0.042,0.131]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0007160,methadone,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.08,0.046,0.114,"[0.046,0.114]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0008644,methadone,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0791,0.067,0.091,"[0.067,0.091]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0019180,methadone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0572,0.037,0.077,"[0.037,0.077]",1.00E-04,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005404,methadone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.024,-0.183,0.231,"[-0.183,0.231]",0.82,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0004609,methadone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0232,-0.132,0.178,"[-0.132,0.178]",0.769,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005392,methadone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0216,-0.043,0.086,"[-0.043,0.086]",0.512,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0018882,methadone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0216,-0.019,0.063,"[-0.019,0.063]",0.303,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0009061,methadone,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0194,-0.008,0.046,"[-0.008,0.046]",0.159,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0021187,methadone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0189,-0.042,0.079,"[-0.042,0.079]",0.54,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0008383,methadone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0162,-0.053,0.086,"[-0.053,0.086]",0.648,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0007739,methadone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0124,-0.006,0.031,"[-0.006,0.031]",0.192,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005302,methadone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0046,-0.191,0.2,"[-0.191,0.2]",0.964,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0008542,methadone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.0045,-0.639,0.648,"[-0.639,0.648]",0.989,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0016218,methadone,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,0.002,-0.163,0.167,"[-0.163,0.167]",0.981,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0007186,methadone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,8.00E-04,-0.322,0.323,"[-0.322,0.323]",0.996,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0005306,methadone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,7.00E-04,-0.602,0.603,"[-0.602,0.603]",0.998,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0019565,methadone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,6.00E-04,-0.458,0.46,"[-0.458,0.46]",0.998,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0019499,methadone,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,5.00E-04,-0.484,0.485,"[-0.484,0.485]",0.998,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0007843,methadone,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,4.00E-04,-0.332,0.333,"[-0.332,0.333]",0.998,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:14184,biolink:associated_with_increased_likelihood_of,MONDO:0003620,methadone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898429208,3.00E-04,-0.356,0.356,"[-0.356,0.356]",0.999,525900,21544500,22070400,"Sample size with methadone, approximately: 525900","Sample size without methadone, approximately: 21544500",All patients number is approximately: 22070400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005546,metformin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,1.0993,1.095,1.104,"[1.095,1.104]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007947,metformin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.8599,0.839,0.88,"[0.839,0.88]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005147,metformin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.7703,0.761,0.78,"[0.761,0.78]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007027,metformin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.7548,0.747,0.763,"[0.747,0.763]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,metformin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.5376,0.523,0.552,"[0.523,0.552]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005149,metformin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.4373,0.405,0.469,"[0.405,0.469]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005306,metformin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.3761,0.369,0.384,"[0.369,0.384]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005302,metformin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.3573,0.342,0.373,"[0.342,0.373]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0009061,metformin,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.3106,0.301,0.32,"[0.301,0.32]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0004609,metformin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.3074,0.293,0.322,"[0.293,0.322]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0000153,metformin,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2979,0.291,0.304,"[0.291,0.304]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005178,metformin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2701,0.265,0.275,"[0.265,0.275]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007540,metformin,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2499,0.243,0.257,"[0.243,0.257]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0008487,metformin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2364,0.219,0.254,"[0.219,0.254]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0011786,metformin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2334,0.213,0.253,"[0.213,0.253]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0010383,metformin,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.2252,0.217,0.233,"[0.217,0.233]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0019499,metformin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.205,0.196,0.214,"[0.196,0.214]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,metformin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.182,0.157,0.207,"[0.157,0.207]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0002406,metformin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1763,0.14,0.212,"[0.14,0.212]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0008399,metformin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1572,0.142,0.172,"[0.142,0.172]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0019350,metformin,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1386,0.132,0.145,"[0.132,0.145]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005392,metformin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1354,0.123,0.147,"[0.123,0.147]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0010526,metformin,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1267,0.117,0.137,"[0.117,0.137]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0000914,metformin,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1017,0.093,0.11,"[0.093,0.11]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0008300,metformin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.1012,0.083,0.12,"[0.083,0.12]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007739,metformin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.098,0.041,0.155,"[0.041,0.155]",0.001,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005364,metformin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0941,0.04,0.148,"[0.04,0.148]",0.001,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0043693,metformin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0908,0.063,0.118,"[0.063,0.118]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0013282,metformin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0885,0.076,0.101,"[0.076,0.101]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0002277,metformin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0756,0.048,0.103,"[0.048,0.103]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0004981,metformin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0605,0.038,0.083,"[0.038,0.083]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0015263,metformin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.048,-0.004,0.1,"[-0.004,0.1]",0.07,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005180,metformin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0403,0.012,0.068,"[0.012,0.068]",0.005,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005083,metformin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0386,0.009,0.068,"[0.009,0.068]",0.01,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0006640,metformin,adrenal cushing syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0372,0.02,0.054,"[0.02,0.054]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005002,metformin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0338,-0.039,0.107,"[-0.039,0.107]",0.364,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005101,metformin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0238,-0.069,0.117,"[-0.069,0.117]",0.615,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005010,metformin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0233,-0.034,0.081,"[-0.034,0.081]",0.427,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005404,metformin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0223,-0.021,0.065,"[-0.021,0.065]",0.31,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0000424,metformin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0223,0.015,0.029,"[0.015,0.029]",1.00E-04,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0003620,metformin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0159,-0.026,0.058,"[-0.026,0.058]",0.462,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007843,metformin,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.011,-0.097,0.118,"[-0.097,0.118]",0.841,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0008394,metformin,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0105,-0.141,0.162,"[-0.141,0.162]",0.892,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007864,metformin,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.009,-0.121,0.139,"[-0.121,0.139]",0.892,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,metformin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0071,-0.094,0.108,"[-0.094,0.108]",0.89,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005148,metformin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0067,-0.042,0.056,"[-0.042,0.056]",0.79,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0007186,metformin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0066,-0.064,0.078,"[-0.064,0.078]",0.856,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0016218,metformin,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0061,-0.064,0.076,"[-0.064,0.076]",0.864,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0019565,metformin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0034,-0.436,0.442,"[-0.436,0.442]",0.988,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0005298,metformin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.002,-0.056,0.06,"[-0.056,0.06]",0.946,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0002316,metformin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,0.0011,-0.135,0.137,"[-0.135,0.137]",0.988,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0008542,metformin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,6.00E-04,-0.765,0.766,"[-0.765,0.766]",0.999,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1431,biolink:associated_with_increased_likelihood_of,MONDO:0021187,metformin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927435226,2.00E-04,-0.126,0.127,"[-0.126,0.127]",0.998,3835300,19578300,23413600,"Sample size with metformin, approximately: 3835300","Sample size without metformin, approximately: 19578300",All patients number is approximately: 23413600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0969324,biolink:associated_with_increased_likelihood_of,MONDO:0000424,mepolizumab,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953224934,0.0131,-1.665,1.691,"[-1.665,1.691]",0.988,6400,21788600,21795000,"Sample size with mepolizumab, approximately: 6400","Sample size without mepolizumab, approximately: 21788600",All patients number is approximately: 21795000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,memantine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,3.6882,3.677,3.7,"[3.677,3.7]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0004609,memantine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.2605,0.249,0.272,"[0.249,0.272]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0002909,memantine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.2565,0.242,0.271,"[0.242,0.271]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0043693,memantine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.2153,0.199,0.232,"[0.199,0.232]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0009693,memantine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1942,0.181,0.207,"[0.181,0.207]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0007186,memantine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1909,0.109,0.273,"[0.109,0.273]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0008487,memantine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1826,0.145,0.22,"[0.145,0.22]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0009891,memantine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1797,0.166,0.194,"[0.166,0.194]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0018882,memantine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1576,0.145,0.17,"[0.145,0.17]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005546,memantine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.1358,0.12,0.152,"[0.12,0.152]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0002406,memantine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.103,0.042,0.164,"[0.042,0.164]",0.001,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0004975,memantine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0991,0.08,0.118,"[0.08,0.118]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0019565,memantine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0958,0.07,0.122,"[0.07,0.122]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0003620,memantine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0863,0.054,0.118,"[0.054,0.118]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0006694,memantine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0751,0.055,0.095,"[0.055,0.095]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0004425,memantine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.074,0.009,0.139,"[0.009,0.139]",0.027,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,memantine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.074,0.063,0.085,"[0.063,0.085]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0018177,memantine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0573,0.045,0.07,"[0.045,0.07]",1.00E-04,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005178,memantine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0414,0.014,0.069,"[0.014,0.069]",0.003,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0007915,memantine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0328,-0.005,0.071,"[-0.005,0.071]",0.089,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005404,memantine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0314,-0.033,0.096,"[-0.033,0.096]",0.34,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,memantine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0309,0.007,0.055,"[0.007,0.055]",0.012,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0002277,memantine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0295,-0.015,0.074,"[-0.015,0.074]",0.194,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0011849,memantine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0285,-0.058,0.115,"[-0.058,0.115]",0.518,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005101,memantine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0145,-0.026,0.055,"[-0.026,0.055]",0.48,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0004981,memantine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0094,-0.078,0.097,"[-0.078,0.097]",0.833,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005146,memantine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0089,-0.033,0.05,"[-0.033,0.05]",0.674,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0011786,memantine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0041,-0.127,0.135,"[-0.127,0.135]",0.951,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0008542,memantine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0029,-0.259,0.265,"[-0.259,0.265]",0.983,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005002,memantine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,0.0018,-1.872,1.875,"[-1.872,1.875]",0.999,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005392,memantine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,9.00E-04,-0.548,0.55,"[-0.548,0.55]",0.997,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0007739,memantine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,7.00E-04,-0.283,0.284,"[-0.283,0.284]",0.996,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0016218,memantine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,6.00E-04,-0.123,0.124,"[-0.123,0.124]",0.992,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:4054,biolink:associated_with_increased_likelihood_of,MONDO:0005300,memantine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.948026434,6.00E-04,-0.229,0.23,"[-0.229,0.23]",0.996,419900,21578200,21998100,"Sample size with memantine, approximately: 419900","Sample size without memantine, approximately: 21578200",All patients number is approximately: 21998100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004975,meloxicam,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,1.0748,1.066,1.084,"[1.066,1.084]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0019369,meloxicam,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.8836,0.877,0.89,"[0.877,0.89]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005146,meloxicam,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.8335,0.823,0.844,"[0.823,0.844]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0015263,meloxicam,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.4584,0.446,0.47,"[0.446,0.47]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0008377,meloxicam,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.3918,0.38,0.404,"[0.38,0.404]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004648,meloxicam,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.2197,0.213,0.227,"[0.213,0.227]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0003620,meloxicam,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1906,0.172,0.209,"[0.172,0.209]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0021187,meloxicam,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1906,0.176,0.205,"[0.176,0.205]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004952,meloxicam,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1713,0.155,0.188,"[0.155,0.188]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005364,meloxicam,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.133,0.113,0.153,"[0.113,0.153]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005392,meloxicam,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1305,0.12,0.141,"[0.12,0.141]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0009891,meloxicam,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1278,0.116,0.139,"[0.116,0.139]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004981,meloxicam,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.126,0.097,0.155,"[0.097,0.155]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0018975,meloxicam,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1254,0.109,0.142,"[0.109,0.142]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005147,meloxicam,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1105,0.1,0.121,"[0.1,0.121]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0000424,meloxicam,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1088,0.096,0.122,"[0.096,0.122]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005404,meloxicam,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.1052,0.084,0.127,"[0.084,0.127]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004979,meloxicam,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0922,0.056,0.128,"[0.056,0.128]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0006694,meloxicam,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0736,0.048,0.099,"[0.048,0.099]",1.00E-04,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0018177,meloxicam,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0209,-0.037,0.079,"[-0.037,0.079]",0.48,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005149,meloxicam,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0194,-0.019,0.057,"[-0.019,0.057]",0.317,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0019565,meloxicam,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0169,-0.019,0.053,"[-0.019,0.053]",0.361,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004609,meloxicam,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0141,-0.036,0.065,"[-0.036,0.065]",0.585,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0019499,meloxicam,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0107,-0.141,0.163,"[-0.141,0.163]",0.89,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005002,meloxicam,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0075,-0.123,0.138,"[-0.123,0.138]",0.911,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0004425,meloxicam,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0065,-0.042,0.055,"[-0.042,0.055]",0.791,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,meloxicam,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.006,-0.094,0.106,"[-0.094,0.106]",0.906,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005133,meloxicam,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0057,-0.069,0.081,"[-0.069,0.081]",0.882,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0011786,meloxicam,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0055,-0.035,0.046,"[-0.035,0.046]",0.789,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0002046,meloxicam,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.004,-0.09,0.098,"[-0.09,0.098]",0.934,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0018882,meloxicam,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0037,-0.073,0.081,"[-0.073,0.081]",0.924,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,meloxicam,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0032,-0.182,0.188,"[-0.182,0.188]",0.973,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005294,meloxicam,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0021,-0.187,0.192,"[-0.187,0.192]",0.982,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0007739,meloxicam,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0017,-0.158,0.161,"[-0.158,0.161]",0.983,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,meloxicam,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0016,-0.533,0.536,"[-0.533,0.536]",0.995,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005306,meloxicam,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0015,-0.038,0.041,"[-0.038,0.041]",0.94,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005546,meloxicam,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0015,-0.263,0.266,"[-0.263,0.266]",0.991,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005302,meloxicam,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,0.0011,-0.368,0.37,"[-0.368,0.37]",0.995,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,meloxicam,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,9.00E-04,-0.137,0.138,"[-0.137,0.138]",0.99,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0016218,meloxicam,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,8.00E-04,-0.403,0.405,"[-0.403,0.405]",0.997,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0002406,meloxicam,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,7.00E-04,-0.394,0.395,"[-0.394,0.395]",0.997,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0015614,meloxicam,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,5.00E-04,-0.01,0.011,"[-0.01,0.011]",0.916,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0007186,meloxicam,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,4.00E-04,-0.385,0.385,"[-0.385,0.385]",0.999,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005300,meloxicam,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,2.00E-04,-0.124,0.125,"[-0.124,0.125]",0.997,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:54677470,biolink:associated_with_increased_likelihood_of,MONDO:0005101,meloxicam,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.806604947,6.51E-05,-0.467,0.467,"[-0.467,0.467]",1,1429300,20856700,22286000,"Sample size with meloxicam, approximately: 1429300","Sample size without meloxicam, approximately: 20856700",All patients number is approximately: 22286000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005300,lurasidone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.8533,0.831,0.876,"[0.831,0.876]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005010,lurasidone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.597,0.566,0.628,"[0.566,0.628]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0002277,lurasidone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.5654,0.536,0.595,"[0.536,0.595]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0001516,lurasidone,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.4074,0.374,0.441,"[0.374,0.441]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005294,lurasidone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.3245,0.3,0.349,"[0.3,0.349]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005180,lurasidone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.2537,0.221,0.287,"[0.221,0.287]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0008300,lurasidone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.23,0.176,0.284,"[0.176,0.284]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005148,lurasidone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.1916,0.161,0.222,"[0.161,0.222]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005101,lurasidone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.1435,0.018,0.269,"[0.018,0.269]",0.025,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0008383,lurasidone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.1348,0.093,0.177,"[0.093,0.177]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005083,lurasidone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.116,0.059,0.173,"[0.059,0.173]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,lurasidone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.1115,-0.097,0.32,"[-0.097,0.32]",0.295,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,lurasidone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0868,0.053,0.121,"[0.053,0.121]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0003620,lurasidone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0765,0.018,0.135,"[0.018,0.135]",0.011,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0011849,lurasidone,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0599,-0.009,0.129,"[-0.009,0.129]",0.089,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0004975,lurasidone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.059,0.032,0.086,"[0.032,0.086]",1.00E-04,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005364,lurasidone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0561,-0.023,0.135,"[-0.023,0.135]",0.163,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0002909,lurasidone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0343,-0.012,0.08,"[-0.012,0.08]",0.144,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0007186,lurasidone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0296,-0.041,0.1,"[-0.041,0.1]",0.409,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0007739,lurasidone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0282,-0.325,0.382,"[-0.325,0.382]",0.876,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0018882,lurasidone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0268,-0.03,0.084,"[-0.03,0.084]",0.357,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005404,lurasidone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0136,-0.208,0.235,"[-0.208,0.235]",0.905,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0021107,lurasidone,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0134,-0.289,0.315,"[-0.289,0.315]",0.931,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0008487,lurasidone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0115,-0.048,0.071,"[-0.048,0.071]",0.703,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0004609,lurasidone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0078,-0.2,0.216,"[-0.2,0.216]",0.941,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0002046,lurasidone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0078,-0.18,0.195,"[-0.18,0.195]",0.935,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005301,lurasidone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0046,-0.221,0.23,"[-0.221,0.23]",0.968,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0002316,lurasidone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0024,-241.401,241.406,"[-241.401,241.406]",1,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0004979,lurasidone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0024,-0.487,0.492,"[-0.487,0.492]",0.992,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005392,lurasidone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,0.0014,-0.831,0.834,"[-0.831,0.834]",0.997,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254219,biolink:associated_with_increased_likelihood_of,MONDO:0005011,lurasidone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904778646,2.00E-04,-0.326,0.326,"[-0.326,0.326]",0.999,117100,21731000,21848100,"Sample size with lurasidone, approximately: 117100","Sample size without lurasidone, approximately: 21731000",All patients number is approximately: 21848100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0253721,biolink:associated_with_increased_likelihood_of,MONDO:0011786,lumateperone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924007469,0.0135,-0.774,0.801,"[-0.774,0.801]",0.973,4600,21789600,21794200,"Sample size with lumateperone, approximately: 4600","Sample size without lumateperone, approximately: 21789600",All patients number is approximately: 21794200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0253721,biolink:associated_with_increased_likelihood_of,MONDO:0008383,lumateperone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924007469,0.0135,-0.825,0.852,"[-0.825,0.852]",0.975,4600,21789600,21794200,"Sample size with lumateperone, approximately: 4600","Sample size without lumateperone, approximately: 21789600",All patients number is approximately: 21794200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0253721,biolink:associated_with_increased_likelihood_of,MONDO:0005147,lumateperone,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924007469,0.0079,-2.362,2.378,"[-2.362,2.378]",0.995,4600,21789600,21794200,"Sample size with lumateperone, approximately: 4600","Sample size without lumateperone, approximately: 21789600",All patients number is approximately: 21794200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0253721,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,lumateperone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924007469,0.0031,-1.224,1.23,"[-1.224,1.23]",0.996,4600,21789600,21794200,"Sample size with lumateperone, approximately: 4600","Sample size without lumateperone, approximately: 21789600",All patients number is approximately: 21794200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3964,biolink:associated_with_increased_likelihood_of,MONDO:0003620,loxapine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954597613,0.0869,-0.249,0.423,"[-0.249,0.423]",0.612,5900,21789600,21795500,"Sample size with loxapine, approximately: 5900","Sample size without loxapine, approximately: 21789600",All patients number is approximately: 21795500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3964,biolink:associated_with_increased_likelihood_of,MONDO:0005147,loxapine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954597613,0.0042,-6.939,6.947,"[-6.939,6.947]",0.999,5900,21789600,21795500,"Sample size with loxapine, approximately: 5900","Sample size without loxapine, approximately: 21789600",All patients number is approximately: 21795500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0019369,lovastatin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.6093,0.598,0.62,"[0.598,0.62]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005546,lovastatin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.3842,0.373,0.395,"[0.373,0.395]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0004425,lovastatin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.3102,0.298,0.322,"[0.298,0.322]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0003620,lovastatin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.2878,0.278,0.297,"[0.278,0.297]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005302,lovastatin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.2186,0.201,0.236,"[0.201,0.236]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0009891,lovastatin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.2047,0.192,0.217,"[0.192,0.217]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005404,lovastatin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.1386,0.104,0.174,"[0.104,0.174]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0009061,lovastatin,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.119,0.101,0.137,"[0.101,0.137]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0007186,lovastatin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.1154,0.085,0.145,"[0.085,0.145]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0008487,lovastatin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.1005,0.079,0.122,"[0.079,0.122]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0006694,lovastatin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.099,0.077,0.121,"[0.077,0.121]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005010,lovastatin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0825,0.035,0.13,"[0.035,0.13]",0.001,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005178,lovastatin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0815,0.05,0.113,"[0.05,0.113]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0004979,lovastatin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0681,0.041,0.096,"[0.041,0.096]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005101,lovastatin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0612,0.024,0.099,"[0.024,0.099]",0.001,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0018177,lovastatin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0547,0.033,0.077,"[0.033,0.077]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,lovastatin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0538,0.031,0.077,"[0.031,0.077]",1.00E-04,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005298,lovastatin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0454,-0.018,0.109,"[-0.018,0.109]",0.159,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005392,lovastatin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0249,0.005,0.045,"[0.005,0.045]",0.017,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0013282,lovastatin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0127,-0.072,0.098,"[-0.072,0.098]",0.769,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0004981,lovastatin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0097,-0.054,0.073,"[-0.054,0.073]",0.764,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005133,lovastatin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0073,-0.104,0.118,"[-0.104,0.118]",0.898,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005002,lovastatin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0072,-0.07,0.085,"[-0.07,0.085]",0.856,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0002046,lovastatin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0065,-0.107,0.12,"[-0.107,0.12]",0.91,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,lovastatin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0057,-0.116,0.127,"[-0.116,0.127]",0.926,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0011786,lovastatin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0046,-0.027,0.036,"[-0.027,0.036]",0.773,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005009,lovastatin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0027,-0.197,0.202,"[-0.197,0.202]",0.979,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005149,lovastatin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0018,-0.11,0.114,"[-0.11,0.114]",0.975,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0002869,lovastatin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0018,-0.876,0.88,"[-0.876,0.88]",0.997,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0008399,lovastatin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0015,-0.031,0.034,"[-0.031,0.034]",0.929,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0007540,lovastatin,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0015,-0.458,0.461,"[-0.458,0.461]",0.995,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0008394,lovastatin,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.0012,-0.408,0.411,"[-0.408,0.411]",0.995,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0004609,lovastatin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,0.001,-0.089,0.091,"[-0.089,0.091]",0.983,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0002909,lovastatin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,3.00E-04,-0.171,0.172,"[-0.171,0.172]",0.997,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005294,lovastatin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,3.00E-04,-0.29,0.291,"[-0.29,0.291]",0.998,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0005364,lovastatin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,3.00E-04,-0.598,0.598,"[-0.598,0.598]",0.999,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0004975,lovastatin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,1.00E-04,-0.508,0.509,"[-0.508,0.509]",1,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248085,biolink:associated_with_increased_likelihood_of,MONDO:0002277,lovastatin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.890322366,1.00E-04,-0.408,0.408,"[-0.408,0.408]",0.999,441500,21502100,21943600,"Sample size with lovastatin, approximately: 441500","Sample size without lovastatin, approximately: 21502100",All patients number is approximately: 21943600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0000153,losartan,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.5222,0.517,0.527,"[0.517,0.527]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0011786,losartan,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.5025,0.493,0.512,"[0.493,0.512]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0007540,losartan,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.4798,0.469,0.491,"[0.469,0.491]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005101,losartan,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.2363,0.228,0.245,"[0.228,0.245]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0019350,losartan,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.1937,0.189,0.199,"[0.189,0.199]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0008644,losartan,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.1896,0.181,0.198,"[0.181,0.198]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0015263,losartan,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.1406,0.135,0.146,"[0.135,0.146]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005306,losartan,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.1096,0.102,0.117,"[0.102,0.117]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0043693,losartan,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.1053,0.084,0.127,"[0.084,0.127]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0004981,losartan,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0851,0.071,0.099,"[0.071,0.099]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0021187,losartan,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0842,0.061,0.108,"[0.061,0.108]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0010526,losartan,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0816,0.061,0.102,"[0.061,0.102]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005147,losartan,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0796,0.073,0.086,"[0.073,0.086]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0018177,losartan,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0793,0.073,0.086,"[0.073,0.086]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0004648,losartan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0779,0.063,0.092,"[0.063,0.092]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0020066,losartan,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0717,0.066,0.078,"[0.066,0.078]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0019180,losartan,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0698,0.044,0.095,"[0.044,0.095]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0019499,losartan,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0663,0.055,0.078,"[0.055,0.078]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0004979,losartan,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0621,0.042,0.082,"[0.042,0.082]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005393,losartan,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0614,0.052,0.07,"[0.052,0.07]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0002406,losartan,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0509,0.041,0.061,"[0.041,0.061]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0009693,losartan,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.049,0.04,0.058,"[0.04,0.058]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0008487,losartan,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0487,0.031,0.066,"[0.031,0.066]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005302,losartan,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.048,0.036,0.06,"[0.036,0.06]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005146,losartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0416,0.016,0.067,"[0.016,0.067]",0.002,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0007739,losartan,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0359,0.015,0.057,"[0.015,0.057]",0.001,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0002316,losartan,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0277,-0.051,0.106,"[-0.051,0.106]",0.49,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,losartan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0263,0.018,0.034,"[0.018,0.034]",1.00E-04,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005546,losartan,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0185,-0.011,0.048,"[-0.011,0.048]",0.219,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0007947,losartan,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0169,-0.01,0.044,"[-0.01,0.044]",0.22,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0002277,losartan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0144,-0.063,0.092,"[-0.063,0.092]",0.716,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005011,losartan,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0092,-0.049,0.068,"[-0.049,0.068]",0.757,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005148,losartan,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0067,-0.031,0.045,"[-0.031,0.045]",0.729,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0021107,losartan,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.006,-0.056,0.068,"[-0.056,0.068]",0.85,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005364,losartan,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0057,-0.05,0.061,"[-0.05,0.061]",0.84,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0004952,losartan,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0053,-0.084,0.094,"[-0.084,0.094]",0.907,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005009,losartan,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0026,-0.154,0.16,"[-0.154,0.16]",0.974,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0011508,losartan,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,0.0013,-0.082,0.084,"[-0.082,0.084]",0.976,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,losartan,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,9.00E-04,-0.259,0.261,"[-0.259,0.261]",0.995,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005404,losartan,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,8.00E-04,-0.119,0.12,"[-0.119,0.12]",0.99,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0019118,losartan,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,8.00E-04,-0.156,0.158,"[-0.156,0.158]",0.992,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0002046,losartan,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,8.00E-04,-0.132,0.133,"[-0.132,0.133]",0.991,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,losartan,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,6.00E-04,-0.52,0.521,"[-0.52,0.521]",0.998,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0013282,losartan,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,6.00E-04,-0.085,0.087,"[-0.085,0.087]",0.989,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0016218,losartan,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,5.00E-04,-0.252,0.253,"[-0.252,0.253]",0.997,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0000477,losartan,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,4.00E-04,-0.057,0.058,"[-0.057,0.058]",0.989,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005392,losartan,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,3.00E-04,-0.303,0.304,"[-0.303,0.304]",0.998,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0018882,losartan,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,2.00E-04,-0.195,0.195,"[-0.195,0.195]",0.999,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005298,losartan,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,2.00E-04,-0.49,0.49,"[-0.49,0.49]",0.999,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0005388,losartan,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,1.00E-04,-0.483,0.483,"[-0.483,0.483]",1,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:25749227,biolink:associated_with_increased_likelihood_of,MONDO:0008542,losartan,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909457422,9.26E-05,-0.889,0.889,"[-0.889,0.889]",1,4096500,19733900,23830400,"Sample size with losartan, approximately: 4096500","Sample size without losartan, approximately: 19733900",All patients number is approximately: 23830400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11658860,biolink:associated_with_increased_likelihood_of,MONDO:0005546,lorcaserin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.90806817,0.0061,-1.365,1.378,"[-1.365,1.378]",0.993,7000,21787900,21794900,"Sample size with lorcaserin, approximately: 7000","Sample size without lorcaserin, approximately: 21787900",All patients number is approximately: 21794900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,lixisenatide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.2973,0.076,0.519,"[0.076,0.519]",0.009,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,MONDO:0004979,lixisenatide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.1419,-0.185,0.469,"[-0.185,0.469]",0.395,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,MONDO:0002869,lixisenatide,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.0328,-0.949,1.014,"[-0.949,1.014]",0.948,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,lixisenatide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.0268,-1.793,1.847,"[-1.793,1.847]",0.977,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,lixisenatide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.0256,-0.26,0.311,"[-0.26,0.311]",0.861,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108336,biolink:associated_with_increased_likelihood_of,MONDO:0043693,lixisenatide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.993714625,0.0086,-0.968,0.986,"[-0.968,0.986]",0.986,7900,21787700,21795600,"Sample size with lixisenatide, approximately: 7900","Sample size without lixisenatide, approximately: 21787700",All patients number is approximately: 21795600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005392,lisinopril,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.9611,0.956,0.966,"[0.956,0.966]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0019565,lisinopril,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.8857,0.879,0.892,"[0.879,0.892]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0007947,lisinopril,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.4982,0.493,0.503,"[0.493,0.503]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005009,lisinopril,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.344,0.334,0.354,"[0.334,0.354]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005146,lisinopril,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.2221,0.214,0.23,"[0.214,0.23]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0001516,lisinopril,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.2002,0.195,0.205,"[0.195,0.205]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0007027,lisinopril,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1919,0.186,0.198,"[0.186,0.198]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0043693,lisinopril,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1912,0.181,0.201,"[0.181,0.201]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,lisinopril,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1729,0.162,0.184,"[0.162,0.184]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005306,lisinopril,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1642,0.159,0.169,"[0.159,0.169]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0010526,lisinopril,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.156,0.144,0.168,"[0.144,0.168]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005149,lisinopril,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1448,0.136,0.154,"[0.136,0.154]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0015614,lisinopril,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1334,0.127,0.14,"[0.127,0.14]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0002316,lisinopril,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1303,0.108,0.152,"[0.108,0.152]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004425,lisinopril,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1125,0.095,0.13,"[0.095,0.13]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005301,lisinopril,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.1041,0.096,0.112,"[0.096,0.112]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0002909,lisinopril,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0765,0.059,0.093,"[0.059,0.093]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004979,lisinopril,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0621,0.039,0.085,"[0.039,0.085]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0007186,lisinopril,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0593,0.035,0.083,"[0.035,0.083]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0000477,lisinopril,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0587,0.041,0.076,"[0.041,0.076]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0010383,lisinopril,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0555,0.051,0.06,"[0.051,0.06]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005393,lisinopril,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0552,0.051,0.059,"[0.051,0.059]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0008377,lisinopril,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0503,0.032,0.068,"[0.032,0.068]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0018882,lisinopril,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0476,0.003,0.092,"[0.003,0.092]",0.035,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005298,lisinopril,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0367,0.001,0.072,"[0.001,0.072]",0.042,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005011,lisinopril,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0309,0.021,0.041,"[0.021,0.041]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004975,lisinopril,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0261,-0.021,0.073,"[-0.021,0.073]",0.277,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005178,lisinopril,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0153,0.008,0.023,"[0.008,0.023]",1.00E-04,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0015564,lisinopril,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0127,-0.029,0.054,"[-0.029,0.054]",0.551,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0010602,lisinopril,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0108,-0.007,0.028,"[-0.007,0.028]",0.221,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004609,lisinopril,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.007,-0.096,0.111,"[-0.096,0.111]",0.894,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004952,lisinopril,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0056,-0.027,0.038,"[-0.027,0.038]",0.736,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005010,lisinopril,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0045,-0.141,0.15,"[-0.141,0.15]",0.952,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0019369,lisinopril,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0041,-10.625,10.633,"[-10.625,10.633]",0.999,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0800026,lisinopril,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0035,-0.112,0.119,"[-0.112,0.119]",0.953,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005404,lisinopril,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0032,-0.071,0.077,"[-0.071,0.077]",0.932,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0000153,lisinopril,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0031,-0.118,0.124,"[-0.118,0.124]",0.96,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0009889,lisinopril,polycystic kidney disease infantile type,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0024,-0.021,0.026,"[-0.021,0.026]",0.836,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0008487,lisinopril,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0018,-0.072,0.076,"[-0.072,0.076]",0.963,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0004648,lisinopril,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0017,-0.21,0.213,"[-0.21,0.213]",0.987,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0019350,lisinopril,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0017,-0.1,0.103,"[-0.1,0.103]",0.974,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0011508,lisinopril,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0016,-0.194,0.197,"[-0.194,0.197]",0.988,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005133,lisinopril,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0015,-0.155,0.158,"[-0.155,0.158]",0.985,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0007540,lisinopril,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.0013,-0.217,0.219,"[-0.217,0.219]",0.99,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0005148,lisinopril,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,0.001,-0.407,0.409,"[-0.407,0.409]",0.996,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0019118,lisinopril,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,9.00E-04,-0.186,0.188,"[-0.186,0.188]",0.993,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0021107,lisinopril,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,4.00E-04,-0.271,0.272,"[-0.271,0.272]",0.998,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0008678,lisinopril,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,4.00E-04,-0.217,0.218,"[-0.217,0.218]",0.997,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0019180,lisinopril,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,3.00E-04,-0.331,0.332,"[-0.331,0.332]",0.999,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0007827,lisinopril,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,3.00E-04,-0.464,0.465,"[-0.464,0.465]",0.999,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5362118,biolink:associated_with_increased_likelihood_of,MONDO:0011786,lisinopril,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.907521875,2.00E-04,-0.284,0.284,"[-0.284,0.284]",0.999,6149200,18533700,24682900,"Sample size with lisinopril, approximately: 6149200","Sample size without lisinopril, approximately: 18533700",All patients number is approximately: 24682900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0009693,liraglutide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.4747,0.455,0.494,"[0.455,0.494]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0019369,liraglutide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.4571,0.425,0.489,"[0.425,0.489]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0000424,liraglutide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.4553,0.431,0.479,"[0.431,0.479]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0008599,liraglutide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.3173,0.297,0.337,"[0.297,0.337]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0043693,liraglutide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.2948,0.274,0.316,"[0.274,0.316]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005300,liraglutide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.2845,0.254,0.315,"[0.254,0.315]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,liraglutide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.2226,0.207,0.238,"[0.207,0.238]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0003620,liraglutide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.2207,0.206,0.236,"[0.206,0.236]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005298,liraglutide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.2074,0.165,0.249,"[0.165,0.249]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0004979,liraglutide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.1334,0.09,0.177,"[0.09,0.177]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0004981,liraglutide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.1275,0.071,0.184,"[0.071,0.184]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005180,liraglutide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.099,0.074,0.124,"[0.074,0.124]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005178,liraglutide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0965,0.054,0.139,"[0.054,0.139]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0002406,liraglutide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0934,0.061,0.126,"[0.061,0.126]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005101,liraglutide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.088,0.042,0.134,"[0.042,0.134]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0019565,liraglutide,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0821,0.04,0.125,"[0.04,0.125]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005546,liraglutide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0637,0.003,0.125,"[0.003,0.125]",0.041,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,liraglutide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0584,0.017,0.099,"[0.017,0.099]",0.005,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005148,liraglutide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0402,0.019,0.061,"[0.019,0.061]",1.00E-04,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0004425,liraglutide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0349,-0.062,0.132,"[-0.062,0.132]",0.482,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0018882,liraglutide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0239,-0.042,0.089,"[-0.042,0.089]",0.474,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0008487,liraglutide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.016,-0.169,0.201,"[-0.169,0.201]",0.866,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005146,liraglutide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.015,-0.161,0.191,"[-0.161,0.191]",0.868,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005002,liraglutide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.011,-0.209,0.231,"[-0.209,0.231]",0.922,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0002046,liraglutide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.009,-0.023,0.041,"[-0.023,0.041]",0.586,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0004648,liraglutide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0039,-0.217,0.225,"[-0.217,0.225]",0.972,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,liraglutide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0037,-0.567,0.574,"[-0.567,0.574]",0.99,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0011786,liraglutide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0031,-0.27,0.276,"[-0.27,0.276]",0.982,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0005149,liraglutide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.0013,-0.124,0.126,"[-0.124,0.126]",0.984,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,liraglutide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,0.001,-5.679,5.681,"[-5.679,5.681]",1,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0002909,liraglutide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,8.00E-04,-0.458,0.459,"[-0.458,0.459]",0.997,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254124,biolink:associated_with_increased_likelihood_of,MONDO:0004609,liraglutide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922225962,4.00E-04,-0.603,0.604,"[-0.603,0.604]",0.999,232100,21667500,21899600,"Sample size with liraglutide, approximately: 232100","Sample size without liraglutide, approximately: 21667500",All patients number is approximately: 21899600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0002909,linagliptin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,1.876,1.85,1.902,"[1.85,1.902]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0007186,linagliptin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.5777,0.553,0.602,"[0.553,0.602]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0004981,linagliptin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.5309,0.51,0.552,"[0.51,0.552]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,linagliptin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.477,0.459,0.495,"[0.459,0.495]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,linagliptin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.3466,0.329,0.364,"[0.329,0.364]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0018882,linagliptin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.3391,0.301,0.377,"[0.301,0.377]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0004609,linagliptin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.314,0.295,0.333,"[0.295,0.333]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0007027,linagliptin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.2021,0.173,0.231,"[0.173,0.231]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0004648,linagliptin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.168,0.15,0.186,"[0.15,0.186]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005178,linagliptin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.1495,0.125,0.174,"[0.125,0.174]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005393,linagliptin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.1318,0.103,0.16,"[0.103,0.16]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005148,linagliptin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.1144,0.09,0.139,"[0.09,0.139]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005147,linagliptin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.1115,0.09,0.133,"[0.09,0.133]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0008399,linagliptin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.1043,0.073,0.136,"[0.073,0.136]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0009693,linagliptin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0717,0.027,0.116,"[0.027,0.116]",0.002,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0009891,linagliptin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0537,-0.063,0.171,"[-0.063,0.171]",0.368,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0021187,linagliptin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.046,0.02,0.072,"[0.02,0.072]",1.00E-04,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005002,linagliptin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0428,-0.091,0.176,"[-0.091,0.176]",0.531,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005364,linagliptin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0285,-0.192,0.249,"[-0.192,0.249]",0.8,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0005300,linagliptin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0186,-0.141,0.178,"[-0.141,0.178]",0.819,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0011849,linagliptin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0112,-0.166,0.188,"[-0.166,0.188]",0.902,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0008383,linagliptin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0104,-0.087,0.108,"[-0.087,0.108]",0.834,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0043693,linagliptin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0089,-0.178,0.196,"[-0.178,0.196]",0.926,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0003620,linagliptin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0071,-0.392,0.406,"[-0.392,0.406]",0.972,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,linagliptin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0042,-0.107,0.116,"[-0.107,0.116]",0.941,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,linagliptin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,0.0013,-0.253,0.256,"[-0.253,0.256]",0.992,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254095,biolink:associated_with_increased_likelihood_of,MONDO:0004975,linagliptin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94359808,8.00E-04,-0.407,0.409,"[-0.407,0.409]",0.997,118900,21723300,21842200,"Sample size with linagliptin, approximately: 118900","Sample size without linagliptin, approximately: 21723300",All patients number is approximately: 21842200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0254055,biolink:associated_with_increased_likelihood_of,MONDO:0005148,levomilnacipran,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909576069,0.0159,-0.786,0.818,"[-0.786,0.818]",0.969,6000,21789300,21795300,"Sample size with levomilnacipran, approximately: 6000","Sample size without levomilnacipran, approximately: 21789300",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0008300,levalbuterol,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.6348,0.626,0.643,"[0.626,0.643]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005011,levalbuterol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.4713,0.461,0.481,"[0.461,0.481]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0002909,levalbuterol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.3803,0.374,0.387,"[0.374,0.387]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005147,levalbuterol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.3208,0.308,0.333,"[0.308,0.333]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0011786,levalbuterol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.2254,0.217,0.234,"[0.217,0.234]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0009693,levalbuterol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.2215,0.213,0.23,"[0.213,0.23]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0015263,levalbuterol,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.2134,0.205,0.221,"[0.205,0.221]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0011122,levalbuterol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1992,0.187,0.212,"[0.187,0.212]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0008738,levalbuterol,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1894,0.181,0.198,"[0.181,0.198]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0018177,levalbuterol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.179,0.172,0.186,"[0.172,0.186]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0009891,levalbuterol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1695,0.161,0.178,"[0.161,0.178]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0021187,levalbuterol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1665,0.153,0.18,"[0.153,0.18]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0008399,levalbuterol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1429,0.135,0.15,"[0.135,0.15]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0021129,levalbuterol,microphthalmos,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1216,0.107,0.137,"[0.107,0.137]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0004981,levalbuterol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.1171,0.11,0.124,"[0.11,0.124]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0002316,levalbuterol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0979,0.077,0.119,"[0.077,0.119]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0002406,levalbuterol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0897,0.077,0.102,"[0.077,0.102]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0007843,levalbuterol,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0855,0.077,0.094,"[0.077,0.094]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0008383,levalbuterol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0598,0.024,0.096,"[0.024,0.096]",0.001,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005294,levalbuterol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0331,-0.012,0.078,"[-0.012,0.078]",0.15,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005010,levalbuterol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0311,0.006,0.056,"[0.006,0.056]",0.014,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0010602,levalbuterol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0294,0.007,0.052,"[0.007,0.052]",0.011,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005301,levalbuterol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0275,-0.013,0.068,"[-0.013,0.068]",0.187,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0011849,levalbuterol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0245,0.013,0.036,"[0.013,0.036]",1.00E-04,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0019369,levalbuterol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0233,-0.02,0.066,"[-0.02,0.066]",0.286,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0043693,levalbuterol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.019,-0.011,0.049,"[-0.011,0.049]",0.21,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0009476,levalbuterol,congenital atresia of small intestine,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0176,-0.071,0.106,"[-0.071,0.106]",0.697,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005298,levalbuterol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.017,-0.113,0.147,"[-0.113,0.147]",0.798,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005101,levalbuterol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0149,0.001,0.029,"[0.001,0.029]",0.033,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005002,levalbuterol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0126,-0.017,0.042,"[-0.017,0.042]",0.406,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0007186,levalbuterol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0101,-0.092,0.112,"[-0.092,0.112]",0.846,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005404,levalbuterol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0057,-0.084,0.096,"[-0.084,0.096]",0.902,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005146,levalbuterol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0046,-0.152,0.161,"[-0.152,0.161]",0.954,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,levalbuterol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0019,-0.102,0.105,"[-0.102,0.105]",0.972,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0010383,levalbuterol,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0019,-0.098,0.102,"[-0.098,0.102]",0.97,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0019565,levalbuterol,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,0.0011,-0.056,0.058,"[-0.056,0.058]",0.969,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0005306,levalbuterol,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,8.00E-04,-0.224,0.226,"[-0.224,0.226]",0.994,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0011508,levalbuterol,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,6.00E-04,-0.138,0.139,"[-0.138,0.139]",0.993,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0019350,levalbuterol,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,3.00E-04,-0.184,0.185,"[-0.184,0.185]",0.998,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0016218,levalbuterol,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,3.00E-04,-0.322,0.322,"[-0.322,0.322]",0.999,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,levalbuterol,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,2.00E-04,-0.415,0.415,"[-0.415,0.415]",0.999,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:123600,biolink:associated_with_increased_likelihood_of,MONDO:0004609,levalbuterol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954372195,1.00E-04,-0.224,0.225,"[-0.224,0.225]",0.999,1235000,21377300,22612300,"Sample size with levalbuterol, approximately: 1235000","Sample size without levalbuterol, approximately: 21377300",All patients number is approximately: 22612300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,leflunomide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.848,0.826,0.87,"[0.826,0.87]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0019369,leflunomide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.7264,0.703,0.75,"[0.703,0.75]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005364,leflunomide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.5513,0.529,0.574,"[0.529,0.574]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,leflunomide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.5331,0.502,0.564,"[0.502,0.564]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005147,leflunomide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.3833,0.35,0.417,"[0.35,0.417]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0002909,leflunomide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.3111,0.278,0.344,"[0.278,0.344]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0007186,leflunomide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.2664,0.209,0.324,"[0.209,0.324]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0011122,leflunomide,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.2532,0.219,0.287,"[0.219,0.287]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005180,leflunomide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.1749,0.142,0.207,"[0.142,0.207]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005404,leflunomide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.1436,0.098,0.189,"[0.098,0.189]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005302,leflunomide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0961,0.054,0.138,"[0.054,0.138]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0021187,leflunomide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0922,0.059,0.125,"[0.059,0.125]",1.00E-04,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0007915,leflunomide,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0689,-0.016,0.154,"[-0.016,0.154]",0.11,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005392,leflunomide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.057,-0.003,0.117,"[-0.003,0.117]",0.061,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005146,leflunomide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.034,-0.062,0.13,"[-0.062,0.13]",0.487,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004609,leflunomide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0267,-0.095,0.149,"[-0.095,0.149]",0.668,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005546,leflunomide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0191,-0.071,0.11,"[-0.071,0.11]",0.678,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004981,leflunomide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.016,-0.037,0.069,"[-0.037,0.069]",0.553,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004648,leflunomide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0142,-0.206,0.234,"[-0.206,0.234]",0.9,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005010,leflunomide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0111,-0.062,0.085,"[-0.062,0.085]",0.768,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005002,leflunomide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.011,-0.178,0.2,"[-0.178,0.2]",0.909,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004979,leflunomide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.009,-0.333,0.351,"[-0.333,0.351]",0.959,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0008383,leflunomide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0058,-0.438,0.45,"[-0.438,0.45]",0.98,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0002277,leflunomide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0037,-0.507,0.514,"[-0.507,0.514]",0.989,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0011849,leflunomide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0035,-0.246,0.253,"[-0.246,0.253]",0.978,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,leflunomide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0031,-0.174,0.18,"[-0.174,0.18]",0.973,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0005101,leflunomide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,0.0012,-0.423,0.425,"[-0.423,0.425]",0.996,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004425,leflunomide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,9.00E-04,-0.294,0.295,"[-0.294,0.295]",0.995,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3899,biolink:associated_with_increased_likelihood_of,MONDO:0004975,leflunomide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.936852478,7.00E-04,-1.414,1.415,"[-1.414,1.415]",0.999,76700,21753400,21830100,"Sample size with leflunomide, approximately: 76700","Sample size without leflunomide, approximately: 21753400",All patients number is approximately: 21830100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242282,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ledipasvir,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998926689,5.3543,5.217,5.492,"[5.217,5.492]",1.00E-04,10500,21784800,21795300,"Sample size with ledipasvir, approximately: 10500","Sample size without ledipasvir, approximately: 21784800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242282,biolink:associated_with_increased_likelihood_of,MONDO:0004981,ledipasvir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998926689,0.1117,-0.195,0.418,"[-0.195,0.418]",0.476,10500,21784800,21795300,"Sample size with ledipasvir, approximately: 10500","Sample size without ledipasvir, approximately: 21784800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242282,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ledipasvir,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998926689,0.1056,-0.224,0.435,"[-0.224,0.435]",0.53,10500,21784800,21795300,"Sample size with ledipasvir, approximately: 10500","Sample size without ledipasvir, approximately: 21784800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242282,biolink:associated_with_increased_likelihood_of,MONDO:0007186,ledipasvir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998926689,0.0244,-0.429,0.478,"[-0.429,0.478]",0.916,10500,21784800,21795300,"Sample size with ledipasvir, approximately: 10500","Sample size without ledipasvir, approximately: 21784800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242282,biolink:associated_with_increased_likelihood_of,MONDO:0043693,ledipasvir,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998926689,0.0079,-1.54,1.555,"[-1.54,1.555]",0.992,10500,21784800,21795300,"Sample size with ledipasvir, approximately: 10500","Sample size without ledipasvir, approximately: 21784800",All patients number is approximately: 21795300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,lamivudine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.5413,0.225,0.858,"[0.225,0.858]",0.001,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0004609,lamivudine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.5282,0.485,0.571,"[0.485,0.571]",1.00E-04,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0007186,lamivudine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.3242,0.246,0.402,"[0.246,0.402]",1.00E-04,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005009,lamivudine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.2046,0.138,0.271,"[0.138,0.271]",1.00E-04,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005180,lamivudine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.188,0.126,0.249,"[0.126,0.249]",1.00E-04,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005002,lamivudine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0902,-0.001,0.181,"[-0.001,0.181]",0.052,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0002046,lamivudine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0698,-0.03,0.17,"[-0.03,0.17]",0.171,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005101,lamivudine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.049,-2.138,2.236,"[-2.138,2.236]",0.965,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005298,lamivudine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0281,-1.826,1.883,"[-1.826,1.883]",0.976,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005404,lamivudine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0271,-0.405,0.46,"[-0.405,0.46]",0.902,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005294,lamivudine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0249,-2.701,2.751,"[-2.701,2.751]",0.986,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005392,lamivudine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0128,-0.534,0.56,"[-0.534,0.56]",0.964,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0005546,lamivudine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0056,-0.293,0.304,"[-0.293,0.304]",0.971,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0004975,lamivudine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0047,-35.84,35.849,"[-35.84,35.849]",1,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60825,biolink:associated_with_increased_likelihood_of,MONDO:0008383,lamivudine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991810271,0.0029,-0.273,0.279,"[-0.273,0.279]",0.984,26500,21777700,21804200,"Sample size with lamivudine, approximately: 26500","Sample size without lamivudine, approximately: 21777700",All patients number is approximately: 21804200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0002406,labetalol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,2.9234,2.914,2.933,"[2.914,2.933]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0016532,labetalol,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.6529,0.646,0.66,"[0.646,0.66]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,labetalol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.647,0.64,0.654,"[0.64,0.654]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0013282,labetalol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.4919,0.487,0.496,"[0.487,0.496]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0018975,labetalol,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.3698,0.364,0.375,"[0.364,0.375]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007915,labetalol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.3465,0.337,0.356,"[0.337,0.356]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0019015,labetalol,congenital omphalocele,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.2345,0.202,0.267,"[0.202,0.267]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007540,labetalol,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.226,0.219,0.233,"[0.219,0.233]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007864,labetalol,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.2157,0.209,0.222,"[0.209,0.222]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0008399,labetalol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.1993,0.194,0.205,"[0.194,0.205]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0000914,labetalol,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.1658,0.161,0.17,"[0.161,0.17]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0008599,labetalol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.1548,0.148,0.161,"[0.148,0.161]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005010,labetalol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.114,0.089,0.139,"[0.089,0.139]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0015263,labetalol,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0939,0.077,0.11,"[0.077,0.11]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005388,labetalol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.091,0.084,0.098,"[0.084,0.098]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0015924,labetalol,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0885,0.083,0.094,"[0.083,0.094]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0003620,labetalol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0776,0.056,0.099,"[0.056,0.099]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0001044,labetalol,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0776,0.068,0.088,"[0.068,0.088]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005083,labetalol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0653,0.048,0.083,"[0.048,0.083]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005147,labetalol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0611,0.052,0.07,"[0.052,0.07]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007972,labetalol,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0537,0.048,0.059,"[0.048,0.059]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,labetalol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0486,0.037,0.06,"[0.037,0.06]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0011122,labetalol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0244,-0.01,0.058,"[-0.01,0.058]",0.161,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0008738,labetalol,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0227,0.004,0.041,"[0.004,0.041]",0.017,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0008383,labetalol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0225,-0.005,0.05,"[-0.005,0.05]",0.113,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0015614,labetalol,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0185,0.003,0.034,"[0.003,0.034]",0.022,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0019080,labetalol,alopecia totalis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0181,-0.006,0.042,"[-0.006,0.042]",0.133,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005009,labetalol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0162,0.008,0.025,"[0.008,0.025]",1.00E-04,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005364,labetalol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0134,-0.096,0.123,"[-0.096,0.123]",0.81,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005116,labetalol,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0086,-0.09,0.107,"[-0.09,0.107]",0.864,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005146,labetalol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0066,-0.077,0.09,"[-0.077,0.09]",0.876,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005148,labetalol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0063,-0.02,0.032,"[-0.02,0.032]",0.634,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0009891,labetalol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0044,-0.045,0.053,"[-0.045,0.053]",0.86,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0010789,labetalol,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0035,-0.033,0.04,"[-0.033,0.04]",0.851,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0002277,labetalol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0026,-0.111,0.116,"[-0.111,0.116]",0.965,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007947,labetalol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0022,-0.13,0.134,"[-0.13,0.134]",0.973,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,labetalol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.0019,-0.067,0.071,"[-0.067,0.071]",0.957,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0010619,labetalol,familial x linked hypophosphatemic vitamin d refractory rickets,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,0.001,-0.132,0.134,"[-0.132,0.134]",0.988,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007818,labetalol,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,8.00E-04,-0.199,0.201,"[-0.199,0.201]",0.994,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0007827,labetalol,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,8.00E-04,-0.262,0.263,"[-0.262,0.263]",0.996,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005404,labetalol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,4.00E-04,-0.076,0.076,"[-0.076,0.076]",0.992,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0008678,labetalol,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,4.00E-04,-0.453,0.454,"[-0.453,0.454]",0.999,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005306,labetalol,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,4.00E-04,-0.546,0.547,"[-0.546,0.547]",0.999,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0005711,labetalol,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,3.00E-04,-0.341,0.342,"[-0.341,0.342]",0.998,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0800026,labetalol,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,2.00E-04,-0.425,0.426,"[-0.425,0.426]",0.999,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0004952,labetalol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,7.46E-05,-1.321,1.321,"[-1.321,1.321]",1,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3869,biolink:associated_with_increased_likelihood_of,MONDO:0004648,labetalol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.965795677,6.74E-05,-1.281,1.281,"[-1.281,1.281]",1,7990800,18349400,26340200,"Sample size with labetalol, approximately: 7990800","Sample size without labetalol, approximately: 18349400",All patients number is approximately: 26340200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005393,ketamine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.6483,0.639,0.657,"[0.639,0.657]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0008738,ketamine,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.6218,0.611,0.632,"[0.611,0.632]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ketamine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.5521,0.542,0.562,"[0.542,0.562]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005711,ketamine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.499,0.487,0.511,"[0.487,0.511]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0009061,ketamine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.3854,0.375,0.396,"[0.375,0.396]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ketamine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.3412,0.332,0.35,"[0.332,0.35]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005010,ketamine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.25,0.23,0.27,"[0.23,0.27]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0019118,ketamine,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.2154,0.205,0.226,"[0.205,0.226]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0010383,ketamine,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.1919,0.178,0.206,"[0.178,0.206]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0018177,ketamine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.1633,0.154,0.172,"[0.154,0.172]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0009693,ketamine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.1472,0.133,0.161,"[0.133,0.161]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0013282,ketamine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.1042,0.088,0.12,"[0.088,0.12]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005083,ketamine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0714,0.043,0.1,"[0.043,0.1]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005002,ketamine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.056,0.008,0.104,"[0.008,0.104]",0.022,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005130,ketamine,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0456,0.035,0.056,"[0.035,0.056]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0007739,ketamine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0446,0.032,0.057,"[0.032,0.057]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ketamine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0395,0.03,0.049,"[0.03,0.049]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005011,ketamine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0392,0.019,0.059,"[0.019,0.059]",1.00E-04,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0021187,ketamine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0364,0.002,0.071,"[0.002,0.071]",0.038,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0008006,ketamine,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0352,-0.009,0.079,"[-0.009,0.079]",0.117,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ketamine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0177,-0.052,0.088,"[-0.052,0.088]",0.619,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0000477,ketamine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0164,-0.004,0.037,"[-0.004,0.037]",0.118,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0010526,ketamine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0091,-0.426,0.444,"[-0.426,0.444]",0.967,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005392,ketamine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0088,-0.048,0.066,"[-0.048,0.066]",0.764,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0008487,ketamine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.007,-0.056,0.07,"[-0.056,0.07]",0.828,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,ketamine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0051,-0.181,0.191,"[-0.181,0.191]",0.957,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0008678,ketamine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0029,-0.021,0.026,"[-0.021,0.026]",0.807,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005306,ketamine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0027,-0.58,0.586,"[-0.58,0.586]",0.993,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ketamine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0025,-0.273,0.278,"[-0.273,0.278]",0.986,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0004425,ketamine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.002,-0.546,0.55,"[-0.546,0.55]",0.994,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0018882,ketamine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0015,-0.142,0.145,"[-0.142,0.145]",0.984,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0011786,ketamine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0014,-0.207,0.209,"[-0.207,0.209]",0.99,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ketamine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,0.0011,-0.357,0.359,"[-0.357,0.359]",0.995,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0005009,ketamine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,9.00E-04,-0.64,0.642,"[-0.64,0.642]",0.998,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0004648,ketamine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,7.00E-04,-0.583,0.584,"[-0.583,0.584]",0.998,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ketamine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,7.00E-04,-0.194,0.195,"[-0.194,0.195]",0.994,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0002316,ketamine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,6.00E-04,-5.509,5.51,"[-5.509,5.51]",1,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0009476,ketamine,congenital atresia of small intestine,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,5.00E-04,-0.408,0.41,"[-0.408,0.41]",0.998,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3821,biolink:associated_with_increased_likelihood_of,MONDO:0019499,ketamine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884601025,2.00E-04,-0.62,0.621,"[-0.62,0.621]",0.999,877700,21204200,22081900,"Sample size with ketamine, approximately: 877700","Sample size without ketamine, approximately: 21204200",All patients number is approximately: 22081900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743034,biolink:associated_with_increased_likelihood_of,MONDO:0002406,ixekizumab,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884710492,0.0723,-0.8,0.945,"[-0.8,0.945]",0.871,10900,21786000,21796900,"Sample size with ixekizumab, approximately: 10900","Sample size without ixekizumab, approximately: 21786000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743034,biolink:associated_with_increased_likelihood_of,MONDO:0016264,ixekizumab,autoimmune liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884710492,0.0651,-0.174,0.304,"[-0.174,0.304]",0.593,10900,21786000,21796900,"Sample size with ixekizumab, approximately: 10900","Sample size without ixekizumab, approximately: 21786000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743034,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ixekizumab,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884710492,0.0175,-0.26,0.295,"[-0.26,0.295]",0.902,10900,21786000,21796900,"Sample size with ixekizumab, approximately: 10900","Sample size without ixekizumab, approximately: 21786000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1743034,biolink:associated_with_increased_likelihood_of,MONDO:0021107,ixekizumab,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.884710492,0.0136,-0.401,0.429,"[-0.401,0.429]",0.949,10900,21786000,21796900,"Sample size with ixekizumab, approximately: 10900","Sample size without ixekizumab, approximately: 21786000",All patients number is approximately: 21796900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0007186,isosorbide dinitrate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.8241,0.812,0.836,"[0.812,0.836]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0007947,isosorbide dinitrate,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.4233,0.413,0.433,"[0.413,0.433]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0018975,isosorbide dinitrate,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.4094,0.399,0.42,"[0.399,0.42]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005393,isosorbide dinitrate,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.2443,0.227,0.261,"[0.227,0.261]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004975,isosorbide dinitrate,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.2414,0.227,0.256,"[0.227,0.256]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004981,isosorbide dinitrate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.2219,0.19,0.254,"[0.19,0.254]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005180,isosorbide dinitrate,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.2176,0.199,0.237,"[0.199,0.237]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004609,isosorbide dinitrate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.21,0.2,0.22,"[0.2,0.22]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004425,isosorbide dinitrate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.2074,0.182,0.233,"[0.182,0.233]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0007739,isosorbide dinitrate,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1883,0.16,0.217,"[0.16,0.217]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005101,isosorbide dinitrate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1818,0.161,0.203,"[0.161,0.203]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005147,isosorbide dinitrate,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1464,0.135,0.158,"[0.135,0.158]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0007027,isosorbide dinitrate,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1365,0.123,0.15,"[0.123,0.15]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005009,isosorbide dinitrate,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1038,0.047,0.161,"[0.047,0.161]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0002277,isosorbide dinitrate,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.1026,0.061,0.144,"[0.061,0.144]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0000424,isosorbide dinitrate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0707,0.058,0.083,"[0.058,0.083]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0009693,isosorbide dinitrate,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0701,0.058,0.082,"[0.058,0.082]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005404,isosorbide dinitrate,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0689,0.042,0.095,"[0.042,0.095]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0007915,isosorbide dinitrate,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0578,0.029,0.086,"[0.029,0.086]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005148,isosorbide dinitrate,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0532,0.042,0.065,"[0.042,0.065]",1.00E-04,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0011849,isosorbide dinitrate,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0349,-0.027,0.097,"[-0.027,0.097]",0.272,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0013282,isosorbide dinitrate,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0304,-0.027,0.088,"[-0.027,0.088]",0.301,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004952,isosorbide dinitrate,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0272,-0.022,0.077,"[-0.022,0.077]",0.281,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005298,isosorbide dinitrate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0264,-0.046,0.099,"[-0.046,0.099]",0.477,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005301,isosorbide dinitrate,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0252,0.006,0.044,"[0.006,0.044]",0.008,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,isosorbide dinitrate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.018,-0.155,0.191,"[-0.155,0.191]",0.838,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005002,isosorbide dinitrate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0148,-0.04,0.069,"[-0.04,0.069]",0.596,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0011429,isosorbide dinitrate,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0112,-0.04,0.063,"[-0.04,0.063]",0.669,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0011786,isosorbide dinitrate,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0092,-0.116,0.134,"[-0.116,0.134]",0.886,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0004979,isosorbide dinitrate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0062,-0.263,0.276,"[-0.263,0.276]",0.964,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,isosorbide dinitrate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0024,-0.137,0.142,"[-0.137,0.142]",0.974,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0005010,isosorbide dinitrate,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0021,-230.421,230.425,"[-230.421,230.425]",1,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0002046,isosorbide dinitrate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.0011,-0.897,0.899,"[-0.897,0.899]",0.998,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,MONDO:0002909,isosorbide dinitrate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,0.001,-0.176,0.178,"[-0.176,0.178]",0.992,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:6883,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,isosorbide dinitrate,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973983593,5.00E-04,-0.088,0.089,"[-0.088,0.089]",0.991,559400,21618400,22177800,"Sample size with isosorbide dinitrate, approximately: 559400","Sample size without isosorbide dinitrate, approximately: 21618400",All patients number is approximately: 22177800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0000424,irbesartan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.6627,0.639,0.686,"[0.639,0.686]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0007186,irbesartan,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.6472,0.629,0.665,"[0.629,0.665]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0019369,irbesartan,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.5929,0.576,0.61,"[0.576,0.61]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0019180,irbesartan,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.2805,0.26,0.301,"[0.26,0.301]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0021187,irbesartan,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.229,0.209,0.249,"[0.209,0.249]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0009693,irbesartan,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.213,0.192,0.234,"[0.192,0.234]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0043693,irbesartan,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.2031,0.18,0.227,"[0.18,0.227]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0002046,irbesartan,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.1555,0.132,0.179,"[0.132,0.179]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005364,irbesartan,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0958,0.07,0.122,"[0.07,0.122]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005180,irbesartan,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0878,0.065,0.111,"[0.065,0.111]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0002909,irbesartan,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0784,0.041,0.116,"[0.041,0.116]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005393,irbesartan,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0742,0.026,0.122,"[0.026,0.122]",0.003,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005147,irbesartan,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0722,0.043,0.101,"[0.043,0.101]",1.00E-04,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005146,irbesartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0547,-0.011,0.12,"[-0.011,0.12]",0.101,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005101,irbesartan,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0415,-0.009,0.092,"[-0.009,0.092]",0.106,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005302,irbesartan,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0382,-0.003,0.08,"[-0.003,0.08]",0.072,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0004609,irbesartan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0257,-0.015,0.066,"[-0.015,0.066]",0.211,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0008399,irbesartan,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0256,-0.034,0.085,"[-0.034,0.085]",0.4,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0007027,irbesartan,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0179,-0.016,0.052,"[-0.016,0.052]",0.308,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0008383,irbesartan,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0166,-0.069,0.102,"[-0.069,0.102]",0.704,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005298,irbesartan,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0158,-0.081,0.113,"[-0.081,0.113]",0.749,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005002,irbesartan,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0129,-0.086,0.112,"[-0.086,0.112]",0.798,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0011786,irbesartan,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0108,-0.252,0.274,"[-0.252,0.274]",0.936,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0008599,irbesartan,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0094,-0.012,0.031,"[-0.012,0.031]",0.389,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0002406,irbesartan,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0087,-0.209,0.226,"[-0.209,0.226]",0.938,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0002277,irbesartan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0075,-0.115,0.13,"[-0.115,0.13]",0.904,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005294,irbesartan,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0048,-0.188,0.197,"[-0.188,0.197]",0.961,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0004425,irbesartan,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0019,-0.278,0.281,"[-0.278,0.281]",0.99,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005404,irbesartan,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,0.0014,-1.571,1.574,"[-1.571,1.574]",0.999,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005300,irbesartan,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,7.00E-04,-0.632,0.634,"[-0.632,0.634]",0.998,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0004979,irbesartan,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,4.00E-04,-0.352,0.353,"[-0.352,0.353]",0.998,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3749,biolink:associated_with_increased_likelihood_of,MONDO:0005010,irbesartan,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897634109,3.00E-04,-424.116,424.116,"[-424.116,424.116]",1,190000,21676400,21866400,"Sample size with irbesartan, approximately: 190000","Sample size without irbesartan, approximately: 21676400",All patients number is approximately: 21866400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0001516,ipratropium,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.4626,0.456,0.469,"[0.456,0.469]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0019180,ipratropium,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.4023,0.397,0.408,"[0.397,0.408]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0019350,ipratropium,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.3772,0.364,0.39,"[0.364,0.39]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ipratropium,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.3045,0.299,0.31,"[0.299,0.31]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0019118,ipratropium,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.2765,0.271,0.282,"[0.271,0.282]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007739,ipratropium,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.2473,0.24,0.254,"[0.24,0.254]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0002316,ipratropium,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.2413,0.233,0.249,"[0.233,0.249]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005404,ipratropium,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.2159,0.208,0.224,"[0.208,0.224]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005180,ipratropium,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.2033,0.195,0.212,"[0.195,0.212]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0015924,ipratropium,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.178,0.171,0.185,"[0.171,0.185]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0009693,ipratropium,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1548,0.149,0.161,"[0.149,0.161]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0009061,ipratropium,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1386,0.133,0.144,"[0.133,0.144]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0020066,ipratropium,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1369,0.128,0.146,"[0.128,0.146]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005011,ipratropium,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1204,0.107,0.133,"[0.107,0.133]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ipratropium,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1029,0.073,0.133,"[0.073,0.133]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0011429,ipratropium,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.1023,0.096,0.108,"[0.096,0.108]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ipratropium,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0969,0.087,0.107,"[0.087,0.107]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005083,ipratropium,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.086,0.068,0.104,"[0.068,0.104]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0008599,ipratropium,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.079,0.072,0.086,"[0.072,0.086]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0002406,ipratropium,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0752,0.054,0.097,"[0.054,0.097]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0001044,ipratropium,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.075,0.064,0.086,"[0.064,0.086]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0008300,ipratropium,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.064,0.045,0.083,"[0.045,0.083]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0006694,ipratropium,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0605,0.053,0.068,"[0.053,0.068]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0000477,ipratropium,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0481,0.039,0.058,"[0.039,0.058]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007540,ipratropium,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0472,0.03,0.064,"[0.03,0.064]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007915,ipratropium,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0408,0.03,0.052,"[0.03,0.052]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ipratropium,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0402,0.034,0.047,"[0.034,0.047]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0004981,ipratropium,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0379,0.029,0.047,"[0.029,0.047]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ipratropium,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0331,0.021,0.045,"[0.021,0.045]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ipratropium,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0275,-0.01,0.065,"[-0.01,0.065]",0.146,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0015564,ipratropium,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0264,0.006,0.047,"[0.006,0.047]",0.011,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0010526,ipratropium,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0261,-0.003,0.055,"[-0.003,0.055]",0.077,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0008738,ipratropium,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0252,0.005,0.045,"[0.005,0.045]",0.015,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0018975,ipratropium,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0173,0.009,0.025,"[0.009,0.025]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007972,ipratropium,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0123,0.006,0.018,"[0.006,0.018]",1.00E-04,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005393,ipratropium,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0105,-0.004,0.025,"[-0.004,0.025]",0.151,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0004975,ipratropium,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0086,-0.017,0.035,"[-0.017,0.035]",0.519,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005294,ipratropium,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0058,-0.053,0.065,"[-0.053,0.065]",0.847,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005364,ipratropium,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0046,-0.116,0.125,"[-0.116,0.125]",0.941,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005009,ipratropium,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0038,-0.058,0.066,"[-0.058,0.066]",0.905,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0013282,ipratropium,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0036,-0.137,0.144,"[-0.137,0.144]",0.96,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007947,ipratropium,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0036,-0.086,0.093,"[-0.086,0.093]",0.937,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005546,ipratropium,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0026,-0.146,0.152,"[-0.146,0.152]",0.972,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005146,ipratropium,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0019,-0.024,0.027,"[-0.024,0.027]",0.886,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,ipratropium,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0016,-0.078,0.081,"[-0.078,0.081]",0.969,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0008678,ipratropium,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0013,-0.049,0.052,"[-0.049,0.052]",0.958,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0009891,ipratropium,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.0011,-0.058,0.06,"[-0.058,0.06]",0.971,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ipratropium,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,0.001,-0.137,0.14,"[-0.137,0.14]",0.988,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0008542,ipratropium,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,8.00E-04,-0.75,0.751,"[-0.75,0.751]",0.998,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005300,ipratropium,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,7.00E-04,-0.37,0.372,"[-0.37,0.372]",0.997,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0005133,ipratropium,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,6.00E-04,-1.16E+07,1.16E+07,"[-11600000,11600000]",1,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0007827,ipratropium,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,5.00E-04,-0.412,0.413,"[-0.412,0.413]",0.998,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0000153,ipratropium,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,3.00E-04,-0.201,0.202,"[-0.201,0.202]",0.998,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0011786,ipratropium,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,3.00E-04,-0.515,0.516,"[-0.515,0.516]",0.999,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0002046,ipratropium,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,2.00E-04,-0.417,0.417,"[-0.417,0.417]",0.999,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0800026,ipratropium,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,2.00E-04,-0.655,0.655,"[-0.655,0.655]",1,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0018882,ipratropium,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,9.71E-05,-0.574,0.574,"[-0.574,0.574]",1,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5956,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ipratropium,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.976808171,2.77E-05,-4.899,4.899,"[-4.899,4.899]",1,7869500,18590000,26459500,"Sample size with ipratropium, approximately: 7869500","Sample size without ipratropium, approximately: 18590000",All patients number is approximately: 26459500,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0244713,biolink:associated_with_increased_likelihood_of,MONDO:0005009,interferon beta 1b,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942338835,0.0039,-1.23,1.238,"[-1.23,1.238]",0.995,2000,21790900,21792900,"Sample size with interferon beta 1b, approximately: 2000","Sample size without interferon beta 1b, approximately: 21790900",All patients number is approximately: 21792900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0254119,biolink:associated_with_increased_likelihood_of,MONDO:0005392,interferon beta 1a,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91378403,0.0044,-0.793,0.801,"[-0.793,0.801]",0.991,10200,21785700,21795900,"Sample size with interferon beta 1a, approximately: 10200","Sample size without interferon beta 1a, approximately: 21785700",All patients number is approximately: 21795900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0004952,insulin regular human,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,2.1253,2.117,2.133,"[2.117,2.133]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005072,insulin regular human,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.4087,0.404,0.414,"[0.404,0.414]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005133,insulin regular human,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.3424,0.337,0.348,"[0.337,0.348]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0019350,insulin regular human,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.2769,0.266,0.288,"[0.266,0.288]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0015614,insulin regular human,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.2668,0.26,0.273,"[0.26,0.273]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0009693,insulin regular human,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.2228,0.21,0.235,"[0.21,0.235]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0006058,insulin regular human,nephroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1719,0.165,0.179,"[0.165,0.179]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0008644,insulin regular human,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1716,0.166,0.178,"[0.166,0.178]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0019499,insulin regular human,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1702,0.155,0.185,"[0.155,0.185]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005147,insulin regular human,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1598,0.15,0.17,"[0.15,0.17]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0007027,insulin regular human,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1542,0.148,0.16,"[0.148,0.16]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0018177,insulin regular human,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1303,0.125,0.136,"[0.125,0.136]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0011122,insulin regular human,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1261,0.093,0.159,"[0.093,0.159]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0043693,insulin regular human,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1168,0.105,0.128,"[0.105,0.128]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0019180,insulin regular human,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1151,0.092,0.138,"[0.092,0.138]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0016532,insulin regular human,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1114,0.105,0.118,"[0.105,0.118]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin regular human,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1086,0.1,0.117,"[0.1,0.117]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0018882,insulin regular human,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1082,0.084,0.132,"[0.084,0.132]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005392,insulin regular human,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.1001,0.084,0.116,"[0.084,0.116]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005178,insulin regular human,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0987,0.092,0.106,"[0.092,0.106]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0019565,insulin regular human,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0848,0.074,0.095,"[0.074,0.095]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005002,insulin regular human,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0835,0.068,0.099,"[0.068,0.099]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0002316,insulin regular human,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0575,0.046,0.069,"[0.046,0.069]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005011,insulin regular human,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0363,0.023,0.049,"[0.023,0.049]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0004979,insulin regular human,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0306,-0.001,0.063,"[-0.001,0.063]",0.06,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0001044,insulin regular human,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0244,0.013,0.036,"[0.013,0.036]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0008487,insulin regular human,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0208,-0.012,0.054,"[-0.012,0.054]",0.218,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0008383,insulin regular human,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0203,0.012,0.029,"[0.012,0.029]",1.00E-04,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,insulin regular human,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0106,-0.017,0.038,"[-0.017,0.038]",0.456,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0018975,insulin regular human,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0103,-0.006,0.027,"[-0.006,0.027]",0.227,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005294,insulin regular human,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0092,-0.044,0.062,"[-0.044,0.062]",0.732,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0010789,insulin regular human,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0081,-0.11,0.126,"[-0.11,0.126]",0.894,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005404,insulin regular human,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0074,-0.091,0.106,"[-0.091,0.106]",0.882,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0008394,insulin regular human,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0067,-0.188,0.202,"[-0.188,0.202]",0.946,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0021107,insulin regular human,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0048,-0.07,0.08,"[-0.07,0.08]",0.901,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0800026,insulin regular human,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0037,-26.919,26.927,"[-26.919,26.927]",1,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0019369,insulin regular human,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0037,-26.919,26.926,"[-26.919,26.926]",1,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0002406,insulin regular human,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0036,-0.167,0.175,"[-0.167,0.175]",0.968,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,insulin regular human,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0027,-0.158,0.164,"[-0.158,0.164]",0.973,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0021187,insulin regular human,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0027,-0.184,0.189,"[-0.184,0.189]",0.977,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0008300,insulin regular human,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0025,-0.316,0.321,"[-0.316,0.321]",0.988,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0007160,insulin regular human,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0023,-0.129,0.133,"[-0.129,0.133]",0.972,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0004648,insulin regular human,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0017,-0.118,0.121,"[-0.118,0.121]",0.978,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005546,insulin regular human,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0013,-0.357,0.36,"[-0.357,0.36]",0.994,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin regular human,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0012,-0.245,0.247,"[-0.245,0.247]",0.992,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005149,insulin regular human,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,0.0012,-0.238,0.24,"[-0.238,0.24]",0.992,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0015564,insulin regular human,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,6.00E-04,-0.372,0.373,"[-0.372,0.373]",0.997,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0011786,insulin regular human,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,4.00E-04,-0.31,0.311,"[-0.31,0.311]",0.998,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005148,insulin regular human,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,3.00E-04,-0.203,0.203,"[-0.203,0.203]",0.998,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0005364,insulin regular human,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,2.00E-04,-0.86,0.861,"[-0.86,0.861]",1,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0306371,biolink:associated_with_increased_likelihood_of,MONDO:0007186,insulin regular human,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972911637,1.00E-04,-0.188,0.188,"[-0.188,0.188]",0.999,3345900,20558400,23904300,"Sample size with insulin regular human, approximately: 3345900","Sample size without insulin regular human, approximately: 20558400",All patients number is approximately: 23904300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005302,insulin isophane,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,2.7642,2.753,2.775,"[2.753,2.775]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0002909,insulin isophane,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.6434,0.63,0.657,"[0.63,0.657]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0015564,insulin isophane,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.468,0.458,0.478,"[0.458,0.478]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005364,insulin isophane,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.3966,0.389,0.404,"[0.389,0.404]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0010789,insulin isophane,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.2498,0.238,0.261,"[0.238,0.261]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005306,insulin isophane,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.2496,0.237,0.262,"[0.237,0.262]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005546,insulin isophane,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.2129,0.204,0.222,"[0.204,0.222]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0008377,insulin isophane,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.1758,0.161,0.191,"[0.161,0.191]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0008542,insulin isophane,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.1396,0.124,0.156,"[0.124,0.156]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0011429,insulin isophane,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.1379,0.123,0.153,"[0.123,0.153]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005011,insulin isophane,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.1189,0.101,0.137,"[0.101,0.137]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0008383,insulin isophane,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0995,0.062,0.137,"[0.062,0.137]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005002,insulin isophane,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0775,0.035,0.12,"[0.035,0.12]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin isophane,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0623,0.043,0.082,"[0.043,0.082]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0004981,insulin isophane,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0548,0.011,0.098,"[0.011,0.098]",0.013,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0011849,insulin isophane,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0531,0.038,0.069,"[0.038,0.069]",1.00E-04,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0021187,insulin isophane,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0482,0.015,0.082,"[0.015,0.082]",0.005,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0007915,insulin isophane,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0422,-0.008,0.093,"[-0.008,0.093]",0.1,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin isophane,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0318,-0.029,0.092,"[-0.029,0.092]",0.302,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005404,insulin isophane,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0172,-0.101,0.136,"[-0.101,0.136]",0.776,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005298,insulin isophane,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0135,-0.062,0.089,"[-0.062,0.089]",0.727,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0003620,insulin isophane,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0132,-0.083,0.109,"[-0.083,0.109]",0.788,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0018882,insulin isophane,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.01,-0.109,0.129,"[-0.109,0.129]",0.869,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0020066,insulin isophane,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.009,-0.092,0.11,"[-0.092,0.11]",0.861,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,insulin isophane,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0063,-0.006,0.018,"[-0.006,0.018]",0.294,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,insulin isophane,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0048,-0.144,0.153,"[-0.144,0.153]",0.949,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005294,insulin isophane,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0024,-0.203,0.208,"[-0.203,0.208]",0.982,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0019565,insulin isophane,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,0.0012,-0.461,0.464,"[-0.461,0.464]",0.996,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0002869,insulin isophane,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,2.00E-04,-0.773,0.773,"[-0.773,0.773]",1,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0021658,biolink:associated_with_increased_likelihood_of,MONDO:0005300,insulin isophane,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966213906,3.85E-05,-0.181,0.181,"[-0.181,0.181]",1,912300,21475900,22388200,"Sample size with insulin isophane, approximately: 912300","Sample size without insulin isophane, approximately: 21475900",All patients number is approximately: 22388200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin glulisine human,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.7995,0.752,0.847,"[0.752,0.847]",1.00E-04,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0002406,insulin glulisine human,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.7885,0.738,0.839,"[0.738,0.839]",1.00E-04,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin glulisine human,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.2558,0.195,0.316,"[0.195,0.316]",1.00E-04,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0007186,insulin glulisine human,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.1739,0.116,0.232,"[0.116,0.232]",1.00E-04,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0005148,insulin glulisine human,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.1191,0.061,0.177,"[0.061,0.177]",1.00E-04,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0004979,insulin glulisine human,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.0828,0.026,0.139,"[0.026,0.139]",0.004,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0005178,insulin glulisine human,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.082,-0.062,0.226,"[-0.062,0.226]",0.265,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0004609,insulin glulisine human,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.0681,-0.041,0.177,"[-0.041,0.177]",0.221,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0005002,insulin glulisine human,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.063,-0.04,0.166,"[-0.04,0.166]",0.229,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0000424,insulin glulisine human,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.0174,-0.182,0.217,"[-0.182,0.217]",0.864,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16136701,biolink:associated_with_increased_likelihood_of,MONDO:0002869,insulin glulisine human,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953337712,0.0022,-0.707,0.712,"[-0.707,0.712]",0.995,19700,21781200,21800900,"Sample size with insulin glulisine human, approximately: 19700","Sample size without insulin glulisine human, approximately: 21781200",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005178,insulin glargine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,1.0494,1.041,1.058,"[1.041,1.058]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005392,insulin glargine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.7101,0.704,0.717,"[0.704,0.717]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007947,insulin glargine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.6256,0.619,0.632,"[0.619,0.632]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005101,insulin glargine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.541,0.535,0.546,"[0.535,0.546]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0004975,insulin glargine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.499,0.475,0.523,"[0.475,0.523]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008383,insulin glargine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.3687,0.361,0.377,"[0.361,0.377]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0000424,insulin glargine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.3312,0.325,0.338,"[0.325,0.338]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008644,insulin glargine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.3118,0.305,0.319,"[0.305,0.319]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0015263,insulin glargine,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.2868,0.279,0.294,"[0.279,0.294]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008377,insulin glargine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.2363,0.218,0.254,"[0.218,0.254]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0001516,insulin glargine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.2001,0.193,0.207,"[0.193,0.207]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0018975,insulin glargine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.1977,0.183,0.213,"[0.183,0.213]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008642,insulin glargine,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.1735,0.144,0.203,"[0.144,0.203]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005388,insulin glargine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.1461,0.139,0.153,"[0.139,0.153]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007160,insulin glargine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.1066,0.081,0.133,"[0.081,0.133]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin glargine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.106,0.094,0.118,"[0.094,0.118]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007540,insulin glargine,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0936,0.087,0.101,"[0.087,0.101]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0019350,insulin glargine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0928,0.086,0.1,"[0.086,0.1]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0011122,insulin glargine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0821,0.063,0.102,"[0.063,0.102]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007186,insulin glargine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0789,0.052,0.106,"[0.052,0.106]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,insulin glargine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.068,0.054,0.082,"[0.054,0.082]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0004981,insulin glargine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0595,0.021,0.098,"[0.021,0.098]",0.003,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007864,insulin glargine,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0563,0.025,0.088,"[0.025,0.088]",0.001,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0004425,insulin glargine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0551,0.03,0.08,"[0.03,0.08]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0019565,insulin glargine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0454,0.036,0.055,"[0.036,0.055]",1.00E-04,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0011429,insulin glargine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0413,-0.008,0.09,"[-0.008,0.09]",0.097,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005180,insulin glargine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0249,-0.001,0.051,"[-0.001,0.051]",0.059,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007843,insulin glargine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0217,-0.102,0.146,"[-0.102,0.146]",0.731,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005298,insulin glargine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0174,-0.064,0.098,"[-0.064,0.098]",0.675,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0002046,insulin glargine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0134,-0.053,0.08,"[-0.053,0.08]",0.693,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0002277,insulin glargine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0132,-0.088,0.114,"[-0.088,0.114]",0.798,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005083,insulin glargine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0122,-0.011,0.035,"[-0.011,0.035]",0.302,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0018882,insulin glargine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0115,-0.055,0.078,"[-0.055,0.078]",0.734,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005149,insulin glargine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0113,-0.041,0.064,"[-0.041,0.064]",0.674,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0007739,insulin glargine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0097,-0.022,0.042,"[-0.022,0.042]",0.549,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0043693,insulin glargine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0081,-0.087,0.104,"[-0.087,0.104]",0.867,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,insulin glargine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0052,-0.077,0.087,"[-0.077,0.087]",0.901,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0019180,insulin glargine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0052,-0.115,0.125,"[-0.115,0.125]",0.933,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0002316,insulin glargine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.005,-0.03,0.04,"[-0.03,0.04]",0.779,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005009,insulin glargine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0037,-0.041,0.049,"[-0.041,0.049]",0.87,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0019369,insulin glargine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0036,-0.119,0.126,"[-0.119,0.126]",0.954,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005011,insulin glargine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0035,-0.08,0.087,"[-0.08,0.087]",0.934,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008394,insulin glargine,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0031,-0.856,0.862,"[-0.856,0.862]",0.994,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0008542,insulin glargine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0019,-0.119,0.123,"[-0.119,0.123]",0.975,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin glargine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0019,-0.209,0.213,"[-0.209,0.213]",0.986,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0004979,insulin glargine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0014,-0.032,0.035,"[-0.032,0.035]",0.935,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005133,insulin glargine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.0013,-0.284,0.287,"[-0.284,0.287]",0.993,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,insulin glargine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,0.001,-0.32,0.322,"[-0.32,0.322]",0.995,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005002,insulin glargine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,2.00E-04,-0.695,0.695,"[-0.695,0.695]",1,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0005294,insulin glargine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,1.00E-04,-0.573,0.573,"[-0.573,0.573]",1,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0004609,insulin glargine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,1.00E-04,-0.188,0.188,"[-0.188,0.188]",0.999,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201497,biolink:associated_with_increased_likelihood_of,MONDO:0015564,insulin glargine,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.979788879,5.92E-05,-0.358,0.358,"[-0.358,0.358]",1,4838400,20157600,24996000,"Sample size with insulin glargine, approximately: 4838400","Sample size without insulin glargine, approximately: 20157600",All patients number is approximately: 24996000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005133,insulin detemir,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,2.0897,2.076,2.103,"[2.076,2.103]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0004609,insulin detemir,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.5312,0.522,0.54,"[0.522,0.54]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0009061,insulin detemir,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.3931,0.38,0.406,"[0.38,0.406]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005148,insulin detemir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.3109,0.3,0.322,"[0.3,0.322]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0002909,insulin detemir,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1666,0.155,0.178,"[0.155,0.178]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,insulin detemir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1107,0.097,0.125,"[0.097,0.125]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0008399,insulin detemir,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1082,0.098,0.119,"[0.098,0.119]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0006694,insulin detemir,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1069,0.084,0.13,"[0.084,0.13]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0043693,insulin detemir,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1002,0.088,0.113,"[0.088,0.113]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin detemir,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.1001,0.058,0.142,"[0.058,0.142]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005364,insulin detemir,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0841,0.074,0.094,"[0.074,0.094]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0007186,insulin detemir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0828,0.057,0.108,"[0.057,0.108]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0000424,insulin detemir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0775,0.067,0.088,"[0.067,0.088]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005301,insulin detemir,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0696,0.044,0.095,"[0.044,0.095]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0010602,insulin detemir,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0453,0.012,0.079,"[0.012,0.079]",0.008,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0000153,insulin detemir,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0414,0.026,0.056,"[0.026,0.056]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0007739,insulin detemir,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0397,-0.002,0.081,"[-0.002,0.081]",0.059,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin detemir,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0388,-0.038,0.116,"[-0.038,0.116]",0.323,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005178,insulin detemir,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0362,0.025,0.047,"[0.025,0.047]",1.00E-04,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0002046,insulin detemir,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0297,0.013,0.047,"[0.013,0.047]",0.001,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0019350,insulin detemir,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0192,-0.027,0.066,"[-0.027,0.066]",0.421,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0002406,insulin detemir,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0183,-0.004,0.041,"[-0.004,0.041]",0.114,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0011786,insulin detemir,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0134,-0.109,0.136,"[-0.109,0.136]",0.83,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0007915,insulin detemir,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0124,-0.013,0.037,"[-0.013,0.037]",0.333,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0011508,insulin detemir,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0084,-0.138,0.155,"[-0.138,0.155]",0.911,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0016218,insulin detemir,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0046,-0.158,0.167,"[-0.158,0.167]",0.956,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0002869,insulin detemir,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0037,-0.114,0.121,"[-0.114,0.121]",0.951,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0004648,insulin detemir,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0035,-0.123,0.13,"[-0.123,0.13]",0.956,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005392,insulin detemir,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0034,-0.067,0.074,"[-0.067,0.074]",0.924,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0005298,insulin detemir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0024,-0.067,0.072,"[-0.067,0.072]",0.946,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0002316,insulin detemir,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.002,-0.016,0.02,"[-0.016,0.02]",0.83,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0020066,insulin detemir,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,0.0011,-0.122,0.124,"[-0.122,0.124]",0.986,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,insulin detemir,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,9.00E-04,-0.675,0.677,"[-0.675,0.677]",0.998,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16137271,biolink:associated_with_increased_likelihood_of,MONDO:0015924,insulin detemir,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.95747708,2.00E-04,-0.499,0.499,"[-0.499,0.499]",0.999,526400,21571800,22098200,"Sample size with insulin detemir, approximately: 526400","Sample size without insulin detemir, approximately: 21571800",All patients number is approximately: 22098200,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005133,insulin aspart human,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,3.3967,3.388,3.405,"[3.388,3.405]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0011429,insulin aspart human,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.8081,0.797,0.819,"[0.797,0.819]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0004609,insulin aspart human,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.5085,0.501,0.516,"[0.501,0.516]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0019180,insulin aspart human,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.4346,0.425,0.444,"[0.425,0.444]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0002909,insulin aspart human,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.383,0.373,0.393,"[0.373,0.393]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005180,insulin aspart human,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.3796,0.368,0.391,"[0.368,0.391]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005301,insulin aspart human,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.2879,0.275,0.3,"[0.275,0.3]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005393,insulin aspart human,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.2534,0.239,0.268,"[0.239,0.268]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0004648,insulin aspart human,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.1889,0.181,0.197,"[0.181,0.197]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005116,insulin aspart human,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0971,0.071,0.123,"[0.071,0.123]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005364,insulin aspart human,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0951,0.07,0.12,"[0.07,0.12]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,insulin aspart human,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0902,0.067,0.114,"[0.067,0.114]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0800026,insulin aspart human,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0821,0.036,0.129,"[0.036,0.129]",0.001,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005404,insulin aspart human,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0776,0.053,0.102,"[0.053,0.102]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,insulin aspart human,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0731,0.055,0.091,"[0.055,0.091]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0007947,insulin aspart human,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0635,0.053,0.074,"[0.053,0.074]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0004979,insulin aspart human,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0581,0.035,0.081,"[0.035,0.081]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0004981,insulin aspart human,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0432,-0.007,0.094,"[-0.007,0.094]",0.094,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005392,insulin aspart human,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0428,-0.009,0.094,"[-0.009,0.094]",0.103,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0007915,insulin aspart human,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.042,0.026,0.058,"[0.026,0.058]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0004425,insulin aspart human,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0415,0.032,0.051,"[0.032,0.051]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005101,insulin aspart human,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0349,-0.091,0.161,"[-0.091,0.161]",0.587,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0003620,insulin aspart human,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0343,-0.041,0.109,"[-0.041,0.109]",0.371,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005178,insulin aspart human,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0324,0.022,0.043,"[0.022,0.043]",1.00E-04,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0008006,insulin aspart human,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0316,-0.038,0.101,"[-0.038,0.101]",0.373,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005302,insulin aspart human,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0256,-0.018,0.07,"[-0.018,0.07]",0.254,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005294,insulin aspart human,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0246,-0.611,0.66,"[-0.611,0.66]",0.94,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005546,insulin aspart human,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0202,-0.01,0.05,"[-0.01,0.05]",0.184,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0002046,insulin aspart human,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.019,-0.073,0.111,"[-0.073,0.111]",0.686,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0007186,insulin aspart human,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.012,-0.091,0.115,"[-0.091,0.115]",0.82,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005388,insulin aspart human,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0107,-0.051,0.072,"[-0.051,0.072]",0.735,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0013282,insulin aspart human,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0095,-0.071,0.09,"[-0.071,0.09]",0.816,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0020066,insulin aspart human,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0051,-0.207,0.217,"[-0.207,0.217]",0.962,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0011786,insulin aspart human,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0044,-0.211,0.22,"[-0.211,0.22]",0.968,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005146,insulin aspart human,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0042,-0.237,0.246,"[-0.237,0.246]",0.973,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0002277,insulin aspart human,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0041,-0.131,0.139,"[-0.131,0.139]",0.953,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0002316,insulin aspart human,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0025,-0.141,0.146,"[-0.141,0.146]",0.972,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0021187,insulin aspart human,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0021,-0.215,0.219,"[-0.215,0.219]",0.985,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0007739,insulin aspart human,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0021,-0.171,0.175,"[-0.171,0.175]",0.981,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0021107,insulin aspart human,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0019,-0.109,0.113,"[-0.109,0.113]",0.973,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005010,insulin aspart human,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0017,-0.161,0.165,"[-0.161,0.165]",0.984,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0000424,insulin aspart human,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,0.0012,-0.464,0.467,"[-0.464,0.467]",0.996,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005298,insulin aspart human,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,6.00E-04,-0.314,0.315,"[-0.314,0.315]",0.997,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0005002,insulin aspart human,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,6.00E-04,-1.075,1.076,"[-1.075,1.076]",0.999,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0123677,biolink:associated_with_increased_likelihood_of,MONDO:0008300,insulin aspart human,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950311456,5.00E-04,-0.649,0.65,"[-0.649,0.65]",0.999,939800,21336800,22276600,"Sample size with insulin aspart human, approximately: 939800","Sample size without insulin aspart human, approximately: 21336800",All patients number is approximately: 22276600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0019499,infliximab,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,1.8878,1.861,1.915,"[1.861,1.915]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005392,infliximab,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.5968,0.56,0.634,"[0.56,0.634]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0008399,infliximab,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.4813,0.45,0.513,"[0.45,0.513]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0009693,infliximab,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.4194,0.379,0.46,"[0.379,0.46]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005180,infliximab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.3134,0.267,0.36,"[0.267,0.36]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0002869,infliximab,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.3041,0.202,0.407,"[0.202,0.407]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0019369,infliximab,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.145,0.095,0.195,"[0.095,0.195]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0004981,infliximab,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.092,-0.049,0.233,"[-0.049,0.233]",0.201,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0008487,infliximab,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0769,0.042,0.112,"[0.042,0.112]",1.00E-04,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005149,infliximab,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0758,-0.221,0.373,"[-0.221,0.373]",0.617,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005147,infliximab,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0498,-0.026,0.125,"[-0.026,0.125]",0.197,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0018882,infliximab,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0484,-0.047,0.144,"[-0.047,0.144]",0.32,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005298,infliximab,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0154,-0.246,0.277,"[-0.246,0.277]",0.908,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005011,infliximab,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0109,-0.377,0.398,"[-0.377,0.398]",0.956,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0005101,infliximab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0095,-0.097,0.116,"[-0.097,0.116]",0.861,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0000477,infliximab,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0069,-0.151,0.165,"[-0.151,0.165]",0.932,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C0666743,biolink:associated_with_increased_likelihood_of,MONDO:0011429,infliximab,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.946817424,0.0012,-0.445,0.447,"[-0.445,0.447]",0.996,54600,21765300,21819900,"Sample size with infliximab, approximately: 54600","Sample size without infliximab, approximately: 21765300",All patients number is approximately: 21819900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005300,indapamide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.584,0.556,0.612,"[0.556,0.612]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0021187,indapamide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.5759,0.538,0.614,"[0.538,0.614]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005302,indapamide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.363,0.331,0.395,"[0.331,0.395]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0009693,indapamide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.2612,0.225,0.297,"[0.225,0.297]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0011508,indapamide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.1491,0.111,0.187,"[0.111,0.187]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005364,indapamide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.1465,0.085,0.208,"[0.085,0.208]",1.00E-04,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,indapamide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.117,0.045,0.189,"[0.045,0.189]",0.001,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0011786,indapamide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.077,-0.126,0.28,"[-0.126,0.28]",0.456,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005298,indapamide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0591,-0.031,0.15,"[-0.031,0.15]",0.2,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005149,indapamide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0508,-0.027,0.128,"[-0.027,0.128]",0.199,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,indapamide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0391,-0.002,0.081,"[-0.002,0.081]",0.065,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0002277,indapamide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0287,-0.16,0.217,"[-0.16,0.217]",0.766,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005002,indapamide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0247,-0.128,0.177,"[-0.128,0.177]",0.751,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0008383,indapamide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0191,-0.146,0.184,"[-0.146,0.184]",0.821,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,indapamide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0184,-0.285,0.322,"[-0.285,0.322]",0.905,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0004648,indapamide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.016,-0.158,0.19,"[-0.158,0.19]",0.857,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,MONDO:0005294,indapamide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,0.0016,-0.611,0.614,"[-0.611,0.614]",0.996,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3702,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,indapamide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902197204,4.00E-04,-0.214,0.215,"[-0.214,0.215]",0.997,44500,21768400,21812900,"Sample size with indapamide, approximately: 44500","Sample size without indapamide, approximately: 21768400",All patients number is approximately: 21812900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:126480325,biolink:associated_with_increased_likelihood_of,MONDO:0005178,inclisiran,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.957782139,0.0065,-2.695,2.708,"[-2.695,2.708]",0.996,2500,21790600,21793100,"Sample size with inclisiran, approximately: 2500","Sample size without inclisiran, approximately: 21790600",All patients number is approximately: 21793100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0000424,imipramine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.6092,0.561,0.657,"[0.561,0.657]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005010,imipramine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.5902,0.556,0.624,"[0.556,0.624]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,imipramine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.5489,0.516,0.582,"[0.516,0.582]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005148,imipramine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.4761,0.43,0.522,"[0.43,0.522]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0008487,imipramine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.4501,0.405,0.496,"[0.405,0.496]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,imipramine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.3575,0.322,0.393,"[0.322,0.393]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005392,imipramine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.2864,0.206,0.366,"[0.206,0.366]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005393,imipramine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.285,0.244,0.326,"[0.244,0.326]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0009693,imipramine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.2615,0.2,0.323,"[0.2,0.323]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005101,imipramine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.2536,0.204,0.303,"[0.204,0.303]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005300,imipramine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.1822,0.145,0.219,"[0.145,0.219]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0008399,imipramine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.1438,0.078,0.21,"[0.078,0.21]",1.00E-04,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005133,imipramine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0355,-0.029,0.1,"[-0.029,0.1]",0.28,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0006694,imipramine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0338,-0.029,0.097,"[-0.029,0.097]",0.292,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005147,imipramine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0219,-0.068,0.111,"[-0.068,0.111]",0.631,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0004425,imipramine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0217,-0.251,0.295,"[-0.251,0.295]",0.876,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0018882,imipramine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0137,-0.202,0.229,"[-0.202,0.229]",0.901,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0007915,imipramine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0125,-0.344,0.369,"[-0.344,0.369]",0.945,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0021107,imipramine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0094,-0.049,0.067,"[-0.049,0.067]",0.751,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0002046,imipramine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0093,-0.332,0.35,"[-0.332,0.35]",0.957,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,imipramine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0051,-0.341,0.351,"[-0.341,0.351]",0.977,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0005002,imipramine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0027,-0.745,0.75,"[-0.745,0.75]",0.994,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0003620,imipramine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0022,-0.501,0.505,"[-0.501,0.505]",0.993,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0002277,imipramine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.0021,-0.44,0.444,"[-0.44,0.444]",0.992,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3696,biolink:associated_with_increased_likelihood_of,MONDO:0019565,imipramine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.832835718,0.002,-0.354,0.358,"[-0.354,0.358]",0.991,36400,21771600,21808000,"Sample size with imipramine, approximately: 36400","Sample size without imipramine, approximately: 21771600",All patients number is approximately: 21808000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0000477,ibuprofen,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.5963,0.591,0.602,"[0.591,0.602]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005116,ibuprofen,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.5554,0.551,0.56,"[0.551,0.56]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0015564,ibuprofen,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.4348,0.428,0.441,"[0.428,0.441]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005404,ibuprofen,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.2392,0.214,0.264,"[0.214,0.264]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0010561,ibuprofen,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.2317,0.218,0.245,"[0.218,0.245]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0015924,ibuprofen,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1852,0.181,0.19,"[0.181,0.19]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0004981,ibuprofen,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1656,0.159,0.172,"[0.159,0.172]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ibuprofen,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.145,0.138,0.152,"[0.138,0.152]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005101,ibuprofen,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1445,0.133,0.156,"[0.133,0.156]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002046,ibuprofen,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1421,0.133,0.152,"[0.133,0.152]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0009693,ibuprofen,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1241,0.117,0.131,"[0.117,0.131]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007915,ibuprofen,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1226,0.118,0.127,"[0.118,0.127]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005302,ibuprofen,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1135,0.108,0.119,"[0.108,0.119]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007818,ibuprofen,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1122,0.098,0.126,"[0.098,0.126]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0019118,ibuprofen,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1058,0.098,0.114,"[0.098,0.114]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0008377,ibuprofen,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.1001,0.095,0.105,"[0.095,0.105]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ibuprofen,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.062,0.045,0.079,"[0.045,0.079]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002316,ibuprofen,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0598,0.051,0.068,"[0.051,0.068]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005392,ibuprofen,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0532,0.028,0.078,"[0.028,0.078]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ibuprofen,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0441,0.036,0.052,"[0.036,0.052]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0800026,ibuprofen,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0402,0.028,0.053,"[0.028,0.053]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ibuprofen,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0328,0.002,0.064,"[0.002,0.064]",0.038,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0009476,ibuprofen,congenital atresia of small intestine,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0326,0.027,0.038,"[0.027,0.038]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0019180,ibuprofen,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0308,0.026,0.036,"[0.026,0.036]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005294,ibuprofen,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0299,-0.007,0.066,"[-0.007,0.066]",0.108,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0010526,ibuprofen,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0291,0.014,0.044,"[0.014,0.044]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0021129,ibuprofen,microphthalmos,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.027,-0.025,0.079,"[-0.025,0.079]",0.306,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007540,ibuprofen,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0257,0.021,0.031,"[0.021,0.031]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0008678,ibuprofen,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0217,-0.02,0.063,"[-0.02,0.063]",0.304,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005388,ibuprofen,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0177,0.011,0.024,"[0.011,0.024]",1.00E-04,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0001044,ibuprofen,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0176,-0.014,0.049,"[-0.014,0.049]",0.274,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0015263,ibuprofen,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0153,0,0.03,"[0,0.03]",0.044,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002869,ibuprofen,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.013,-0.012,0.038,"[-0.012,0.038]",0.301,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0000153,ibuprofen,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0125,-0.001,0.026,"[-0.001,0.026]",0.07,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ibuprofen,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.012,-0.009,0.033,"[-0.009,0.033]",0.266,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ibuprofen,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0106,-0.039,0.06,"[-0.039,0.06]",0.675,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002277,ibuprofen,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0103,-0.021,0.041,"[-0.021,0.041]",0.516,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0019015,ibuprofen,congenital omphalocele,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0097,-0.049,0.068,"[-0.049,0.068]",0.746,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0008300,ibuprofen,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0083,-0.063,0.08,"[-0.063,0.08]",0.82,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0002406,ibuprofen,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0069,-0.102,0.116,"[-0.102,0.116]",0.902,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0008642,ibuprofen,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0067,-0.057,0.071,"[-0.057,0.071]",0.837,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005002,ibuprofen,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0065,-0.057,0.07,"[-0.057,0.07]",0.839,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0011786,ibuprofen,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.006,-6.809,6.821,"[-6.809,6.821]",0.999,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007843,ibuprofen,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0048,-0.261,0.271,"[-0.261,0.271]",0.972,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0004952,ibuprofen,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0046,-0.051,0.06,"[-0.051,0.06]",0.871,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0013282,ibuprofen,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0042,-0.102,0.11,"[-0.102,0.11]",0.938,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0018882,ibuprofen,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.003,-0.064,0.07,"[-0.064,0.07]",0.93,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007160,ibuprofen,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0025,-0.082,0.087,"[-0.082,0.087]",0.954,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0008542,ibuprofen,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0024,-0.107,0.112,"[-0.107,0.112]",0.966,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007827,ibuprofen,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0012,-0.241,0.244,"[-0.241,0.244]",0.992,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0019499,ibuprofen,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0011,-0.269,0.272,"[-0.269,0.272]",0.993,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0007947,ibuprofen,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0011,-0.129,0.131,"[-0.129,0.131]",0.987,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005130,ibuprofen,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,0.0011,-0.06,0.062,"[-0.06,0.062]",0.973,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0004609,ibuprofen,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,8.00E-04,-0.079,0.081,"[-0.079,0.081]",0.985,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0021187,ibuprofen,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,7.00E-04,-0.202,0.203,"[-0.202,0.203]",0.995,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005083,ibuprofen,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,6.00E-04,-0.129,0.131,"[-0.129,0.131]",0.993,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ibuprofen,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,4.00E-04,-0.809,0.81,"[-0.809,0.81]",0.999,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3326923,biolink:associated_with_increased_likelihood_of,MONDO:0005306,ibuprofen,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.799225219,6.50E-05,-0.666,0.667,"[-0.666,0.667]",1,8055300,16442000,24497300,"Sample size with ibuprofen, approximately: 8055300","Sample size without ibuprofen, approximately: 16442000",All patients number is approximately: 24497300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,ibandronate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,1.1099,1.084,1.135,"[1.084,1.135]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0003620,ibandronate,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.8365,0.811,0.862,"[0.811,0.862]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ibandronate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.7873,0.755,0.82,"[0.755,0.82]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0019369,ibandronate,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.6104,0.572,0.649,"[0.572,0.649]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0043693,ibandronate,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.4383,0.393,0.484,"[0.393,0.484]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0007186,ibandronate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.3501,0.309,0.392,"[0.309,0.392]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005101,ibandronate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.1634,0.121,0.205,"[0.121,0.205]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005302,ibandronate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.1279,0.097,0.159,"[0.097,0.159]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ibandronate,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.1051,0.067,0.144,"[0.067,0.144]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0008599,ibandronate,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.1037,0.049,0.158,"[0.049,0.158]",1.00E-04,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ibandronate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0945,0.02,0.169,"[0.02,0.169]",0.013,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0002046,ibandronate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0703,-0.016,0.157,"[-0.016,0.157]",0.111,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ibandronate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0644,-0.012,0.141,"[-0.012,0.141]",0.098,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005300,ibandronate,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0374,-0.044,0.119,"[-0.044,0.119]",0.37,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ibandronate,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0258,-0.092,0.144,"[-0.092,0.144]",0.668,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005009,ibandronate,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0137,-0.032,0.06,"[-0.032,0.06]",0.557,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,ibandronate,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0112,-0.148,0.17,"[-0.148,0.17]",0.891,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ibandronate,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.009,-0.128,0.146,"[-0.128,0.146]",0.898,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0008399,ibandronate,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0089,-0.056,0.074,"[-0.056,0.074]",0.787,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0002869,ibandronate,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0051,-0.206,0.216,"[-0.206,0.216]",0.962,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005146,ibandronate,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0046,-0.264,0.273,"[-0.264,0.273]",0.973,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0000477,ibandronate,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0039,-0.565,0.573,"[-0.565,0.573]",0.989,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,ibandronate,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0039,-0.098,0.106,"[-0.098,0.106]",0.94,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005364,ibandronate,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0037,-0.154,0.161,"[-0.154,0.161]",0.963,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005294,ibandronate,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0031,-0.725,0.731,"[-0.725,0.731]",0.993,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0005010,ibandronate,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0031,-0.224,0.231,"[-0.224,0.231]",0.979,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ibandronate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0021,-0.612,0.616,"[-0.612,0.616]",0.995,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:41060,biolink:associated_with_increased_likelihood_of,MONDO:0015924,ibandronate,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930031975,0.0018,-0.243,0.247,"[-0.243,0.247]",0.988,58500,21756800,21815300,"Sample size with ibandronate, approximately: 58500","Sample size without ibandronate, approximately: 21756800",All patients number is approximately: 21815300,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C1434792,biolink:associated_with_increased_likelihood_of,MONDO:0015564,ibalizumab,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998937533,0.0155,-2.66E+22,2.66E+22,"[-2.66E+22,2.66E+22]",1,100,21792300,21792400,"Sample size with ibalizumab, approximately: 100","Sample size without ibalizumab, approximately: 21792300",All patients number is approximately: 21792400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0003620,hydroxyurea,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,1.0675,1.044,1.091,"[1.044,1.091]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005178,hydroxyurea,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.6163,0.576,0.656,"[0.576,0.656]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0004609,hydroxyurea,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.5948,0.571,0.619,"[0.571,0.619]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0009693,hydroxyurea,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.5193,0.492,0.547,"[0.492,0.547]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0004425,hydroxyurea,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.4924,0.466,0.519,"[0.466,0.519]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0018882,hydroxyurea,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.4847,0.457,0.513,"[0.457,0.513]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0008399,hydroxyurea,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.3751,0.351,0.399,"[0.351,0.399]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005149,hydroxyurea,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.2783,0.035,0.521,"[0.035,0.521]",0.025,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0009891,hydroxyurea,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.2678,0.231,0.305,"[0.231,0.305]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0002277,hydroxyurea,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.1439,0.08,0.208,"[0.08,0.208]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0018177,hydroxyurea,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.136,0.107,0.165,"[0.107,0.165]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,hydroxyurea,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0875,0.061,0.113,"[0.061,0.113]",1.00E-04,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0018975,hydroxyurea,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0649,0.025,0.105,"[0.025,0.105]",0.002,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0019565,hydroxyurea,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0427,-0.165,0.251,"[-0.165,0.251]",0.688,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0004975,hydroxyurea,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0228,-0.066,0.112,"[-0.066,0.112]",0.615,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005180,hydroxyurea,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0207,-0.01,0.052,"[-0.01,0.052]",0.193,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005009,hydroxyurea,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0142,-0.24,0.269,"[-0.24,0.269]",0.913,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005300,hydroxyurea,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0115,-1.294,1.317,"[-1.294,1.317]",0.986,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005301,hydroxyurea,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0115,-0.061,0.084,"[-0.061,0.084]",0.757,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0004981,hydroxyurea,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0033,-0.663,0.67,"[-0.663,0.67]",0.992,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0004952,hydroxyurea,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.003,-0.06,0.066,"[-0.06,0.066]",0.927,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3657,biolink:associated_with_increased_likelihood_of,MONDO:0005294,hydroxyurea,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.937279129,0.0014,-0.307,0.31,"[-0.307,0.31]",0.993,61700,21762300,21824000,"Sample size with hydroxyurea, approximately: 61700","Sample size without hydroxyurea, approximately: 21762300",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,hydroxychloroquine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.6816,0.639,0.724,"[0.639,0.724]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0019369,hydroxychloroquine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.5445,0.532,0.557,"[0.532,0.557]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005546,hydroxychloroquine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.4611,0.438,0.484,"[0.438,0.484]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0009891,hydroxychloroquine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.442,0.428,0.456,"[0.428,0.456]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,hydroxychloroquine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.4198,0.4,0.439,"[0.4,0.439]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0018177,hydroxychloroquine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.3021,0.282,0.323,"[0.282,0.323]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0009693,hydroxychloroquine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.2998,0.279,0.32,"[0.279,0.32]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0008383,hydroxychloroquine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.2436,0.226,0.261,"[0.226,0.261]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005149,hydroxychloroquine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1791,0.161,0.197,"[0.161,0.197]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005364,hydroxychloroquine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1786,0.148,0.21,"[0.148,0.21]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0003620,hydroxychloroquine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1732,0.143,0.204,"[0.143,0.204]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,hydroxychloroquine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1707,0.114,0.227,"[0.114,0.227]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0021107,hydroxychloroquine,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1543,0.136,0.173,"[0.136,0.173]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005711,hydroxychloroquine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.1277,0.112,0.144,"[0.112,0.144]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005300,hydroxychloroquine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.108,0.007,0.209,"[0.007,0.209]",0.035,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0008399,hydroxychloroquine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0978,0.067,0.129,"[0.067,0.129]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0004648,hydroxychloroquine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0969,0.074,0.119,"[0.074,0.119]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0004979,hydroxychloroquine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0962,-0.003,0.195,"[-0.003,0.195]",0.056,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005101,hydroxychloroquine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0913,0.066,0.116,"[0.066,0.116]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0002909,hydroxychloroquine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0889,0.069,0.109,"[0.069,0.109]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0008487,hydroxychloroquine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0825,0.025,0.14,"[0.025,0.14]",0.005,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0015924,hydroxychloroquine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0652,0.051,0.08,"[0.051,0.08]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0009061,hydroxychloroquine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0454,0.026,0.065,"[0.026,0.065]",1.00E-04,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0011786,hydroxychloroquine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0444,-0.019,0.108,"[-0.019,0.108]",0.169,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0004609,hydroxychloroquine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0354,-0.034,0.105,"[-0.034,0.105]",0.32,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0011508,hydroxychloroquine,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0336,-0.109,0.176,"[-0.109,0.176]",0.644,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0021187,hydroxychloroquine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0199,-0.086,0.126,"[-0.086,0.126]",0.714,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0002869,hydroxychloroquine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0165,-0.236,0.268,"[-0.236,0.268]",0.898,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005302,hydroxychloroquine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0134,-0.049,0.076,"[-0.049,0.076]",0.675,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0004975,hydroxychloroquine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0129,-0.197,0.223,"[-0.197,0.223]",0.904,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0002046,hydroxychloroquine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0121,-0.165,0.189,"[-0.165,0.189]",0.894,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0007915,hydroxychloroquine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0108,-0.095,0.117,"[-0.095,0.117]",0.842,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005010,hydroxychloroquine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0099,-0.221,0.241,"[-0.221,0.241]",0.933,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005306,hydroxychloroquine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0096,-0.108,0.127,"[-0.108,0.127]",0.874,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0018882,hydroxychloroquine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0096,-0.004,0.023,"[-0.004,0.023]",0.166,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005298,hydroxychloroquine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.009,-0.153,0.171,"[-0.153,0.171]",0.914,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0016218,hydroxychloroquine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.006,-0.161,0.173,"[-0.161,0.173]",0.944,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005294,hydroxychloroquine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0037,-0.067,0.075,"[-0.067,0.075]",0.918,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0002277,hydroxychloroquine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0036,-0.125,0.132,"[-0.125,0.132]",0.957,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0007739,hydroxychloroquine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0025,-0.151,0.156,"[-0.151,0.156]",0.974,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3652,biolink:associated_with_increased_likelihood_of,MONDO:0005009,hydroxychloroquine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902117069,0.0022,-0.168,0.172,"[-0.168,0.172]",0.979,350500,21610600,21961100,"Sample size with hydroxychloroquine, approximately: 350500","Sample size without hydroxychloroquine, approximately: 21610600",All patients number is approximately: 21961100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0011429,hydromorphone,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,1.2017,1.197,1.206,"[1.197,1.206]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0004981,hydromorphone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.6591,0.652,0.667,"[0.652,0.667]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005711,hydromorphone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.4425,0.43,0.455,"[0.43,0.455]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0004952,hydromorphone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.3465,0.338,0.355,"[0.338,0.355]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005404,hydromorphone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.296,0.272,0.32,"[0.272,0.32]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005180,hydromorphone,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.2933,0.288,0.299,"[0.288,0.299]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0000914,hydromorphone,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.286,0.282,0.29,"[0.282,0.29]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008399,hydromorphone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.2622,0.258,0.267,"[0.258,0.267]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005148,hydromorphone,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1991,0.19,0.208,"[0.19,0.208]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0009889,hydromorphone,polycystic kidney disease infantile type,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1959,0.188,0.204,"[0.188,0.204]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005178,hydromorphone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1911,0.176,0.206,"[0.176,0.206]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0007915,hydromorphone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1805,0.172,0.189,"[0.172,0.189]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0002277,hydromorphone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1481,0.12,0.176,"[0.12,0.176]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0007540,hydromorphone,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1348,0.121,0.148,"[0.121,0.148]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0018975,hydromorphone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1274,0.122,0.132,"[0.122,0.132]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0011122,hydromorphone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.1017,0.073,0.13,"[0.073,0.13]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008394,hydromorphone,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0933,0.075,0.112,"[0.075,0.112]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0002316,hydromorphone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0781,0.071,0.086,"[0.071,0.086]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0004975,hydromorphone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0695,0.047,0.092,"[0.047,0.092]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005133,hydromorphone,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0684,0.045,0.092,"[0.045,0.092]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0007739,hydromorphone,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0653,0.06,0.071,"[0.06,0.071]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0006640,hydromorphone,adrenal cushing syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0578,0.053,0.062,"[0.053,0.062]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0015564,hydromorphone,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0535,0.048,0.059,"[0.048,0.059]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0009891,hydromorphone,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0528,0.031,0.075,"[0.031,0.075]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0018882,hydromorphone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0509,0.016,0.086,"[0.016,0.086]",0.004,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0019118,hydromorphone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0408,0.035,0.046,"[0.035,0.046]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,hydromorphone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0376,0.029,0.046,"[0.029,0.046]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0004425,hydromorphone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.034,0.027,0.041,"[0.027,0.041]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0002869,hydromorphone,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0176,-0.027,0.063,"[-0.027,0.063]",0.444,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0015263,hydromorphone,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0162,0.008,0.024,"[0.008,0.024]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0002406,hydromorphone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0159,-0.052,0.084,"[-0.052,0.084]",0.644,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0004609,hydromorphone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0114,-0.037,0.06,"[-0.037,0.06]",0.647,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008599,hydromorphone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0112,0.005,0.017,"[0.005,0.017]",1.00E-04,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0000153,hydromorphone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.009,-0.048,0.066,"[-0.048,0.066]",0.755,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005130,hydromorphone,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0063,-0.081,0.093,"[-0.081,0.093]",0.888,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0010526,hydromorphone,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0049,-0.009,0.019,"[-0.009,0.019]",0.488,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005009,hydromorphone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0046,-0.053,0.062,"[-0.053,0.062]",0.876,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005294,hydromorphone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0045,-0.04,0.049,"[-0.04,0.049]",0.844,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0000424,hydromorphone,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0043,-0.03,0.039,"[-0.03,0.039]",0.809,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008542,hydromorphone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0028,-0.13,0.135,"[-0.13,0.135]",0.966,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005146,hydromorphone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.002,-0.133,0.137,"[-0.133,0.137]",0.977,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0002046,hydromorphone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0018,-0.261,0.265,"[-0.261,0.265]",0.989,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008642,hydromorphone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0017,-0.243,0.246,"[-0.243,0.246]",0.989,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0011508,hydromorphone,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,0.0014,-0.058,0.06,"[-0.058,0.06]",0.964,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0009264,hydromorphone,gastroschisis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,6.00E-04,-0.136,0.137,"[-0.136,0.137]",0.993,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,hydromorphone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,6.00E-04,-0.45,0.451,"[-0.45,0.451]",0.998,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0008300,hydromorphone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,5.00E-04,-0.089,0.09,"[-0.089,0.09]",0.991,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0005301,hydromorphone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,5.00E-04,-0.378,0.379,"[-0.378,0.379]",0.998,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0007160,hydromorphone,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,4.00E-04,-0.108,0.109,"[-0.108,0.109]",0.994,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0011786,hydromorphone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,2.00E-04,-0.334,0.335,"[-0.334,0.335]",0.999,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0000477,hydromorphone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,2.00E-04,-0.485,0.485,"[-0.485,0.485]",1,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0019350,hydromorphone,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,2.00E-04,-0.558,0.559,"[-0.558,0.559]",1,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0013282,hydromorphone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,2.00E-04,-0.121,0.121,"[-0.121,0.121]",0.998,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5284570,biolink:associated_with_increased_likelihood_of,MONDO:0021107,hydromorphone,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933916382,8.05E-06,-0.652,0.652,"[-0.652,0.652]",1,9856400,16817300,26673700,"Sample size with hydromorphone, approximately: 9856400","Sample size without hydromorphone, approximately: 16817300",All patients number is approximately: 26673700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0007540,hydrochlorothiazide,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.6835,0.671,0.696,"[0.671,0.696]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005133,hydrochlorothiazide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.4533,0.448,0.459,"[0.448,0.459]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0007186,hydrochlorothiazide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.4015,0.387,0.416,"[0.387,0.416]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0013282,hydrochlorothiazide,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.3718,0.363,0.381,"[0.363,0.381]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0018177,hydrochlorothiazide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.3205,0.313,0.328,"[0.313,0.328]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008300,hydrochlorothiazide,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.2489,0.233,0.265,"[0.233,0.265]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0015564,hydrochlorothiazide,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1944,0.179,0.21,"[0.179,0.21]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0020066,hydrochlorothiazide,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1519,0.142,0.162,"[0.142,0.162]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0018882,hydrochlorothiazide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.149,0.116,0.182,"[0.116,0.182]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0000153,hydrochlorothiazide,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1412,0.127,0.155,"[0.127,0.155]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0002046,hydrochlorothiazide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1367,0.109,0.164,"[0.109,0.164]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005364,hydrochlorothiazide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1364,0.081,0.192,"[0.081,0.192]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0019369,hydrochlorothiazide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.135,0.111,0.159,"[0.111,0.159]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0019565,hydrochlorothiazide,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1155,0.102,0.129,"[0.102,0.129]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008542,hydrochlorothiazide,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.1068,0.089,0.125,"[0.089,0.125]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0015614,hydrochlorothiazide,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0768,0.07,0.083,"[0.07,0.083]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0021107,hydrochlorothiazide,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0677,0.033,0.103,"[0.033,0.103]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0004979,hydrochlorothiazide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0674,0.031,0.104,"[0.031,0.104]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005711,hydrochlorothiazide,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0546,0.023,0.086,"[0.023,0.086]",0.001,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0009891,hydrochlorothiazide,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0524,0.045,0.06,"[0.045,0.06]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008377,hydrochlorothiazide,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0416,0.03,0.053,"[0.03,0.053]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0002277,hydrochlorothiazide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0365,0.027,0.046,"[0.027,0.046]",1.00E-04,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008678,hydrochlorothiazide,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.034,-0.014,0.082,"[-0.014,0.082]",0.162,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005404,hydrochlorothiazide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0317,-0.009,0.072,"[-0.009,0.072]",0.124,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0004952,hydrochlorothiazide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0282,0.009,0.047,"[0.009,0.047]",0.003,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,hydrochlorothiazide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0273,-0.013,0.067,"[-0.013,0.067]",0.179,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0002406,hydrochlorothiazide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0257,-0.014,0.065,"[-0.014,0.065]",0.199,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0043693,hydrochlorothiazide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0249,0,0.05,"[0,0.05]",0.052,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005180,hydrochlorothiazide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0227,0.006,0.04,"[0.006,0.04]",0.008,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0002869,hydrochlorothiazide,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0203,-0.011,0.052,"[-0.011,0.052]",0.21,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0019118,hydrochlorothiazide,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0104,-0.046,0.067,"[-0.046,0.067]",0.718,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005546,hydrochlorothiazide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0097,-0.022,0.042,"[-0.022,0.042]",0.55,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0007739,hydrochlorothiazide,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0092,-0.052,0.07,"[-0.052,0.07]",0.769,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0011508,hydrochlorothiazide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0082,-0.056,0.072,"[-0.056,0.072]",0.802,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,hydrochlorothiazide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0064,-0.117,0.13,"[-0.117,0.13]",0.919,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008487,hydrochlorothiazide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0047,-0.008,0.018,"[-0.008,0.018]",0.487,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0007947,hydrochlorothiazide,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0045,-18.329,18.338,"[-18.329,18.338]",1,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005130,hydrochlorothiazide,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0044,-0.101,0.109,"[-0.101,0.109]",0.935,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005392,hydrochlorothiazide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0039,-0.134,0.141,"[-0.134,0.141]",0.956,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0021187,hydrochlorothiazide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0038,-0.104,0.112,"[-0.104,0.112]",0.945,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0003620,hydrochlorothiazide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0034,-0.205,0.212,"[-0.205,0.212]",0.975,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0002316,hydrochlorothiazide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0027,-0.125,0.131,"[-0.125,0.131]",0.967,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0016218,hydrochlorothiazide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0026,-0.342,0.347,"[-0.342,0.347]",0.988,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0004975,hydrochlorothiazide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0024,-0.022,0.026,"[-0.022,0.026]",0.848,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0008383,hydrochlorothiazide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0017,-0.086,0.09,"[-0.086,0.09]",0.969,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0004425,hydrochlorothiazide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0016,-0.091,0.094,"[-0.091,0.094]",0.973,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,hydrochlorothiazide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0015,-0.101,0.104,"[-0.101,0.104]",0.978,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0000477,hydrochlorothiazide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0015,-0.287,0.29,"[-0.287,0.29]",0.992,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0015924,hydrochlorothiazide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0014,-0.375,0.377,"[-0.375,0.377]",0.994,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005146,hydrochlorothiazide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,0.0013,-0.12,0.123,"[-0.12,0.123]",0.983,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0011429,hydrochlorothiazide,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,9.00E-04,-0.147,0.148,"[-0.147,0.148]",0.991,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005300,hydrochlorothiazide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,7.00E-04,-0.172,0.174,"[-0.172,0.174]",0.994,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,hydrochlorothiazide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,4.00E-04,-0.639,0.639,"[-0.639,0.639]",0.999,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0011786,hydrochlorothiazide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,1.00E-04,-0.328,0.329,"[-0.328,0.329]",0.999,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3639,biolink:associated_with_increased_likelihood_of,MONDO:0005149,hydrochlorothiazide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91329455,1.79E-05,-0.098,0.098,"[-0.098,0.098]",1,3467900,19734500,23202400,"Sample size with hydrochlorothiazide, approximately: 3467900","Sample size without hydrochlorothiazide, approximately: 19734500",All patients number is approximately: 23202400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,hydralazine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,3.0848,3.08,3.09,"[3.08,3.09]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005404,hydralazine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.9952,0.988,1.002,"[0.988,1.002]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005546,hydralazine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.7476,0.734,0.761,"[0.734,0.761]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0000914,hydralazine,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.4444,0.439,0.45,"[0.439,0.45]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005178,hydralazine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.4181,0.414,0.422,"[0.414,0.422]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0008383,hydralazine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.3765,0.37,0.383,"[0.37,0.383]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0018177,hydralazine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.3507,0.346,0.356,"[0.346,0.356]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0010619,hydralazine,familial x linked hypophosphatemic vitamin d refractory rickets,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.3005,0.296,0.305,"[0.296,0.305]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0013282,hydralazine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.2896,0.282,0.298,"[0.282,0.298]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0007739,hydralazine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.2739,0.263,0.285,"[0.263,0.285]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0021187,hydralazine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.2678,0.258,0.278,"[0.258,0.278]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004981,hydralazine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.2074,0.203,0.212,"[0.203,0.212]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0008599,hydralazine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.191,0.186,0.196,"[0.186,0.196]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005393,hydralazine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.1388,0.133,0.145,"[0.133,0.145]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005009,hydralazine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.1132,0.105,0.121,"[0.105,0.121]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0008678,hydralazine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.1083,0.101,0.115,"[0.101,0.115]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0018975,hydralazine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0966,0.088,0.105,"[0.088,0.105]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,hydralazine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0956,0.063,0.129,"[0.063,0.129]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005147,hydralazine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0828,0.076,0.09,"[0.076,0.09]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0002046,hydralazine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0699,0.06,0.08,"[0.06,0.08]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0002277,hydralazine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0664,0.057,0.076,"[0.057,0.076]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004609,hydralazine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0604,0.054,0.067,"[0.054,0.067]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005083,hydralazine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0567,0.039,0.074,"[0.039,0.074]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005180,hydralazine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0537,0.048,0.059,"[0.048,0.059]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0008399,hydralazine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0441,0.035,0.053,"[0.035,0.053]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0016532,hydralazine,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0424,0.035,0.05,"[0.035,0.05]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0011429,hydralazine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0378,0.025,0.051,"[0.025,0.051]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0001516,hydralazine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0353,0.028,0.042,"[0.028,0.042]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0007972,hydralazine,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0281,0.018,0.038,"[0.018,0.038]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0011122,hydralazine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0262,0.011,0.042,"[0.011,0.042]",0.001,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005711,hydralazine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0178,0.012,0.024,"[0.012,0.024]",1.00E-04,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005146,hydralazine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0126,-0.011,0.036,"[-0.011,0.036]",0.287,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0010526,hydralazine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.012,-0.024,0.048,"[-0.024,0.048]",0.509,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0003620,hydralazine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0106,-0.009,0.031,"[-0.009,0.031]",0.3,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0002406,hydralazine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0105,-0.053,0.074,"[-0.053,0.074]",0.748,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005294,hydralazine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0103,-0.032,0.052,"[-0.032,0.052]",0.63,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0000424,hydralazine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0069,-0.017,0.031,"[-0.017,0.031]",0.572,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0007186,hydralazine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0066,-0.002,0.016,"[-0.002,0.016]",0.148,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0019565,hydralazine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0058,-0.003,0.014,"[-0.003,0.014]",0.177,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0007160,hydralazine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0057,-0.046,0.057,"[-0.046,0.057]",0.829,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0011786,hydralazine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0057,-0.072,0.084,"[-0.072,0.084]",0.887,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005002,hydralazine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0048,-0.087,0.097,"[-0.087,0.097]",0.919,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0000477,hydralazine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0035,-0.084,0.091,"[-0.084,0.091]",0.938,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005298,hydralazine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.003,-0.114,0.12,"[-0.114,0.12]",0.96,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0000153,hydralazine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.003,-0.144,0.15,"[-0.144,0.15]",0.969,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005301,hydralazine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0019,-0.224,0.228,"[-0.224,0.228]",0.987,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005133,hydralazine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,0.0014,-1.16E+07,1.16E+07,"[-11600000,11600000]",1,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0005364,hydralazine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,6.00E-04,-0.187,0.189,"[-0.187,0.189]",0.995,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0007827,hydralazine,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,5.00E-04,-0.251,0.251,"[-0.251,0.251]",0.997,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004648,hydralazine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,5.00E-04,-0.252,0.253,"[-0.252,0.253]",0.997,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004425,hydralazine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,3.00E-04,-0.037,0.038,"[-0.037,0.038]",0.987,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004975,hydralazine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,2.00E-04,-0.51,0.51,"[-0.51,0.51]",0.999,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0008642,hydralazine,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,2.00E-04,-0.72,0.72,"[-0.72,0.72]",1,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0019499,hydralazine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,2.00E-04,-1.189,1.19,"[-1.189,1.19]",1,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3637,biolink:associated_with_increased_likelihood_of,MONDO:0004952,hydralazine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969000524,1.00E-04,-0.955,0.955,"[-0.955,0.955]",1,8360900,18602300,26963200,"Sample size with hydralazine, approximately: 8360900","Sample size without hydralazine, approximately: 18602300",All patients number is approximately: 26963200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005711,haloperidol,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.6526,0.648,0.657,"[0.648,0.657]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005147,haloperidol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.4499,0.441,0.459,"[0.441,0.459]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008487,haloperidol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.4013,0.396,0.406,"[0.396,0.406]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0018975,haloperidol,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.3419,0.336,0.347,"[0.336,0.347]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0016532,haloperidol,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2924,0.287,0.298,"[0.287,0.298]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005083,haloperidol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2899,0.273,0.307,"[0.273,0.307]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0019369,haloperidol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2843,0.279,0.29,"[0.279,0.29]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0000424,haloperidol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2526,0.246,0.259,"[0.246,0.259]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008644,haloperidol,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2438,0.238,0.249,"[0.238,0.249]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0018177,haloperidol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2219,0.216,0.227,"[0.216,0.227]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0011786,haloperidol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.2196,0.201,0.238,"[0.201,0.238]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0010526,haloperidol,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.201,0.191,0.211,"[0.191,0.211]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0007864,haloperidol,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.1796,0.173,0.186,"[0.173,0.186]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0000914,haloperidol,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.1147,0.109,0.12,"[0.109,0.12]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008399,haloperidol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0972,0.092,0.103,"[0.092,0.103]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008006,haloperidol,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0834,0.067,0.099,"[0.067,0.099]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0013282,haloperidol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0755,0.066,0.085,"[0.066,0.085]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008383,haloperidol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0531,0.048,0.058,"[0.048,0.058]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0009891,haloperidol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0474,0.042,0.053,"[0.042,0.053]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0007915,haloperidol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0424,0.033,0.051,"[0.033,0.051]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004981,haloperidol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0411,0.036,0.046,"[0.036,0.046]",1.00E-04,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004648,haloperidol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0362,0.007,0.065,"[0.007,0.065]",0.015,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005101,haloperidol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.022,-0.069,0.113,"[-0.069,0.113]",0.637,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004425,haloperidol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0139,-0.101,0.129,"[-0.101,0.129]",0.813,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008738,haloperidol,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0135,-0.004,0.031,"[-0.004,0.031]",0.137,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005388,haloperidol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0134,-0.102,0.129,"[-0.102,0.129]",0.819,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0015564,haloperidol,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.013,-0.024,0.05,"[-0.024,0.05]",0.495,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0002316,haloperidol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0124,-0.061,0.086,"[-0.061,0.086]",0.742,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004952,haloperidol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0087,-0.06,0.078,"[-0.06,0.078]",0.805,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005010,haloperidol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0075,-0.035,0.049,"[-0.035,0.049]",0.727,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0000477,haloperidol,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0071,-0.079,0.093,"[-0.079,0.093]",0.87,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0018882,haloperidol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0039,-0.218,0.225,"[-0.218,0.225]",0.972,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,haloperidol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0034,-0.082,0.089,"[-0.082,0.089]",0.938,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005404,haloperidol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0034,-0.128,0.135,"[-0.128,0.135]",0.959,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,haloperidol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0031,-0.097,0.103,"[-0.097,0.103]",0.951,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0019499,haloperidol,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0022,-0.069,0.073,"[-0.069,0.073]",0.951,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005133,haloperidol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.0011,-0.184,0.186,"[-0.184,0.186]",0.991,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008542,haloperidol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,0.001,-0.281,0.283,"[-0.281,0.283]",0.994,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005364,haloperidol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,7.00E-04,-0.273,0.275,"[-0.273,0.275]",0.996,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005009,haloperidol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,6.00E-04,-0.378,0.38,"[-0.378,0.38]",0.998,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0002277,haloperidol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,4.00E-04,-0.565,0.566,"[-0.565,0.566]",0.999,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0005301,haloperidol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,3.00E-04,-0.594,0.594,"[-0.594,0.594]",0.999,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004975,haloperidol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,2.00E-04,-1.138,1.139,"[-1.138,1.139]",1,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0008678,haloperidol,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,2.00E-04,-0.617,0.617,"[-0.617,0.617]",1,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0004609,haloperidol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,9.47E-05,-0.469,0.469,"[-0.469,0.469]",1,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0007947,haloperidol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,8.52E-05,-0.386,0.386,"[-0.386,0.386]",1,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3559,biolink:associated_with_increased_likelihood_of,MONDO:0800026,haloperidol,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955695847,7.65E-05,-0.522,0.522,"[-0.522,0.522]",1,2911600,20699900,23611500,"Sample size with haloperidol, approximately: 2911600","Sample size without haloperidol, approximately: 20699900",All patients number is approximately: 23611500,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364648,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,guselkumab,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.8827222,0.0176,-0.456,0.491,"[-0.456,0.491]",0.942,7100,21788100,21795200,"Sample size with guselkumab, approximately: 7100","Sample size without guselkumab, approximately: 21788100",All patients number is approximately: 21795200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364648,biolink:associated_with_increased_likelihood_of,MONDO:0005178,guselkumab,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.8827222,0.0096,-0.623,0.643,"[-0.623,0.643]",0.976,7100,21788100,21795200,"Sample size with guselkumab, approximately: 7100","Sample size without guselkumab, approximately: 21788100",All patients number is approximately: 21795200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0002909,guar gum,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.7523,0.73,0.775,"[0.73,0.775]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0007027,guar gum,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.556,0.535,0.577,"[0.535,0.577]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0006694,guar gum,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.5309,0.511,0.551,"[0.511,0.551]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005010,guar gum,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.3887,0.365,0.412,"[0.365,0.412]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005546,guar gum,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.2853,0.265,0.306,"[0.265,0.306]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005302,guar gum,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.2332,0.21,0.257,"[0.21,0.257]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005180,guar gum,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.2282,0.195,0.261,"[0.195,0.261]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0000424,guar gum,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.2251,0.195,0.255,"[0.195,0.255]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0008399,guar gum,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.2036,0.179,0.228,"[0.179,0.228]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0007160,guar gum,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.1532,0.112,0.194,"[0.112,0.194]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0007739,guar gum,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.1243,0.072,0.177,"[0.072,0.177]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005393,guar gum,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.1227,0.101,0.145,"[0.101,0.145]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0008599,guar gum,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.103,0.078,0.128,"[0.078,0.128]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005178,guar gum,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0754,0.042,0.109,"[0.042,0.109]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005083,guar gum,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0749,0.006,0.144,"[0.006,0.144]",0.033,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0004975,guar gum,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0639,0.035,0.093,"[0.035,0.093]",1.00E-04,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0002869,guar gum,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0599,-0.002,0.121,"[-0.002,0.121]",0.056,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005002,guar gum,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0219,-0.084,0.127,"[-0.084,0.127]",0.684,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005404,guar gum,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0123,-0.227,0.251,"[-0.227,0.251]",0.92,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0007186,guar gum,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0083,-0.041,0.058,"[-0.041,0.058]",0.742,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005711,guar gum,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0077,-0.072,0.088,"[-0.072,0.088]",0.85,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005364,guar gum,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0053,-0.269,0.28,"[-0.269,0.28]",0.97,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005146,guar gum,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0038,-0.246,0.254,"[-0.246,0.254]",0.976,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0008383,guar gum,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0016,-0.306,0.309,"[-0.306,0.309]",0.992,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108446,biolink:associated_with_increased_likelihood_of,MONDO:0005009,guar gum,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974038382,0.0012,-1.131,1.134,"[-1.131,1.134]",0.998,94800,21765500,21860300,"Sample size with guar gum, approximately: 94800","Sample size without guar gum, approximately: 21765500",All patients number is approximately: 21860300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005546,guanfacine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.5988,0.573,0.624,"[0.573,0.624]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0016218,guanfacine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.5639,0.542,0.586,"[0.542,0.586]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005178,guanfacine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.3909,0.363,0.419,"[0.363,0.419]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0021187,guanfacine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.3612,0.334,0.389,"[0.334,0.389]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005300,guanfacine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.3398,0.306,0.374,"[0.306,0.374]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0018177,guanfacine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.2785,0.25,0.307,"[0.25,0.307]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0007843,guanfacine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.2738,0.236,0.312,"[0.236,0.312]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0007027,guanfacine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.2594,0.233,0.286,"[0.233,0.286]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005180,guanfacine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.2333,0.193,0.274,"[0.193,0.274]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0007473,guanfacine,duane syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.2289,0.192,0.266,"[0.192,0.266]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0011122,guanfacine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.161,0.129,0.193,"[0.129,0.193]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005083,guanfacine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.1374,0.063,0.211,"[0.063,0.211]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0004425,guanfacine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.1319,0.059,0.205,"[0.059,0.205]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0011786,guanfacine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.1158,0.092,0.14,"[0.092,0.14]",1.00E-04,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005133,guanfacine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.1082,0.047,0.17,"[0.047,0.17]",0.001,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0008300,guanfacine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0465,-0.034,0.127,"[-0.034,0.127]",0.257,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,guanfacine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0271,-0.113,0.167,"[-0.113,0.167]",0.705,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0004981,guanfacine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0221,-0.092,0.136,"[-0.092,0.136]",0.703,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005010,guanfacine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0212,-0.145,0.187,"[-0.145,0.187]",0.802,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0004609,guanfacine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0162,-0.077,0.109,"[-0.077,0.109]",0.733,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005148,guanfacine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0113,-0.023,0.046,"[-0.023,0.046]",0.518,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005302,guanfacine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0106,-0.16,0.181,"[-0.16,0.181]",0.903,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,guanfacine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0101,-0.272,0.292,"[-0.272,0.292]",0.944,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0018882,guanfacine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.01,-0.145,0.165,"[-0.145,0.165]",0.9,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0007947,guanfacine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0061,-0.221,0.233,"[-0.221,0.233]",0.958,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0003620,guanfacine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0028,-1.183,1.189,"[-1.183,1.189]",0.996,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0004975,guanfacine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0027,-0.393,0.398,"[-0.393,0.398]",0.989,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0005009,guanfacine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.002,-0.443,0.447,"[-0.443,0.447]",0.993,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0015924,guanfacine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,0.0018,-0.776,0.78,"[-0.776,0.78]",0.996,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3519,biolink:associated_with_increased_likelihood_of,MONDO:0002277,guanfacine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900126595,7.00E-04,-0.451,0.453,"[-0.451,0.453]",0.998,125300,21719600,21844900,"Sample size with guanfacine, approximately: 125300","Sample size without guanfacine, approximately: 21719600",All patients number is approximately: 21844900,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C2353893,biolink:associated_with_increased_likelihood_of,MONDO:0004981,golimumab,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.935450123,0.1777,-0.245,0.6,"[-0.245,0.6]",0.41,14000,21783600,21797600,"Sample size with golimumab, approximately: 14000","Sample size without golimumab, approximately: 21783600",All patients number is approximately: 21797600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C2353893,biolink:associated_with_increased_likelihood_of,MONDO:0021187,golimumab,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.935450123,0.0455,-0.135,0.226,"[-0.135,0.226]",0.622,14000,21783600,21797600,"Sample size with golimumab, approximately: 14000","Sample size without golimumab, approximately: 21783600",All patients number is approximately: 21797600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C2353893,biolink:associated_with_increased_likelihood_of,MONDO:0005404,golimumab,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.935450123,0.0148,-0.465,0.495,"[-0.465,0.495]",0.952,14000,21783600,21797600,"Sample size with golimumab, approximately: 14000","Sample size without golimumab, approximately: 21783600",All patients number is approximately: 21797600,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C2353893,biolink:associated_with_increased_likelihood_of,MONDO:0011786,golimumab,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.935450123,0.0027,-0.748,0.753,"[-0.748,0.753]",0.994,14000,21783600,21797600,"Sample size with golimumab, approximately: 14000","Sample size without golimumab, approximately: 21783600",All patients number is approximately: 21797600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0004609,glyburide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,2.5554,2.542,2.569,"[2.542,2.569]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005180,glyburide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.3346,0.314,0.356,"[0.314,0.356]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0004648,glyburide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.2739,0.249,0.298,"[0.249,0.298]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0015453,glyburide,cogan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.244,0.222,0.266,"[0.222,0.266]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0004981,glyburide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.2134,0.192,0.235,"[0.192,0.235]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0006694,glyburide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.1925,0.166,0.219,"[0.166,0.219]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005010,glyburide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.1111,0.093,0.129,"[0.093,0.129]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005178,glyburide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0802,0.051,0.109,"[0.051,0.109]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0018177,glyburide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0794,0.044,0.115,"[0.044,0.115]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005148,glyburide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0785,0.056,0.102,"[0.056,0.102]",1.00E-04,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0004425,glyburide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0261,-0.009,0.061,"[-0.009,0.061]",0.14,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0043693,glyburide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0178,-0.04,0.076,"[-0.04,0.076]",0.548,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005002,glyburide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0168,-0.134,0.168,"[-0.134,0.168]",0.827,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005300,glyburide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0144,-0.131,0.16,"[-0.131,0.16]",0.847,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005298,glyburide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0088,-0.598,0.616,"[-0.598,0.616]",0.977,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005294,glyburide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0046,-0.308,0.317,"[-0.308,0.317]",0.977,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0007027,glyburide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0033,-0.024,0.03,"[-0.024,0.03]",0.813,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005101,glyburide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0031,-0.122,0.128,"[-0.122,0.128]",0.961,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0021107,glyburide,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0028,-0.249,0.254,"[-0.249,0.254]",0.982,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0007186,glyburide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0026,-0.127,0.132,"[-0.127,0.132]",0.968,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,glyburide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0017,-0.258,0.262,"[-0.258,0.262]",0.99,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0005546,glyburide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0012,-0.763,0.765,"[-0.763,0.765]",0.998,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,glyburide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,0.0011,-0.557,0.559,"[-0.557,0.559]",0.997,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,glyburide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,9.00E-04,-0.459,0.461,"[-0.459,0.461]",0.997,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3488,biolink:associated_with_increased_likelihood_of,MONDO:0004975,glyburide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.926295065,3.00E-04,-0.153,0.154,"[-0.153,0.154]",0.997,180100,21678900,21859000,"Sample size with glyburide, approximately: 180100","Sample size without glyburide, approximately: 21678900",All patients number is approximately: 21859000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0007186,glipizide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.5955,0.588,0.603,"[0.588,0.603]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005133,glipizide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.4358,0.428,0.443,"[0.428,0.443]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004609,glipizide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.4301,0.423,0.438,"[0.423,0.438]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0002277,glipizide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1909,0.173,0.209,"[0.173,0.209]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,glipizide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1471,0.136,0.158,"[0.136,0.158]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005146,glipizide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1453,0.122,0.169,"[0.122,0.169]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004981,glipizide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.122,0.102,0.141,"[0.102,0.141]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0043693,glipizide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1208,0.112,0.129,"[0.112,0.129]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005178,glipizide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.118,0.109,0.127,"[0.109,0.127]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,glipizide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1132,0.081,0.145,"[0.081,0.145]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005180,glipizide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1075,0.098,0.117,"[0.098,0.117]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0007739,glipizide,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.1057,0.081,0.13,"[0.081,0.13]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005393,glipizide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0952,0.082,0.108,"[0.082,0.108]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004975,glipizide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0793,0.051,0.108,"[0.051,0.108]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0002316,glipizide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0748,0.04,0.11,"[0.04,0.11]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0018882,glipizide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0704,0.051,0.09,"[0.051,0.09]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005306,glipizide,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0637,0.053,0.075,"[0.053,0.075]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,glipizide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0596,0.009,0.111,"[0.009,0.111]",0.022,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004952,glipizide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0416,0.025,0.058,"[0.025,0.058]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0007027,glipizide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0388,0.02,0.057,"[0.02,0.057]",1.00E-04,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0011849,glipizide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0358,0.013,0.059,"[0.013,0.059]",0.002,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0006694,glipizide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0184,-0.003,0.04,"[-0.003,0.04]",0.089,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0000153,glipizide,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0181,-0.034,0.07,"[-0.034,0.07]",0.496,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0008300,glipizide,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0152,-0.073,0.103,"[-0.073,0.103]",0.734,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005404,glipizide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0116,-0.108,0.132,"[-0.108,0.132]",0.849,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0021187,glipizide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0101,-0.028,0.048,"[-0.028,0.048]",0.602,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0002406,glipizide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0068,-0.046,0.06,"[-0.046,0.06]",0.801,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005101,glipizide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0067,-0.087,0.101,"[-0.087,0.101]",0.89,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005002,glipizide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0052,-0.02,0.031,"[-0.02,0.031]",0.691,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0021107,glipizide,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0046,-0.05,0.059,"[-0.05,0.059]",0.868,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004648,glipizide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0034,-0.082,0.089,"[-0.082,0.089]",0.938,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0011786,glipizide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.003,-0.098,0.104,"[-0.098,0.104]",0.953,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0019565,glipizide,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0027,-0.219,0.224,"[-0.219,0.224]",0.981,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0003620,glipizide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0023,-0.099,0.103,"[-0.099,0.103]",0.964,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0019180,glipizide,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0021,-0.135,0.139,"[-0.135,0.139]",0.976,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0010602,glipizide,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0017,-0.029,0.033,"[-0.029,0.033]",0.913,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005010,glipizide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0014,-43.3,43.302,"[-43.3,43.302]",1,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0016218,glipizide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0011,-0.679,0.682,"[-0.679,0.682]",0.998,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0004425,glipizide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0011,-0.265,0.267,"[-0.265,0.267]",0.994,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0010526,glipizide,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.0011,-0.27,0.272,"[-0.27,0.272]",0.993,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0011508,glipizide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,0.001,-0.103,0.105,"[-0.103,0.105]",0.986,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005546,glipizide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,5.00E-04,-0.308,0.309,"[-0.308,0.309]",0.997,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005300,glipizide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,3.00E-04,-0.659,0.66,"[-0.659,0.66]",0.999,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3478,biolink:associated_with_increased_likelihood_of,MONDO:0005392,glipizide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.943280182,3.00E-04,-0.277,0.278,"[-0.277,0.278]",0.998,1193900,21164500,22358400,"Sample size with glipizide, approximately: 1193900","Sample size without glipizide, approximately: 21164500",All patients number is approximately: 22358400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0018882,glimepiride,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.5685,0.557,0.58,"[0.557,0.58]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005393,glimepiride,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.475,0.463,0.487,"[0.463,0.487]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005133,glimepiride,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.4019,0.392,0.412,"[0.392,0.412]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0010602,glimepiride,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.2291,0.216,0.243,"[0.216,0.243]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0004648,glimepiride,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.2114,0.202,0.221,"[0.202,0.221]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0004979,glimepiride,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1526,0.131,0.174,"[0.131,0.174]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005101,glimepiride,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1445,0.118,0.171,"[0.118,0.171]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005364,glimepiride,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1391,0.122,0.156,"[0.122,0.156]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005404,glimepiride,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1344,0.104,0.165,"[0.104,0.165]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0004975,glimepiride,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1285,0.11,0.147,"[0.11,0.147]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0010789,glimepiride,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.1223,0.113,0.132,"[0.113,0.132]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005147,glimepiride,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0962,0.071,0.122,"[0.071,0.122]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005011,glimepiride,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0741,0.052,0.096,"[0.052,0.096]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0019499,glimepiride,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0655,0.053,0.078,"[0.053,0.078]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0008383,glimepiride,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0567,0.044,0.07,"[0.044,0.07]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0018177,glimepiride,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0547,0.042,0.067,"[0.042,0.067]",1.00E-04,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0011786,glimepiride,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0485,0.012,0.085,"[0.012,0.085]",0.01,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005306,glimepiride,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0482,0.019,0.077,"[0.019,0.077]",0.001,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0007915,glimepiride,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.041,0.004,0.078,"[0.004,0.078]",0.028,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0011849,glimepiride,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0366,-0.052,0.125,"[-0.052,0.125]",0.418,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005546,glimepiride,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0348,-2.77E-05,0.07,"[-0.0000277,0.07]",0.05,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005302,glimepiride,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0284,-0.018,0.075,"[-0.018,0.075]",0.233,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005083,glimepiride,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0227,-0.038,0.084,"[-0.038,0.084]",0.466,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0019565,glimepiride,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0214,-0.053,0.096,"[-0.053,0.096]",0.573,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,glimepiride,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.017,-0.029,0.063,"[-0.029,0.063]",0.473,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0002909,glimepiride,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0073,-0.007,0.021,"[-0.007,0.021]",0.314,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0015924,glimepiride,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0059,-0.084,0.096,"[-0.084,0.096]",0.898,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0004609,glimepiride,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0058,-0.141,0.152,"[-0.141,0.152]",0.938,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,glimepiride,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0031,-0.35,0.356,"[-0.35,0.356]",0.986,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,glimepiride,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0029,-0.138,0.144,"[-0.138,0.144]",0.968,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0008487,glimepiride,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0029,-0.227,0.233,"[-0.227,0.233]",0.981,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0002406,glimepiride,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0028,-0.37,0.375,"[-0.37,0.375]",0.988,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0002046,glimepiride,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0021,-0.405,0.409,"[-0.405,0.409]",0.992,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005146,glimepiride,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.002,-0.292,0.296,"[-0.292,0.296]",0.989,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1481,biolink:associated_with_increased_likelihood_of,MONDO:0005294,glimepiride,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939196792,0.0012,-0.33,0.333,"[-0.33,0.333]",0.994,485100,21526100,22011200,"Sample size with glimepiride, approximately: 485100","Sample size without glimepiride, approximately: 21526100",All patients number is approximately: 22011200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0005011,glecaprevir,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.2478,-0.047,0.542,"[-0.047,0.542]",0.099,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0005009,glecaprevir,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.2424,0.058,0.427,"[0.058,0.427]",0.01,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0005149,glecaprevir,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.2172,-1.511,1.945,"[-1.511,1.945]",0.805,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0004981,glecaprevir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.1406,-0.283,0.565,"[-0.283,0.565]",0.516,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0018882,glecaprevir,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0918,-0.031,0.215,"[-0.031,0.215]",0.143,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0005302,glecaprevir,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0642,-0.006,0.134,"[-0.006,0.134]",0.073,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0007186,glecaprevir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0312,-0.612,0.674,"[-0.612,0.674]",0.924,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0011786,glecaprevir,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0089,-0.697,0.714,"[-0.697,0.714]",0.98,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0000424,glecaprevir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0062,-1.193,1.205,"[-1.193,1.205]",0.992,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252742,biolink:associated_with_increased_likelihood_of,MONDO:0005393,glecaprevir,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999872487,0.0048,-1.359,1.369,"[-1.359,1.369]",0.994,13300,21781800,21795100,"Sample size with glecaprevir, approximately: 13300","Sample size without glecaprevir, approximately: 21781800",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0004609,glatiramer,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,2.0204,1.953,2.088,"[1.953,2.088]",1.00E-04,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0002406,glatiramer,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0366,-0.04,0.113,"[-0.04,0.113]",0.349,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0005148,glatiramer,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0228,-0.343,0.389,"[-0.343,0.389]",0.903,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0005392,glatiramer,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0181,-0.495,0.531,"[-0.495,0.531]",0.945,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0005009,glatiramer,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0083,-0.912,0.928,"[-0.912,0.928]",0.986,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0007186,glatiramer,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0081,-0.673,0.689,"[-0.673,0.689]",0.981,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:65370,biolink:associated_with_increased_likelihood_of,MONDO:0005546,glatiramer,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.902502116,0.0048,-0.153,0.162,"[-0.153,0.162]",0.953,17700,21781200,21798900,"Sample size with glatiramer, approximately: 17700","Sample size without glatiramer, approximately: 21781200",All patients number is approximately: 21798900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0004609,gemfibrozil,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.4773,0.463,0.492,"[0.463,0.492]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,gemfibrozil,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.4657,0.451,0.48,"[0.451,0.48]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0000424,gemfibrozil,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.3281,0.309,0.347,"[0.309,0.347]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005298,gemfibrozil,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.3232,0.286,0.36,"[0.286,0.36]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0003620,gemfibrozil,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.2377,0.213,0.263,"[0.213,0.263]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005180,gemfibrozil,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.2093,0.186,0.233,"[0.186,0.233]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0018177,gemfibrozil,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.1024,0.071,0.134,"[0.071,0.134]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0008399,gemfibrozil,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.1023,0.062,0.142,"[0.062,0.142]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0006694,gemfibrozil,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0746,0.047,0.102,"[0.047,0.102]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0004425,gemfibrozil,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0731,0.044,0.103,"[0.044,0.103]",1.00E-04,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0018882,gemfibrozil,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0555,0.008,0.103,"[0.008,0.103]",0.023,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,gemfibrozil,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0454,-0.009,0.1,"[-0.009,0.1]",0.101,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005178,gemfibrozil,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0452,0.004,0.086,"[0.004,0.086]",0.03,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005300,gemfibrozil,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0446,0.003,0.086,"[0.003,0.086]",0.034,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005083,gemfibrozil,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0284,-0.08,0.137,"[-0.08,0.137]",0.607,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0009693,gemfibrozil,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0241,0.003,0.045,"[0.003,0.045]",0.026,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0002406,gemfibrozil,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0204,-0.067,0.108,"[-0.067,0.108]",0.646,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0002277,gemfibrozil,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0126,-0.096,0.121,"[-0.096,0.121]",0.819,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0011786,gemfibrozil,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0069,-0.164,0.178,"[-0.164,0.178]",0.937,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005101,gemfibrozil,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0062,-0.111,0.123,"[-0.111,0.123]",0.917,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0002909,gemfibrozil,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0054,-0.208,0.218,"[-0.208,0.218]",0.96,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0007915,gemfibrozil,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0045,-0.141,0.15,"[-0.141,0.15]",0.952,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005010,gemfibrozil,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.004,-0.283,0.291,"[-0.283,0.291]",0.978,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005146,gemfibrozil,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0029,-0.411,0.416,"[-0.411,0.416]",0.989,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0004981,gemfibrozil,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0026,-0.287,0.292,"[-0.287,0.292]",0.986,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0007186,gemfibrozil,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,0.0016,-0.181,0.184,"[-0.181,0.184]",0.986,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3463,biolink:associated_with_increased_likelihood_of,MONDO:0005302,gemfibrozil,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.894738644,8.00E-04,-0.397,0.398,"[-0.397,0.398]",0.997,167900,21702400,21870300,"Sample size with gemfibrozil, approximately: 167900","Sample size without gemfibrozil, approximately: 21702400",All patients number is approximately: 21870300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0005294,galantamine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.7088,0.637,0.78,"[0.637,0.78]",1.00E-04,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0003620,galantamine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.4889,0.448,0.53,"[0.448,0.53]",1.00E-04,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0004979,galantamine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.2312,0.147,0.315,"[0.147,0.315]",1.00E-04,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0002406,galantamine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.1696,0.125,0.215,"[0.125,0.215]",1.00E-04,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0004981,galantamine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.1666,-0.025,0.358,"[-0.025,0.358]",0.088,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0005178,galantamine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.1022,-0.006,0.21,"[-0.006,0.21]",0.063,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0002909,galantamine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.0889,-0.009,0.187,"[-0.009,0.187]",0.074,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0005010,galantamine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.0495,-0.116,0.215,"[-0.116,0.215]",0.557,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0007186,galantamine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.0177,-0.197,0.232,"[-0.197,0.232]",0.871,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0004975,galantamine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.0119,-0.408,0.432,"[-0.408,0.432]",0.956,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:9651,biolink:associated_with_increased_likelihood_of,MONDO:0005392,galantamine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.952557606,0.0029,-0.868,0.873,"[-0.868,0.873]",0.995,17400,21782000,21799400,"Sample size with galantamine, approximately: 17400","Sample size without galantamine, approximately: 21782000",All patients number is approximately: 21799400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0018177,furosemide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.9798,0.974,0.986,"[0.974,0.986]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0021187,furosemide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.4495,0.434,0.465,"[0.434,0.465]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0006694,furosemide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.4313,0.423,0.439,"[0.423,0.439]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0019565,furosemide,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.3752,0.35,0.4,"[0.35,0.4]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0002277,furosemide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.3655,0.356,0.375,"[0.356,0.375]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005002,furosemide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.2492,0.237,0.261,"[0.237,0.261]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0019350,furosemide,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.2394,0.227,0.251,"[0.227,0.251]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005711,furosemide,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.2336,0.226,0.241,"[0.226,0.241]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004952,furosemide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1996,0.195,0.205,"[0.195,0.205]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0001516,furosemide,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1942,0.189,0.2,"[0.189,0.2]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,furosemide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1916,0.163,0.22,"[0.163,0.22]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007915,furosemide,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1811,0.176,0.186,"[0.176,0.186]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005393,furosemide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1656,0.146,0.185,"[0.146,0.185]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005180,furosemide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1627,0.157,0.169,"[0.157,0.169]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007843,furosemide,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1413,0.118,0.164,"[0.118,0.164]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004609,furosemide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1317,0.115,0.149,"[0.115,0.149]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0002406,furosemide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1193,0.099,0.14,"[0.099,0.14]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0009061,furosemide,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.1071,0.101,0.113,"[0.101,0.113]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004425,furosemide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0952,0.073,0.118,"[0.073,0.118]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0002046,furosemide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0823,0.062,0.102,"[0.062,0.102]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0015263,furosemide,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0811,0.075,0.087,"[0.075,0.087]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,furosemide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.08,0.074,0.086,"[0.074,0.086]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0020066,furosemide,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0734,0.065,0.082,"[0.065,0.082]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008006,furosemide,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0665,0.046,0.087,"[0.046,0.087]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005306,furosemide,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.056,0.023,0.089,"[0.023,0.089]",0.001,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005404,furosemide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0518,0.044,0.06,"[0.044,0.06]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0800026,furosemide,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0483,0.006,0.09,"[0.006,0.09]",0.024,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007739,furosemide,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0453,0.033,0.058,"[0.033,0.058]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008599,furosemide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0423,0.035,0.049,"[0.035,0.049]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005546,furosemide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0419,0.016,0.068,"[0.016,0.068]",0.002,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005133,furosemide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0403,0.024,0.057,"[0.024,0.057]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0013282,furosemide,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0383,0.001,0.075,"[0.001,0.075]",0.042,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007903,furosemide,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0374,0.003,0.072,"[0.003,0.072]",0.035,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005302,furosemide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0343,0.029,0.04,"[0.029,0.04]",1.00E-04,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0000424,furosemide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0321,0.002,0.062,"[0.002,0.062]",0.035,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005149,furosemide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0227,-0.032,0.078,"[-0.032,0.078]",0.418,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007818,furosemide,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0176,-0.034,0.07,"[-0.034,0.07]",0.506,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0002869,furosemide,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0131,0.004,0.022,"[0.004,0.022]",0.005,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005009,furosemide,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0122,-0.028,0.053,"[-0.028,0.053]",0.557,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007160,furosemide,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0113,-0.037,0.06,"[-0.037,0.06]",0.647,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0019015,furosemide,congenital omphalocele,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0101,-0.021,0.041,"[-0.021,0.041]",0.52,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0007540,furosemide,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.009,-0.085,0.103,"[-0.085,0.103]",0.851,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0019118,furosemide,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0061,-0.103,0.115,"[-0.103,0.115]",0.912,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004648,furosemide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0057,-0.115,0.126,"[-0.115,0.126]",0.926,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0010526,furosemide,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0057,-0.037,0.048,"[-0.037,0.048]",0.793,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004979,furosemide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0049,-0.098,0.108,"[-0.098,0.108]",0.926,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008300,furosemide,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0038,-0.04,0.048,"[-0.04,0.048]",0.865,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0009264,furosemide,gastroschisis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0038,-0.126,0.134,"[-0.126,0.134]",0.954,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008642,furosemide,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0037,-0.071,0.079,"[-0.071,0.079]",0.923,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005130,furosemide,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0035,-0.093,0.1,"[-0.093,0.1]",0.944,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005298,furosemide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0033,-0.114,0.121,"[-0.114,0.121]",0.957,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0043693,furosemide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0028,-0.107,0.113,"[-0.107,0.113]",0.96,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0002316,furosemide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0028,-0.113,0.119,"[-0.113,0.119]",0.962,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005148,furosemide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0025,-0.271,0.276,"[-0.271,0.276]",0.986,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005364,furosemide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0024,-0.097,0.102,"[-0.097,0.102]",0.963,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005101,furosemide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0017,-0.14,0.143,"[-0.14,0.143]",0.981,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005388,furosemide,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0015,-0.234,0.237,"[-0.234,0.237]",0.99,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005072,furosemide,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.0013,-0.177,0.18,"[-0.177,0.18]",0.989,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0011786,furosemide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,0.001,-0.27,0.272,"[-0.27,0.272]",0.994,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,furosemide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,8.00E-04,-0.288,0.289,"[-0.288,0.289]",0.996,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0016218,furosemide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,8.00E-04,-0.353,0.355,"[-0.353,0.355]",0.996,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0009889,furosemide,polycystic kidney disease infantile type,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,6.00E-04,-0.152,0.153,"[-0.152,0.153]",0.994,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0000153,furosemide,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,4.00E-04,-0.191,0.191,"[-0.191,0.191]",0.997,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0000477,furosemide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,4.00E-04,-0.204,0.205,"[-0.204,0.205]",0.997,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0001044,furosemide,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,4.00E-04,-0.041,0.042,"[-0.041,0.042]",0.983,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0004975,furosemide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,3.00E-04,-0.632,0.632,"[-0.632,0.632]",0.999,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0011429,furosemide,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,3.00E-04,-0.348,0.349,"[-0.348,0.349]",0.999,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005392,furosemide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,2.00E-04,-0.251,0.251,"[-0.251,0.251]",0.999,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008542,furosemide,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,2.00E-04,-0.682,0.683,"[-0.682,0.683]",1,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0005146,furosemide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,6.02E-05,-0.635,0.635,"[-0.635,0.635]",1,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0008394,furosemide,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,5.04E-05,-1.042,1.042,"[-1.042,1.042]",1,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3440,biolink:associated_with_increased_likelihood_of,MONDO:0019499,furosemide,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.969225115,1.42E-05,-1.106,1.106,"[-1.106,1.106]",1,8621900,18504400,27126300,"Sample size with furosemide, approximately: 8621900","Sample size without furosemide, approximately: 18504400",All patients number is approximately: 27126300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005009,fosinopril,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.788,0.734,0.842,"[0.734,0.842]",1.00E-04,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005294,fosinopril,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.392,0.28,0.504,"[0.28,0.504]",1.00E-04,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0008383,fosinopril,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.219,0.15,0.288,"[0.15,0.288]",1.00E-04,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005146,fosinopril,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.19,0.107,0.273,"[0.107,0.273]",1.00E-04,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0002406,fosinopril,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.1232,0.064,0.182,"[0.064,0.182]",1.00E-04,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005010,fosinopril,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.059,-0.115,0.233,"[-0.115,0.233]",0.507,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0007186,fosinopril,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.034,-0.279,0.348,"[-0.279,0.348]",0.831,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0004975,fosinopril,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.0158,-0.401,0.432,"[-0.401,0.432]",0.941,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,fosinopril,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.0039,-0.171,0.179,"[-0.171,0.179]",0.965,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005546,fosinopril,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.002,-0.655,0.659,"[-0.655,0.659]",0.995,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45357796,biolink:associated_with_increased_likelihood_of,MONDO:0005178,fosinopril,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.922327185,0.0018,-0.272,0.275,"[-0.272,0.275]",0.99,20400,21778800,21799200,"Sample size with fosinopril, approximately: 20400","Sample size without fosinopril, approximately: 21778800",All patients number is approximately: 21799200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:131536,biolink:associated_with_increased_likelihood_of,MONDO:0005009,fosamprenavir,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.973082958,0.0235,-1.366,1.413,"[-1.366,1.413]",0.974,1100,21791600,21792700,"Sample size with fosamprenavir, approximately: 1100","Sample size without fosamprenavir, approximately: 21791600",All patients number is approximately: 21792700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0002406,formoterol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,1.6448,1.627,1.663,"[1.627,1.663]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0000914,formoterol,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.6346,0.621,0.649,"[0.621,0.649]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005133,formoterol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.5648,0.552,0.578,"[0.552,0.578]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0008487,formoterol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.4491,0.423,0.475,"[0.423,0.475]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0010602,formoterol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.4076,0.392,0.423,"[0.392,0.423]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0008383,formoterol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.3499,0.337,0.363,"[0.337,0.363]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0009891,formoterol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.2425,0.225,0.26,"[0.225,0.26]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005147,formoterol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.1905,0.169,0.212,"[0.169,0.212]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005009,formoterol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.1369,0.118,0.156,"[0.118,0.156]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005083,formoterol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0911,0.04,0.143,"[0.04,0.143]",0.001,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0021187,formoterol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0812,0.046,0.116,"[0.046,0.116]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0011786,formoterol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0705,0.041,0.1,"[0.041,0.1]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005130,formoterol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0647,0.049,0.08,"[0.049,0.08]",1.00E-04,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0010526,formoterol,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0369,-0.006,0.079,"[-0.006,0.079]",0.09,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0007186,formoterol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.032,-0.032,0.096,"[-0.032,0.096]",0.328,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005148,formoterol,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0316,-0.025,0.088,"[-0.025,0.088]",0.274,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0002316,formoterol,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0282,-0.038,0.095,"[-0.038,0.095]",0.405,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0001516,formoterol,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0238,0.009,0.039,"[0.009,0.039]",0.002,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005294,formoterol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0217,-0.082,0.126,"[-0.082,0.126]",0.683,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005298,formoterol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0202,-0.083,0.123,"[-0.083,0.123]",0.7,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0007818,formoterol,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0164,-0.08,0.112,"[-0.08,0.112]",0.738,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005711,formoterol,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0161,-0.064,0.096,"[-0.064,0.096]",0.694,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0008542,formoterol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0145,-0.027,0.056,"[-0.027,0.056]",0.49,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,formoterol,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0111,-0.067,0.089,"[-0.067,0.089]",0.78,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0004979,formoterol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.011,-0.038,0.06,"[-0.038,0.06]",0.662,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005388,formoterol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0091,-0.169,0.187,"[-0.169,0.187]",0.921,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0018975,formoterol,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0089,-0.004,0.022,"[-0.004,0.022]",0.175,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0015564,formoterol,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0081,-0.031,0.047,"[-0.031,0.047]",0.681,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0002277,formoterol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0074,-0.175,0.19,"[-0.175,0.19]",0.936,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0004609,formoterol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0061,-0.465,0.477,"[-0.465,0.477]",0.98,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0007947,formoterol,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0057,-0.079,0.091,"[-0.079,0.091]",0.895,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0019565,formoterol,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0035,-1.948,1.955,"[-1.948,1.955]",0.997,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005101,formoterol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0033,-0.09,0.096,"[-0.09,0.096]",0.944,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005546,formoterol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0028,-0.104,0.109,"[-0.104,0.109]",0.959,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0018882,formoterol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0025,-0.176,0.181,"[-0.176,0.181]",0.978,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0004952,formoterol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0024,-0.285,0.289,"[-0.285,0.289]",0.987,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,formoterol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,0.0016,-0.415,0.418,"[-0.415,0.418]",0.994,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0002909,formoterol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,8.00E-04,-0.739,0.74,"[-0.739,0.74]",0.998,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0005301,formoterol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,7.00E-04,-0.39,0.391,"[-0.39,0.391]",0.997,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0004425,formoterol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,6.00E-04,-0.534,0.535,"[-0.534,0.535]",0.998,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0800026,formoterol,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,5.00E-04,-0.764,0.766,"[-0.764,0.766]",0.999,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:5147,biolink:associated_with_increased_likelihood_of,MONDO:0020066,formoterol,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996410015,3.00E-04,-0.167,0.168,"[-0.167,0.168]",0.998,1924500,21054600,22979100,"Sample size with formoterol, approximately: 1924500","Sample size without formoterol, approximately: 21054600",All patients number is approximately: 22979100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0003620,fomepizole,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.747,0.616,0.877,"[0.616,0.877]",1.00E-04,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0011786,fomepizole,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.6213,0.549,0.693,"[0.549,0.693]",1.00E-04,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0002909,fomepizole,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.5087,0.449,0.568,"[0.449,0.568]",1.00E-04,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0005300,fomepizole,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0773,-0.23,0.385,"[-0.23,0.385]",0.622,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0011122,fomepizole,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0697,-0.07,0.21,"[-0.07,0.21]",0.329,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0002869,fomepizole,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0303,-0.293,0.354,"[-0.293,0.354]",0.854,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0000424,fomepizole,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0155,-0.449,0.48,"[-0.449,0.48]",0.948,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0004425,fomepizole,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0124,-0.049,0.074,"[-0.049,0.074]",0.692,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3406,biolink:associated_with_increased_likelihood_of,MONDO:0005149,fomepizole,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.992102744,0.0029,-1.94,1.946,"[-1.94,1.946]",0.998,5900,21790300,21796200,"Sample size with fomepizole, approximately: 5900","Sample size without fomepizole, approximately: 21790300",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0007186,fluvoxamine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,1.0054,0.946,1.065,"[0.946,1.065]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005546,fluvoxamine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.653,0.593,0.713,"[0.593,0.713]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0021187,fluvoxamine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.6107,0.551,0.67,"[0.551,0.67]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0000424,fluvoxamine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.6046,0.533,0.676,"[0.533,0.676]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0008487,fluvoxamine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.4915,0.453,0.53,"[0.453,0.53]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0011122,fluvoxamine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.2786,0.212,0.345,"[0.212,0.345]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0004981,fluvoxamine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.2538,0.206,0.302,"[0.206,0.302]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0004609,fluvoxamine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.1129,-0.004,0.23,"[-0.004,0.23]",0.058,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0004979,fluvoxamine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0782,0.038,0.119,"[0.038,0.119]",1.00E-04,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0004648,fluvoxamine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0462,-0.111,0.204,"[-0.111,0.204]",0.565,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005302,fluvoxamine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0458,-0.037,0.128,"[-0.037,0.128]",0.278,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0008599,fluvoxamine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0397,-0.028,0.108,"[-0.028,0.108]",0.252,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005148,fluvoxamine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.039,-0.209,0.287,"[-0.209,0.287]",0.758,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005178,fluvoxamine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0251,-0.05,0.1,"[-0.05,0.1]",0.511,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0003620,fluvoxamine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.019,-0.48,0.518,"[-0.48,0.518]",0.94,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005101,fluvoxamine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0168,-0.72,0.753,"[-0.72,0.753]",0.964,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005002,fluvoxamine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0056,-0.097,0.108,"[-0.097,0.108]",0.914,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005149,fluvoxamine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0051,-0.598,0.608,"[-0.598,0.608]",0.987,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0005392,fluvoxamine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0045,-2.876,2.885,"[-2.876,2.885]",0.998,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,fluvoxamine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0043,-0.542,0.55,"[-0.542,0.55]",0.988,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0011849,fluvoxamine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0041,-0.307,0.315,"[-0.307,0.315]",0.979,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3404,biolink:associated_with_increased_likelihood_of,MONDO:0002046,fluvoxamine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862772717,0.0031,-2.574,2.58,"[-2.574,2.58]",0.998,40100,21769400,21809500,"Sample size with fluvoxamine, approximately: 40100","Sample size without fluvoxamine, approximately: 21769400",All patients number is approximately: 21809500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548972,biolink:associated_with_increased_likelihood_of,MONDO:0005178,fluvastatin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.901277475,0.021,-0.388,0.43,"[-0.388,0.43]",0.92,8100,21787000,21795100,"Sample size with fluvastatin, approximately: 8100","Sample size without fluvastatin, approximately: 21787000",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005011,fluticasone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.9362,0.929,0.943,"[0.929,0.943]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005711,fluticasone,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.7791,0.768,0.79,"[0.768,0.79]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0019180,fluticasone,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.4732,0.464,0.483,"[0.464,0.483]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004981,fluticasone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.3274,0.313,0.342,"[0.313,0.342]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008599,fluticasone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.204,0.198,0.209,"[0.198,0.209]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,fluticasone,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1958,0.189,0.202,"[0.189,0.202]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,fluticasone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1934,0.183,0.204,"[0.183,0.204]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0002909,fluticasone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1677,0.162,0.174,"[0.162,0.174]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008300,fluticasone,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1412,0.134,0.148,"[0.134,0.148]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0021107,fluticasone,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1266,0.106,0.147,"[0.106,0.147]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005149,fluticasone,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1259,0.119,0.132,"[0.119,0.132]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005146,fluticasone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.1193,0.099,0.14,"[0.099,0.14]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0043693,fluticasone,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0913,0.063,0.12,"[0.063,0.12]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007027,fluticasone,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0858,0.079,0.092,"[0.079,0.092]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0001516,fluticasone,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0839,0.074,0.093,"[0.074,0.093]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005010,fluticasone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0811,0.054,0.108,"[0.054,0.108]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0018975,fluticasone,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0735,0.064,0.083,"[0.064,0.083]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0018882,fluticasone,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0546,0.032,0.077,"[0.032,0.077]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005546,fluticasone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.054,0.048,0.06,"[0.048,0.06]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005002,fluticasone,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0474,9.45E-05,0.095,"[0.0000945,0.095]",0.05,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0015614,fluticasone,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0463,0.039,0.054,"[0.039,0.054]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0019118,fluticasone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0456,0.019,0.072,"[0.019,0.072]",0.001,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008642,fluticasone,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0361,0.021,0.051,"[0.021,0.051]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005294,fluticasone,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0329,-0.011,0.077,"[-0.011,0.077]",0.139,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008678,fluticasone,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0216,-0.001,0.045,"[-0.001,0.045]",0.065,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005101,fluticasone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0206,-0.012,0.053,"[-0.012,0.053]",0.212,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008399,fluticasone,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0204,0.01,0.031,"[0.01,0.031]",1.00E-04,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0011786,fluticasone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0182,-0.033,0.07,"[-0.033,0.07]",0.489,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007947,fluticasone,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0151,0.004,0.026,"[0.004,0.026]",0.009,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0800026,fluticasone,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0133,-0.063,0.089,"[-0.063,0.089]",0.732,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005364,fluticasone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0128,-0.075,0.1,"[-0.075,0.1]",0.773,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,fluticasone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0124,-0.012,0.036,"[-0.012,0.036]",0.311,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0019565,fluticasone,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0114,-0.069,0.092,"[-0.069,0.092]",0.781,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004952,fluticasone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0112,-0.079,0.102,"[-0.079,0.102]",0.808,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0011429,fluticasone,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0098,-0.019,0.038,"[-0.019,0.038]",0.498,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005300,fluticasone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.009,-0.047,0.065,"[-0.047,0.065]",0.753,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005306,fluticasone,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0083,-0.025,0.041,"[-0.025,0.041]",0.623,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007540,fluticasone,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0081,-0.1,0.117,"[-0.1,0.117]",0.883,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005392,fluticasone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0067,-0.152,0.165,"[-0.152,0.165]",0.934,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007186,fluticasone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0053,-0.085,0.095,"[-0.085,0.095]",0.907,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007160,fluticasone,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0053,-0.017,0.027,"[-0.017,0.027]",0.634,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0000153,fluticasone,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0032,-0.149,0.155,"[-0.149,0.155]",0.967,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0000477,fluticasone,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0024,-0.025,0.03,"[-0.025,0.03]",0.866,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0021187,fluticasone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0023,-0.293,0.297,"[-0.293,0.297]",0.988,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004975,fluticasone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.002,-0.111,0.115,"[-0.111,0.115]",0.973,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005298,fluticasone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0018,-0.012,0.015,"[-0.012,0.015]",0.795,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0002277,fluticasone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0017,-0.352,0.356,"[-0.352,0.356]",0.992,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0008487,fluticasone,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0014,-0.156,0.158,"[-0.156,0.158]",0.986,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0019080,fluticasone,alopecia totalis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0013,-0.039,0.041,"[-0.039,0.041]",0.949,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,fluticasone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0013,-0.147,0.15,"[-0.147,0.15]",0.987,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0015924,fluticasone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.0011,-0.193,0.195,"[-0.193,0.195]",0.991,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004425,fluticasone,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,0.001,-0.36,0.362,"[-0.36,0.362]",0.995,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007818,fluticasone,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,6.00E-04,-0.043,0.044,"[-0.043,0.044]",0.98,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005302,fluticasone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,5.00E-04,-0.999,1.001,"[-0.999,1.001]",0.999,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0013282,fluticasone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,5.00E-04,-0.036,0.037,"[-0.036,0.037]",0.978,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0015564,fluticasone,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,4.00E-04,-2.63E+08,2.63E+08,"[-263000000,263000000]",1,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0007864,fluticasone,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,4.00E-04,-0.504,0.505,"[-0.504,0.505]",0.999,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0002316,fluticasone,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,4.00E-04,-0.349,0.35,"[-0.349,0.35]",0.998,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0010526,fluticasone,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,3.00E-04,-1.863,1.863,"[-1.863,1.863]",1,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004979,fluticasone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,2.00E-04,-0.916,0.917,"[-0.916,0.917]",1,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0004648,fluticasone,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,2.00E-04,-0.147,0.147,"[-0.147,0.147]",0.997,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0016218,fluticasone,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,1.00E-04,-0.374,0.375,"[-0.374,0.375]",0.999,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005404,fluticasone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,1.00E-04,-0.609,0.609,"[-0.609,0.609]",1,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252416,biolink:associated_with_increased_likelihood_of,MONDO:0005083,fluticasone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.849916059,6.06E-05,-0.411,0.411,"[-0.411,0.411]",1,5096700,18825100,23921800,"Sample size with fluticasone, approximately: 5096700","Sample size without fluticasone, approximately: 18825100",All patients number is approximately: 23921800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005302,fluphenazine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.3387,0.261,0.417,"[0.261,0.417]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0002406,fluphenazine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.324,0.282,0.366,"[0.282,0.366]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005009,fluphenazine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.3187,0.208,0.429,"[0.208,0.429]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0002277,fluphenazine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.2848,0.188,0.382,"[0.188,0.382]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005546,fluphenazine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.2661,0.146,0.386,"[0.146,0.386]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0007915,fluphenazine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.2566,0.146,0.367,"[0.146,0.367]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0004975,fluphenazine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.25,-0.055,0.555,"[-0.055,0.555]",0.108,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005294,fluphenazine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.2366,0.192,0.281,"[0.192,0.281]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,fluphenazine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.1637,0.124,0.203,"[0.124,0.203]",1.00E-04,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0007739,fluphenazine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.0391,-0.403,0.482,"[-0.403,0.482]",0.862,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005002,fluphenazine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.0384,-1.539,1.616,"[-1.539,1.616]",0.962,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3372,biolink:associated_with_increased_likelihood_of,MONDO:0005180,fluphenazine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.959675891,0.017,-0.943,0.977,"[-0.943,0.977]",0.972,18400,21783300,21801700,"Sample size with fluphenazine, approximately: 18400","Sample size without fluphenazine, approximately: 21783300",All patients number is approximately: 21801700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0019180,fluoxetine,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.8278,0.819,0.837,"[0.819,0.837]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0008542,fluoxetine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.7056,0.699,0.712,"[0.699,0.712]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0004952,fluoxetine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.574,0.567,0.581,"[0.567,0.581]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0008644,fluoxetine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.2738,0.265,0.282,"[0.265,0.282]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0008738,fluoxetine,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.2013,0.192,0.21,"[0.192,0.21]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005302,fluoxetine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1696,0.16,0.179,"[0.16,0.179]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0000424,fluoxetine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1518,0.142,0.162,"[0.142,0.162]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0019118,fluoxetine,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1499,0.135,0.165,"[0.135,0.165]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005392,fluoxetine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1124,0.1,0.125,"[0.1,0.125]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005083,fluoxetine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1108,0.082,0.14,"[0.082,0.14]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0004609,fluoxetine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1047,0.096,0.113,"[0.096,0.113]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0009891,fluoxetine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.1046,0.096,0.113,"[0.096,0.113]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0009693,fluoxetine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0875,0.059,0.116,"[0.059,0.116]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0016532,fluoxetine,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0866,0.074,0.099,"[0.074,0.099]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0008300,fluoxetine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0836,0.059,0.108,"[0.059,0.108]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005404,fluoxetine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.07,0.041,0.099,"[0.041,0.099]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0007027,fluoxetine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0688,0.06,0.077,"[0.06,0.077]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0007739,fluoxetine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0636,0.001,0.126,"[0.001,0.126]",0.047,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0019369,fluoxetine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0636,0.034,0.093,"[0.034,0.093]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005393,fluoxetine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0617,0.049,0.074,"[0.049,0.074]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0021187,fluoxetine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0429,0.001,0.085,"[0.001,0.085]",0.046,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005009,fluoxetine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0347,0.024,0.046,"[0.024,0.046]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005146,fluoxetine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0326,0.021,0.044,"[0.021,0.044]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005306,fluoxetine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0294,-0.012,0.071,"[-0.012,0.071]",0.163,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0009061,fluoxetine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0242,0.003,0.045,"[0.003,0.045]",0.025,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0004981,fluoxetine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0234,-0.073,0.12,"[-0.073,0.12]",0.636,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0002869,fluoxetine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0215,0.011,0.032,"[0.011,0.032]",1.00E-04,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005148,fluoxetine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.02,-0.049,0.089,"[-0.049,0.089]",0.569,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005301,fluoxetine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0179,-0.025,0.061,"[-0.025,0.061]",0.415,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0043693,fluoxetine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0145,-0.055,0.085,"[-0.055,0.085]",0.684,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,fluoxetine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0103,-0.152,0.173,"[-0.152,0.173]",0.901,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0016218,fluoxetine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.009,-0.111,0.129,"[-0.111,0.129]",0.883,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005011,fluoxetine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0078,-0.076,0.091,"[-0.076,0.091]",0.855,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0019499,fluoxetine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0054,-0.161,0.171,"[-0.161,0.171]",0.949,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0004648,fluoxetine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0048,-0.114,0.123,"[-0.114,0.123]",0.937,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005010,fluoxetine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0033,-0.233,0.24,"[-0.233,0.24]",0.978,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005364,fluoxetine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0031,-0.003,0.009,"[-0.003,0.009]",0.308,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,fluoxetine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0017,-0.192,0.196,"[-0.192,0.196]",0.987,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0020066,fluoxetine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0017,-0.363,0.367,"[-0.363,0.367]",0.993,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0008678,fluoxetine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0015,-0.595,0.598,"[-0.595,0.598]",0.996,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0005298,fluoxetine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.0013,-0.297,0.299,"[-0.297,0.299]",0.993,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0007540,fluoxetine,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,0.001,-0.579,0.581,"[-0.579,0.581]",0.997,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,fluoxetine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,9.00E-04,-0.66,0.661,"[-0.66,0.661]",0.998,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,fluoxetine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,9.00E-04,-0.707,0.708,"[-0.707,0.708]",0.998,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0007843,fluoxetine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,6.00E-04,-0.312,0.313,"[-0.312,0.313]",0.997,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0002909,fluoxetine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,5.00E-04,-0.091,0.093,"[-0.091,0.093]",0.991,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0011786,fluoxetine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,3.00E-04,-0.461,0.461,"[-0.461,0.461]",0.999,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3386,biolink:associated_with_increased_likelihood_of,MONDO:0002316,fluoxetine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.815069069,2.00E-04,-0.171,0.171,"[-0.171,0.171]",0.998,1264900,21052700,22317600,"Sample size with fluoxetine, approximately: 1264900","Sample size without fluoxetine, approximately: 21052700",All patients number is approximately: 22317600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0000424,flunisolide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.5755,0.528,0.623,"[0.528,0.623]",1.00E-04,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0043693,flunisolide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.546,0.509,0.583,"[0.509,0.583]",1.00E-04,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0002909,flunisolide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.2935,0.26,0.327,"[0.26,0.327]",1.00E-04,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0009891,flunisolide,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0884,0.036,0.141,"[0.036,0.141]",0.001,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,flunisolide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.082,0.022,0.142,"[0.022,0.142]",0.007,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0008383,flunisolide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0633,0.007,0.12,"[0.007,0.12]",0.027,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0005300,flunisolide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.032,-0.005,0.069,"[-0.005,0.069]",0.092,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0021187,flunisolide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0205,-0.088,0.129,"[-0.088,0.129]",0.712,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,flunisolide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0046,-4.882,4.891,"[-4.882,4.891]",0.999,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0011786,flunisolide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0029,-0.244,0.25,"[-0.244,0.25]",0.982,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0004981,flunisolide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0023,-0.581,0.585,"[-0.581,0.585]",0.994,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0004975,flunisolide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0016,-0.372,0.375,"[-0.372,0.375]",0.993,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0255465,biolink:associated_with_increased_likelihood_of,MONDO:0004648,flunisolide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882179921,0.0015,-0.213,0.216,"[-0.213,0.216]",0.989,39700,21768400,21808100,"Sample size with flunisolide, approximately: 39700","Sample size without flunisolide, approximately: 21768400",All patients number is approximately: 21808100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252262,biolink:associated_with_increased_likelihood_of,MONDO:0021187,fingolimod,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903839683,0.508,0.024,0.992,"[0.024,0.992]",0.04,5600,21788400,21794000,"Sample size with fingolimod, approximately: 5600","Sample size without fingolimod, approximately: 21788400",All patients number is approximately: 21794000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252262,biolink:associated_with_increased_likelihood_of,MONDO:0005148,fingolimod,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903839683,0.0309,-0.697,0.759,"[-0.697,0.759]",0.934,5600,21788400,21794000,"Sample size with fingolimod, approximately: 5600","Sample size without fingolimod, approximately: 21788400",All patients number is approximately: 21794000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0005300,finerenone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,1.0086,0.92,1.097,"[0.92,1.097]",1.00E-04,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0004979,finerenone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0882,0.002,0.174,"[0.002,0.174]",0.044,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0005298,finerenone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0757,-0.822,0.974,"[-0.822,0.974]",0.869,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0007186,finerenone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0709,-0.171,0.313,"[-0.171,0.313]",0.566,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,finerenone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0431,-0.055,0.142,"[-0.055,0.142]",0.391,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0005149,finerenone,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0192,-0.906,0.944,"[-0.906,0.944]",0.968,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252261,biolink:associated_with_increased_likelihood_of,MONDO:0020066,finerenone,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962090126,0.0148,-0.505,0.535,"[-0.505,0.535]",0.956,10400,21786900,21797300,"Sample size with finerenone, approximately: 10400","Sample size without finerenone, approximately: 21786900",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0002046,fenofibrate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.8043,0.791,0.818,"[0.791,0.818]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0011122,fenofibrate,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.748,0.735,0.761,"[0.735,0.761]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0003620,fenofibrate,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.4774,0.468,0.487,"[0.468,0.487]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0002909,fenofibrate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.4415,0.43,0.453,"[0.43,0.453]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004425,fenofibrate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.2978,0.287,0.309,"[0.287,0.309]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005393,fenofibrate,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.283,0.266,0.3,"[0.266,0.3]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005002,fenofibrate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.2607,0.184,0.338,"[0.184,0.338]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005178,fenofibrate,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.2068,0.194,0.22,"[0.194,0.22]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005180,fenofibrate,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.2005,0.186,0.215,"[0.186,0.215]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005302,fenofibrate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.1691,0.154,0.184,"[0.154,0.184]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004975,fenofibrate,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.1609,0.145,0.177,"[0.145,0.177]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0018177,fenofibrate,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.1514,0.131,0.172,"[0.131,0.172]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005404,fenofibrate,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.1058,0.074,0.138,"[0.074,0.138]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0006694,fenofibrate,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0952,0.068,0.122,"[0.068,0.122]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,fenofibrate,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0675,0.055,0.08,"[0.055,0.08]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,fenofibrate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0598,0.031,0.089,"[0.031,0.089]",1.00E-04,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0011786,fenofibrate,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0594,0.006,0.113,"[0.006,0.113]",0.03,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0016532,fenofibrate,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0533,0.008,0.099,"[0.008,0.099]",0.021,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0011849,fenofibrate,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0513,0.019,0.084,"[0.019,0.084]",0.002,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005546,fenofibrate,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0323,0.003,0.061,"[0.003,0.061]",0.028,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0008487,fenofibrate,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0309,-0.033,0.095,"[-0.033,0.095]",0.344,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,fenofibrate,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0309,-0.041,0.103,"[-0.041,0.103]",0.4,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005101,fenofibrate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0268,-0.05,0.104,"[-0.05,0.104]",0.495,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004952,fenofibrate,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0112,-0.114,0.136,"[-0.114,0.136]",0.861,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005392,fenofibrate,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0096,-0.077,0.096,"[-0.077,0.096]",0.828,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0002277,fenofibrate,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0089,-0.128,0.146,"[-0.128,0.146]",0.898,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005146,fenofibrate,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.008,-0.239,0.255,"[-0.239,0.255]",0.949,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0015924,fenofibrate,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0075,-0.096,0.111,"[-0.096,0.111]",0.886,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004981,fenofibrate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0064,-0.152,0.165,"[-0.152,0.165]",0.937,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0021107,fenofibrate,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.006,-0.081,0.093,"[-0.081,0.093]",0.892,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0021187,fenofibrate,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0037,-0.295,0.302,"[-0.295,0.302]",0.98,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005300,fenofibrate,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0031,-0.08,0.086,"[-0.08,0.086]",0.941,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005149,fenofibrate,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0029,-0.097,0.103,"[-0.097,0.103]",0.955,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0007186,fenofibrate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0024,-0.119,0.124,"[-0.119,0.124]",0.969,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005130,fenofibrate,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.002,-0.216,0.22,"[-0.216,0.22]",0.986,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004979,fenofibrate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0017,-0.354,0.358,"[-0.354,0.358]",0.992,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0004609,fenofibrate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0016,-0.439,0.442,"[-0.439,0.442]",0.994,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005298,fenofibrate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0013,-0.367,0.37,"[-0.367,0.37]",0.995,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0011508,fenofibrate,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,0.0011,-0.114,0.116,"[-0.114,0.116]",0.985,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0005133,fenofibrate,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,7.00E-04,-0.592,0.594,"[-0.592,0.594]",0.998,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0009891,fenofibrate,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,7.00E-04,-0.091,0.092,"[-0.091,0.092]",0.989,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0000477,fenofibrate,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,6.00E-04,-0.392,0.394,"[-0.392,0.394]",0.997,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0252207,biolink:associated_with_increased_likelihood_of,MONDO:0018882,fenofibrate,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898408348,5.00E-04,-0.655,0.656,"[-0.655,0.656]",0.999,453900,21552000,22005900,"Sample size with fenofibrate, approximately: 453900","Sample size without fenofibrate, approximately: 21552000",All patients number is approximately: 22005900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005010,felodipine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,1.0718,1.045,1.098,"[1.045,1.098]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0003620,felodipine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.8611,0.839,0.883,"[0.839,0.883]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,felodipine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.6487,0.626,0.671,"[0.626,0.671]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0004609,felodipine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.572,0.55,0.594,"[0.55,0.594]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0043693,felodipine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.4303,0.405,0.456,"[0.405,0.456]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0000424,felodipine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.4238,0.392,0.456,"[0.392,0.456]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0008399,felodipine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.3688,0.332,0.406,"[0.332,0.406]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0008599,felodipine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.3445,0.314,0.375,"[0.314,0.375]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005148,felodipine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.3033,0.274,0.333,"[0.274,0.333]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0009693,felodipine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.2649,0.229,0.3,"[0.229,0.3]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0002909,felodipine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.2258,0.188,0.263,"[0.188,0.263]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005300,felodipine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.1908,0.147,0.235,"[0.147,0.235]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005302,felodipine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.1159,0.062,0.17,"[0.062,0.17]",1.00E-04,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0011786,felodipine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0839,0.017,0.15,"[0.017,0.15]",0.013,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005392,felodipine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0661,0.016,0.116,"[0.016,0.116]",0.01,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0007186,felodipine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0534,-0.077,0.184,"[-0.077,0.184]",0.422,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005393,felodipine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0304,0.002,0.059,"[0.002,0.059]",0.035,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005083,felodipine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0188,-0.199,0.236,"[-0.199,0.236]",0.865,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0007739,felodipine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0112,-0.143,0.166,"[-0.143,0.166]",0.887,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0004981,felodipine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0083,-0.153,0.17,"[-0.153,0.17]",0.92,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0005011,felodipine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.003,-0.467,0.473,"[-0.467,0.473]",0.99,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,felodipine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0022,-0.212,0.217,"[-0.212,0.217]",0.984,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0002277,felodipine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,0.0015,-0.739,0.742,"[-0.739,0.742]",0.997,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3333,biolink:associated_with_increased_likelihood_of,MONDO:0002046,felodipine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911012077,3.00E-04,-0.219,0.219,"[-0.219,0.219]",0.998,73000,21752400,21825400,"Sample size with felodipine, approximately: 73000","Sample size without felodipine, approximately: 21752400",All patients number is approximately: 21825400,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,factor viii,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.5676,0.409,0.726,"[0.409,0.726]",1.00E-04,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0003620,factor viii,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.3896,0.135,0.644,"[0.135,0.644]",0.003,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0005300,factor viii,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.2728,0.03,0.516,"[0.03,0.516]",0.028,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0005009,factor viii,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.2601,0.117,0.403,"[0.117,0.403]",1.00E-04,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0002277,factor viii,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.1493,-0.075,0.373,"[-0.075,0.373]",0.192,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0010602,factor viii,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.0469,-0.874,0.968,"[-0.874,0.968]",0.92,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0005148,factor viii,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.0299,-0.711,0.771,"[-0.711,0.771]",0.937,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2157,biolink:associated_with_increased_likelihood_of,MONDO:0005146,factor viii,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.962525491,0.0225,-0.744,0.789,"[-0.744,0.789]",0.954,4900,21790200,21795100,"Sample size with factor viii, approximately: 4900","Sample size without factor viii, approximately: 21790200",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005180,factor ix,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,2.3814,2.366,2.397,"[2.366,2.397]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0002909,factor ix,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,1.1034,1.088,1.118,"[1.088,1.118]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,factor ix,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.771,0.758,0.784,"[0.758,0.784]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0010602,factor ix,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.693,0.676,0.709,"[0.676,0.709]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0019565,factor ix,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.5025,0.482,0.523,"[0.482,0.523]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005147,factor ix,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.4359,0.423,0.449,"[0.423,0.449]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005392,factor ix,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.2497,0.225,0.274,"[0.225,0.274]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0008644,factor ix,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.202,0.189,0.215,"[0.189,0.215]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0006694,factor ix,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1813,0.167,0.195,"[0.167,0.195]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0007027,factor ix,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1785,0.163,0.194,"[0.163,0.194]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0004609,factor ix,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1647,0.15,0.179,"[0.15,0.179]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0002046,factor ix,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1513,0.102,0.2,"[0.102,0.2]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0004981,factor ix,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1222,0.085,0.159,"[0.085,0.159]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0011508,factor ix,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1192,0.092,0.146,"[0.092,0.146]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0013282,factor ix,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.1135,0.082,0.145,"[0.082,0.145]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005002,factor ix,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0926,0.066,0.119,"[0.066,0.119]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005083,factor ix,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0864,0.045,0.128,"[0.045,0.128]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0000153,factor ix,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.049,-0.014,0.112,"[-0.014,0.112]",0.126,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0009693,factor ix,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0485,0.009,0.088,"[0.009,0.088]",0.017,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0007915,factor ix,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0431,-0.019,0.105,"[-0.019,0.105]",0.172,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0021187,factor ix,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0412,0.02,0.063,"[0.02,0.063]",1.00E-04,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005546,factor ix,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0309,-0.011,0.072,"[-0.011,0.072]",0.144,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0002316,factor ix,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0148,-0.137,0.167,"[-0.137,0.167]",0.849,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0002869,factor ix,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0139,-0.234,0.262,"[-0.234,0.262]",0.913,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005364,factor ix,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0128,-0.205,0.231,"[-0.205,0.231]",0.908,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005130,factor ix,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0062,-0.17,0.182,"[-0.17,0.182]",0.945,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0000424,factor ix,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0058,-0.008,0.02,"[-0.008,0.02]",0.418,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0005011,factor ix,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,0.0025,-0.231,0.236,"[-0.231,0.236]",0.983,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
NCBIGene:2158,biolink:associated_with_increased_likelihood_of,MONDO:0021107,factor ix,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.986079699,1.00E-04,-0.238,0.238,"[-0.238,0.238]",0.999,276600,21727100,22003700,"Sample size with factor ix, approximately: 276600","Sample size without factor ix, approximately: 21727100",All patients number is approximately: 22003700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0003620,exenatide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.8334,0.809,0.858,"[0.809,0.858]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005178,exenatide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.3785,0.343,0.414,"[0.343,0.414]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005147,exenatide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.3026,0.271,0.334,"[0.271,0.334]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005010,exenatide,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.2784,0.245,0.312,"[0.245,0.312]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0008487,exenatide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.2735,0.242,0.305,"[0.242,0.305]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0007027,exenatide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.2586,0.217,0.3,"[0.217,0.3]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005300,exenatide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.1527,0.098,0.207,"[0.098,0.207]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0004975,exenatide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.1332,0.085,0.181,"[0.085,0.181]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005393,exenatide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.1255,0.078,0.173,"[0.078,0.173]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0043693,exenatide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0755,0.044,0.107,"[0.044,0.107]",1.00E-04,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0019369,exenatide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0656,0.003,0.129,"[0.003,0.129]",0.041,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0006694,exenatide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0629,0.016,0.11,"[0.016,0.11]",0.009,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0021187,exenatide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0608,0.021,0.1,"[0.021,0.1]",0.003,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0011786,exenatide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0486,-0.014,0.111,"[-0.014,0.111]",0.129,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0004425,exenatide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0417,-0.133,0.216,"[-0.133,0.216]",0.639,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,exenatide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0165,-0.089,0.122,"[-0.089,0.122]",0.759,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005101,exenatide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0148,-0.195,0.224,"[-0.195,0.224]",0.89,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0004609,exenatide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0126,-0.159,0.184,"[-0.159,0.184]",0.886,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0011122,exenatide,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0115,-0.03,0.053,"[-0.03,0.053]",0.589,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0007186,exenatide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0113,-0.09,0.113,"[-0.09,0.113]",0.828,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005294,exenatide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0106,-0.722,0.743,"[-0.722,0.743]",0.977,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005302,exenatide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0068,-0.248,0.262,"[-0.248,0.262]",0.958,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,exenatide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0041,-1.086,1.094,"[-1.086,1.094]",0.994,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0004981,exenatide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.0032,-0.177,0.184,"[-0.177,0.184]",0.972,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0018177,exenatide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,0.003,-0.146,0.152,"[-0.146,0.152]",0.968,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,exenatide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,7.00E-04,-0.948,0.949,"[-0.948,0.949]",0.999,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0009693,exenatide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,5.00E-04,-0.079,0.08,"[-0.079,0.08]",0.99,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:45588096,biolink:associated_with_increased_likelihood_of,MONDO:0005298,exenatide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.933373978,5.00E-04,-0.579,0.58,"[-0.579,0.58]",0.999,72900,21751100,21824000,"Sample size with exenatide, approximately: 72900","Sample size without exenatide, approximately: 21751100",All patients number is approximately: 21824000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005009,evolocumab,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,1.0237,1.001,1.046,"[1.001,1.046]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005300,evolocumab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.6278,0.603,0.653,"[0.603,0.653]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005011,evolocumab,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.3205,0.271,0.37,"[0.271,0.37]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005393,evolocumab,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.2774,0.233,0.321,"[0.233,0.321]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005180,evolocumab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.1796,0.097,0.262,"[0.097,0.262]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005294,evolocumab,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.1489,-0.16,0.457,"[-0.16,0.457]",0.344,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005002,evolocumab,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.1428,0.039,0.247,"[0.039,0.247]",0.007,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0043693,evolocumab,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.1381,0.106,0.17,"[0.106,0.17]",1.00E-04,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005392,evolocumab,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0657,-0.026,0.158,"[-0.026,0.158]",0.162,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0004648,evolocumab,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0461,-0.431,0.523,"[-0.431,0.523]",0.85,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005101,evolocumab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0432,-0.069,0.155,"[-0.069,0.155]",0.451,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005302,evolocumab,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0404,-0.099,0.18,"[-0.099,0.18]",0.57,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0011786,evolocumab,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.039,-0.036,0.114,"[-0.036,0.114]",0.31,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0002277,evolocumab,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0343,-0.043,0.112,"[-0.043,0.112]",0.385,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0003620,evolocumab,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0227,-0.303,0.348,"[-0.303,0.348]",0.891,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0002909,evolocumab,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,0.0197,-0.207,0.246,"[-0.207,0.246]",0.864,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2364655,biolink:associated_with_increased_likelihood_of,MONDO:0005306,evolocumab,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911509395,3.00E-04,-0.804,0.804,"[-0.804,0.804]",0.999,66200,21754000,21820200,"Sample size with evolocumab, approximately: 66200","Sample size without evolocumab, approximately: 21754000",All patients number is approximately: 21820200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:193962,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,etravirine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.996227096,0.0076,-8034.036,8034.051,"[-8034.036,8034.051]",1,2800,21790900,21793700,"Sample size with etravirine, approximately: 2800","Sample size without etravirine, approximately: 21790900",All patients number is approximately: 21793700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0005010,ethacrynate,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,1.1632,1.109,1.218,"[1.109,1.218]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0005302,ethacrynate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.4638,0.424,0.504,"[0.424,0.504]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0007027,ethacrynate,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.3536,0.315,0.393,"[0.315,0.393]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ethacrynate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.2129,0.168,0.258,"[0.168,0.258]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0004425,ethacrynate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.1896,0.151,0.228,"[0.151,0.228]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ethacrynate,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.1752,0.119,0.231,"[0.119,0.231]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0005148,ethacrynate,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.1708,0.106,0.235,"[0.106,0.235]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0007915,ethacrynate,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.1103,0.05,0.171,"[0.05,0.171]",1.00E-04,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ethacrynate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.0996,-0.016,0.215,"[-0.016,0.215]",0.09,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,ethacrynate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.083,-0.17,0.336,"[-0.17,0.336]",0.521,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0011122,ethacrynate,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.0809,-0.054,0.215,"[-0.054,0.215]",0.238,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ethacrynate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.0285,-0.186,0.243,"[-0.186,0.243]",0.794,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3278,biolink:associated_with_increased_likelihood_of,MONDO:0008383,ethacrynate,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.96055553,0.0037,-1.01,1.017,"[-1.01,1.017]",0.994,20800,21785000,21805800,"Sample size with ethacrynate, approximately: 20800","Sample size without ethacrynate, approximately: 21785000",All patients number is approximately: 21805800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0008399,etanercept,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.4184,0.358,0.479,"[0.358,0.479]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005133,etanercept,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.3978,0.258,0.538,"[0.258,0.538]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005180,etanercept,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.3177,0.258,0.378,"[0.258,0.378]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0043693,etanercept,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.2839,0.228,0.34,"[0.228,0.34]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0009693,etanercept,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.2828,0.231,0.334,"[0.231,0.334]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005011,etanercept,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.2804,-0.033,0.594,"[-0.033,0.594]",0.079,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005302,etanercept,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.1626,0.112,0.213,"[0.112,0.213]",1.00E-04,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,etanercept,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.1316,0.04,0.223,"[0.04,0.223]",0.005,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005010,etanercept,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0778,0.008,0.148,"[0.008,0.148]",0.03,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0004979,etanercept,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0461,-0.15,0.242,"[-0.15,0.242]",0.644,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005300,etanercept,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0346,-0.359,0.428,"[-0.359,0.428]",0.863,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005146,etanercept,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0233,-0.08,0.126,"[-0.08,0.126]",0.658,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0002046,etanercept,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0219,-0.491,0.535,"[-0.491,0.535]",0.933,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,etanercept,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0208,-0.141,0.182,"[-0.141,0.182]",0.801,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005298,etanercept,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0177,-0.452,0.487,"[-0.452,0.487]",0.941,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0002277,etanercept,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0149,-0.154,0.183,"[-0.154,0.183]",0.862,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0019369,etanercept,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0145,-0.632,0.661,"[-0.632,0.661]",0.965,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0007915,etanercept,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.005,-0.32,0.33,"[-0.32,0.33]",0.976,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0002909,etanercept,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0035,-1.019,1.026,"[-1.019,1.026]",0.995,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005083,etanercept,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0033,-0.25,0.256,"[-0.25,0.256]",0.98,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005149,etanercept,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0031,-0.221,0.227,"[-0.221,0.227]",0.979,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0004981,etanercept,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0022,-0.606,0.61,"[-0.606,0.61]",0.994,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:4875,biolink:associated_with_increased_likelihood_of,MONDO:0005294,etanercept,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897550201,0.0016,-0.553,0.556,"[-0.553,0.556]",0.996,58300,21756800,21815100,"Sample size with etanercept, approximately: 58300","Sample size without etanercept, approximately: 21756800",All patients number is approximately: 21815100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005302,esmolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,1.231,1.219,1.243,"[1.219,1.243]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005392,esmolol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.9054,0.892,0.918,"[0.892,0.918]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0015263,esmolol,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.6597,0.645,0.674,"[0.645,0.674]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0018882,esmolol,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.6506,0.637,0.664,"[0.637,0.664]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0000424,esmolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.5595,0.544,0.575,"[0.544,0.575]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0011508,esmolol,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.3905,0.377,0.404,"[0.377,0.404]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0002909,esmolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.2716,0.258,0.285,"[0.258,0.285]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005178,esmolol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.2326,0.218,0.247,"[0.218,0.247]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005002,esmolol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.1989,0.172,0.226,"[0.172,0.226]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005388,esmolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.1257,0.108,0.143,"[0.108,0.143]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0008399,esmolol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.1178,0.102,0.134,"[0.102,0.134]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,esmolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0936,0.081,0.106,"[0.081,0.106]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0006694,esmolol,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0901,0.075,0.105,"[0.075,0.105]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0018177,esmolol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0558,0.037,0.074,"[0.037,0.074]",1.00E-04,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0008487,esmolol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0537,-0.03,0.138,"[-0.03,0.138]",0.21,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005146,esmolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0513,-0.057,0.159,"[-0.057,0.159]",0.352,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0004981,esmolol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0275,-0.008,0.063,"[-0.008,0.063]",0.127,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0011849,esmolol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0268,0.003,0.05,"[0.003,0.05]",0.027,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005083,esmolol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0252,-0.025,0.075,"[-0.025,0.075]",0.323,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0007915,esmolol,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0251,-0.045,0.095,"[-0.045,0.095]",0.48,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0000153,esmolol,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0179,-0.047,0.083,"[-0.047,0.083]",0.587,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,esmolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.01,-0.241,0.261,"[-0.241,0.261]",0.938,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005011,esmolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0085,-0.156,0.173,"[-0.156,0.173]",0.92,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0008678,esmolol,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0031,-0.281,0.287,"[-0.281,0.287]",0.983,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0004648,esmolol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0026,-0.177,0.182,"[-0.177,0.182]",0.977,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0004425,esmolol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0016,-0.599,0.602,"[-0.599,0.602]",0.996,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005133,esmolol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0012,-0.222,0.224,"[-0.222,0.224]",0.992,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0010526,esmolol,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,0.0012,-0.373,0.375,"[-0.373,0.375]",0.995,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0005009,esmolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,5.00E-04,-0.483,0.484,"[-0.483,0.484]",0.999,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:59768,biolink:associated_with_increased_likelihood_of,MONDO:0002869,esmolol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92871946,2.98E-05,-0.319,0.319,"[-0.319,0.319]",1,348700,21581300,21930000,"Sample size with esmolol, approximately: 348700","Sample size without esmolol, approximately: 21581300",All patients number is approximately: 21930000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:182137,biolink:associated_with_increased_likelihood_of,MONDO:0018882,esketamine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.935313552,0.0381,-0.259,0.335,"[-0.259,0.335]",0.802,2900,21790600,21793500,"Sample size with esketamine, approximately: 2900","Sample size without esketamine, approximately: 21790600",All patients number is approximately: 21793500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008542,escitalopram,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.6802,0.674,0.686,"[0.674,0.686]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005133,escitalopram,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.5314,0.525,0.537,"[0.525,0.537]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0018177,escitalopram,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.5097,0.501,0.518,"[0.501,0.518]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008300,escitalopram,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.5082,0.493,0.523,"[0.493,0.523]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004952,escitalopram,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.4496,0.444,0.456,"[0.444,0.456]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005146,escitalopram,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.4112,0.401,0.421,"[0.401,0.421]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008644,escitalopram,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.3147,0.307,0.322,"[0.307,0.322]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0011786,escitalopram,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.3084,0.301,0.316,"[0.301,0.316]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,escitalopram,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.2702,0.264,0.277,"[0.264,0.277]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004975,escitalopram,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.2132,0.204,0.222,"[0.204,0.222]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0002406,escitalopram,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.2062,0.188,0.225,"[0.188,0.225]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0007186,escitalopram,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1846,0.165,0.204,"[0.165,0.204]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005083,escitalopram,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1797,0.162,0.198,"[0.162,0.198]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0019180,escitalopram,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1659,0.145,0.187,"[0.145,0.187]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0009891,escitalopram,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1539,0.144,0.164,"[0.144,0.164]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005180,escitalopram,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1445,0.133,0.156,"[0.133,0.156]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,escitalopram,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1408,0.133,0.148,"[0.133,0.148]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0016532,escitalopram,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1305,0.12,0.141,"[0.12,0.141]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005149,escitalopram,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1201,0.091,0.15,"[0.091,0.15]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0011429,escitalopram,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1174,0.077,0.158,"[0.077,0.158]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005011,escitalopram,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.1029,0.085,0.121,"[0.085,0.121]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0000424,escitalopram,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0937,0.085,0.103,"[0.085,0.103]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0002316,escitalopram,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0871,0.057,0.117,"[0.057,0.117]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0015564,escitalopram,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0599,0.021,0.099,"[0.021,0.099]",0.002,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0019499,escitalopram,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0586,0.042,0.075,"[0.042,0.075]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005002,escitalopram,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0518,0.03,0.073,"[0.03,0.073]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005546,escitalopram,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0486,0.035,0.062,"[0.035,0.062]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0021187,escitalopram,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0468,0.006,0.088,"[0.006,0.088]",0.026,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005404,escitalopram,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0431,0.014,0.073,"[0.014,0.073]",0.004,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008642,escitalopram,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0422,-0.004,0.089,"[-0.004,0.089]",0.076,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0019118,escitalopram,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0349,-0.005,0.075,"[-0.005,0.075]",0.089,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0009693,escitalopram,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0326,0.015,0.051,"[0.015,0.051]",1.00E-04,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004981,escitalopram,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0305,-0.054,0.115,"[-0.054,0.115]",0.479,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0010383,escitalopram,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0246,-0.007,0.057,"[-0.007,0.057]",0.132,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0043693,escitalopram,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0217,-0.04,0.083,"[-0.04,0.083]",0.488,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0018975,escitalopram,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0203,-0.004,0.045,"[-0.004,0.045]",0.108,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0019565,escitalopram,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0191,-0.029,0.067,"[-0.029,0.067]",0.434,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0020066,escitalopram,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0153,-0.072,0.102,"[-0.072,0.102]",0.73,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008006,escitalopram,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0147,-0.082,0.112,"[-0.082,0.112]",0.767,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004648,escitalopram,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0124,-0.037,0.062,"[-0.037,0.062]",0.624,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0007947,escitalopram,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0123,-0.025,0.05,"[-0.025,0.05]",0.522,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0002277,escitalopram,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0098,-0.09,0.11,"[-0.09,0.11]",0.847,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005302,escitalopram,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0097,-0.061,0.08,"[-0.061,0.08]",0.787,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0008599,escitalopram,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0095,-0.001,0.02,"[-0.001,0.02]",0.068,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004979,escitalopram,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0091,-0.03,0.048,"[-0.03,0.048]",0.648,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0007827,escitalopram,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.007,-0.11,0.124,"[-0.11,0.124]",0.906,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0002909,escitalopram,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0034,-0.325,0.332,"[-0.325,0.332]",0.984,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0002869,escitalopram,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0033,-0.119,0.126,"[-0.119,0.126]",0.958,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0004609,escitalopram,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0029,-0.183,0.189,"[-0.183,0.189]",0.975,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,escitalopram,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,0.0015,-0.2,0.203,"[-0.2,0.203]",0.988,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:146570,biolink:associated_with_increased_likelihood_of,MONDO:0005298,escitalopram,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.811466305,2.00E-04,-0.297,0.297,"[-0.297,0.297]",0.999,1489900,20937600,22427500,"Sample size with escitalopram, approximately: 1489900","Sample size without escitalopram, approximately: 20937600",All patients number is approximately: 22427500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,ertugliflozin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,1.4639,1.426,1.501,"[1.426,1.501]",1.00E-04,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005298,ertugliflozin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,1.2586,1.221,1.296,"[1.221,1.296]",1.00E-04,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0007027,ertugliflozin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.3741,0.315,0.433,"[0.315,0.433]",1.00E-04,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0007186,ertugliflozin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.1829,0.096,0.27,"[0.096,0.27]",1.00E-04,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0002406,ertugliflozin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.1474,0.094,0.2,"[0.094,0.2]",1.00E-04,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0004979,ertugliflozin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0958,-0.089,0.281,"[-0.089,0.281]",0.31,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005147,ertugliflozin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0781,-0.145,0.301,"[-0.145,0.301]",0.493,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0000424,ertugliflozin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0639,-0.453,0.581,"[-0.453,0.581]",0.808,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005300,ertugliflozin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0597,-0.19,0.31,"[-0.19,0.31]",0.639,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005149,ertugliflozin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0466,-0.03,0.123,"[-0.03,0.123]",0.235,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005178,ertugliflozin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0057,-0.447,0.459,"[-0.447,0.459]",0.98,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0005009,ertugliflozin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0047,-0.825,0.834,"[-0.825,0.834]",0.991,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251923,biolink:associated_with_increased_likelihood_of,MONDO:0002909,ertugliflozin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.966162864,0.0022,-0.124,0.128,"[-0.124,0.128]",0.973,17200,21783900,21801100,"Sample size with ertugliflozin, approximately: 17200","Sample size without ertugliflozin, approximately: 21783900",All patients number is approximately: 21801100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0002277,eplerenone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,1.2904,1.264,1.317,"[1.264,1.317]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,eplerenone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.8515,0.829,0.874,"[0.829,0.874]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0007186,eplerenone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.7289,0.708,0.75,"[0.708,0.75]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0003620,eplerenone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.6509,0.63,0.672,"[0.63,0.672]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0007027,eplerenone,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.5,0.479,0.521,"[0.479,0.521]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0011508,eplerenone,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.4479,0.424,0.472,"[0.424,0.472]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0008542,eplerenone,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.2015,0.174,0.229,"[0.174,0.229]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0019350,eplerenone,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.1713,0.146,0.196,"[0.146,0.196]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0010602,eplerenone,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.1523,0.124,0.18,"[0.124,0.18]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005178,eplerenone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.1441,0.121,0.167,"[0.121,0.167]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005101,eplerenone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.1367,0.064,0.209,"[0.064,0.209]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005011,eplerenone,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0914,0.048,0.134,"[0.048,0.134]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0008599,eplerenone,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.072,0.046,0.098,"[0.046,0.098]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0011122,eplerenone,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.071,0.047,0.095,"[0.047,0.095]",1.00E-04,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0008383,eplerenone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0682,-0.02,0.157,"[-0.02,0.157]",0.131,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005301,eplerenone,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0491,0.008,0.09,"[0.008,0.09]",0.018,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0007915,eplerenone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0409,-0.087,0.169,"[-0.087,0.169]",0.532,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005393,eplerenone,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0262,-0.013,0.066,"[-0.013,0.066]",0.194,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005149,eplerenone,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0249,-0.145,0.195,"[-0.145,0.195]",0.774,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0021187,eplerenone,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0232,-0.017,0.064,"[-0.017,0.064]",0.263,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005300,eplerenone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0141,-0.307,0.335,"[-0.307,0.335]",0.932,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005388,eplerenone,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0095,-0.138,0.157,"[-0.138,0.157]",0.899,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0015924,eplerenone,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0061,-0.281,0.293,"[-0.281,0.293]",0.967,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005010,eplerenone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0058,-0.24,0.252,"[-0.24,0.252]",0.963,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0002046,eplerenone,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0031,-0.246,0.252,"[-0.246,0.252]",0.98,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005146,eplerenone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0019,-0.244,0.248,"[-0.244,0.248]",0.988,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:443872,biolink:associated_with_increased_likelihood_of,MONDO:0005009,eplerenone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.954106013,0.0015,-0.413,0.416,"[-0.413,0.416]",0.994,83200,21762200,21845400,"Sample size with eplerenone, approximately: 83200","Sample size without eplerenone, approximately: 21762200",All patients number is approximately: 21845400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0005298,entecavir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.8247,0.755,0.895,"[0.755,0.895]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0005147,entecavir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.484,0.426,0.542,"[0.426,0.542]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,entecavir,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.4785,0.409,0.548,"[0.409,0.548]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0005178,entecavir,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.2816,0.217,0.346,"[0.217,0.346]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,entecavir,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.2601,0.155,0.365,"[0.155,0.365]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0005101,entecavir,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.207,0.102,0.312,"[0.102,0.312]",1.00E-04,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0008383,entecavir,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.1411,0.025,0.257,"[0.025,0.257]",0.017,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0000424,entecavir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0633,-0.011,0.137,"[-0.011,0.137]",0.093,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0009693,entecavir,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0605,-0.016,0.137,"[-0.016,0.137]",0.123,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0011786,entecavir,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0554,-0.086,0.197,"[-0.086,0.197]",0.443,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0004981,entecavir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0379,-0.789,0.864,"[-0.789,0.864]",0.928,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0005002,entecavir,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0361,-0.569,0.641,"[-0.569,0.641]",0.907,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0018882,entecavir,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0268,-0.715,0.769,"[-0.715,0.769]",0.943,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0002909,entecavir,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0076,-0.274,0.289,"[-0.274,0.289]",0.958,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0004975,entecavir,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0043,-8413.932,8413.941,"[-8413.932,8413.941]",1,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398508,biolink:associated_with_increased_likelihood_of,MONDO:0004609,entecavir,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.908445324,0.0016,-0.861,0.864,"[-0.861,0.864]",0.997,18200,21782700,21800900,"Sample size with entecavir, approximately: 18200","Sample size without entecavir, approximately: 21782700",All patients number is approximately: 21800900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005002,emtricitabine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,1.4207,1.302,1.539,"[1.302,1.539]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005300,emtricitabine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,1.403,1.369,1.437,"[1.369,1.437]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0002406,emtricitabine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,1.0596,1.025,1.094,"[1.025,1.094]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0007186,emtricitabine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.6019,0.538,0.666,"[0.538,0.666]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0043693,emtricitabine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.6017,0.56,0.643,"[0.56,0.643]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005393,emtricitabine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.5251,0.483,0.567,"[0.483,0.567]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0007027,emtricitabine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.5251,0.488,0.562,"[0.488,0.562]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0008599,emtricitabine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.4665,0.415,0.518,"[0.415,0.518]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0002277,emtricitabine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.352,0.263,0.441,"[0.263,0.441]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0004952,emtricitabine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.3244,0.172,0.477,"[0.172,0.477]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0009693,emtricitabine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.1921,0.131,0.253,"[0.131,0.253]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005083,emtricitabine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.1778,0.082,0.273,"[0.082,0.273]",1.00E-04,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005146,emtricitabine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.1745,-0.127,0.476,"[-0.127,0.476]",0.256,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0011849,emtricitabine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0961,-0.005,0.197,"[-0.005,0.197]",0.062,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0004975,emtricitabine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.071,-0.036,0.178,"[-0.036,0.178]",0.195,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0000424,emtricitabine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0559,-0.125,0.237,"[-0.125,0.237]",0.545,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005298,emtricitabine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0474,-0.401,0.496,"[-0.401,0.496]",0.836,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0004425,emtricitabine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0202,-0.21,0.25,"[-0.21,0.25]",0.863,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0003620,emtricitabine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0133,-0.445,0.472,"[-0.445,0.472]",0.955,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0002046,emtricitabine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0098,-0.887,0.906,"[-0.887,0.906]",0.983,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,emtricitabine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0098,-0.293,0.313,"[-0.293,0.313]",0.949,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0018882,emtricitabine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0096,-0.283,0.302,"[-0.283,0.302]",0.949,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0004979,emtricitabine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0082,-0.273,0.289,"[-0.273,0.289]",0.954,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005392,emtricitabine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.008,-0.623,0.639,"[-0.623,0.639]",0.98,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0002909,emtricitabine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,0.0029,-3.333,3.338,"[-3.333,3.338]",0.999,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60877,biolink:associated_with_increased_likelihood_of,MONDO:0005133,emtricitabine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.999348293,8.61E-05,-0.655,0.655,"[-0.655,0.655]",1,109500,21716100,21825600,"Sample size with emtricitabine, approximately: 109500","Sample size without emtricitabine, approximately: 21716100",All patients number is approximately: 21825600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0002046,empagliflozin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.9334,0.915,0.951,"[0.915,0.951]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0004609,empagliflozin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.7421,0.733,0.751,"[0.733,0.751]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0018882,empagliflozin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.4852,0.474,0.496,"[0.474,0.496]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005010,empagliflozin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.3737,0.36,0.387,"[0.36,0.387]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,empagliflozin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.3708,0.341,0.401,"[0.341,0.401]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005302,empagliflozin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.3221,0.298,0.346,"[0.298,0.346]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005306,empagliflozin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.2606,0.247,0.274,"[0.247,0.274]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0018177,empagliflozin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.2207,0.206,0.236,"[0.206,0.236]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005101,empagliflozin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.1769,0.159,0.195,"[0.159,0.195]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0008487,empagliflozin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.1447,0.098,0.191,"[0.098,0.191]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0008377,empagliflozin,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.1204,0.104,0.137,"[0.104,0.137]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0004975,empagliflozin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0703,0.027,0.114,"[0.027,0.114]",0.002,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,empagliflozin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0703,0.052,0.088,"[0.052,0.088]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0043693,empagliflozin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0649,0.053,0.077,"[0.053,0.077]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005393,empagliflozin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.061,0.025,0.097,"[0.025,0.097]",0.001,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005011,empagliflozin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0607,0.04,0.081,"[0.04,0.081]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0020066,empagliflozin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0523,0.036,0.069,"[0.036,0.069]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005002,empagliflozin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0496,0.013,0.086,"[0.013,0.086]",0.007,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0002909,empagliflozin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0366,0.024,0.049,"[0.024,0.049]",1.00E-04,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005300,empagliflozin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0262,-0.06,0.112,"[-0.06,0.112]",0.551,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0003620,empagliflozin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0247,-0.105,0.155,"[-0.105,0.155]",0.71,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0002277,empagliflozin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0244,-0.087,0.136,"[-0.087,0.136]",0.667,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0002406,empagliflozin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0241,-0.035,0.084,"[-0.035,0.084]",0.428,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0004952,empagliflozin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0235,-0.025,0.072,"[-0.025,0.072]",0.347,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0001516,empagliflozin,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0172,-0.001,0.035,"[-0.001,0.035]",0.065,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0015924,empagliflozin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0097,-0.057,0.077,"[-0.057,0.077]",0.778,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0011508,empagliflozin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0076,-0.203,0.218,"[-0.203,0.218]",0.943,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,empagliflozin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0065,-0.039,0.051,"[-0.039,0.051]",0.779,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0008542,empagliflozin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0061,-0.169,0.181,"[-0.169,0.181]",0.946,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0011786,empagliflozin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0047,-0.11,0.12,"[-0.11,0.12]",0.937,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0013282,empagliflozin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0037,-0.118,0.126,"[-0.118,0.126]",0.953,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005364,empagliflozin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.003,-0.137,0.143,"[-0.137,0.143]",0.966,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0019118,empagliflozin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0027,-0.192,0.198,"[-0.192,0.198]",0.978,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005146,empagliflozin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.002,-0.054,0.058,"[-0.054,0.058]",0.945,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0005388,empagliflozin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0014,-0.241,0.244,"[-0.241,0.244]",0.991,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0002316,empagliflozin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.0012,-0.098,0.1,"[-0.098,0.1]",0.981,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0021107,empagliflozin,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,0.001,-0.075,0.077,"[-0.075,0.077]",0.979,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251778,biolink:associated_with_increased_likelihood_of,MONDO:0004979,empagliflozin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.94687343,6.00E-04,-0.153,0.154,"[-0.153,0.154]",0.994,687900,21456400,22144300,"Sample size with empagliflozin, approximately: 687900","Sample size without empagliflozin, approximately: 21456400",All patients number is approximately: 22144300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0003620,efavirenz,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.2182,0.068,0.368,"[0.068,0.368]",0.004,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0002869,efavirenz,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.1886,-0.131,0.508,"[-0.131,0.508]",0.248,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0005146,efavirenz,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.1477,-0.109,0.404,"[-0.109,0.404]",0.259,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0005392,efavirenz,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.1385,-0.141,0.419,"[-0.141,0.419]",0.332,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0005180,efavirenz,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.094,-0.102,0.29,"[-0.102,0.29]",0.347,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0007186,efavirenz,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.0181,-6.499,6.536,"[-6.499,6.536]",0.996,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0005294,efavirenz,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.0172,-0.679,0.714,"[-0.679,0.714]",0.961,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:64139,biolink:associated_with_increased_likelihood_of,MONDO:0009693,efavirenz,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995343853,0.0093,-1.645,1.664,"[-1.645,1.664]",0.991,9500,21785600,21795100,"Sample size with efavirenz, approximately: 9500","Sample size without efavirenz, approximately: 21785600",All patients number is approximately: 21795100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002406,duloxetine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.714,0.708,0.72,"[0.708,0.72]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005306,duloxetine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.5319,0.523,0.541,"[0.523,0.541]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002909,duloxetine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.328,0.32,0.336,"[0.32,0.336]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0800026,duloxetine,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.2301,0.223,0.238,"[0.223,0.238]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0018882,duloxetine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.2206,0.213,0.228,"[0.213,0.228]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005002,duloxetine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.2182,0.21,0.227,"[0.21,0.227]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005404,duloxetine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.1788,0.169,0.188,"[0.169,0.188]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005101,duloxetine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.1515,0.139,0.164,"[0.139,0.164]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0000914,duloxetine,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.1463,0.135,0.157,"[0.135,0.157]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0000424,duloxetine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.1406,0.132,0.149,"[0.132,0.149]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005301,duloxetine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.1155,0.096,0.135,"[0.096,0.135]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0004609,duloxetine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0934,0.049,0.137,"[0.049,0.137]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005392,duloxetine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0887,0.072,0.105,"[0.072,0.105]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0015924,duloxetine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0534,0.007,0.1,"[0.007,0.1]",0.025,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005011,duloxetine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0513,0.036,0.067,"[0.036,0.067]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002869,duloxetine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0491,-0.004,0.102,"[-0.004,0.102]",0.069,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0008377,duloxetine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0476,0.041,0.054,"[0.041,0.054]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005083,duloxetine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0475,0.021,0.074,"[0.021,0.074]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0019369,duloxetine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0405,0.032,0.049,"[0.032,0.049]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005298,duloxetine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0342,-0.03,0.098,"[-0.03,0.098]",0.294,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0043693,duloxetine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0327,-0.012,0.077,"[-0.012,0.077]",0.153,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0009891,duloxetine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0316,0.018,0.045,"[0.018,0.045]",1.00E-04,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002046,duloxetine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.027,-0.02,0.074,"[-0.02,0.074]",0.259,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0004979,duloxetine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0225,-0.071,0.116,"[-0.071,0.116]",0.638,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002316,duloxetine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.021,-0.039,0.081,"[-0.039,0.081]",0.495,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0019499,duloxetine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0209,-0.014,0.056,"[-0.014,0.056]",0.235,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0002277,duloxetine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0189,-0.048,0.086,"[-0.048,0.086]",0.579,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005180,duloxetine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.018,-0.001,0.037,"[-0.001,0.037]",0.065,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005149,duloxetine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0161,-0.002,0.034,"[-0.002,0.034]",0.075,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0013282,duloxetine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0136,-0.065,0.093,"[-0.065,0.093]",0.735,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0019350,duloxetine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0117,-0.097,0.12,"[-0.097,0.12]",0.833,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0004648,duloxetine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.011,-0.064,0.086,"[-0.064,0.086]",0.772,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0016218,duloxetine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0106,-0.069,0.091,"[-0.069,0.091]",0.796,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005294,duloxetine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0079,-0.021,0.037,"[-0.021,0.037]",0.593,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005116,duloxetine,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0058,-0.154,0.165,"[-0.154,0.165]",0.943,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,duloxetine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0055,-0.177,0.188,"[-0.177,0.188]",0.953,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0018975,duloxetine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0049,-0.008,0.018,"[-0.008,0.018]",0.469,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0004975,duloxetine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.004,-0.116,0.124,"[-0.116,0.124]",0.948,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005300,duloxetine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0038,-0.182,0.19,"[-0.182,0.19]",0.968,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0004981,duloxetine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0031,-0.116,0.123,"[-0.116,0.123]",0.959,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005364,duloxetine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0027,-0.085,0.09,"[-0.085,0.09]",0.952,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0007186,duloxetine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0023,-0.194,0.199,"[-0.194,0.199]",0.982,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0007947,duloxetine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0021,-0.229,0.233,"[-0.229,0.233]",0.986,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0010787,duloxetine,kearns sayre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.002,-0.298,0.302,"[-0.298,0.302]",0.99,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005009,duloxetine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0019,-0.171,0.175,"[-0.171,0.175]",0.983,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0003620,duloxetine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0017,-0.315,0.318,"[-0.315,0.318]",0.992,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,duloxetine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0013,-0.268,0.271,"[-0.268,0.271]",0.993,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0000153,duloxetine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0013,-26.017,26.02,"[-26.017,26.02]",1,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005146,duloxetine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.0012,-0.445,0.447,"[-0.445,0.447]",0.996,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005133,duloxetine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.001,-0.344,0.346,"[-0.344,0.346]",0.995,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005010,duloxetine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,0.001,-1.103,1.105,"[-1.103,1.105]",0.999,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0008487,duloxetine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,6.00E-04,-0.527,0.528,"[-0.527,0.528]",0.998,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005546,duloxetine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,5.00E-04,-0.88,0.881,"[-0.88,0.881]",0.999,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,duloxetine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,4.00E-04,-0.162,0.163,"[-0.162,0.163]",0.996,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0011429,duloxetine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,5.22E-05,-0.249,0.249,"[-0.249,0.249]",1,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:122252,biolink:associated_with_increased_likelihood_of,MONDO:0005388,duloxetine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.866695931,6.34E-06,-0.197,0.197,"[-0.197,0.197]",1,1435600,21095600,22531200,"Sample size with duloxetine, approximately: 1435600","Sample size without duloxetine, approximately: 21095600",All patients number is approximately: 22531200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005133,dulaglutide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,1.5033,1.483,1.523,"[1.483,1.523]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0011786,dulaglutide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.545,0.525,0.565,"[0.525,0.565]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0000424,dulaglutide,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.4884,0.467,0.51,"[0.467,0.51]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005364,dulaglutide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.4437,0.431,0.457,"[0.431,0.457]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0009693,dulaglutide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.3562,0.338,0.374,"[0.338,0.374]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0007160,dulaglutide,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.2675,0.244,0.291,"[0.244,0.291]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0007186,dulaglutide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.2339,0.206,0.262,"[0.206,0.262]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0004979,dulaglutide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.2337,0.202,0.265,"[0.202,0.265]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005101,dulaglutide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.2144,0.182,0.247,"[0.182,0.247]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0008383,dulaglutide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.1887,0.17,0.207,"[0.17,0.207]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,dulaglutide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.1885,0.174,0.203,"[0.174,0.203]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0008599,dulaglutide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.1642,0.145,0.183,"[0.145,0.183]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,dulaglutide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.1366,0.123,0.151,"[0.123,0.151]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0002406,dulaglutide,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.1183,0.039,0.197,"[0.039,0.197]",0.003,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0015924,dulaglutide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.089,0.075,0.103,"[0.075,0.103]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0002046,dulaglutide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0845,0.057,0.112,"[0.057,0.112]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0008399,dulaglutide,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0668,0.015,0.118,"[0.015,0.118]",0.011,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005178,dulaglutide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0659,0.026,0.106,"[0.026,0.106]",0.001,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005146,dulaglutide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0577,-0.076,0.192,"[-0.076,0.192]",0.399,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005180,dulaglutide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0513,0.028,0.075,"[0.028,0.075]",1.00E-04,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0004952,dulaglutide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0216,-0.048,0.092,"[-0.048,0.092]",0.546,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0008487,dulaglutide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.019,-0.056,0.094,"[-0.056,0.094]",0.621,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005300,dulaglutide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.017,-0.166,0.2,"[-0.166,0.2]",0.855,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,dulaglutide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0166,-0.066,0.099,"[-0.066,0.099]",0.692,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005302,dulaglutide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0141,-0.346,0.374,"[-0.346,0.374]",0.939,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0002909,dulaglutide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0128,-0.033,0.058,"[-0.033,0.058]",0.58,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0000477,dulaglutide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0093,-0.403,0.421,"[-0.403,0.421]",0.965,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0021107,dulaglutide,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0091,-0.176,0.194,"[-0.176,0.194]",0.923,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005392,dulaglutide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0088,-0.021,0.038,"[-0.021,0.038]",0.56,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0005388,dulaglutide,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0041,-0.115,0.123,"[-0.115,0.123]",0.947,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0004648,dulaglutide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0024,-0.519,0.524,"[-0.519,0.524]",0.993,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0004609,dulaglutide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,0.0012,-0.546,0.548,"[-0.546,0.548]",0.997,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0002277,dulaglutide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,6.00E-04,-0.249,0.251,"[-0.249,0.251]",0.996,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0004425,dulaglutide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,5.00E-04,-0.228,0.229,"[-0.228,0.229]",0.996,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,dulaglutide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,5.00E-04,-0.179,0.18,"[-0.179,0.18]",0.995,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0019369,dulaglutide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,4.00E-04,-0.157,0.158,"[-0.157,0.158]",0.996,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2108027,biolink:associated_with_increased_likelihood_of,MONDO:0007027,dulaglutide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.927723848,2.00E-04,-0.028,0.029,"[-0.028,0.029]",0.988,266900,21650000,21916900,"Sample size with dulaglutide, approximately: 266900","Sample size without dulaglutide, approximately: 21650000",All patients number is approximately: 21916900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0007186,droperidol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,1.8206,1.805,1.836,"[1.805,1.836]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005178,droperidol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.773,0.752,0.794,"[0.752,0.794]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0019369,droperidol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.6186,0.596,0.641,"[0.596,0.641]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0008487,droperidol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.4993,0.477,0.522,"[0.477,0.522]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0004609,droperidol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.3477,0.324,0.372,"[0.324,0.372]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0019350,droperidol,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.341,0.32,0.362,"[0.32,0.362]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0004952,droperidol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.3146,0.288,0.342,"[0.288,0.342]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005300,droperidol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.2774,0.248,0.307,"[0.248,0.307]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0002277,droperidol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.2687,0.246,0.292,"[0.246,0.292]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005180,droperidol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.202,0.184,0.22,"[0.184,0.22]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005083,droperidol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.1378,0.069,0.207,"[0.069,0.207]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0009061,droperidol,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.1346,0.115,0.155,"[0.115,0.155]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005101,droperidol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0627,-0.038,0.163,"[-0.038,0.163]",0.222,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005393,droperidol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0588,0.032,0.086,"[0.032,0.086]",1.00E-04,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0002869,droperidol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0527,-0.005,0.11,"[-0.005,0.11]",0.073,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0004979,droperidol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0524,0.012,0.093,"[0.012,0.093]",0.012,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0009693,droperidol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0473,0.007,0.088,"[0.007,0.088]",0.021,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005301,droperidol,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0438,-0.012,0.1,"[-0.012,0.1]",0.125,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0002406,droperidol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0323,-0.005,0.069,"[-0.005,0.069]",0.088,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005298,droperidol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0185,-0.097,0.134,"[-0.097,0.134]",0.754,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005002,droperidol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0144,-0.085,0.114,"[-0.085,0.114]",0.776,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005009,droperidol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0114,-0.27,0.293,"[-0.27,0.293]",0.937,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0008599,droperidol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0098,-0.008,0.028,"[-0.008,0.028]",0.287,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0005546,droperidol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0086,-0.139,0.157,"[-0.139,0.157]",0.909,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0000477,droperidol,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0051,-0.116,0.126,"[-0.116,0.126]",0.934,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,droperidol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0042,-0.281,0.289,"[-0.281,0.289]",0.977,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0004975,droperidol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,0.0012,-0.539,0.542,"[-0.539,0.542]",0.997,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3168,biolink:associated_with_increased_likelihood_of,MONDO:0002046,droperidol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91855396,8.00E-04,-12.438,12.44,"[-12.438,12.44]",1,130600,21721200,21851800,"Sample size with droperidol, approximately: 130600","Sample size without droperidol, approximately: 21721200",All patients number is approximately: 21851800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005404,doxepin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.494,0.473,0.515,"[0.473,0.515]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0009891,doxepin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.4002,0.383,0.418,"[0.383,0.418]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0002909,doxepin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.3713,0.355,0.388,"[0.355,0.388]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0010602,doxepin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.357,0.34,0.374,"[0.34,0.374]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0007739,doxepin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.3508,0.328,0.374,"[0.328,0.374]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0009693,doxepin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.3169,0.301,0.333,"[0.301,0.333]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0018975,doxepin,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.2984,0.282,0.315,"[0.282,0.315]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0002046,doxepin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.2807,0.261,0.3,"[0.261,0.3]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005180,doxepin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.2712,0.25,0.292,"[0.25,0.292]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004979,doxepin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.2481,0.22,0.276,"[0.22,0.276]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005302,doxepin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.1814,0.152,0.211,"[0.152,0.211]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005393,doxepin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.1745,0.147,0.202,"[0.147,0.202]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004648,doxepin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.1512,0.127,0.176,"[0.127,0.176]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0008599,doxepin,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.1476,0.132,0.164,"[0.132,0.164]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005133,doxepin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.107,0.089,0.125,"[0.089,0.125]",1.00E-04,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0008383,doxepin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0341,0.014,0.054,"[0.014,0.054]",0.001,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0002869,doxepin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0309,-0.076,0.138,"[-0.076,0.138]",0.572,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0011786,doxepin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0281,-0.033,0.089,"[-0.033,0.089]",0.367,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0002406,doxepin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0273,-0.044,0.099,"[-0.044,0.099]",0.454,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005146,doxepin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0225,-0.197,0.243,"[-0.197,0.243]",0.841,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005101,doxepin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0217,-0.061,0.105,"[-0.061,0.105]",0.609,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004975,doxepin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0152,-0.229,0.259,"[-0.229,0.259]",0.903,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0011849,doxepin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0142,-0.088,0.116,"[-0.088,0.116]",0.785,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,doxepin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0132,-0.104,0.13,"[-0.104,0.13]",0.824,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004425,doxepin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0118,-0.186,0.209,"[-0.186,0.209]",0.907,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005002,doxepin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0095,-0.279,0.298,"[-0.279,0.298]",0.949,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004981,doxepin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.009,-0.01,0.028,"[-0.01,0.028]",0.351,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005388,doxepin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0083,-0.091,0.108,"[-0.091,0.108]",0.87,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005148,doxepin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0078,-0.009,0.024,"[-0.009,0.024]",0.356,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005010,doxepin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0067,-0.087,0.1,"[-0.087,0.1]",0.888,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0003620,doxepin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0067,-0.212,0.226,"[-0.212,0.226]",0.952,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,doxepin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0047,-0.205,0.215,"[-0.205,0.215]",0.965,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0008487,doxepin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0043,-0.31,0.318,"[-0.31,0.318]",0.979,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,doxepin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0037,-0.053,0.06,"[-0.053,0.06]",0.898,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0018882,doxepin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0022,-0.268,0.273,"[-0.268,0.273]",0.987,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005300,doxepin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0016,-0.203,0.206,"[-0.203,0.206]",0.987,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0007186,doxepin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0014,-0.23,0.233,"[-0.23,0.233]",0.991,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0005298,doxepin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.0013,-0.19,0.192,"[-0.19,0.192]",0.989,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0004609,doxepin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,0.001,-0.354,0.356,"[-0.354,0.356]",0.996,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0007818,doxepin,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,6.00E-04,-0.495,0.497,"[-0.495,0.497]",0.998,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0019369,doxepin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,5.00E-04,-0.843,0.844,"[-0.843,0.844]",0.999,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3158,biolink:associated_with_increased_likelihood_of,MONDO:0002277,doxepin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.850628043,4.00E-04,-0.491,0.492,"[-0.491,0.492]",0.999,234000,21678700,21912700,"Sample size with doxepin, approximately: 234000","Sample size without doxepin, approximately: 21678700",All patients number is approximately: 21912700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0007186,doxazosin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.6961,0.686,0.706,"[0.686,0.706]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0004648,doxazosin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.5437,0.535,0.552,"[0.535,0.552]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0002909,doxazosin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.4439,0.432,0.455,"[0.432,0.455]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005180,doxazosin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.4394,0.422,0.457,"[0.422,0.457]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0000424,doxazosin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.4181,0.406,0.431,"[0.406,0.431]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0009693,doxazosin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.3726,0.361,0.384,"[0.361,0.384]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0003620,doxazosin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.3166,0.303,0.33,"[0.303,0.33]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0016532,doxazosin,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.3143,0.3,0.328,"[0.3,0.328]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0013282,doxazosin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.2758,0.254,0.298,"[0.254,0.298]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0006640,doxazosin,adrenal cushing syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.1484,0.136,0.161,"[0.136,0.161]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0018177,doxazosin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.1433,0.131,0.156,"[0.131,0.156]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0021187,doxazosin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.1231,0.087,0.159,"[0.087,0.159]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0006694,doxazosin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.1196,0.106,0.133,"[0.106,0.133]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0001516,doxazosin,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0997,0.085,0.115,"[0.085,0.115]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005711,doxazosin,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0976,0.063,0.132,"[0.063,0.132]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0004981,doxazosin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0909,0.063,0.119,"[0.063,0.119]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0011849,doxazosin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0894,0.071,0.108,"[0.071,0.108]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0004975,doxazosin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0845,0.066,0.103,"[0.066,0.103]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005178,doxazosin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0682,0.05,0.086,"[0.05,0.086]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0007915,doxazosin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0676,0.008,0.127,"[0.008,0.127]",0.027,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0002277,doxazosin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0675,0.037,0.098,"[0.037,0.098]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005002,doxazosin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0613,0.037,0.085,"[0.037,0.085]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0015263,doxazosin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0497,0.033,0.067,"[0.033,0.067]",1.00E-04,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0008383,doxazosin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0493,0.006,0.093,"[0.006,0.093]",0.027,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005364,doxazosin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0486,0.018,0.079,"[0.018,0.079]",0.002,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005302,doxazosin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0429,-0.007,0.093,"[-0.007,0.093]",0.091,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0004609,doxazosin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.014,-0.039,0.067,"[-0.039,0.067]",0.607,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0011786,doxazosin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0138,-0.059,0.087,"[-0.059,0.087]",0.711,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005011,doxazosin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0131,-0.119,0.145,"[-0.119,0.145]",0.846,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005009,doxazosin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0111,-0.114,0.136,"[-0.114,0.136]",0.862,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005294,doxazosin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0045,-0.25,0.259,"[-0.25,0.259]",0.972,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0018882,doxazosin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0042,-0.136,0.145,"[-0.136,0.145]",0.954,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005392,doxazosin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0037,-0.097,0.104,"[-0.097,0.104]",0.943,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0010526,doxazosin,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0033,-0.293,0.299,"[-0.293,0.299]",0.983,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0008487,doxazosin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0031,-0.167,0.173,"[-0.167,0.173]",0.972,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0015924,doxazosin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0029,-0.416,0.421,"[-0.416,0.421]",0.989,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,doxazosin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,0.0016,-0.185,0.188,"[-0.185,0.188]",0.987,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0019565,doxazosin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,9.00E-04,-0.379,0.381,"[-0.379,0.381]",0.996,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005300,doxazosin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,7.00E-04,-0.196,0.197,"[-0.196,0.197]",0.994,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,MONDO:0005546,doxazosin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,3.00E-04,-0.409,0.41,"[-0.409,0.41]",0.999,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3157,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,doxazosin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.929034021,1.00E-04,-0.545,0.545,"[-0.545,0.545]",1,430800,21604100,22034900,"Sample size with doxazosin, approximately: 430800","Sample size without doxazosin, approximately: 21604100",All patients number is approximately: 22034900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251589,biolink:associated_with_increased_likelihood_of,MONDO:0007186,doravirine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.997236078,0.005,-0.717,0.727,"[-0.717,0.727]",0.989,1600,21791400,21793000,"Sample size with doravirine, approximately: 1600","Sample size without doravirine, approximately: 21791400",All patients number is approximately: 21793000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005546,donepezil,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,3.6152,3.602,3.628,"[3.602,3.628]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0000477,donepezil,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.5957,0.572,0.62,"[0.572,0.62]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0004609,donepezil,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.3629,0.354,0.372,"[0.354,0.372]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0018882,donepezil,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.246,0.236,0.256,"[0.236,0.256]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0004975,donepezil,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.2452,0.229,0.262,"[0.229,0.262]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0011786,donepezil,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.2441,0.228,0.26,"[0.228,0.26]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0009693,donepezil,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.2262,0.21,0.242,"[0.21,0.242]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0003620,donepezil,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.1929,0.184,0.202,"[0.184,0.202]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0008377,donepezil,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.1808,0.169,0.192,"[0.169,0.192]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005404,donepezil,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.1648,0.134,0.196,"[0.134,0.196]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0043693,donepezil,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.1445,0.134,0.155,"[0.134,0.155]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0001516,donepezil,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0534,0.036,0.071,"[0.036,0.071]",1.00E-04,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0004981,donepezil,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0419,0.006,0.077,"[0.006,0.077]",0.021,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0006694,donepezil,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0408,0.009,0.073,"[0.009,0.073]",0.012,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0007915,donepezil,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0306,-0.048,0.109,"[-0.048,0.109]",0.445,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0007186,donepezil,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0218,-0.06,0.103,"[-0.06,0.103]",0.599,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0008383,donepezil,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0154,-0.037,0.067,"[-0.037,0.067]",0.562,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005302,donepezil,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0125,-0.018,0.043,"[-0.018,0.043]",0.418,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005364,donepezil,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0101,-0.007,0.027,"[-0.007,0.027]",0.24,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005149,donepezil,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0085,-0.016,0.033,"[-0.016,0.033]",0.499,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0019369,donepezil,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0075,-0.1,0.115,"[-0.1,0.115]",0.891,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0004648,donepezil,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0075,-0.208,0.223,"[-0.208,0.223]",0.945,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0007027,donepezil,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0066,-0.011,0.025,"[-0.011,0.025]",0.474,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0019180,donepezil,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0059,-0.063,0.074,"[-0.063,0.074]",0.866,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005392,donepezil,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0058,-0.05,0.061,"[-0.05,0.061]",0.838,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0016218,donepezil,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0045,-0.091,0.101,"[-0.091,0.101]",0.926,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0002277,donepezil,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0036,-0.172,0.179,"[-0.172,0.179]",0.968,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0007739,donepezil,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.002,-0.369,0.373,"[-0.369,0.373]",0.992,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0002316,donepezil,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.002,-0.121,0.125,"[-0.121,0.125]",0.974,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0004979,donepezil,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0017,-0.253,0.256,"[-0.253,0.256]",0.99,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,donepezil,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0015,-0.293,0.296,"[-0.293,0.296]",0.992,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0019118,donepezil,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0014,-0.109,0.112,"[-0.109,0.112]",0.98,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0008599,donepezil,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,0.0013,-0.033,0.036,"[-0.033,0.036]",0.94,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3152,biolink:associated_with_increased_likelihood_of,MONDO:0005300,donepezil,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.947678096,3.00E-04,-0.522,0.523,"[-0.522,0.523]",0.999,580500,21487800,22068300,"Sample size with donepezil, approximately: 580500","Sample size without donepezil, approximately: 21487800",All patients number is approximately: 22068300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0011786,dolutegravir,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,1.8406,1.634,2.048,"[1.634,2.048]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0043693,dolutegravir,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.83,0.783,0.877,"[0.783,0.877]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0021187,dolutegravir,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.7487,0.702,0.795,"[0.702,0.795]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0007947,dolutegravir,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.7403,0.686,0.795,"[0.686,0.795]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0007186,dolutegravir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.7139,0.664,0.764,"[0.664,0.764]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005002,dolutegravir,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.6754,0.437,0.914,"[0.437,0.914]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005393,dolutegravir,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.5855,0.544,0.627,"[0.544,0.627]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0006694,dolutegravir,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.4334,0.394,0.472,"[0.394,0.472]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0004425,dolutegravir,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.1543,0.101,0.207,"[0.101,0.207]",1.00E-04,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005300,dolutegravir,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.0704,0.028,0.113,"[0.028,0.113]",0.001,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,dolutegravir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.0613,-0.095,0.218,"[-0.095,0.218]",0.443,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005298,dolutegravir,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.0447,-0.055,0.144,"[-0.055,0.144]",0.378,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005010,dolutegravir,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.0135,-8.786,8.813,"[-8.786,8.813]",0.998,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0007739,dolutegravir,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.0064,-0.38,0.393,"[-0.38,0.393]",0.974,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005011,dolutegravir,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,0.003,-0.252,0.258,"[-0.252,0.258]",0.982,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251580,biolink:associated_with_increased_likelihood_of,MONDO:0005178,dolutegravir,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.98930875,6.00E-04,-0.041,0.042,"[-0.041,0.042]",0.979,35400,21772900,21808300,"Sample size with dolutegravir, approximately: 35400","Sample size without dolutegravir, approximately: 21772900",All patients number is approximately: 21808300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5271565,biolink:associated_with_increased_likelihood_of,MONDO:0003620,dimethyl fumarate,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900841682,0.2353,0.119,0.352,"[0.119,0.352]",1.00E-04,14000,21783300,21797300,"Sample size with dimethyl fumarate, approximately: 14000","Sample size without dimethyl fumarate, approximately: 21783300",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5271565,biolink:associated_with_increased_likelihood_of,MONDO:0002869,dimethyl fumarate,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900841682,0.0605,-0.585,0.706,"[-0.585,0.706]",0.854,14000,21783300,21797300,"Sample size with dimethyl fumarate, approximately: 14000","Sample size without dimethyl fumarate, approximately: 21783300",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5271565,biolink:associated_with_increased_likelihood_of,MONDO:0004609,dimethyl fumarate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.900841682,0.0036,-0.552,0.559,"[-0.552,0.559]",0.99,14000,21783300,21797300,"Sample size with dimethyl fumarate, approximately: 14000","Sample size without dimethyl fumarate, approximately: 21783300",All patients number is approximately: 21797300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0007947,diltiazem,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.6171,0.611,0.623,"[0.611,0.623]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0009693,diltiazem,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.3469,0.341,0.353,"[0.341,0.353]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0010602,diltiazem,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.3127,0.306,0.319,"[0.306,0.319]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005147,diltiazem,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.2886,0.283,0.294,"[0.283,0.294]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0011786,diltiazem,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.2485,0.237,0.26,"[0.237,0.26]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0015263,diltiazem,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.2374,0.232,0.243,"[0.232,0.243]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005178,diltiazem,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.2098,0.2,0.22,"[0.2,0.22]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0019565,diltiazem,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1936,0.17,0.217,"[0.17,0.217]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0007915,diltiazem,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.18,0.167,0.193,"[0.167,0.193]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0018177,diltiazem,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1489,0.143,0.155,"[0.143,0.155]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005133,diltiazem,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1383,0.133,0.144,"[0.133,0.144]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0015924,diltiazem,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1308,0.124,0.137,"[0.124,0.137]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0008383,diltiazem,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1297,0.117,0.143,"[0.117,0.143]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005146,diltiazem,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.1215,0.103,0.14,"[0.103,0.14]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0006694,diltiazem,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0962,0.083,0.109,"[0.083,0.109]",1.00E-04,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005301,diltiazem,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0386,0.01,0.068,"[0.01,0.068]",0.009,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0002316,diltiazem,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0374,0.007,0.067,"[0.007,0.067]",0.015,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0007186,diltiazem,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0356,0.011,0.06,"[0.011,0.06]",0.004,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0010526,diltiazem,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0244,-0.076,0.125,"[-0.076,0.125]",0.633,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0019118,diltiazem,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0224,-0.015,0.06,"[-0.015,0.06]",0.242,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0018882,diltiazem,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0162,-0.054,0.086,"[-0.054,0.086]",0.65,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0002277,diltiazem,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0129,-0.03,0.056,"[-0.03,0.056]",0.554,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0021187,diltiazem,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0123,-0.033,0.058,"[-0.033,0.058]",0.596,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005009,diltiazem,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0103,-0.061,0.082,"[-0.061,0.082]",0.777,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,diltiazem,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0098,-0.027,0.046,"[-0.027,0.046]",0.597,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0008399,diltiazem,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0095,0.004,0.015,"[0.004,0.015]",0.001,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0003620,diltiazem,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0061,-0.134,0.146,"[-0.134,0.146]",0.932,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005546,diltiazem,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0059,-0.042,0.054,"[-0.042,0.054]",0.807,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005364,diltiazem,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0055,-0.089,0.1,"[-0.089,0.1]",0.909,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005300,diltiazem,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0045,-0.086,0.095,"[-0.086,0.095]",0.922,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0020066,diltiazem,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0044,-0.064,0.072,"[-0.064,0.072]",0.9,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0004952,diltiazem,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.004,-0.064,0.072,"[-0.064,0.072]",0.909,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005101,diltiazem,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0038,-0.172,0.179,"[-0.172,0.179]",0.966,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0004981,diltiazem,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0037,-0.083,0.09,"[-0.083,0.09]",0.933,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0007827,diltiazem,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0033,-0.071,0.077,"[-0.071,0.077]",0.929,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0019350,diltiazem,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.003,-0.165,0.171,"[-0.165,0.171]",0.972,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005392,diltiazem,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.003,-0.133,0.139,"[-0.133,0.139]",0.966,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0800026,diltiazem,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0029,-0.221,0.227,"[-0.221,0.227]",0.98,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0013282,diltiazem,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0028,-0.037,0.043,"[-0.037,0.043]",0.89,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0019369,diltiazem,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0027,-0.117,0.123,"[-0.117,0.123]",0.965,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005302,diltiazem,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0025,-0.064,0.069,"[-0.064,0.069]",0.941,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0019180,diltiazem,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.002,-0.172,0.176,"[-0.172,0.176]",0.982,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0002046,diltiazem,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0019,-0.133,0.137,"[-0.133,0.137]",0.978,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0008542,diltiazem,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,0.0015,-0.154,0.157,"[-0.154,0.157]",0.984,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0004648,diltiazem,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,8.00E-04,-0.197,0.198,"[-0.197,0.198]",0.993,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0008006,diltiazem,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,6.00E-04,-0.161,0.162,"[-0.161,0.162]",0.994,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0008487,diltiazem,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,3.00E-04,-0.448,0.448,"[-0.448,0.448]",0.999,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0246186,biolink:associated_with_increased_likelihood_of,MONDO:0005298,diltiazem,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.953303751,1.00E-04,-0.591,0.591,"[-0.591,0.591]",1,2951300,20734600,23685900,"Sample size with diltiazem, approximately: 2951300","Sample size without diltiazem, approximately: 20734600",All patients number is approximately: 23685900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0011508,digoxin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,1.703,1.697,1.709,"[1.697,1.709]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0000424,digoxin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.3176,0.31,0.325,"[0.31,0.325]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0007843,digoxin,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.2801,0.273,0.287,"[0.273,0.287]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005388,digoxin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.2389,0.231,0.247,"[0.231,0.247]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0009061,digoxin,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.1947,0.186,0.204,"[0.186,0.204]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0007739,digoxin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.1607,0.127,0.194,"[0.127,0.194]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005302,digoxin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.1276,0.109,0.146,"[0.109,0.146]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0018975,digoxin,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.1003,0.092,0.109,"[0.092,0.109]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005711,digoxin,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0998,0.087,0.112,"[0.087,0.112]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,digoxin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0991,0.083,0.115,"[0.083,0.115]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0007915,digoxin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0974,0.08,0.115,"[0.08,0.115]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0004609,digoxin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0917,0.084,0.1,"[0.084,0.1]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005083,digoxin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.063,0.042,0.083,"[0.042,0.083]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0004979,digoxin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0487,0.021,0.076,"[0.021,0.076]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0000477,digoxin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0454,0.003,0.087,"[0.003,0.087]",0.034,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0002046,digoxin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0415,-0.005,0.088,"[-0.005,0.088]",0.077,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0018177,digoxin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0372,0.028,0.047,"[0.028,0.047]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0008399,digoxin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0263,0.02,0.033,"[0.02,0.033]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0009693,digoxin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0238,0.014,0.034,"[0.014,0.034]",1.00E-04,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0015924,digoxin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0217,-0.02,0.063,"[-0.02,0.063]",0.308,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0011849,digoxin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0214,-0.016,0.059,"[-0.016,0.059]",0.265,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0010602,digoxin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0206,-0.002,0.043,"[-0.002,0.043]",0.075,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0007186,digoxin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0181,-0.093,0.129,"[-0.093,0.129]",0.749,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0010526,digoxin,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.016,-0.062,0.094,"[-0.062,0.094]",0.688,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0008006,digoxin,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0097,-0.054,0.074,"[-0.054,0.074]",0.767,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005294,digoxin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0051,-0.113,0.123,"[-0.113,0.123]",0.933,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0004952,digoxin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0051,-0.042,0.052,"[-0.042,0.052]",0.83,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0005010,digoxin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0024,-0.219,0.224,"[-0.219,0.224]",0.983,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0004981,digoxin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0017,-0.382,0.386,"[-0.382,0.386]",0.993,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0004975,digoxin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.0013,-0.105,0.108,"[-0.105,0.108]",0.981,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,digoxin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.001,-0.169,0.171,"[-0.169,0.171]",0.991,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0002277,digoxin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,0.001,-0.354,0.356,"[-0.354,0.356]",0.996,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,digoxin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,9.00E-04,-0.296,0.298,"[-0.296,0.298]",0.995,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:145795,biolink:associated_with_increased_likelihood_of,MONDO:0000153,digoxin,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97322839,6.00E-04,-0.102,0.104,"[-0.102,0.104]",0.991,1852900,21185700,23038600,"Sample size with digoxin, approximately: 1852900","Sample size without digoxin, approximately: 21185700",All patients number is approximately: 23038600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0008487,diclofenac,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.6883,0.678,0.698,"[0.678,0.698]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0000914,diclofenac,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.5558,0.55,0.562,"[0.55,0.562]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0004609,diclofenac,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.5502,0.538,0.562,"[0.538,0.562]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0004981,diclofenac,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.4525,0.436,0.469,"[0.436,0.469]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0008399,diclofenac,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.3886,0.382,0.395,"[0.382,0.395]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0000153,diclofenac,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.3155,0.31,0.321,"[0.31,0.321]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0000477,diclofenac,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.3119,0.294,0.33,"[0.294,0.33]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0008542,diclofenac,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.262,0.246,0.278,"[0.246,0.278]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0002316,diclofenac,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1954,0.182,0.209,"[0.182,0.209]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0011786,diclofenac,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1904,0.173,0.208,"[0.173,0.208]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,diclofenac,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1893,0.184,0.194,"[0.184,0.194]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005392,diclofenac,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1703,0.165,0.175,"[0.165,0.175]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0020066,diclofenac,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1654,0.134,0.197,"[0.134,0.197]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0043693,diclofenac,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1644,0.142,0.187,"[0.142,0.187]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0004975,diclofenac,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1559,0.134,0.177,"[0.134,0.177]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0021187,diclofenac,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1504,0.126,0.175,"[0.126,0.175]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0007903,diclofenac,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.1471,0.141,0.153,"[0.141,0.153]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005147,diclofenac,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0926,0.083,0.102,"[0.083,0.102]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0000424,diclofenac,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0856,0.078,0.093,"[0.078,0.093]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0008383,diclofenac,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0771,0.049,0.105,"[0.049,0.105]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005149,diclofenac,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0537,0.038,0.069,"[0.038,0.069]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0002277,diclofenac,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0527,0.005,0.1,"[0.005,0.1]",0.03,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0004979,diclofenac,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.037,0.014,0.06,"[0.014,0.06]",0.001,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005300,diclofenac,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0359,0.01,0.062,"[0.01,0.062]",0.006,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,diclofenac,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0317,-0.008,0.072,"[-0.008,0.072]",0.118,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0007160,diclofenac,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0301,0.022,0.038,"[0.022,0.038]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,diclofenac,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.029,0.003,0.055,"[0.003,0.055]",0.028,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005306,diclofenac,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0273,-0.022,0.076,"[-0.022,0.076]",0.274,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0007915,diclofenac,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0265,0.016,0.037,"[0.016,0.037]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0015263,diclofenac,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0238,0.014,0.034,"[0.014,0.034]",1.00E-04,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0011122,diclofenac,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.023,0.004,0.042,"[0.004,0.042]",0.018,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0800026,diclofenac,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0209,0.001,0.041,"[0.001,0.041]",0.041,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0011429,diclofenac,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0153,0.002,0.029,"[0.002,0.029]",0.026,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0019118,diclofenac,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0123,-0.02,0.045,"[-0.02,0.045]",0.455,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0004425,diclofenac,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0121,-0.07,0.094,"[-0.07,0.094]",0.773,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0007739,diclofenac,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0109,-0.046,0.067,"[-0.046,0.067]",0.706,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005364,diclofenac,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0101,-0.073,0.093,"[-0.073,0.093]",0.811,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005133,diclofenac,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0079,-0.041,0.057,"[-0.041,0.057]",0.751,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005546,diclofenac,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0061,-0.145,0.157,"[-0.145,0.157]",0.937,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0013282,diclofenac,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0059,-0.005,0.016,"[-0.005,0.016]",0.269,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0007186,diclofenac,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0052,-0.148,0.158,"[-0.148,0.158]",0.947,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0015564,diclofenac,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0045,-0.077,0.086,"[-0.077,0.086]",0.914,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0019180,diclofenac,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0031,-0.095,0.101,"[-0.095,0.101]",0.951,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0019565,diclofenac,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0028,-0.341,0.347,"[-0.341,0.347]",0.987,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005298,diclofenac,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0026,-0.09,0.096,"[-0.09,0.096]",0.956,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0011508,diclofenac,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.002,-0.088,0.092,"[-0.088,0.092]",0.965,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0002406,diclofenac,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0018,-0.307,0.31,"[-0.307,0.31]",0.991,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0002046,diclofenac,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0017,-0.051,0.055,"[-0.051,0.055]",0.951,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005146,diclofenac,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0017,-0.299,0.302,"[-0.299,0.302]",0.991,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005010,diclofenac,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,0.0016,-0.156,0.159,"[-0.156,0.159]",0.984,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249731,biolink:associated_with_increased_likelihood_of,MONDO:0005301,diclofenac,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.82852745,7.00E-04,-0.162,0.164,"[-0.162,0.164]",0.993,2324300,20563700,22888000,"Sample size with diclofenac, approximately: 2324300","Sample size without diclofenac, approximately: 20563700",All patients number is approximately: 22888000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005010,desvenlafaxine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.7646,0.741,0.788,"[0.741,0.788]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005133,desvenlafaxine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.6466,0.611,0.682,"[0.611,0.682]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005298,desvenlafaxine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.4801,0.449,0.511,"[0.449,0.511]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005546,desvenlafaxine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.3929,0.368,0.418,"[0.368,0.418]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,desvenlafaxine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.2946,0.27,0.319,"[0.27,0.319]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005002,desvenlafaxine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.193,0.157,0.229,"[0.157,0.229]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005300,desvenlafaxine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.1595,0.133,0.186,"[0.133,0.186]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005101,desvenlafaxine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.1468,0.084,0.209,"[0.084,0.209]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0008399,desvenlafaxine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.1209,0.073,0.169,"[0.073,0.169]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005404,desvenlafaxine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.1101,0.069,0.152,"[0.069,0.152]",1.00E-04,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0002316,desvenlafaxine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0629,-0.023,0.149,"[-0.023,0.149]",0.153,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0019369,desvenlafaxine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0599,-0.001,0.12,"[-0.001,0.12]",0.052,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0004425,desvenlafaxine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0442,-0.197,0.286,"[-0.197,0.286]",0.72,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0004609,desvenlafaxine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0274,-0.103,0.158,"[-0.103,0.158]",0.681,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005306,desvenlafaxine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0237,-0.033,0.08,"[-0.033,0.08]",0.41,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005392,desvenlafaxine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0201,-0.061,0.101,"[-0.061,0.101]",0.627,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005301,desvenlafaxine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0166,-0.211,0.244,"[-0.211,0.244]",0.887,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0003620,desvenlafaxine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0117,-0.164,0.188,"[-0.164,0.188]",0.896,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0007915,desvenlafaxine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0078,-0.265,0.28,"[-0.265,0.28]",0.956,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0002869,desvenlafaxine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0071,-0.142,0.156,"[-0.142,0.156]",0.925,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,desvenlafaxine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0069,-0.22,0.234,"[-0.22,0.234]",0.953,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0004979,desvenlafaxine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0046,-0.39,0.399,"[-0.39,0.399]",0.982,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0004648,desvenlafaxine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0039,-0.33,0.338,"[-0.33,0.338]",0.982,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0000477,desvenlafaxine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0017,-0.43,0.434,"[-0.43,0.434]",0.994,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0007186,desvenlafaxine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,0.0014,-0.664,0.667,"[-0.664,0.667]",0.997,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005146,desvenlafaxine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,9.00E-04,-0.504,0.506,"[-0.504,0.506]",0.997,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:125017,biolink:associated_with_increased_likelihood_of,MONDO:0005302,desvenlafaxine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.862129767,5.00E-04,-0.517,0.518,"[-0.517,0.518]",0.999,90100,21740900,21831000,"Sample size with desvenlafaxine, approximately: 90100","Sample size without desvenlafaxine, approximately: 21740900",All patients number is approximately: 21831000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0019369,desmopressin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,1.0524,1.043,1.062,"[1.043,1.062]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0000424,desmopressin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.8218,0.81,0.834,"[0.81,0.834]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0008738,desmopressin,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.5377,0.525,0.551,"[0.525,0.551]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0009891,desmopressin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.5164,0.504,0.529,"[0.504,0.529]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005180,desmopressin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.4641,0.443,0.485,"[0.443,0.485]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005010,desmopressin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.3933,0.382,0.405,"[0.382,0.405]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0009693,desmopressin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.316,0.304,0.328,"[0.304,0.328]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005178,desmopressin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.3058,0.29,0.321,"[0.29,0.321]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0007027,desmopressin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.3015,0.289,0.314,"[0.289,0.314]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0002406,desmopressin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.2484,0.23,0.267,"[0.23,0.267]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005011,desmopressin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.1504,0.129,0.172,"[0.129,0.172]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0008599,desmopressin,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.1418,0.131,0.153,"[0.131,0.153]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005101,desmopressin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0964,0.082,0.111,"[0.082,0.111]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0011786,desmopressin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.089,0.069,0.109,"[0.069,0.109]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005300,desmopressin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0562,-0.087,0.199,"[-0.087,0.199]",0.441,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0004609,desmopressin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0393,0.028,0.051,"[0.028,0.051]",1.00E-04,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0007915,desmopressin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.024,-0.001,0.049,"[-0.001,0.049]",0.057,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0006694,desmopressin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0216,-0.005,0.048,"[-0.005,0.048]",0.112,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005148,desmopressin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0188,-0.014,0.051,"[-0.014,0.051]",0.259,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0000477,desmopressin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0049,-0.073,0.083,"[-0.073,0.083]",0.902,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0002869,desmopressin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0048,-0.085,0.094,"[-0.085,0.094]",0.916,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005146,desmopressin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0047,-0.101,0.11,"[-0.101,0.11]",0.93,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0015564,desmopressin,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.003,-0.087,0.093,"[-0.087,0.093]",0.947,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0003620,desmopressin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0016,-0.159,0.163,"[-0.159,0.163]",0.985,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0004975,desmopressin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,0.0015,-0.298,0.301,"[-0.298,0.301]",0.992,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005546,desmopressin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,3.00E-04,-0.668,0.669,"[-0.668,0.669]",0.999,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16051933,biolink:associated_with_increased_likelihood_of,MONDO:0005302,desmopressin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960053024,1.00E-04,-0.312,0.313,"[-0.312,0.313]",0.999,457900,21664100,22122000,"Sample size with desmopressin, approximately: 457900","Sample size without desmopressin, approximately: 21664100",All patients number is approximately: 22122000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0005148,desipramine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.575,0.486,0.664,"[0.486,0.664]",1.00E-04,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0005298,desipramine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.4684,0.351,0.586,"[0.351,0.586]",1.00E-04,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0002277,desipramine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.4009,0.226,0.576,"[0.226,0.576]",1.00E-04,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0009693,desipramine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.1215,0.003,0.241,"[0.003,0.241]",0.045,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0005300,desipramine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.0912,0,0.182,"[0,0.182]",0.049,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0005010,desipramine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.0767,-0.222,0.375,"[-0.222,0.375]",0.614,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0008383,desipramine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.0163,-0.19,0.222,"[-0.19,0.222]",0.877,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0000424,desipramine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.01,-0.372,0.392,"[-0.372,0.392]",0.959,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0005404,desipramine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.0027,-0.449,0.454,"[-0.449,0.454]",0.991,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0018882,desipramine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,0.0012,-0.357,0.36,"[-0.357,0.36]",0.995,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0011786,desipramine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,9.00E-04,-0.955,0.957,"[-0.955,0.957]",0.999,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2995,biolink:associated_with_increased_likelihood_of,MONDO:0004981,desipramine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.854688017,3.26E-05,-0.739,0.74,"[-0.739,0.74]",1,17000,21783300,21800300,"Sample size with desipramine, approximately: 17000","Sample size without desipramine, approximately: 21783300",All patients number is approximately: 21800300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005147,darunavir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.5171,0.425,0.609,"[0.425,0.609]",1.00E-04,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0007186,darunavir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.3572,0.18,0.535,"[0.18,0.535]",1.00E-04,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005148,darunavir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.3299,0.188,0.472,"[0.188,0.472]",1.00E-04,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0043693,darunavir,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.3078,0.221,0.395,"[0.221,0.395]",1.00E-04,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0018177,darunavir,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.2561,0.079,0.433,"[0.079,0.433]",0.005,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0002277,darunavir,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.1815,0.121,0.242,"[0.121,0.242]",1.00E-04,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0004609,darunavir,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.1763,-0.045,0.397,"[-0.045,0.397]",0.118,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,darunavir,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.1496,-0.159,0.459,"[-0.159,0.459]",0.343,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005180,darunavir,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.1423,0.011,0.273,"[0.011,0.273]",0.033,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0002046,darunavir,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.1089,-0.339,0.557,"[-0.339,0.557]",0.634,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005010,darunavir,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0878,-0.439,0.615,"[-0.439,0.615]",0.744,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,darunavir,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0654,-0.216,0.347,"[-0.216,0.347]",0.649,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005146,darunavir,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0164,-34.594,34.627,"[-34.594,34.627]",0.999,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0015564,darunavir,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0083,-46.117,46.134,"[-46.117,46.134]",1,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0005546,darunavir,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0044,-0.998,1.006,"[-0.998,1.006]",0.993,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:213039,biolink:associated_with_increased_likelihood_of,MONDO:0004979,darunavir,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.995488454,0.0022,-0.048,0.053,"[-0.048,0.053]",0.93,13600,21784500,21798100,"Sample size with darunavir, approximately: 13600","Sample size without darunavir, approximately: 21784500",All patients number is approximately: 21798100,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0002046,dapagliflozin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,1.1916,1.176,1.207,"[1.176,1.207]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0000424,dapagliflozin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.7403,0.72,0.761,"[0.72,0.761]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0004981,dapagliflozin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.5626,0.547,0.579,"[0.547,0.579]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005180,dapagliflozin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.442,0.425,0.459,"[0.425,0.459]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,dapagliflozin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.4174,0.404,0.431,"[0.404,0.431]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0004609,dapagliflozin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.3625,0.348,0.377,"[0.348,0.377]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0002909,dapagliflozin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.3515,0.334,0.369,"[0.334,0.369]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005009,dapagliflozin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.3205,0.303,0.338,"[0.303,0.338]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0007186,dapagliflozin,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.3014,0.28,0.323,"[0.28,0.323]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0009693,dapagliflozin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.1872,0.17,0.205,"[0.17,0.205]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005302,dapagliflozin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.1634,0.129,0.198,"[0.129,0.198]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0018882,dapagliflozin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.1621,0.13,0.195,"[0.13,0.195]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005147,dapagliflozin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.1546,0.131,0.178,"[0.131,0.178]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,dapagliflozin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.106,0.092,0.12,"[0.092,0.12]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005393,dapagliflozin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0865,0.049,0.124,"[0.049,0.124]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005101,dapagliflozin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0691,0.005,0.134,"[0.005,0.134]",0.036,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0043693,dapagliflozin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0618,0.042,0.082,"[0.042,0.082]",1.00E-04,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005392,dapagliflozin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0339,-0.002,0.07,"[-0.002,0.07]",0.068,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005002,dapagliflozin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0079,-0.142,0.158,"[-0.142,0.158]",0.917,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005298,dapagliflozin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0067,-0.304,0.318,"[-0.304,0.318]",0.966,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0004425,dapagliflozin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0064,-0.094,0.107,"[-0.094,0.107]",0.901,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005306,dapagliflozin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0046,-0.15,0.159,"[-0.15,0.159]",0.954,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005149,dapagliflozin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0031,-0.114,0.12,"[-0.114,0.12]",0.959,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005294,dapagliflozin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.003,-0.537,0.543,"[-0.537,0.543]",0.991,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0019369,dapagliflozin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0016,-0.761,0.764,"[-0.761,0.764]",0.997,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0011786,dapagliflozin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.0013,-1.118,1.12,"[-1.118,1.12]",0.998,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0002869,dapagliflozin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,0.001,-0.124,0.126,"[-0.124,0.126]",0.987,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,dapagliflozin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,8.00E-04,-0.423,0.425,"[-0.423,0.425]",0.997,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C22193,biolink:associated_with_increased_likelihood_of,MONDO:0005300,dapagliflozin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.941365149,6.00E-04,-0.211,0.212,"[-0.211,0.212]",0.996,256600,21665100,21921700,"Sample size with dapagliflozin, approximately: 256600","Sample size without dapagliflozin, approximately: 21665100",All patients number is approximately: 21921700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005364,cyclosporine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.6319,0.62,0.643,"[0.62,0.643]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0007186,cyclosporine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.4524,0.438,0.466,"[0.438,0.466]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005178,cyclosporine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.3767,0.351,0.402,"[0.351,0.402]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0019369,cyclosporine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.3432,0.308,0.379,"[0.308,0.379]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005146,cyclosporine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.3356,0.314,0.357,"[0.314,0.357]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0009693,cyclosporine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.2956,0.28,0.311,"[0.28,0.311]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0019499,cyclosporine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.266,0.25,0.282,"[0.25,0.282]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0018177,cyclosporine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.2493,0.234,0.265,"[0.234,0.265]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005101,cyclosporine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.2433,0.21,0.276,"[0.21,0.276]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0009891,cyclosporine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.2341,0.22,0.249,"[0.22,0.249]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005180,cyclosporine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.2117,0.19,0.233,"[0.19,0.233]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002909,cyclosporine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1915,0.172,0.211,"[0.172,0.211]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002869,cyclosporine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1616,0.119,0.204,"[0.119,0.204]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,cyclosporine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1526,0.13,0.175,"[0.13,0.175]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0007027,cyclosporine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1387,0.117,0.16,"[0.117,0.16]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0018882,cyclosporine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1355,0.106,0.165,"[0.106,0.165]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005148,cyclosporine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.1027,0.078,0.128,"[0.078,0.128]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0019350,cyclosporine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0836,0.029,0.138,"[0.029,0.138]",0.003,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0008383,cyclosporine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.082,0.017,0.147,"[0.017,0.147]",0.014,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0008399,cyclosporine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0795,0.047,0.112,"[0.047,0.112]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005546,cyclosporine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0715,0.031,0.112,"[0.031,0.112]",1.00E-04,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005298,cyclosporine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0711,0.029,0.114,"[0.029,0.114]",0.001,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002316,cyclosporine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0507,-0.004,0.106,"[-0.004,0.106]",0.071,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0003620,cyclosporine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0409,0.004,0.078,"[0.004,0.078]",0.031,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0007915,cyclosporine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0348,-0.054,0.124,"[-0.054,0.124]",0.444,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005404,cyclosporine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0295,-0.016,0.075,"[-0.016,0.075]",0.199,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005294,cyclosporine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0224,-0.173,0.218,"[-0.173,0.218]",0.822,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0004979,cyclosporine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0219,-0.157,0.201,"[-0.157,0.201]",0.81,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005133,cyclosporine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0209,-0.019,0.061,"[-0.019,0.061]",0.307,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002406,cyclosporine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.019,-0.043,0.081,"[-0.043,0.081]",0.548,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0004952,cyclosporine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0163,-0.048,0.081,"[-0.048,0.081]",0.618,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005149,cyclosporine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0158,-0.067,0.099,"[-0.067,0.099]",0.708,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0004981,cyclosporine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0147,-0.081,0.11,"[-0.081,0.11]",0.763,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005011,cyclosporine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0115,-0.018,0.041,"[-0.018,0.041]",0.446,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0008487,cyclosporine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0106,-0.088,0.109,"[-0.088,0.109]",0.834,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005002,cyclosporine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0101,-0.1,0.12,"[-0.1,0.12]",0.857,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005130,cyclosporine,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0096,-0.007,0.026,"[-0.007,0.026]",0.244,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005392,cyclosporine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0065,-0.13,0.143,"[-0.13,0.143]",0.925,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002046,cyclosporine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0065,-0.045,0.058,"[-0.045,0.058]",0.804,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0007739,cyclosporine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0056,-0.26,0.271,"[-0.26,0.271]",0.967,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0013282,cyclosporine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0034,-0.101,0.108,"[-0.101,0.108]",0.95,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0016218,cyclosporine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0025,-0.189,0.194,"[-0.189,0.194]",0.98,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0011786,cyclosporine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0021,-0.265,0.27,"[-0.265,0.27]",0.987,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0011429,cyclosporine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0017,-0.187,0.191,"[-0.187,0.191]",0.986,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0004609,cyclosporine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0016,-0.268,0.271,"[-0.268,0.271]",0.991,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0002277,cyclosporine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0016,-0.089,0.092,"[-0.089,0.092]",0.972,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0021187,cyclosporine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0015,-0.091,0.094,"[-0.091,0.094]",0.975,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,cyclosporine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0014,-0.508,0.511,"[-0.508,0.511]",0.996,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005010,cyclosporine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0014,-241.318,241.321,"[-241.318,241.321]",1,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005302,cyclosporine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0013,-0.038,0.041,"[-0.038,0.041]",0.95,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0005300,cyclosporine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,0.0012,-0.842,0.844,"[-0.842,0.844]",0.998,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250682,biolink:associated_with_increased_likelihood_of,MONDO:0007827,cyclosporine,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.877766549,5.00E-04,-0.151,0.152,"[-0.151,0.152]",0.995,277200,21662700,21939900,"Sample size with cyclosporine, approximately: 277200","Sample size without cyclosporine, approximately: 21662700",All patients number is approximately: 21939900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:586,biolink:associated_with_increased_likelihood_of,MONDO:0005180,creatine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.833840905,0.0103,-2.115,2.135,"[-2.115,2.135]",0.992,8700,21785700,21794400,"Sample size with creatine, approximately: 8700","Sample size without creatine, approximately: 21785700",All patients number is approximately: 21794400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005546,colestipol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.7846,0.756,0.814,"[0.756,0.814]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005178,colestipol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.3955,0.359,0.432,"[0.359,0.432]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0043693,colestipol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.3345,0.281,0.388,"[0.281,0.388]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0008399,colestipol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.3187,0.268,0.369,"[0.268,0.369]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0008599,colestipol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1526,0.102,0.203,"[0.102,0.203]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0007027,colestipol,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1317,0.096,0.167,"[0.096,0.167]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,colestipol,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1307,0.066,0.195,"[0.066,0.195]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005146,colestipol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1173,0.059,0.175,"[0.059,0.175]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0009693,colestipol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1075,0.054,0.161,"[0.054,0.161]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0002406,colestipol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.1018,0.052,0.151,"[0.052,0.151]",1.00E-04,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005392,colestipol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0875,0.026,0.149,"[0.026,0.149]",0.006,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005364,colestipol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0576,0.002,0.113,"[0.002,0.113]",0.042,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005404,colestipol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0501,-0.069,0.17,"[-0.069,0.17]",0.411,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005294,colestipol,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0483,-0.11,0.207,"[-0.11,0.207]",0.55,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005302,colestipol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.045,-0.033,0.123,"[-0.033,0.123]",0.26,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005083,colestipol,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0404,-0.247,0.327,"[-0.247,0.327]",0.783,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0011122,colestipol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0248,-0.021,0.071,"[-0.021,0.071]",0.289,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0005002,colestipol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0198,-0.217,0.257,"[-0.217,0.257]",0.87,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0011786,colestipol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0152,-0.21,0.241,"[-0.21,0.241]",0.895,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,colestipol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0061,-1.584,1.596,"[-1.584,1.596]",0.994,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0004981,colestipol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0046,-0.545,0.554,"[-0.545,0.554]",0.987,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0004648,colestipol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0022,-0.777,0.781,"[-0.777,0.781]",0.996,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0007186,colestipol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,0.0011,-0.731,0.734,"[-0.731,0.734]",0.998,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0004979,colestipol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,4.00E-04,-0.484,0.484,"[-0.484,0.484]",0.999,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:3084661,biolink:associated_with_increased_likelihood_of,MONDO:0002046,colestipol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.863179125,5.54E-05,-0.654,0.654,"[-0.654,0.654]",1,42300,21769600,21811900,"Sample size with colestipol, approximately: 42300","Sample size without colestipol, approximately: 21769600",All patients number is approximately: 21811900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,colesevelam,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.8854,0.846,0.925,"[0.846,0.925]",1.00E-04,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0007027,colesevelam,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.4437,0.351,0.536,"[0.351,0.536]",1.00E-04,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0043693,colesevelam,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.3277,0.268,0.388,"[0.268,0.388]",1.00E-04,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0011122,colesevelam,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.3196,0.233,0.406,"[0.233,0.406]",1.00E-04,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0008399,colesevelam,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.1839,0.093,0.275,"[0.093,0.275]",1.00E-04,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005178,colesevelam,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.1631,0.071,0.255,"[0.071,0.255]",0.001,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005002,colesevelam,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0884,-0.385,0.562,"[-0.385,0.562]",0.714,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0004981,colesevelam,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0836,-0.013,0.18,"[-0.013,0.18]",0.089,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005392,colesevelam,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0484,-0.134,0.231,"[-0.134,0.231]",0.602,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005546,colesevelam,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.03,-0.491,0.551,"[-0.491,0.551]",0.91,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0021187,colesevelam,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0257,-0.02,0.072,"[-0.02,0.072]",0.273,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0002277,colesevelam,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0222,-0.246,0.29,"[-0.246,0.29]",0.871,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005298,colesevelam,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0139,-0.127,0.155,"[-0.127,0.155]",0.848,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005011,colesevelam,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0119,-0.127,0.15,"[-0.127,0.15]",0.867,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005146,colesevelam,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0078,-0.6,0.616,"[-0.6,0.616]",0.98,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0011786,colesevelam,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0076,-0.577,0.592,"[-0.577,0.592]",0.98,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005101,colesevelam,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0045,-2.674,2.683,"[-2.674,2.683]",0.997,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,MONDO:0005300,colesevelam,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,0.0032,-0.632,0.638,"[-0.632,0.638]",0.992,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:160051,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,colesevelam,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.891696644,2.00E-04,-0.818,0.818,"[-0.818,0.818]",1,29400,21775600,21805000,"Sample size with colesevelam, approximately: 29400","Sample size without colesevelam, approximately: 21775600",All patients number is approximately: 21805000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0004609,clozapine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,1.3475,1.306,1.389,"[1.306,1.389]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0007027,clozapine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.4995,0.468,0.531,"[0.468,0.531]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0008487,clozapine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.4677,0.43,0.506,"[0.43,0.506]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0002277,clozapine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.4646,0.42,0.509,"[0.42,0.509]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005147,clozapine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.3607,0.312,0.41,"[0.312,0.41]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0002406,clozapine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.2481,0.214,0.282,"[0.214,0.282]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005010,clozapine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.2327,0.181,0.285,"[0.181,0.285]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005302,clozapine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.1825,0.126,0.238,"[0.126,0.238]",1.00E-04,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0019350,clozapine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0839,-0.073,0.24,"[-0.073,0.24]",0.293,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005083,clozapine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0718,-0.034,0.177,"[-0.034,0.177]",0.182,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005294,clozapine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0587,-0.307,0.424,"[-0.307,0.424]",0.753,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0011786,clozapine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0374,-0.266,0.341,"[-0.266,0.341]",0.809,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0007186,clozapine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0232,-0.072,0.118,"[-0.072,0.118]",0.631,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,clozapine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0218,-0.165,0.209,"[-0.165,0.209]",0.819,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0011122,clozapine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0165,-0.092,0.125,"[-0.092,0.125]",0.765,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0002046,clozapine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0102,-0.383,0.403,"[-0.383,0.403]",0.959,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:135398737,biolink:associated_with_increased_likelihood_of,MONDO:0005101,clozapine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.955468227,0.0021,-0.63,0.634,"[-0.63,0.634]",0.995,38900,21774400,21813300,"Sample size with clozapine, approximately: 38900","Sample size without clozapine, approximately: 21774400",All patients number is approximately: 21813300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005002,clonidine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,1.515,1.501,1.529,"[1.501,1.529]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005546,clonidine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.6174,0.612,0.623,"[0.612,0.623]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0010561,clonidine,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.394,0.381,0.407,"[0.381,0.407]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008644,clonidine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.3064,0.298,0.315,"[0.298,0.315]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0001044,clonidine,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.2701,0.26,0.28,"[0.26,0.28]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0001516,clonidine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.2076,0.202,0.213,"[0.202,0.213]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005178,clonidine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.1949,0.187,0.202,"[0.187,0.202]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0007947,clonidine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.1598,0.154,0.165,"[0.154,0.165]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0016532,clonidine,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.1319,0.124,0.14,"[0.124,0.14]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0004975,clonidine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.116,0.083,0.149,"[0.083,0.149]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0018177,clonidine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.1146,0.109,0.12,"[0.109,0.12]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0018975,clonidine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.1089,0.103,0.115,"[0.103,0.115]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008599,clonidine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0909,0.085,0.096,"[0.085,0.096]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005404,clonidine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0905,0.067,0.114,"[0.067,0.114]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0009061,clonidine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0761,0.068,0.084,"[0.068,0.084]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005009,clonidine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0517,0.043,0.061,"[0.043,0.061]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0007540,clonidine,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0492,0.02,0.079,"[0.02,0.079]",0.001,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0002316,clonidine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0427,0.003,0.082,"[0.003,0.082]",0.033,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0007739,clonidine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0371,0.011,0.063,"[0.011,0.063]",0.005,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0004981,clonidine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0364,-0.036,0.109,"[-0.036,0.109]",0.324,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0009693,clonidine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0344,0.016,0.053,"[0.016,0.053]",1.00E-04,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0011122,clonidine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0317,-0.002,0.065,"[-0.002,0.065]",0.064,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0021187,clonidine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0289,-0.012,0.07,"[-0.012,0.07]",0.164,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0002277,clonidine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0248,-0.019,0.069,"[-0.019,0.069]",0.271,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0002406,clonidine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0207,-0.013,0.054,"[-0.013,0.054]",0.225,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0010526,clonidine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0159,-0.073,0.105,"[-0.073,0.105]",0.726,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0011849,clonidine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0145,-0.011,0.04,"[-0.011,0.04]",0.257,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005302,clonidine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0131,-0.052,0.078,"[-0.052,0.078]",0.693,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0004952,clonidine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.012,-0.045,0.069,"[-0.045,0.069]",0.678,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0018882,clonidine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0091,-0.049,0.067,"[-0.049,0.067]",0.759,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0021129,clonidine,microphthalmos,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.008,-16.164,16.18,"[-16.164,16.18]",0.999,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0019369,clonidine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.008,-16.163,16.179,"[-16.163,16.179]",0.999,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0007186,clonidine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.008,-0.06,0.076,"[-0.06,0.076]",0.817,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,clonidine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0068,-0.174,0.187,"[-0.174,0.187]",0.941,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0019015,clonidine,congenital omphalocele,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.006,-0.124,0.136,"[-0.124,0.136]",0.927,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0009264,clonidine,gastroschisis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0055,-0.136,0.147,"[-0.136,0.147]",0.94,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0002046,clonidine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.005,-0.096,0.106,"[-0.096,0.106]",0.922,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,clonidine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0048,-0.04,0.049,"[-0.04,0.049]",0.833,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008300,clonidine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0043,-0.073,0.081,"[-0.073,0.081]",0.913,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,clonidine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0028,-0.075,0.08,"[-0.075,0.08]",0.943,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008542,clonidine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0021,-0.172,0.176,"[-0.172,0.176]",0.981,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0019350,clonidine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0018,-0.17,0.174,"[-0.17,0.174]",0.983,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0011786,clonidine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0017,-0.424,0.428,"[-0.424,0.428]",0.994,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0004425,clonidine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0015,-0.208,0.211,"[-0.208,0.211]",0.989,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0007843,clonidine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0014,-0.1,0.103,"[-0.1,0.103]",0.979,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008383,clonidine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,0.0011,-0.098,0.1,"[-0.098,0.1]",0.983,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0003620,clonidine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,9.00E-04,-0.335,0.337,"[-0.335,0.337]",0.996,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0008487,clonidine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,8.00E-04,-0.33,0.332,"[-0.33,0.332]",0.996,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0016218,clonidine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,7.00E-04,-0.288,0.29,"[-0.288,0.29]",0.996,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005101,clonidine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,7.00E-04,-0.181,0.183,"[-0.181,0.183]",0.994,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0004609,clonidine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,4.00E-04,-0.309,0.309,"[-0.309,0.309]",0.998,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005298,clonidine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,2.00E-04,-0.647,0.648,"[-0.647,0.648]",0.999,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005392,clonidine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,2.00E-04,-0.267,0.267,"[-0.267,0.267]",0.999,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2803,biolink:associated_with_increased_likelihood_of,MONDO:0005301,clonidine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.909928402,7.37E-05,-0.412,0.412,"[-0.412,0.412]",1,2358900,20729700,23088600,"Sample size with clonidine, approximately: 2358900","Sample size without clonidine, approximately: 20729700",All patients number is approximately: 23088600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2801,biolink:associated_with_increased_likelihood_of,MONDO:0008399,clomipramine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.864978747,0.0537,-0.272,0.379,"[-0.272,0.379]",0.746,9600,21786600,21796200,"Sample size with clomipramine, approximately: 9600","Sample size without clomipramine, approximately: 21786600",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2801,biolink:associated_with_increased_likelihood_of,MONDO:0005392,clomipramine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.864978747,0.019,-0.272,0.31,"[-0.272,0.31]",0.898,9600,21786600,21796200,"Sample size with clomipramine, approximately: 9600","Sample size without clomipramine, approximately: 21786600",All patients number is approximately: 21796200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0000153,clevidipine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,1.786,1.77,1.802,"[1.77,1.802]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0006694,clevidipine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,1.0194,1.002,1.036,"[1.002,1.036]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0004648,clevidipine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.9944,0.976,1.013,"[0.976,1.013]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0019565,clevidipine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.7778,0.76,0.795,"[0.76,0.795]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0043693,clevidipine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.7594,0.741,0.778,"[0.741,0.778]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0018177,clevidipine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.7561,0.724,0.788,"[0.724,0.788]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0008599,clevidipine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.7234,0.704,0.743,"[0.704,0.743]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,clevidipine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.7107,0.688,0.733,"[0.688,0.733]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005364,clevidipine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.6633,0.646,0.681,"[0.646,0.681]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005392,clevidipine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.3219,0.291,0.353,"[0.291,0.353]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0009891,clevidipine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.2903,0.269,0.311,"[0.269,0.311]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005180,clevidipine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.1461,0.117,0.175,"[0.117,0.175]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0004981,clevidipine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0908,0.054,0.128,"[0.054,0.128]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0008399,clevidipine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0836,0.04,0.127,"[0.04,0.127]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0011849,clevidipine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0511,-0.044,0.146,"[-0.044,0.146]",0.291,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0021187,clevidipine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0508,0.028,0.074,"[0.028,0.074]",1.00E-04,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005146,clevidipine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0434,-0.054,0.141,"[-0.054,0.141]",0.381,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0002406,clevidipine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0291,-0.045,0.103,"[-0.045,0.103]",0.439,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0004952,clevidipine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0234,-0.026,0.073,"[-0.026,0.073]",0.351,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005148,clevidipine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0173,-0.01,0.044,"[-0.01,0.044]",0.209,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0016218,clevidipine,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.015,-0.178,0.208,"[-0.178,0.208]",0.879,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0018882,clevidipine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.01,-1242.642,1242.662,"[-1242.642,1242.662]",1,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0005306,clevidipine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0041,-0.113,0.121,"[-0.113,0.121]",0.945,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,clevidipine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,0.0019,-0.687,0.691,"[-0.687,0.691]",0.996,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250321,biolink:associated_with_increased_likelihood_of,MONDO:0002909,clevidipine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994227149,3.00E-04,-0.673,0.674,"[-0.673,0.674]",0.999,397100,21752400,22149500,"Sample size with clevidipine, approximately: 397100","Sample size without clevidipine, approximately: 21752400",All patients number is approximately: 22149500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0002909,cladribine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.8024,0.741,0.864,"[0.741,0.864]",1.00E-04,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0002869,cladribine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.4617,0.38,0.544,"[0.38,0.544]",1.00E-04,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0004979,cladribine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.1862,0.048,0.324,"[0.048,0.324]",0.008,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0005146,cladribine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.0379,-0.096,0.172,"[-0.096,0.172]",0.58,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0021187,cladribine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.026,-0.315,0.367,"[-0.315,0.367]",0.881,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0005178,cladribine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.0219,-0.624,0.668,"[-0.624,0.668]",0.947,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0007186,cladribine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.0132,-0.47,0.496,"[-0.47,0.496]",0.957,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0011122,cladribine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,0.0049,-0.524,0.534,"[-0.524,0.534]",0.985,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:20279,biolink:associated_with_increased_likelihood_of,MONDO:0000424,cladribine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.985970022,9.00E-04,-2.76,2.761,"[-2.76,2.761]",1,6100,21789900,21796000,"Sample size with cladribine, approximately: 6100","Sample size without cladribine, approximately: 21789900",All patients number is approximately: 21796000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0013282,citalopram,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.7704,0.762,0.779,"[0.762,0.779]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004609,citalopram,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.3954,0.38,0.41,"[0.38,0.41]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0002046,citalopram,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.377,0.363,0.391,"[0.363,0.391]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005147,citalopram,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.2346,0.227,0.242,"[0.227,0.242]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0010602,citalopram,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.2111,0.203,0.219,"[0.203,0.219]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0007540,citalopram,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.2018,0.194,0.21,"[0.194,0.21]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005302,citalopram,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.1826,0.164,0.201,"[0.164,0.201]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005178,citalopram,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.178,0.167,0.189,"[0.167,0.189]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005101,citalopram,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.1259,0.112,0.139,"[0.112,0.139]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0010526,citalopram,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0874,0.058,0.117,"[0.058,0.117]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0007915,citalopram,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0752,0.055,0.096,"[0.055,0.096]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005083,citalopram,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0635,0.035,0.091,"[0.035,0.091]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0008599,citalopram,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0618,0.055,0.069,"[0.055,0.069]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0019180,citalopram,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0608,0.037,0.085,"[0.037,0.085]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0019369,citalopram,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0565,0.017,0.096,"[0.017,0.096]",0.005,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0009693,citalopram,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0539,0.042,0.066,"[0.042,0.066]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0011849,citalopram,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0402,-0.008,0.089,"[-0.008,0.089]",0.104,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0008383,citalopram,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0401,0.002,0.078,"[0.002,0.078]",0.041,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0009891,citalopram,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0313,0.018,0.044,"[0.018,0.044]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0007739,citalopram,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0285,-0.042,0.099,"[-0.042,0.099]",0.428,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0008399,citalopram,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0237,0.016,0.031,"[0.016,0.031]",1.00E-04,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005294,citalopram,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0221,-0.028,0.072,"[-0.028,0.072]",0.39,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0000153,citalopram,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0204,-0.072,0.113,"[-0.072,0.113]",0.665,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0003620,citalopram,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0197,-0.033,0.073,"[-0.033,0.073]",0.466,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005146,citalopram,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0183,-0.089,0.126,"[-0.089,0.126]",0.739,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004979,citalopram,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0161,-0.097,0.129,"[-0.097,0.129]",0.781,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0000424,citalopram,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0123,-0.002,0.026,"[-0.002,0.026]",0.086,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005300,citalopram,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0113,-0.145,0.168,"[-0.145,0.168]",0.887,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0018882,citalopram,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0112,-0.074,0.097,"[-0.074,0.097]",0.797,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005010,citalopram,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0076,-0.184,0.199,"[-0.184,0.199]",0.938,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005298,citalopram,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0058,-0.245,0.257,"[-0.245,0.257]",0.964,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004648,citalopram,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0044,-0.014,0.023,"[-0.014,0.023]",0.643,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,citalopram,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0044,-0.032,0.041,"[-0.032,0.041]",0.814,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0011429,citalopram,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0043,-0.069,0.078,"[-0.069,0.078]",0.908,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0002406,citalopram,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.004,-0.169,0.177,"[-0.169,0.177]",0.964,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0019118,citalopram,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0038,-0.267,0.275,"[-0.267,0.275]",0.978,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005011,citalopram,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0033,-0.082,0.089,"[-0.082,0.089]",0.939,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005306,citalopram,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0028,-0.035,0.041,"[-0.035,0.041]",0.885,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005180,citalopram,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.002,-0.004,0.008,"[-0.004,0.008]",0.536,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005301,citalopram,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0014,-0.291,0.294,"[-0.291,0.294]",0.992,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005002,citalopram,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.0013,-0.259,0.261,"[-0.259,0.261]",0.992,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004425,citalopram,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.001,-0.996,0.998,"[-0.996,0.998]",0.998,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004981,citalopram,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,0.001,-0.588,0.59,"[-0.588,0.59]",0.997,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0009061,citalopram,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,9.00E-04,-0.011,0.012,"[-0.011,0.012]",0.884,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0011786,citalopram,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,5.00E-04,-1.027,1.028,"[-1.027,1.028]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0002316,citalopram,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,5.00E-04,-3.048,3.049,"[-3.048,3.049]",1,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005404,citalopram,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,3.00E-04,-0.317,0.317,"[-0.317,0.317]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0004975,citalopram,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,3.00E-04,-0.776,0.777,"[-0.776,0.777]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,citalopram,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,2.00E-04,-0.318,0.318,"[-0.318,0.318]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0007947,citalopram,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,2.00E-04,-0.171,0.171,"[-0.171,0.171]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0002909,citalopram,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,1.00E-04,-0.37,0.37,"[-0.37,0.37]",0.999,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
CHEBI:3723,biolink:associated_with_increased_likelihood_of,MONDO:0005009,citalopram,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.829587768,1.00E-04,-0.085,0.085,"[-0.085,0.085]",0.998,1318500,21055900,22374400,"Sample size with citalopram, approximately: 1318500","Sample size without citalopram, approximately: 21055900",All patients number is approximately: 22374400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0005178,choline fenofibrate,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.5583,0.498,0.619,"[0.498,0.619]",1.00E-04,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0007186,choline fenofibrate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.2844,0.223,0.346,"[0.223,0.346]",1.00E-04,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0005148,choline fenofibrate,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.1632,-0.113,0.44,"[-0.113,0.44]",0.247,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0005009,choline fenofibrate,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0557,-0.141,0.253,"[-0.141,0.253]",0.58,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0011786,choline fenofibrate,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0526,-0.426,0.531,"[-0.426,0.531]",0.829,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0005083,choline fenofibrate,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0402,-0.295,0.376,"[-0.295,0.376]",0.814,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,choline fenofibrate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0391,-0.269,0.347,"[-0.269,0.347]",0.804,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0005149,choline fenofibrate,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0304,-0.478,0.539,"[-0.478,0.539]",0.907,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0004981,choline fenofibrate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0298,-0.117,0.177,"[-0.117,0.177]",0.69,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11350701,biolink:associated_with_increased_likelihood_of,MONDO:0043693,choline fenofibrate,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998440572,0.0106,-0.562,0.583,"[-0.562,0.583]",0.971,12300,21784700,21797000,"Sample size with choline fenofibrate, approximately: 12300","Sample size without choline fenofibrate, approximately: 21784700",All patients number is approximately: 21797000,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005393,cholestyramine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.4147,0.401,0.429,"[0.401,0.429]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0009891,cholestyramine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.3858,0.37,0.401,"[0.37,0.401]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0008599,cholestyramine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2541,0.24,0.268,"[0.24,0.268]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005364,cholestyramine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2313,0.218,0.244,"[0.218,0.244]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005146,cholestyramine,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2299,0.206,0.253,"[0.206,0.253]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,cholestyramine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2256,0.21,0.241,"[0.21,0.241]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0004975,cholestyramine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2215,0.203,0.24,"[0.203,0.24]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0002909,cholestyramine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.22,0.204,0.236,"[0.204,0.236]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005302,cholestyramine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.2196,0.203,0.236,"[0.203,0.236]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0002046,cholestyramine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.1588,0.141,0.176,"[0.141,0.176]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005101,cholestyramine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.1327,0.101,0.165,"[0.101,0.165]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005083,cholestyramine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.1226,0.081,0.164,"[0.081,0.164]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0000477,cholestyramine,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.1053,0.03,0.181,"[0.03,0.181]",0.006,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0007186,cholestyramine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.1048,0.074,0.136,"[0.074,0.136]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0020066,cholestyramine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0849,0.064,0.106,"[0.064,0.106]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0000424,cholestyramine,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0669,0.052,0.082,"[0.052,0.082]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005404,cholestyramine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0657,0.022,0.11,"[0.022,0.11]",0.004,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005147,cholestyramine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0654,0.044,0.087,"[0.044,0.087]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0007915,cholestyramine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0625,0,0.125,"[0,0.125]",0.052,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0004981,cholestyramine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0572,-0.018,0.132,"[-0.018,0.132]",0.137,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0008738,cholestyramine,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0526,0.036,0.069,"[0.036,0.069]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0043693,cholestyramine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0367,0.021,0.052,"[0.021,0.052]",1.00E-04,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0003620,cholestyramine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0356,-0.104,0.175,"[-0.104,0.175]",0.618,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0011849,cholestyramine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.028,0.005,0.05,"[0.005,0.05]",0.015,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005388,cholestyramine,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0263,-0.062,0.115,"[-0.062,0.115]",0.56,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005300,cholestyramine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0207,-0.076,0.117,"[-0.076,0.117]",0.674,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0011429,cholestyramine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0192,-0.058,0.096,"[-0.058,0.096]",0.623,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0002406,cholestyramine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0118,-0.07,0.093,"[-0.07,0.093]",0.776,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0004952,cholestyramine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0073,-0.048,0.062,"[-0.048,0.062]",0.794,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005002,cholestyramine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0073,-0.265,0.279,"[-0.265,0.279]",0.958,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005294,cholestyramine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0061,-0.325,0.337,"[-0.325,0.337]",0.971,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005010,cholestyramine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0055,-0.088,0.099,"[-0.088,0.099]",0.908,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,cholestyramine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0052,-0.034,0.044,"[-0.034,0.044]",0.793,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005148,cholestyramine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0045,-0.46,0.469,"[-0.46,0.469]",0.985,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005011,cholestyramine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0037,-0.208,0.215,"[-0.208,0.215]",0.973,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005392,cholestyramine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0036,-0.099,0.106,"[-0.099,0.106]",0.946,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0011786,cholestyramine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0028,-0.076,0.082,"[-0.076,0.082]",0.944,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0005133,cholestyramine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0024,-0.15,0.155,"[-0.15,0.155]",0.975,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,cholestyramine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0018,-0.207,0.21,"[-0.207,0.21]",0.987,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201625,biolink:associated_with_increased_likelihood_of,MONDO:0004425,cholestyramine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.892886699,0.0011,-0.217,0.219,"[-0.217,0.219]",0.992,241000,21691700,21932700,"Sample size with cholestyramine, approximately: 241000","Sample size without cholestyramine, approximately: 21691700",All patients number is approximately: 21932700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005392,chlorpromazine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,1.0222,1.005,1.04,"[1.005,1.04]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0002909,chlorpromazine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.5582,0.541,0.575,"[0.541,0.575]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0009891,chlorpromazine,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.4774,0.462,0.493,"[0.462,0.493]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0004609,chlorpromazine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.4324,0.418,0.447,"[0.418,0.447]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0006694,chlorpromazine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.3193,0.303,0.336,"[0.303,0.336]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005178,chlorpromazine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.2502,0.233,0.267,"[0.233,0.267]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005101,chlorpromazine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.2015,0.183,0.22,"[0.183,0.22]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0018177,chlorpromazine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.1774,0.157,0.198,"[0.157,0.198]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005180,chlorpromazine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.1525,0.137,0.168,"[0.137,0.168]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0008383,chlorpromazine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0846,-0.002,0.171,"[-0.002,0.171]",0.055,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0007027,chlorpromazine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0735,0.056,0.091,"[0.056,0.091]",1.00E-04,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0002277,chlorpromazine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0623,-0.067,0.192,"[-0.067,0.192]",0.345,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005302,chlorpromazine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0599,0.019,0.1,"[0.019,0.1]",0.004,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0011122,chlorpromazine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0505,0.007,0.093,"[0.007,0.093]",0.021,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0018882,chlorpromazine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0461,-0.034,0.126,"[-0.034,0.126]",0.258,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005306,chlorpromazine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0437,0.002,0.086,"[0.002,0.086]",0.041,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0011849,chlorpromazine,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.042,0.005,0.079,"[0.005,0.079]",0.028,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0004981,chlorpromazine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0413,-0.032,0.115,"[-0.032,0.115]",0.272,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0004425,chlorpromazine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.041,0.01,0.072,"[0.01,0.072]",0.009,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0004975,chlorpromazine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0337,-0.057,0.124,"[-0.057,0.124]",0.467,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005404,chlorpromazine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0277,-0.167,0.222,"[-0.167,0.222]",0.78,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0004952,chlorpromazine,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0134,-0.095,0.121,"[-0.095,0.121]",0.808,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005301,chlorpromazine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0118,-0.302,0.326,"[-0.302,0.326]",0.941,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,chlorpromazine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0082,-0.114,0.131,"[-0.114,0.131]",0.896,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0043693,chlorpromazine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0082,-0.013,0.029,"[-0.013,0.029]",0.44,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0005002,chlorpromazine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0028,-0.215,0.22,"[-0.215,0.22]",0.98,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,chlorpromazine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,0.0018,-0.304,0.307,"[-0.304,0.307]",0.991,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0250090,biolink:associated_with_increased_likelihood_of,MONDO:0007186,chlorpromazine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.944305336,4.00E-04,-0.287,0.288,"[-0.287,0.288]",0.998,193000,21721400,21914400,"Sample size with chlorpromazine, approximately: 193000","Sample size without chlorpromazine, approximately: 21721400",All patients number is approximately: 21914400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0004981,chlorothiazide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,1.8427,1.831,1.854,"[1.831,1.854]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0008599,chlorothiazide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.859,0.848,0.87,"[0.848,0.87]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0018177,chlorothiazide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.7962,0.783,0.809,"[0.783,0.809]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0008738,chlorothiazide,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.7533,0.739,0.767,"[0.739,0.767]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005392,chlorothiazide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.7274,0.709,0.746,"[0.709,0.746]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0004979,chlorothiazide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.5289,0.517,0.54,"[0.517,0.54]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0043693,chlorothiazide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.4655,0.453,0.478,"[0.453,0.478]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0019369,chlorothiazide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.4058,0.394,0.418,"[0.394,0.418]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0008644,chlorothiazide,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.3613,0.35,0.373,"[0.35,0.373]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005148,chlorothiazide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.2804,0.269,0.292,"[0.269,0.292]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0009693,chlorothiazide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.2726,0.25,0.295,"[0.25,0.295]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0010526,chlorothiazide,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.2223,0.19,0.255,"[0.19,0.255]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0011786,chlorothiazide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.2015,0.162,0.241,"[0.162,0.241]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0008383,chlorothiazide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.1875,0.142,0.233,"[0.142,0.233]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0013282,chlorothiazide,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.169,0.15,0.188,"[0.15,0.188]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0002909,chlorothiazide,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.1219,0.097,0.147,"[0.097,0.147]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005393,chlorothiazide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.1197,0.085,0.154,"[0.085,0.154]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0006694,chlorothiazide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0996,0.086,0.113,"[0.086,0.113]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0008399,chlorothiazide,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0968,0.078,0.115,"[0.078,0.115]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0004425,chlorothiazide,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0907,0.058,0.123,"[0.058,0.123]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0009891,chlorothiazide,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0895,0.076,0.103,"[0.076,0.103]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0002046,chlorothiazide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0853,0.029,0.142,"[0.029,0.142]",0.003,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005083,chlorothiazide,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.084,0.05,0.118,"[0.05,0.118]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0002316,chlorothiazide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0679,0.034,0.102,"[0.034,0.102]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005302,chlorothiazide,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0674,0.045,0.09,"[0.045,0.09]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,chlorothiazide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0646,0.015,0.115,"[0.015,0.115]",0.011,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005002,chlorothiazide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.06,0.001,0.119,"[0.001,0.119]",0.046,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0004952,chlorothiazide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.043,0.032,0.055,"[0.032,0.055]",1.00E-04,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0000477,chlorothiazide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0404,-0.016,0.096,"[-0.016,0.096]",0.158,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0002277,chlorothiazide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0393,-0.095,0.174,"[-0.095,0.174]",0.567,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0015924,chlorothiazide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0087,-0.137,0.155,"[-0.137,0.155]",0.907,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005364,chlorothiazide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0031,-0.398,0.404,"[-0.398,0.404]",0.988,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0004648,chlorothiazide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0019,-1.349,1.353,"[-1.349,1.353]",0.998,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005149,chlorothiazide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,0.0011,-0.564,0.567,"[-0.564,0.567]",0.997,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005300,chlorothiazide,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,6.00E-04,-0.078,0.079,"[-0.078,0.079]",0.989,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2720,biolink:associated_with_increased_likelihood_of,MONDO:0005546,chlorothiazide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.990323027,4.00E-04,-0.607,0.608,"[-0.607,0.608]",0.999,597900,21678800,22276700,"Sample size with chlorothiazide, approximately: 597900","Sample size without chlorothiazide, approximately: 21678800",All patients number is approximately: 22276700,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201831,biolink:associated_with_increased_likelihood_of,MONDO:0005009,certolizumab pegol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91750357,0.0779,-0.057,0.213,"[-0.057,0.213]",0.259,11300,21785000,21796300,"Sample size with certolizumab pegol, approximately: 11300","Sample size without certolizumab pegol, approximately: 21785000",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201831,biolink:associated_with_increased_likelihood_of,MONDO:0005178,certolizumab pegol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91750357,0.0381,-0.25,0.327,"[-0.25,0.327]",0.796,11300,21785000,21796300,"Sample size with certolizumab pegol, approximately: 11300","Sample size without certolizumab pegol, approximately: 21785000",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201831,biolink:associated_with_increased_likelihood_of,MONDO:0002869,certolizumab pegol,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91750357,0.0124,-0.564,0.589,"[-0.564,0.589]",0.966,11300,21785000,21796300,"Sample size with certolizumab pegol, approximately: 11300","Sample size without certolizumab pegol, approximately: 21785000",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201831,biolink:associated_with_increased_likelihood_of,MONDO:0007186,certolizumab pegol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.91750357,0.0087,-0.827,0.844,"[-0.827,0.844]",0.984,11300,21785000,21796300,"Sample size with certolizumab pegol, approximately: 11300","Sample size without certolizumab pegol, approximately: 21785000",All patients number is approximately: 21796300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005116,celecoxib,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.5391,0.527,0.552,"[0.527,0.552]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0002406,celecoxib,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.5259,0.518,0.534,"[0.518,0.534]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,celecoxib,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.5096,0.502,0.517,"[0.502,0.517]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0010602,celecoxib,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.2503,0.241,0.26,"[0.241,0.26]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0009693,celecoxib,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.1702,0.154,0.186,"[0.154,0.186]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005364,celecoxib,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.138,0.13,0.146,"[0.13,0.146]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005101,celecoxib,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.1329,0.106,0.16,"[0.106,0.16]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005178,celecoxib,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.1259,0.116,0.136,"[0.116,0.136]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005392,celecoxib,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.1138,0.102,0.126,"[0.102,0.126]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0009891,celecoxib,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.1055,0.089,0.123,"[0.089,0.123]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0007027,celecoxib,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0882,0.066,0.11,"[0.066,0.11]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0019180,celecoxib,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0774,0.034,0.121,"[0.034,0.121]",0.001,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0006694,celecoxib,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0699,0.044,0.096,"[0.044,0.096]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005146,celecoxib,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.057,0.019,0.095,"[0.019,0.095]",0.003,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0011849,celecoxib,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0509,0.024,0.078,"[0.024,0.078]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0009061,celecoxib,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0494,0.033,0.066,"[0.033,0.066]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,celecoxib,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0399,0.013,0.067,"[0.013,0.067]",0.004,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0000424,celecoxib,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0368,0.018,0.055,"[0.018,0.055]",1.00E-04,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005306,celecoxib,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0262,-0.014,0.067,"[-0.014,0.067]",0.205,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0007739,celecoxib,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0174,-0.025,0.06,"[-0.025,0.06]",0.424,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0002277,celecoxib,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0152,-0.061,0.091,"[-0.061,0.091]",0.695,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0008487,celecoxib,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0138,-0.061,0.089,"[-0.061,0.089]",0.72,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0007186,celecoxib,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0126,0.004,0.022,"[0.004,0.022]",0.007,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,celecoxib,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.011,-0.006,0.028,"[-0.006,0.028]",0.211,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0002046,celecoxib,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0097,-0.092,0.111,"[-0.092,0.111]",0.852,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0002316,celecoxib,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0089,-0.086,0.103,"[-0.086,0.103]",0.854,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005002,celecoxib,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0081,-0.15,0.166,"[-0.15,0.166]",0.92,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005298,celecoxib,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0081,-0.076,0.092,"[-0.076,0.092]",0.849,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0004975,celecoxib,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.008,-0.129,0.145,"[-0.129,0.145]",0.909,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005404,celecoxib,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0074,-0.137,0.151,"[-0.137,0.151]",0.92,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0003620,celecoxib,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0062,-0.103,0.115,"[-0.103,0.115]",0.911,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0018882,celecoxib,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0047,-0.139,0.148,"[-0.139,0.148]",0.948,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0020066,celecoxib,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0047,-0.204,0.214,"[-0.204,0.214]",0.965,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005009,celecoxib,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.004,-0.166,0.174,"[-0.166,0.174]",0.963,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0043693,celecoxib,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0039,-0.052,0.06,"[-0.052,0.06]",0.893,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005133,celecoxib,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.0036,-0.083,0.09,"[-0.083,0.09]",0.935,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005294,celecoxib,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,0.002,-0.192,0.196,"[-0.192,0.196]",0.984,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0005010,celecoxib,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,6.00E-04,-0.439,0.44,"[-0.439,0.44]",0.998,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0015924,celecoxib,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,4.00E-04,-0.311,0.312,"[-0.311,0.312]",0.998,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2662,biolink:associated_with_increased_likelihood_of,MONDO:0004648,celecoxib,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.911049643,2.00E-04,-1.179,1.18,"[-1.179,1.18]",1,1342400,21119300,22461700,"Sample size with celecoxib, approximately: 1342400","Sample size without celecoxib, approximately: 21119300",All patients number is approximately: 22461700,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005711,carvedilol,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.8931,0.887,0.899,"[0.887,0.899]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0011429,carvedilol,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.8517,0.834,0.87,"[0.834,0.87]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005009,carvedilol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.7522,0.747,0.758,"[0.747,0.758]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005147,carvedilol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.3655,0.36,0.371,"[0.36,0.371]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0004981,carvedilol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.3167,0.308,0.325,"[0.308,0.325]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005302,carvedilol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.2811,0.275,0.287,"[0.275,0.287]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005011,carvedilol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.2779,0.267,0.289,"[0.267,0.289]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0021187,carvedilol,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.2478,0.238,0.258,"[0.238,0.258]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005178,carvedilol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.2474,0.238,0.257,"[0.238,0.257]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0010526,carvedilol,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.1981,0.177,0.22,"[0.177,0.22]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,carvedilol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.1645,0.146,0.183,"[0.146,0.183]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005149,carvedilol,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.1581,0.144,0.172,"[0.144,0.172]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005404,carvedilol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.1209,0.111,0.131,"[0.111,0.131]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0011786,carvedilol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.1065,0.075,0.138,"[0.075,0.138]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0009891,carvedilol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0973,0.078,0.116,"[0.078,0.116]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0000424,carvedilol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0909,0.081,0.101,"[0.081,0.101]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0019499,carvedilol,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0855,0.057,0.114,"[0.057,0.114]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008377,carvedilol,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0838,0.077,0.091,"[0.077,0.091]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008599,carvedilol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.075,0.069,0.081,"[0.069,0.081]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0018177,carvedilol,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0685,0.061,0.076,"[0.061,0.076]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005002,carvedilol,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0654,0.033,0.098,"[0.033,0.098]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0002909,carvedilol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0509,0.036,0.065,"[0.036,0.065]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0000153,carvedilol,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0494,0.02,0.078,"[0.02,0.078]",0.001,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008642,carvedilol,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0346,0.013,0.056,"[0.013,0.056]",0.001,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0004975,carvedilol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0326,0.008,0.057,"[0.008,0.057]",0.008,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005146,carvedilol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0241,-0.051,0.099,"[-0.051,0.099]",0.53,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0004425,carvedilol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0237,0.013,0.034,"[0.013,0.034]",1.00E-04,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0004952,carvedilol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.018,-0.055,0.091,"[-0.055,0.091]",0.627,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005364,carvedilol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0161,-0.068,0.1,"[-0.068,0.1]",0.707,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0004609,carvedilol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0155,-0.03,0.061,"[-0.03,0.061]",0.501,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005392,carvedilol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0154,-0.026,0.057,"[-0.026,0.057]",0.464,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0002277,carvedilol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0123,-0.059,0.083,"[-0.059,0.083]",0.734,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005300,carvedilol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0088,-0.022,0.04,"[-0.022,0.04]",0.581,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0013282,carvedilol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.008,-0.003,0.019,"[-0.003,0.019]",0.145,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0007739,carvedilol,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0058,-0.065,0.077,"[-0.065,0.077]",0.874,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0007540,carvedilol,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0031,-0.2,0.207,"[-0.2,0.207]",0.976,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005101,carvedilol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0028,-0.156,0.162,"[-0.156,0.162]",0.972,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005133,carvedilol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.002,-0.3,0.304,"[-0.3,0.304]",0.99,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0002046,carvedilol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0019,-0.058,0.062,"[-0.058,0.062]",0.951,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008394,carvedilol,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0018,-0.103,0.107,"[-0.103,0.107]",0.974,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,carvedilol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,0.0013,-0.152,0.155,"[-0.152,0.155]",0.987,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0005298,carvedilol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,7.00E-04,-0.63,0.632,"[-0.63,0.632]",0.998,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0002406,carvedilol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,5.00E-04,-0.389,0.39,"[-0.389,0.39]",0.998,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008487,carvedilol,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,5.00E-04,-0.675,0.676,"[-0.675,0.676]",0.999,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2585,biolink:associated_with_increased_likelihood_of,MONDO:0008542,carvedilol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.945792148,4.00E-04,-0.159,0.16,"[-0.159,0.16]",0.996,2994900,20546000,23540900,"Sample size with carvedilol, approximately: 2994900","Sample size without carvedilol, approximately: 20546000",All patients number is approximately: 23540900,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0005180,cariprazine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.496,0.447,0.545,"[0.447,0.545]",1.00E-04,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0004425,cariprazine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.4266,0.372,0.482,"[0.372,0.482]",1.00E-04,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0019369,cariprazine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.3054,0.226,0.385,"[0.226,0.385]",1.00E-04,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0004609,cariprazine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.2214,0.131,0.312,"[0.131,0.312]",1.00E-04,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,cariprazine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.143,0.093,0.193,"[0.093,0.193]",1.00E-04,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0002277,cariprazine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0747,0.001,0.148,"[0.001,0.148]",0.047,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0005301,cariprazine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0609,-0.009,0.131,"[-0.009,0.131]",0.088,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0015924,cariprazine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0571,-0.526,0.64,"[-0.526,0.64]",0.848,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0005133,cariprazine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0496,-0.169,0.268,"[-0.169,0.268]",0.656,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0005298,cariprazine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0281,-0.369,0.426,"[-0.369,0.426]",0.89,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0002046,cariprazine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0247,-0.24,0.289,"[-0.24,0.289]",0.855,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,cariprazine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0221,-0.245,0.289,"[-0.245,0.289]",0.871,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0004975,cariprazine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0212,-0.333,0.376,"[-0.333,0.376]",0.907,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0005083,cariprazine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0152,-0.137,0.167,"[-0.137,0.167]",0.844,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,cariprazine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0089,-0.251,0.269,"[-0.251,0.269]",0.947,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0002909,cariprazine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0056,-1.101,1.112,"[-1.101,1.112]",0.992,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0003620,cariprazine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0052,-0.908,0.918,"[-0.908,0.918]",0.991,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL2028019,biolink:associated_with_increased_likelihood_of,MONDO:0007915,cariprazine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.906207024,0.0016,-0.437,0.44,"[-0.437,0.44]",0.994,30700,21775900,21806600,"Sample size with cariprazine, approximately: 30700","Sample size without cariprazine, approximately: 21775900",All patients number is approximately: 21806600,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0019499,captopril,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,1.5625,1.548,1.577,"[1.548,1.577]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0010602,captopril,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,1.0684,1.05,1.087,"[1.05,1.087]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0021187,captopril,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.8582,0.842,0.874,"[0.842,0.874]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,captopril,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.5122,0.491,0.533,"[0.491,0.533]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0002909,captopril,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.375,0.348,0.402,"[0.348,0.402]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005180,captopril,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.3601,0.342,0.378,"[0.342,0.378]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0004648,captopril,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.3504,0.334,0.367,"[0.334,0.367]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0009693,captopril,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.3049,0.288,0.322,"[0.288,0.322]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005364,captopril,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.2905,0.275,0.306,"[0.275,0.306]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0008399,captopril,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.2817,0.263,0.301,"[0.263,0.301]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0008383,captopril,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.2123,0.197,0.228,"[0.197,0.228]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0008542,captopril,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.2058,0.188,0.224,"[0.188,0.224]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0010383,captopril,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.1446,0.125,0.164,"[0.125,0.164]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0018177,captopril,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.1273,0.102,0.153,"[0.102,0.153]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0000424,captopril,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.1216,0.105,0.139,"[0.105,0.139]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005298,captopril,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.1207,0.081,0.16,"[0.081,0.16]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0043693,captopril,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0796,0.056,0.103,"[0.056,0.103]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005146,captopril,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0716,0.021,0.122,"[0.021,0.122]",0.006,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0011849,captopril,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0663,0.037,0.095,"[0.037,0.095]",1.00E-04,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005011,captopril,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0398,0.01,0.069,"[0.01,0.069]",0.009,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0007915,captopril,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0389,-0.058,0.136,"[-0.058,0.136]",0.433,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0005101,captopril,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.029,-0.078,0.136,"[-0.078,0.136]",0.595,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0018882,captopril,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0164,-0.086,0.119,"[-0.086,0.119]",0.754,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0004975,captopril,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0059,-0.177,0.188,"[-0.177,0.188]",0.95,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0002046,captopril,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0036,-0.239,0.246,"[-0.239,0.246]",0.977,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0004609,captopril,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0024,-0.363,0.368,"[-0.363,0.368]",0.99,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C06867,biolink:associated_with_increased_likelihood_of,MONDO:0008678,captopril,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972007956,0.0021,-0.028,0.032,"[-0.028,0.032]",0.892,214800,21747700,21962500,"Sample size with captopril, approximately: 214800","Sample size without captopril, approximately: 21747700",All patients number is approximately: 21962500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005146,capsaicin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.8495,0.831,0.868,"[0.831,0.868]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005301,capsaicin,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.7113,0.692,0.73,"[0.692,0.73]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005392,capsaicin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.607,0.587,0.627,"[0.587,0.627]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0004648,capsaicin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.5766,0.563,0.59,"[0.563,0.59]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,capsaicin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.438,0.424,0.452,"[0.424,0.452]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005364,capsaicin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.3996,0.386,0.414,"[0.386,0.414]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0007027,capsaicin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.3526,0.335,0.37,"[0.335,0.37]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0002909,capsaicin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.3441,0.328,0.36,"[0.328,0.36]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005546,capsaicin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.2902,0.259,0.322,"[0.259,0.322]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005133,capsaicin,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.248,0.231,0.265,"[0.231,0.265]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0043693,capsaicin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.1922,0.177,0.208,"[0.177,0.208]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,capsaicin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.1877,0.152,0.223,"[0.152,0.223]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0007915,capsaicin,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.131,0.107,0.155,"[0.107,0.155]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0011849,capsaicin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0905,0.053,0.128,"[0.053,0.128]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0008383,capsaicin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0801,0.015,0.146,"[0.015,0.146]",0.016,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0021187,capsaicin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.073,0.054,0.091,"[0.054,0.091]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005148,capsaicin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0515,0.031,0.072,"[0.031,0.072]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0009693,capsaicin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0426,0.028,0.057,"[0.028,0.057]",1.00E-04,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0019369,capsaicin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0246,-0.108,0.157,"[-0.108,0.157]",0.716,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005009,capsaicin,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0233,-0.115,0.162,"[-0.115,0.162]",0.742,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005404,capsaicin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0139,-0.027,0.054,"[-0.027,0.054]",0.501,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0000477,capsaicin,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0134,-0.105,0.131,"[-0.105,0.131]",0.824,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0015924,capsaicin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0126,-0.089,0.114,"[-0.089,0.114]",0.807,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0005388,capsaicin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0042,-0.398,0.406,"[-0.398,0.406]",0.984,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0007827,capsaicin,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0042,-0.515,0.523,"[-0.515,0.523]",0.987,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0004979,capsaicin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0018,-0.492,0.495,"[-0.492,0.495]",0.994,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0004981,capsaicin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0012,-0.172,0.174,"[-0.172,0.174]",0.989,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0004425,capsaicin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0012,-0.781,0.784,"[-0.781,0.784]",0.998,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1548943,biolink:associated_with_increased_likelihood_of,MONDO:0006694,capsaicin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.904397918,0.0011,-0.017,0.019,"[-0.017,0.019]",0.902,216700,21711400,21928100,"Sample size with capsaicin, approximately: 216700","Sample size without capsaicin, approximately: 21711400",All patients number is approximately: 21928100,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0004648,candesartan,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,1.029,1.002,1.056,"[1.002,1.056]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0000424,candesartan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.7307,0.692,0.769,"[0.692,0.769]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,candesartan,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.5959,0.568,0.624,"[0.568,0.624]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0043693,candesartan,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.4,0.361,0.439,"[0.361,0.439]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0004981,candesartan,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.378,0.339,0.417,"[0.339,0.417]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0004609,candesartan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.3745,0.34,0.409,"[0.34,0.409]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0004425,candesartan,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.3638,0.33,0.398,"[0.33,0.398]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0002909,candesartan,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.3635,0.321,0.406,"[0.321,0.406]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0009693,candesartan,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.3478,0.304,0.391,"[0.304,0.391]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0011122,candesartan,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.2933,0.249,0.338,"[0.249,0.338]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0002277,candesartan,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.1808,0.091,0.271,"[0.091,0.271]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005180,candesartan,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.1602,0.109,0.211,"[0.109,0.211]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0011786,candesartan,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.152,0.102,0.202,"[0.102,0.202]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0008383,candesartan,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.1161,0.075,0.157,"[0.075,0.157]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0002406,candesartan,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.1009,0.056,0.146,"[0.056,0.146]",1.00E-04,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0007915,candesartan,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.046,-0.057,0.149,"[-0.057,0.149]",0.383,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0018177,candesartan,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0366,-0.034,0.107,"[-0.034,0.107]",0.31,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0019369,candesartan,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0169,-0.064,0.098,"[-0.064,0.098]",0.683,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0008487,candesartan,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0069,-0.064,0.078,"[-0.064,0.078]",0.85,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005101,candesartan,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0034,-0.212,0.219,"[-0.212,0.219]",0.976,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0004975,candesartan,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0029,-0.37,0.376,"[-0.37,0.376]",0.988,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005300,candesartan,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.002,-0.581,0.585,"[-0.581,0.585]",0.995,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005146,candesartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0015,-0.83,0.833,"[-0.83,0.833]",0.997,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005302,candesartan,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0013,-1.274,1.277,"[-1.274,1.277]",0.998,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,candesartan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0013,-0.865,0.867,"[-0.865,0.867]",0.998,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005546,candesartan,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,0.0011,-0.7,0.702,"[-0.7,0.702]",0.998,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
KEGG.COMPOUND:C07468,biolink:associated_with_increased_likelihood_of,MONDO:0005009,candesartan,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905168663,1.00E-04,-0.744,0.745,"[-0.744,0.745]",1,53600,21758600,21812200,"Sample size with candesartan, approximately: 53600","Sample size without candesartan, approximately: 21758600",All patients number is approximately: 21812200,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004979,canagliflozin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,1.5583,1.545,1.572,"[1.545,1.572]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,canagliflozin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.7691,0.758,0.781,"[0.758,0.781]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0018975,canagliflozin,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.7585,0.748,0.769,"[0.748,0.769]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0018882,canagliflozin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.7232,0.711,0.735,"[0.711,0.735]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004975,canagliflozin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.647,0.631,0.663,"[0.631,0.663]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0002406,canagliflozin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.5366,0.519,0.554,"[0.519,0.554]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005306,canagliflozin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.3345,0.318,0.351,"[0.318,0.351]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0043693,canagliflozin,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.2361,0.222,0.25,"[0.222,0.25]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004952,canagliflozin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.2272,0.206,0.248,"[0.206,0.248]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0011849,canagliflozin,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1921,0.131,0.253,"[0.131,0.253]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005393,canagliflozin,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1714,0.15,0.193,"[0.15,0.193]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0009693,canagliflozin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.165,0.148,0.182,"[0.148,0.182]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004648,canagliflozin,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1591,0.129,0.189,"[0.129,0.189]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004425,canagliflozin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1189,0.065,0.172,"[0.065,0.172]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005148,canagliflozin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1151,0.07,0.16,"[0.07,0.16]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,canagliflozin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1148,0.096,0.133,"[0.096,0.133]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0002277,canagliflozin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.1092,0.077,0.141,"[0.077,0.141]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0008599,canagliflozin,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0691,0.057,0.081,"[0.057,0.081]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005010,canagliflozin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0567,0.028,0.085,"[0.028,0.085]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0007027,canagliflozin,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0474,0.031,0.064,"[0.031,0.064]",1.00E-04,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005146,canagliflozin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0466,-0.036,0.129,"[-0.036,0.129]",0.267,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005546,canagliflozin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0417,-0.035,0.118,"[-0.035,0.118]",0.286,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0011429,canagliflozin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0339,-0.014,0.082,"[-0.014,0.082]",0.165,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005302,canagliflozin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0285,0.004,0.053,"[0.004,0.053]",0.024,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004981,canagliflozin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0245,-0.036,0.085,"[-0.036,0.085]",0.426,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0011786,canagliflozin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0187,-0.068,0.106,"[-0.068,0.106]",0.674,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005149,canagliflozin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0102,-0.094,0.114,"[-0.094,0.114]",0.848,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005404,canagliflozin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0101,-0.156,0.177,"[-0.156,0.177]",0.905,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005300,canagliflozin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0041,-0.569,0.577,"[-0.569,0.577]",0.989,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005364,canagliflozin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0028,-0.007,0.013,"[-0.007,0.013]",0.586,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0005298,canagliflozin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0024,-0.134,0.139,"[-0.134,0.139]",0.973,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0004609,canagliflozin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0024,-0.168,0.173,"[-0.168,0.173]",0.978,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0008542,canagliflozin,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,0.0016,-0.15,0.153,"[-0.15,0.153]",0.984,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0002869,canagliflozin,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,4.00E-04,-0.54,0.54,"[-0.54,0.54]",0.999,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0019118,canagliflozin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,3.00E-04,-0.682,0.683,"[-0.682,0.683]",0.999,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249580,biolink:associated_with_increased_likelihood_of,MONDO:0011508,canagliflozin,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.980974293,1.00E-04,-0.492,0.492,"[-0.492,0.492]",1,687200,21626300,22313500,"Sample size with canagliflozin, approximately: 687200","Sample size without canagliflozin, approximately: 21626300",All patients number is approximately: 22313500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0009061,calcitriol,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,1.0617,1.05,1.073,"[1.05,1.073]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0019369,calcitriol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.8334,0.824,0.843,"[0.824,0.843]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0000424,calcitriol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.7839,0.768,0.8,"[0.768,0.8]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0015564,calcitriol,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.4328,0.421,0.444,"[0.421,0.444]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005393,calcitriol,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.4216,0.41,0.433,"[0.41,0.433]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005364,calcitriol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.333,0.319,0.347,"[0.319,0.347]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0002909,calcitriol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.1927,0.172,0.214,"[0.172,0.214]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005147,calcitriol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.1654,0.148,0.183,"[0.148,0.183]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0004975,calcitriol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.1641,0.136,0.192,"[0.136,0.192]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005298,calcitriol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.093,0.051,0.135,"[0.051,0.135]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0010602,calcitriol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0863,0.074,0.099,"[0.074,0.099]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0008383,calcitriol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0851,0.075,0.095,"[0.075,0.095]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0007186,calcitriol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0698,0.044,0.096,"[0.044,0.096]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005130,calcitriol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0539,0.042,0.066,"[0.042,0.066]",1.00E-04,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0004981,calcitriol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0458,-0.002,0.094,"[-0.002,0.094]",0.062,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0011849,calcitriol,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0322,-0.026,0.091,"[-0.026,0.091]",0.281,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005146,calcitriol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0231,-0.033,0.079,"[-0.033,0.079]",0.415,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0002406,calcitriol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0181,-0.008,0.044,"[-0.008,0.044]",0.176,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,calcitriol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0163,0.002,0.031,"[0.002,0.031]",0.026,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0004609,calcitriol,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0121,-0.055,0.079,"[-0.055,0.079]",0.726,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0009693,calcitriol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0096,-0.01,0.029,"[-0.01,0.029]",0.332,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0003620,calcitriol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0095,-0.091,0.11,"[-0.091,0.11]",0.852,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0008678,calcitriol,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0086,-0.127,0.144,"[-0.127,0.144]",0.902,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005101,calcitriol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0079,-0.142,0.158,"[-0.142,0.158]",0.918,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005072,calcitriol,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0077,-0.025,0.041,"[-0.025,0.041]",0.651,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0008599,calcitriol,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0054,-0.007,0.017,"[-0.007,0.017]",0.382,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0008542,calcitriol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0037,-0.186,0.193,"[-0.186,0.193]",0.969,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0002277,calcitriol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0033,-0.172,0.178,"[-0.172,0.178]",0.971,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005392,calcitriol,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0021,-0.247,0.251,"[-0.247,0.251]",0.987,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005133,calcitriol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0021,-0.15,0.154,"[-0.15,0.154]",0.979,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0004648,calcitriol,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,0.0013,-0.272,0.274,"[-0.272,0.274]",0.993,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005300,calcitriol,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,2.00E-04,-0.389,0.389,"[-0.389,0.389]",0.999,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0005010,calcitriol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,2.00E-04,-0.151,0.152,"[-0.151,0.152]",0.998,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0007540,calcitriol,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,1.00E-04,-0.238,0.239,"[-0.238,0.239]",0.999,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242363,biolink:associated_with_increased_likelihood_of,MONDO:0019499,calcitriol,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.950132238,9.54E-05,-0.403,0.403,"[-0.403,0.403]",1,516800,21603900,22120700,"Sample size with calcitriol, approximately: 516800","Sample size without calcitriol, approximately: 21603900",All patients number is approximately: 22120700,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0019369,calcitonin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.8753,0.821,0.929,"[0.821,0.929]",1.00E-04,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0005298,calcitonin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.1832,0.084,0.282,"[0.084,0.282]",1.00E-04,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0002277,calcitonin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.1517,-0.017,0.321,"[-0.017,0.321]",0.078,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0002909,calcitonin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.1009,0.019,0.183,"[0.019,0.183]",0.016,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0004609,calcitonin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.0624,-0.247,0.372,"[-0.247,0.372]",0.693,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0009693,calcitonin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.022,-0.646,0.69,"[-0.646,0.69]",0.949,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0011122,calcitonin,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.0139,-0.268,0.296,"[-0.268,0.296]",0.923,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0005392,calcitonin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.0115,-0.526,0.549,"[-0.526,0.549]",0.967,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,calcitonin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.0081,-0.591,0.607,"[-0.591,0.607]",0.979,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0000424,calcitonin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,0.001,-0.287,0.289,"[-0.287,0.289]",0.995,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0011786,calcitonin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,5.00E-04,-1.215,1.216,"[-1.215,1.216]",0.999,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:3586,biolink:associated_with_increased_likelihood_of,MONDO:0005149,calcitonin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.97032816,4.57E-05,-0.188,0.188,"[-0.188,0.188]",1,16900,21783600,21800500,"Sample size with calcitonin, approximately: 16900","Sample size without calcitonin, approximately: 21783600",All patients number is approximately: 21800500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0019369,calcipotriene,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.4614,0.42,0.502,"[0.42,0.502]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0043693,calcipotriene,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.3452,0.292,0.398,"[0.292,0.398]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0008487,calcipotriene,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.254,0.215,0.293,"[0.215,0.293]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005148,calcipotriene,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.2332,0.198,0.269,"[0.198,0.269]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0011122,calcipotriene,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.1483,0.09,0.206,"[0.09,0.206]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0007160,calcipotriene,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.1154,0.065,0.166,"[0.065,0.166]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0007027,calcipotriene,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.1012,0.038,0.165,"[0.038,0.165]",0.002,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005010,calcipotriene,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0785,0.045,0.112,"[0.045,0.112]",1.00E-04,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0003620,calcipotriene,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0704,-0.23,0.371,"[-0.23,0.371]",0.646,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0011786,calcipotriene,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0648,-0.016,0.146,"[-0.016,0.146]",0.116,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0002909,calcipotriene,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0637,0.015,0.112,"[0.015,0.112]",0.01,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005178,calcipotriene,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0616,-0.011,0.134,"[-0.011,0.134]",0.097,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0002046,calcipotriene,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0473,-0.163,0.258,"[-0.163,0.258]",0.66,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005101,calcipotriene,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.036,-0.103,0.175,"[-0.103,0.175]",0.611,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0007186,calcipotriene,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0221,-0.531,0.576,"[-0.531,0.576]",0.938,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005002,calcipotriene,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0189,-0.179,0.217,"[-0.179,0.217]",0.851,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,calcipotriene,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0162,-0.145,0.177,"[-0.145,0.177]",0.844,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005011,calcipotriene,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0153,-0.328,0.358,"[-0.328,0.358]",0.93,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005180,calcipotriene,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0128,-0.102,0.128,"[-0.102,0.128]",0.827,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0002869,calcipotriene,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0122,-0.099,0.123,"[-0.099,0.123]",0.829,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005083,calcipotriene,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0113,-0.248,0.271,"[-0.248,0.271]",0.932,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0004425,calcipotriene,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0109,-0.31,0.332,"[-0.31,0.332]",0.947,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0004981,calcipotriene,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0088,-0.251,0.269,"[-0.251,0.269]",0.947,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0018882,calcipotriene,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0045,-0.567,0.576,"[-0.567,0.576]",0.988,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0005546,calcipotriene,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0029,-0.516,0.522,"[-0.516,0.522]",0.991,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:5288783,biolink:associated_with_increased_likelihood_of,MONDO:0004979,calcipotriene,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.883199811,0.0014,-0.401,0.404,"[-0.401,0.404]",0.994,65500,21755100,21820600,"Sample size with calcipotriene, approximately: 65500","Sample size without calcipotriene, approximately: 21755100",All patients number is approximately: 21820600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0008300,bupropion,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.8673,0.858,0.876,"[0.858,0.876]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0018882,bupropion,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.6375,0.629,0.646,"[0.629,0.646]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0011786,bupropion,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.488,0.481,0.496,"[0.481,0.496]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0002406,bupropion,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.3675,0.353,0.382,"[0.353,0.382]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0013282,bupropion,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.3043,0.286,0.323,"[0.286,0.323]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005364,bupropion,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.2022,0.189,0.215,"[0.189,0.215]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,bupropion,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1432,0.107,0.179,"[0.107,0.179]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0002316,bupropion,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1416,0.045,0.238,"[0.045,0.238]",0.004,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005147,bupropion,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1333,0.122,0.145,"[0.122,0.145]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0043693,bupropion,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1283,0.103,0.154,"[0.103,0.154]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0008383,bupropion,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1169,0.107,0.127,"[0.107,0.127]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0000424,bupropion,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1141,0.105,0.123,"[0.105,0.123]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0019180,bupropion,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1085,0.087,0.13,"[0.087,0.13]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0021187,bupropion,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.1049,0.09,0.12,"[0.09,0.12]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005180,bupropion,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0901,0.061,0.119,"[0.061,0.119]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007903,bupropion,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0721,0.064,0.081,"[0.064,0.081]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007915,bupropion,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0678,0.054,0.081,"[0.054,0.081]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005101,bupropion,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0557,-0.019,0.131,"[-0.019,0.131]",0.146,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007027,bupropion,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0538,0.046,0.062,"[0.046,0.062]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0002909,bupropion,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0492,0.033,0.065,"[0.033,0.065]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0019565,bupropion,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0435,0.016,0.071,"[0.016,0.071]",0.002,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007160,bupropion,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0408,0.027,0.054,"[0.027,0.054]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0003620,bupropion,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0359,-0.008,0.08,"[-0.008,0.08]",0.108,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0008399,bupropion,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0278,0.017,0.039,"[0.017,0.039]",1.00E-04,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007540,bupropion,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0236,-0.026,0.073,"[-0.026,0.073]",0.348,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0004609,bupropion,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0198,-0.095,0.134,"[-0.095,0.134]",0.735,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005300,bupropion,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0182,-0.12,0.157,"[-0.12,0.157]",0.797,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,bupropion,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0175,-0.005,0.04,"[-0.005,0.04]",0.12,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005298,bupropion,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0161,-0.052,0.084,"[-0.052,0.084]",0.642,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005392,bupropion,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0149,-0.085,0.115,"[-0.085,0.115]",0.771,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0010526,bupropion,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0129,-0.05,0.076,"[-0.05,0.076]",0.689,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0008487,bupropion,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0126,-0.01,0.035,"[-0.01,0.035]",0.275,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0015614,bupropion,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0098,0.002,0.018,"[0.002,0.018]",0.018,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0021107,bupropion,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0076,-0.047,0.062,"[-0.047,0.062]",0.786,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007186,bupropion,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0075,-0.071,0.086,"[-0.071,0.086]",0.853,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0002277,bupropion,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0063,-0.23,0.242,"[-0.23,0.242]",0.958,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0000153,bupropion,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0062,-0.113,0.126,"[-0.113,0.126]",0.918,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007739,bupropion,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0061,-0.067,0.079,"[-0.067,0.079]",0.87,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0006694,bupropion,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.006,-0.003,0.015,"[-0.003,0.015]",0.178,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0019118,bupropion,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0058,-0.214,0.226,"[-0.214,0.226]",0.959,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005404,bupropion,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0045,-0.204,0.213,"[-0.204,0.213]",0.966,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0019350,bupropion,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0041,-0.113,0.121,"[-0.113,0.121]",0.946,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,bupropion,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0038,-0.166,0.174,"[-0.166,0.174]",0.965,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0011508,bupropion,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0034,-0.083,0.09,"[-0.083,0.09]",0.939,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0004648,bupropion,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.003,-0.108,0.114,"[-0.108,0.114]",0.958,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0800026,bupropion,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.003,-0.348,0.354,"[-0.348,0.354]",0.987,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0019369,bupropion,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0027,-0.207,0.212,"[-0.207,0.212]",0.98,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0007947,bupropion,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0023,-0.147,0.152,"[-0.147,0.152]",0.976,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005130,bupropion,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0023,-0.106,0.11,"[-0.106,0.11]",0.967,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0002869,bupropion,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0018,-0.156,0.16,"[-0.156,0.16]",0.982,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0004975,bupropion,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0015,-0.583,0.586,"[-0.583,0.586]",0.996,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0004981,bupropion,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.0011,-0.418,0.421,"[-0.418,0.421]",0.996,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005146,bupropion,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,0.001,-0.392,0.394,"[-0.392,0.394]",0.996,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0005306,bupropion,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,5.00E-04,-0.588,0.589,"[-0.588,0.589]",0.999,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0009693,bupropion,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,4.00E-04,-0.014,0.015,"[-0.014,0.015]",0.961,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:444,biolink:associated_with_increased_likelihood_of,MONDO:0015924,bupropion,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.846512342,4.00E-04,-0.387,0.387,"[-0.387,0.387]",0.998,1625000,20861100,22486100,"Sample size with bupropion, approximately: 1625000","Sample size without bupropion, approximately: 20861100",All patients number is approximately: 22486100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0004975,buprenorphine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.9807,0.965,0.996,"[0.965,0.996]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0002909,buprenorphine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.5806,0.559,0.603,"[0.559,0.603]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005180,buprenorphine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.416,0.398,0.434,"[0.398,0.434]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0004979,buprenorphine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.3792,0.354,0.405,"[0.354,0.405]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0002277,buprenorphine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.3676,0.338,0.397,"[0.338,0.397]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0008599,buprenorphine,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.2212,0.207,0.236,"[0.207,0.236]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005306,buprenorphine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.2175,0.2,0.235,"[0.2,0.235]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0004648,buprenorphine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.2052,0.192,0.218,"[0.192,0.218]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0010602,buprenorphine,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.1876,0.172,0.203,"[0.172,0.203]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0002406,buprenorphine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.1726,0.15,0.195,"[0.15,0.195]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005133,buprenorphine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.1682,0.153,0.183,"[0.153,0.183]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0018177,buprenorphine,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.1174,0.101,0.134,"[0.101,0.134]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0004425,buprenorphine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.1062,0.039,0.173,"[0.039,0.173]",0.002,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005404,buprenorphine,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0495,-0.146,0.245,"[-0.146,0.245]",0.619,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0007915,buprenorphine,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0461,-0.04,0.132,"[-0.04,0.132]",0.295,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0009693,buprenorphine,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0357,0.019,0.052,"[0.019,0.052]",1.00E-04,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0019369,buprenorphine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.032,-0.009,0.073,"[-0.009,0.073]",0.125,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0008487,buprenorphine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0256,-0.103,0.154,"[-0.103,0.154]",0.695,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0009061,buprenorphine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0163,-0.003,0.036,"[-0.003,0.036]",0.097,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0007027,buprenorphine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0158,-0.007,0.039,"[-0.007,0.039]",0.18,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0008383,buprenorphine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0158,-0.139,0.171,"[-0.139,0.171]",0.842,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005393,buprenorphine,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0143,-0.014,0.042,"[-0.014,0.042]",0.315,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005002,buprenorphine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0121,-0.153,0.177,"[-0.153,0.177]",0.886,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0008542,buprenorphine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0091,-0.114,0.133,"[-0.114,0.133]",0.885,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0013282,buprenorphine,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0086,-0.051,0.068,"[-0.051,0.068]",0.777,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,buprenorphine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0063,-0.222,0.234,"[-0.222,0.234]",0.957,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0011786,buprenorphine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0052,-0.119,0.13,"[-0.119,0.13]",0.935,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005101,buprenorphine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0049,-0.226,0.236,"[-0.226,0.236]",0.967,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0003620,buprenorphine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0043,-0.163,0.172,"[-0.163,0.172]",0.96,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,buprenorphine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0041,-0.979,0.987,"[-0.979,0.987]",0.994,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0020066,buprenorphine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.004,-0.255,0.263,"[-0.255,0.263]",0.976,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005302,buprenorphine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0026,-0.751,0.756,"[-0.751,0.756]",0.995,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0021187,buprenorphine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,0.0024,-0.103,0.108,"[-0.103,0.108]",0.964,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0018882,buprenorphine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,9.00E-04,-0.326,0.327,"[-0.326,0.327]",0.996,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0005294,buprenorphine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,2.00E-04,-0.486,0.486,"[-0.486,0.486]",0.999,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:644073,biolink:associated_with_increased_likelihood_of,MONDO:0004609,buprenorphine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.876743671,9.65E-05,-0.298,0.298,"[-0.298,0.298]",0.999,379700,21600500,21980200,"Sample size with buprenorphine, approximately: 379700","Sample size without buprenorphine, approximately: 21600500",All patients number is approximately: 21980200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0008599,bumetanide,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.3168,0.31,0.323,"[0.31,0.323]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0009061,bumetanide,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.2933,0.285,0.301,"[0.285,0.301]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005002,bumetanide,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.2589,0.244,0.274,"[0.244,0.274]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005393,bumetanide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.2545,0.242,0.267,"[0.242,0.267]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0019180,bumetanide,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.2052,0.193,0.217,"[0.193,0.217]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0004952,bumetanide,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.2006,0.194,0.207,"[0.194,0.207]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0011429,bumetanide,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1878,0.176,0.2,"[0.176,0.2]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005178,bumetanide,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1755,0.168,0.183,"[0.168,0.183]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0004609,bumetanide,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1727,0.158,0.187,"[0.158,0.187]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0016532,bumetanide,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1487,0.132,0.166,"[0.132,0.166]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0004975,bumetanide,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1279,0.09,0.166,"[0.09,0.166]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0007186,bumetanide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1279,0.104,0.152,"[0.104,0.152]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0800026,bumetanide,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1195,0.112,0.127,"[0.112,0.127]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0008399,bumetanide,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.117,0.11,0.124,"[0.11,0.124]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0002316,bumetanide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.1125,0.093,0.132,"[0.093,0.132]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005083,bumetanide,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0935,0.072,0.115,"[0.072,0.115]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0006694,bumetanide,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0934,0.08,0.107,"[0.08,0.107]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0011849,bumetanide,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0724,0.037,0.108,"[0.037,0.108]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0008383,bumetanide,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0642,0.036,0.093,"[0.036,0.093]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0009693,bumetanide,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0578,0.049,0.066,"[0.049,0.066]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0007864,bumetanide,klippel trenaunay syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0451,0.017,0.073,"[0.017,0.073]",0.002,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0020066,bumetanide,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.045,0.004,0.086,"[0.004,0.086]",0.032,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005147,bumetanide,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0433,0.022,0.064,"[0.022,0.064]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005404,bumetanide,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0344,0.005,0.064,"[0.005,0.064]",0.022,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0006640,bumetanide,adrenal cushing syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0258,0.006,0.045,"[0.006,0.045]",0.009,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0007915,bumetanide,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0252,0.009,0.042,"[0.009,0.042]",0.003,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005148,bumetanide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0152,0.007,0.023,"[0.007,0.023]",1.00E-04,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0018882,bumetanide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0127,-0.088,0.114,"[-0.088,0.114]",0.805,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0003620,bumetanide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0112,-0.138,0.161,"[-0.138,0.161]",0.883,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005298,bumetanide,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0111,-0.072,0.094,"[-0.072,0.094]",0.794,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,bumetanide,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0082,-0.095,0.111,"[-0.095,0.111]",0.876,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0019118,bumetanide,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0079,-0.042,0.057,"[-0.042,0.057]",0.753,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0019499,bumetanide,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0076,-0.104,0.119,"[-0.104,0.119]",0.894,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0002046,bumetanide,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0066,-0.036,0.049,"[-0.036,0.049]",0.76,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0008487,bumetanide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0054,-0.172,0.183,"[-0.172,0.183]",0.952,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0002277,bumetanide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0054,-0.117,0.127,"[-0.117,0.127]",0.931,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0015564,bumetanide,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0043,-63.353,63.361,"[-63.353,63.361]",1,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0019369,bumetanide,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0043,-63.353,63.361,"[-63.353,63.361]",1,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0004648,bumetanide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0033,-0.098,0.105,"[-0.098,0.105]",0.949,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0016218,bumetanide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0031,-0.103,0.109,"[-0.103,0.109]",0.954,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005009,bumetanide,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0031,-0.079,0.086,"[-0.079,0.086]",0.941,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005294,bumetanide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0025,-0.292,0.297,"[-0.292,0.297]",0.987,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005392,bumetanide,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0014,-0.156,0.159,"[-0.156,0.159]",0.986,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,bumetanide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.0012,-0.225,0.228,"[-0.225,0.228]",0.992,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0010789,bumetanide,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,0.001,-0.327,0.329,"[-0.327,0.329]",0.995,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0008394,bumetanide,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,9.00E-04,-0.229,0.231,"[-0.229,0.231]",0.994,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0015924,bumetanide,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,8.00E-04,-0.298,0.299,"[-0.298,0.299]",0.996,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0009891,bumetanide,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,7.00E-04,-0.254,0.255,"[-0.254,0.255]",0.996,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005149,bumetanide,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,6.00E-04,-0.413,0.415,"[-0.413,0.415]",0.998,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,bumetanide,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,3.00E-04,-0.153,0.154,"[-0.153,0.154]",0.997,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005116,bumetanide,whipple disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,3.00E-04,-0.044,0.044,"[-0.044,0.044]",0.99,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2471,biolink:associated_with_increased_likelihood_of,MONDO:0005146,bumetanide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.974100085,1.00E-04,-0.076,0.076,"[-0.076,0.076]",0.997,1658800,21294600,22953400,"Sample size with bumetanide, approximately: 1658800","Sample size without bumetanide, approximately: 21294600",All patients number is approximately: 22953400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0018177,budesonide,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.6598,0.651,0.668,"[0.651,0.668]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0006058,budesonide,nephroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.3488,0.341,0.357,"[0.341,0.357]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005133,budesonide,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.2924,0.285,0.299,"[0.285,0.299]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008644,budesonide,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.2765,0.269,0.284,"[0.269,0.284]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005393,budesonide,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.2706,0.261,0.28,"[0.261,0.28]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0015263,budesonide,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.2309,0.222,0.24,"[0.222,0.24]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008542,budesonide,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.1856,0.171,0.2,"[0.171,0.2]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0009061,budesonide,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.1656,0.15,0.181,"[0.15,0.181]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0011786,budesonide,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.153,0.137,0.169,"[0.137,0.169]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0018975,budesonide,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.147,0.135,0.159,"[0.135,0.159]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005011,budesonide,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.1058,0.089,0.122,"[0.089,0.122]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005180,budesonide,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.1034,0.086,0.12,"[0.086,0.12]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007818,budesonide,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.1015,0.086,0.117,"[0.086,0.117]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0004981,budesonide,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.094,0.072,0.116,"[0.072,0.116]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005146,budesonide,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0651,0.051,0.079,"[0.051,0.079]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0018882,budesonide,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0606,0.028,0.094,"[0.028,0.094]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0015614,budesonide,dermatitis herpetiformis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0554,0.048,0.063,"[0.048,0.063]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005101,budesonide,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0549,0.009,0.101,"[0.009,0.101]",0.019,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005083,budesonide,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0513,0.022,0.081,"[0.022,0.081]",0.001,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0004979,budesonide,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0509,0.021,0.08,"[0.021,0.08]",0.001,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0019499,budesonide,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0432,0.034,0.053,"[0.034,0.053]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007739,budesonide,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0386,0.025,0.053,"[0.025,0.053]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0002277,budesonide,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0342,-0.033,0.101,"[-0.033,0.101]",0.316,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008377,budesonide,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0216,0.014,0.03,"[0.014,0.03]",1.00E-04,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0010526,budesonide,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0209,-0.109,0.151,"[-0.109,0.151]",0.752,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0021187,budesonide,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0206,-0.101,0.142,"[-0.101,0.142]",0.739,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005711,budesonide,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0196,-0.037,0.077,"[-0.037,0.077]",0.501,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008300,budesonide,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0173,-0.105,0.14,"[-0.105,0.14]",0.782,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007947,budesonide,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0164,-0.03,0.063,"[-0.03,0.063]",0.488,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0013282,budesonide,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0143,-0.027,0.056,"[-0.027,0.056]",0.501,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007160,budesonide,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.012,-0.025,0.049,"[-0.025,0.049]",0.527,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0011508,budesonide,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0119,-0.104,0.128,"[-0.104,0.128]",0.84,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005072,budesonide,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.009,-0.097,0.115,"[-0.097,0.115]",0.867,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007027,budesonide,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0079,0,0.016,"[0,0.016]",0.062,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0010602,budesonide,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0078,-0.018,0.034,"[-0.018,0.034]",0.558,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008642,budesonide,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0078,-0.043,0.058,"[-0.043,0.058]",0.762,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008399,budesonide,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0071,-0.002,0.017,"[-0.002,0.017]",0.14,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007827,budesonide,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0068,-0.101,0.115,"[-0.101,0.115]",0.901,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0043693,budesonide,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0063,-0.101,0.113,"[-0.101,0.113]",0.908,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008738,budesonide,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0061,-0.003,0.016,"[-0.003,0.016]",0.21,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005294,budesonide,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0057,-0.024,0.035,"[-0.024,0.035]",0.705,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0002316,budesonide,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0054,-0.072,0.083,"[-0.072,0.083]",0.892,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0007186,budesonide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0041,-0.247,0.255,"[-0.247,0.255]",0.975,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0019180,budesonide,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.004,-0.146,0.154,"[-0.146,0.154]",0.958,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0000477,budesonide,focal dystonia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0033,-0.167,0.173,"[-0.167,0.173]",0.969,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,budesonide,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0032,-0.045,0.052,"[-0.045,0.052]",0.897,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005364,budesonide,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0027,-0.222,0.228,"[-0.222,0.228]",0.981,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0019565,budesonide,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.0012,-0.618,0.621,"[-0.618,0.621]",0.997,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0016218,budesonide,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,0.001,-0.421,0.423,"[-0.421,0.423]",0.996,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0004648,budesonide,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,7.00E-04,-0.152,0.153,"[-0.152,0.153]",0.993,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0008487,budesonide,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,7.00E-04,-0.264,0.265,"[-0.264,0.265]",0.996,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,budesonide,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,4.00E-04,-0.563,0.564,"[-0.563,0.564]",0.999,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0005546,budesonide,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,4.00E-04,-0.659,0.66,"[-0.659,0.66]",0.999,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0020066,budesonide,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,4.00E-04,-0.464,0.465,"[-0.464,0.465]",0.999,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0003620,budesonide,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,2.00E-04,-0.044,0.045,"[-0.044,0.045]",0.991,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242500,biolink:associated_with_increased_likelihood_of,MONDO:0000153,budesonide,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972794592,1.00E-04,-0.3,0.3,"[-0.3,0.3]",0.999,2761000,20725800,23486800,"Sample size with budesonide, approximately: 2761000","Sample size without budesonide, approximately: 20725800",All patients number is approximately: 23486800,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C3491331,biolink:associated_with_increased_likelihood_of,MONDO:0005300,brodalumab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.938440436,0.0325,-0.774,0.839,"[-0.774,0.839]",0.937,400,21792100,21792500,"Sample size with brodalumab, approximately: 400","Sample size without brodalumab, approximately: 21792100",All patients number is approximately: 21792500,,infores:isb-EHRMLA-data,prediction,computational_model
UMLS:C3491331,biolink:associated_with_increased_likelihood_of,MONDO:0011849,brodalumab,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.938440436,0.0137,-0.599,0.626,"[-0.599,0.626]",0.965,400,21792100,21792500,"Sample size with brodalumab, approximately: 400","Sample size without brodalumab, approximately: 21792100",All patients number is approximately: 21792500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0002277,brexpiprazole,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.7674,0.687,0.848,"[0.687,0.848]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0007186,brexpiprazole,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.7079,0.634,0.782,"[0.634,0.782]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0002046,brexpiprazole,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.6626,0.619,0.706,"[0.619,0.706]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0004975,brexpiprazole,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.4054,0.337,0.474,"[0.337,0.474]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0002909,brexpiprazole,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.2725,0.224,0.321,"[0.224,0.321]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0008487,brexpiprazole,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.272,0.147,0.397,"[0.147,0.397]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005180,brexpiprazole,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.2347,0.136,0.334,"[0.136,0.334]",1.00E-04,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005083,brexpiprazole,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.2059,0.047,0.364,"[0.047,0.364]",0.011,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0011786,brexpiprazole,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0995,-0.134,0.333,"[-0.134,0.333]",0.403,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005300,brexpiprazole,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0381,-0.09,0.166,"[-0.09,0.166]",0.559,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,brexpiprazole,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0303,-0.669,0.729,"[-0.669,0.729]",0.932,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005002,brexpiprazole,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0248,-0.257,0.307,"[-0.257,0.307]",0.863,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,brexpiprazole,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0234,-0.555,0.602,"[-0.555,0.602]",0.937,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0004981,brexpiprazole,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0155,-0.622,0.653,"[-0.622,0.653]",0.962,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0007915,brexpiprazole,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0114,-0.43,0.453,"[-0.43,0.453]",0.96,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005133,brexpiprazole,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0095,-1.21,1.229,"[-1.21,1.229]",0.988,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,brexpiprazole,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.0081,-0.831,0.847,"[-0.831,0.847]",0.985,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0249379,biolink:associated_with_increased_likelihood_of,MONDO:0005101,brexpiprazole,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.916703497,0.004,-1.25,1.258,"[-1.25,1.258]",0.995,28100,21779300,21807400,"Sample size with brexpiprazole, approximately: 28100","Sample size without brexpiprazole, approximately: 21779300",All patients number is approximately: 21807400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005180,bisoprolol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.6409,0.619,0.663,"[0.619,0.663]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005546,bisoprolol,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.5103,0.492,0.528,"[0.492,0.528]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005010,bisoprolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.4365,0.417,0.456,"[0.417,0.456]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005009,bisoprolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.3454,0.321,0.37,"[0.321,0.37]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005130,bisoprolol,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.3449,0.322,0.368,"[0.322,0.368]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005147,bisoprolol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.3308,0.306,0.355,"[0.306,0.355]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0019369,bisoprolol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.217,0.192,0.242,"[0.192,0.242]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0002277,bisoprolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.1586,0.112,0.206,"[0.112,0.206]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005011,bisoprolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.1404,0.1,0.181,"[0.1,0.181]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0002046,bisoprolol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.1285,0.024,0.233,"[0.024,0.233]",0.016,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0011122,bisoprolol,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.1074,0.084,0.131,"[0.084,0.131]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,bisoprolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0898,0.036,0.143,"[0.036,0.143]",0.001,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0008383,bisoprolol,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0773,0.052,0.103,"[0.052,0.103]",1.00E-04,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0006694,bisoprolol,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0344,0.005,0.063,"[0.005,0.063]",0.02,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0009693,bisoprolol,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0242,-0.045,0.094,"[-0.045,0.094]",0.496,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0000424,bisoprolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0214,-0.072,0.115,"[-0.072,0.115]",0.654,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005146,bisoprolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0187,-0.067,0.104,"[-0.067,0.104]",0.669,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005101,bisoprolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0155,-0.047,0.078,"[-0.047,0.078]",0.628,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0002909,bisoprolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0152,-0.033,0.063,"[-0.033,0.063]",0.532,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0004975,bisoprolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0132,-0.081,0.108,"[-0.081,0.108]",0.785,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005298,bisoprolol,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0125,-0.183,0.208,"[-0.183,0.208]",0.901,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0011786,bisoprolol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0072,-0.092,0.107,"[-0.092,0.107]",0.887,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0004981,bisoprolol,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0063,-0.293,0.306,"[-0.293,0.306]",0.967,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0004952,bisoprolol,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0052,-0.143,0.153,"[-0.143,0.153]",0.945,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0004979,bisoprolol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0044,-0.139,0.148,"[-0.139,0.148]",0.951,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0004425,bisoprolol,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.0029,-0.263,0.269,"[-0.263,0.269]",0.983,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0007186,bisoprolol,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,0.001,-0.618,0.62,"[-0.618,0.62]",0.997,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2405,biolink:associated_with_increased_likelihood_of,MONDO:0005364,bisoprolol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.9035264,5.00E-04,-0.495,0.496,"[-0.495,0.496]",0.998,116500,21724300,21840800,"Sample size with bisoprolol, approximately: 116500","Sample size without bisoprolol, approximately: 21724300",All patients number is approximately: 21840800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251991,biolink:associated_with_increased_likelihood_of,MONDO:0005009,bempedoic acid,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.923196762,0.0062,-2.975,2.988,"[-2.975,2.988]",0.997,6900,21787800,21794700,"Sample size with bempedoic acid, approximately: 6900","Sample size without bempedoic acid, approximately: 21787800",All patients number is approximately: 21794700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005130,beclomethasone,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,1.2559,1.246,1.266,"[1.246,1.266]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005392,beclomethasone,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,1.1578,1.14,1.175,"[1.14,1.175]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0004979,beclomethasone,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.3076,0.289,0.326,"[0.289,0.326]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0019369,beclomethasone,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.2772,0.263,0.291,"[0.263,0.291]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005302,beclomethasone,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.1455,0.113,0.178,"[0.113,0.178]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005146,beclomethasone,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.1234,0.103,0.144,"[0.103,0.144]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0004975,beclomethasone,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.1162,0.092,0.14,"[0.092,0.14]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0008383,beclomethasone,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.1076,0.095,0.12,"[0.095,0.12]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0009693,beclomethasone,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.106,0.086,0.126,"[0.086,0.126]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0009061,beclomethasone,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0888,0.067,0.11,"[0.067,0.11]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005178,beclomethasone,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0791,0.043,0.115,"[0.043,0.115]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,beclomethasone,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0652,0.031,0.099,"[0.031,0.099]",1.00E-04,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005101,beclomethasone,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0535,0.008,0.099,"[0.008,0.099]",0.02,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005404,beclomethasone,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0478,-0.001,0.097,"[-0.001,0.097]",0.056,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0002406,beclomethasone,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0451,-0.013,0.104,"[-0.013,0.104]",0.131,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0019118,beclomethasone,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0444,0.011,0.078,"[0.011,0.078]",0.009,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005010,beclomethasone,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0431,-0.022,0.108,"[-0.022,0.108]",0.191,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0004952,beclomethasone,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0296,-0.021,0.08,"[-0.021,0.08]",0.249,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005083,beclomethasone,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0244,-0.048,0.097,"[-0.048,0.097]",0.511,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0004981,beclomethasone,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0219,-0.05,0.094,"[-0.05,0.094]",0.554,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0018177,beclomethasone,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.016,-0.009,0.041,"[-0.009,0.041]",0.203,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0007915,beclomethasone,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.015,-0.118,0.148,"[-0.118,0.148]",0.826,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,beclomethasone,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0121,-0.223,0.247,"[-0.223,0.247]",0.92,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005300,beclomethasone,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0117,-0.065,0.088,"[-0.065,0.088]",0.764,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0002909,beclomethasone,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0113,-0.017,0.04,"[-0.017,0.04]",0.44,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0013282,beclomethasone,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0106,-0.075,0.096,"[-0.075,0.096]",0.807,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0004609,beclomethasone,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0093,-0.231,0.249,"[-0.231,0.249]",0.94,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005298,beclomethasone,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.008,-0.106,0.122,"[-0.106,0.122]",0.891,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005388,beclomethasone,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0076,-0.109,0.124,"[-0.109,0.124]",0.898,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0002277,beclomethasone,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0063,-0.109,0.122,"[-0.109,0.122]",0.914,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0011786,beclomethasone,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0041,-0.21,0.218,"[-0.21,0.218]",0.97,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005546,beclomethasone,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.003,-0.306,0.312,"[-0.306,0.312]",0.985,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0011429,beclomethasone,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0028,-0.186,0.192,"[-0.186,0.192]",0.977,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005009,beclomethasone,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0023,-0.24,0.245,"[-0.24,0.245]",0.985,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,beclomethasone,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0022,-0.18,0.184,"[-0.18,0.184]",0.981,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005364,beclomethasone,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.002,-0.261,0.265,"[-0.261,0.265]",0.988,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0003620,beclomethasone,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,0.0011,-0.161,0.163,"[-0.161,0.163]",0.989,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0007186,beclomethasone,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,7.00E-04,-1.046,1.047,"[-1.046,1.047]",0.999,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0005133,beclomethasone,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,5.00E-04,-0.703,0.704,"[-0.703,0.704]",0.999,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0243494,biolink:associated_with_increased_likelihood_of,MONDO:0002869,beclomethasone,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.898054948,4.00E-04,-0.579,0.58,"[-0.579,0.58]",0.999,453600,21511100,21964700,"Sample size with beclomethasone, approximately: 453600","Sample size without beclomethasone, approximately: 21511100",All patients number is approximately: 21964700,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0000424,baricitinib,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,1.9887,1.958,2.019,"[1.958,2.019]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0021187,baricitinib,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,1.3162,1.283,1.349,"[1.283,1.349]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0008487,baricitinib,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.7092,0.682,0.736,"[0.682,0.736]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0003620,baricitinib,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.4842,0.459,0.509,"[0.459,0.509]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0009891,baricitinib,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.391,0.358,0.424,"[0.358,0.424]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0011122,baricitinib,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.3209,0.289,0.353,"[0.289,0.353]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0019369,baricitinib,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.2904,0.25,0.331,"[0.25,0.331]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005178,baricitinib,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.2372,0.193,0.281,"[0.193,0.281]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,baricitinib,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.1914,0.165,0.218,"[0.165,0.218]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005180,baricitinib,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.1201,0.089,0.152,"[0.089,0.152]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005546,baricitinib,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.1057,0.054,0.158,"[0.054,0.158]",1.00E-04,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005298,baricitinib,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.0255,-0.057,0.108,"[-0.057,0.108]",0.546,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0002277,baricitinib,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.0198,-0.164,0.204,"[-0.164,0.204]",0.833,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,baricitinib,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.0088,-0.281,0.298,"[-0.281,0.298]",0.953,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005002,baricitinib,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.0052,-0.495,0.505,"[-0.495,0.505]",0.984,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248873,biolink:associated_with_increased_likelihood_of,MONDO:0005404,baricitinib,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.991354085,0.0018,-0.598,0.601,"[-0.598,0.601]",0.995,69400,21766000,21835400,"Sample size with baricitinib, approximately: 69400","Sample size without baricitinib, approximately: 21766000",All patients number is approximately: 21835400,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0007903,azithromycin,li fraumeni syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.7503,0.742,0.758,"[0.742,0.758]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0015263,azithromycin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.7486,0.744,0.754,"[0.744,0.754]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0008738,azithromycin,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.5498,0.545,0.555,"[0.545,0.555]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005180,azithromycin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.3125,0.305,0.32,"[0.305,0.32]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0007947,azithromycin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.276,0.271,0.281,"[0.271,0.281]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0009891,azithromycin,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.2233,0.219,0.228,"[0.219,0.228]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0008644,azithromycin,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.2179,0.213,0.223,"[0.213,0.223]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0018177,azithromycin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.2017,0.197,0.206,"[0.197,0.206]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,azithromycin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.1867,0.181,0.192,"[0.181,0.192]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0016532,azithromycin,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.1485,0.143,0.154,"[0.143,0.154]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0008006,azithromycin,moebius syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0888,0.082,0.095,"[0.082,0.095]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005388,azithromycin,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0837,0.078,0.089,"[0.078,0.089]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0001516,azithromycin,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0812,0.076,0.087,"[0.076,0.087]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0004981,azithromycin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0625,0.033,0.092,"[0.033,0.092]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0004425,azithromycin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0514,-0.015,0.117,"[-0.015,0.117]",0.128,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0020066,azithromycin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0475,0.04,0.055,"[0.04,0.055]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0006694,azithromycin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.043,0.038,0.048,"[0.038,0.048]",1.00E-04,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005149,azithromycin,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0303,0.006,0.054,"[0.006,0.054]",0.013,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0007843,azithromycin,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0248,-0.07,0.119,"[-0.07,0.119]",0.606,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0021187,azithromycin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0216,0.002,0.042,"[0.002,0.042]",0.034,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0004979,azithromycin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0088,-0.016,0.034,"[-0.016,0.034]",0.492,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005148,azithromycin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0076,-0.139,0.155,"[-0.139,0.155]",0.919,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005146,azithromycin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0072,-0.01,0.025,"[-0.01,0.025]",0.423,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0002406,azithromycin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0056,-0.62,0.631,"[-0.62,0.631]",0.986,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0019369,azithromycin,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.005,-13.564,13.574,"[-13.564,13.574]",0.999,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0800026,azithromycin,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.005,-13.565,13.575,"[-13.565,13.575]",0.999,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005147,azithromycin,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0032,-0.004,0.01,"[-0.004,0.01]",0.396,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,azithromycin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0031,-0.069,0.075,"[-0.069,0.075]",0.932,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0011429,azithromycin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0014,-0.131,0.133,"[-0.131,0.133]",0.984,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0002277,azithromycin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0013,-1.551,1.553,"[-1.551,1.553]",0.999,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,azithromycin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0013,-0.188,0.19,"[-0.188,0.19]",0.989,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0007827,azithromycin,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,0.0012,-0.211,0.213,"[-0.211,0.213]",0.991,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0009693,azithromycin,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,6.00E-04,-0.011,0.012,"[-0.011,0.012]",0.915,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005306,azithromycin,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,5.00E-04,-0.369,0.37,"[-0.369,0.37]",0.998,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0015564,azithromycin,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,5.00E-04,-0.233,0.234,"[-0.233,0.234]",0.996,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0013282,azithromycin,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,3.00E-04,-0.078,0.078,"[-0.078,0.078]",0.995,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0005302,azithromycin,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,3.00E-04,-0.306,0.307,"[-0.306,0.307]",0.998,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242518,biolink:associated_with_increased_likelihood_of,MONDO:0019118,azithromycin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.831063196,6.06E-06,-0.03,0.03,"[-0.03,0.03]",1,4894900,18930100,23825000,"Sample size with azithromycin, approximately: 4894900","Sample size without azithromycin, approximately: 18930100",All patients number is approximately: 23825000,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0011122,azilsartan,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.3012,0.217,0.385,"[0.217,0.385]",1.00E-04,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0005010,azilsartan,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.1826,0.112,0.253,"[0.112,0.253]",1.00E-04,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0004609,azilsartan,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.1779,0.04,0.316,"[0.04,0.316]",0.012,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0005002,azilsartan,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.1468,0.045,0.249,"[0.045,0.249]",0.005,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0000424,azilsartan,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.1193,0.026,0.212,"[0.026,0.212]",0.012,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0002046,azilsartan,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0817,-0.4,0.564,"[-0.4,0.564]",0.74,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0005146,azilsartan,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0606,-0.089,0.21,"[-0.089,0.21]",0.427,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,azilsartan,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0245,-0.628,0.677,"[-0.628,0.677]",0.941,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0021187,azilsartan,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0233,-0.228,0.274,"[-0.228,0.274]",0.856,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0004981,azilsartan,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0226,-0.229,0.274,"[-0.229,0.274]",0.86,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0007186,azilsartan,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0195,-0.8,0.839,"[-0.8,0.839]",0.963,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,MONDO:0004425,azilsartan,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0195,-0.443,0.482,"[-0.443,0.482]",0.934,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,azilsartan,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0103,-0.537,0.558,"[-0.537,0.558]",0.97,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,azilsartan,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0034,-1.015,1.022,"[-1.015,1.022]",0.995,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248802,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,azilsartan,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924421143,0.0033,-1.137,1.144,"[-1.137,1.144]",0.995,22000,21779900,21801900,"Sample size with azilsartan, approximately: 22000","Sample size without azilsartan, approximately: 21779900",All patients number is approximately: 21801900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0019369,azathioprine,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.6135,0.56,0.667,"[0.56,0.667]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0002046,azathioprine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.5086,0.459,0.558,"[0.459,0.558]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0018882,azathioprine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.4564,0.431,0.482,"[0.431,0.482]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0002909,azathioprine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.3845,0.354,0.415,"[0.354,0.415]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005178,azathioprine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.3806,0.353,0.408,"[0.353,0.408]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,azathioprine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.3598,0.33,0.39,"[0.33,0.39]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0007027,azathioprine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.3275,0.296,0.359,"[0.296,0.359]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,azathioprine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.2457,0.212,0.28,"[0.212,0.28]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0008377,azathioprine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.2241,0.178,0.27,"[0.178,0.27]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005294,azathioprine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.1875,0.081,0.294,"[0.081,0.294]",0.001,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0008399,azathioprine,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.1476,0.11,0.185,"[0.11,0.185]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0021187,azathioprine,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.1122,0.084,0.14,"[0.084,0.14]",1.00E-04,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0004981,azathioprine,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0847,0.028,0.141,"[0.028,0.141]",0.003,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005302,azathioprine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0615,0.026,0.097,"[0.026,0.097]",0.001,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,azathioprine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0476,-0.012,0.108,"[-0.012,0.108]",0.12,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0004979,azathioprine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0354,-0.248,0.319,"[-0.248,0.319]",0.807,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0043693,azathioprine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0179,-0.008,0.044,"[-0.008,0.044]",0.179,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0011122,azathioprine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0174,-0.076,0.111,"[-0.076,0.111]",0.716,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005002,azathioprine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.017,-0.279,0.313,"[-0.279,0.313]",0.91,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0020066,azathioprine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0113,-0.106,0.129,"[-0.106,0.129]",0.851,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005010,azathioprine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0087,-0.042,0.059,"[-0.042,0.059]",0.734,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0006694,azathioprine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0081,-0.02,0.036,"[-0.02,0.036]",0.575,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0002869,azathioprine,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0069,-0.205,0.219,"[-0.205,0.219]",0.949,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005011,azathioprine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0064,-0.342,0.355,"[-0.342,0.355]",0.971,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005364,azathioprine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0025,-0.355,0.36,"[-0.355,0.36]",0.989,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005009,azathioprine,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0024,-1.063,1.068,"[-1.063,1.068]",0.997,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0011429,azathioprine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0023,-0.204,0.209,"[-0.204,0.209]",0.982,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0003620,azathioprine,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0016,-0.391,0.395,"[-0.391,0.395]",0.994,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0002406,azathioprine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,0.0016,-0.167,0.171,"[-0.167,0.171]",0.986,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005133,azathioprine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,8.00E-04,-0.218,0.22,"[-0.218,0.22]",0.994,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005300,azathioprine,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,5.00E-04,-0.66,0.661,"[-0.66,0.661]",0.999,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2265,biolink:associated_with_increased_likelihood_of,MONDO:0005306,azathioprine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.915692534,2.00E-04,-0.621,0.621,"[-0.621,0.621]",1,95300,21742600,21837900,"Sample size with azathioprine, approximately: 95300","Sample size without azathioprine, approximately: 21742600",All patients number is approximately: 21837900,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0004952,atorvastatin,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,1.4762,1.473,1.48,"[1.473,1.48]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005392,atorvastatin,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,1.1124,1.107,1.118,"[1.107,1.118]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005546,atorvastatin,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.4907,0.485,0.496,"[0.485,0.496]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0002277,atorvastatin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.4838,0.47,0.497,"[0.47,0.497]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005010,atorvastatin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.3593,0.346,0.373,"[0.346,0.373]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0019565,atorvastatin,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.3003,0.285,0.316,"[0.285,0.316]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005711,atorvastatin,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.2391,0.231,0.248,"[0.231,0.248]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0002909,atorvastatin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.2272,0.223,0.232,"[0.223,0.232]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008487,atorvastatin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1913,0.179,0.203,"[0.179,0.203]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008642,atorvastatin,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1913,0.177,0.206,"[0.177,0.206]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005178,atorvastatin,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1891,0.18,0.198,"[0.18,0.198]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005130,atorvastatin,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1806,0.175,0.186,"[0.175,0.186]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0004979,atorvastatin,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1783,0.164,0.192,"[0.164,0.192]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008300,atorvastatin,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1544,0.148,0.161,"[0.148,0.161]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005148,atorvastatin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1445,0.123,0.166,"[0.123,0.166]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0015263,atorvastatin,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.1017,0.096,0.107,"[0.096,0.107]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008383,atorvastatin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0987,0.087,0.111,"[0.087,0.111]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0001676,atorvastatin,erythropoietic protoporphyria,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0939,0.054,0.134,"[0.054,0.134]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0000914,atorvastatin,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0818,0.074,0.089,"[0.074,0.089]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0016532,atorvastatin,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0709,0.038,0.104,"[0.038,0.104]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0009061,atorvastatin,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.067,0.062,0.072,"[0.062,0.072]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005298,atorvastatin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0663,-0.001,0.134,"[-0.001,0.134]",0.055,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005294,atorvastatin,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0483,0.031,0.066,"[0.031,0.066]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008399,atorvastatin,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0422,0.027,0.057,"[0.027,0.057]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0001516,atorvastatin,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0392,0.034,0.044,"[0.034,0.044]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0007972,atorvastatin,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0354,0.029,0.042,"[0.029,0.042]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0000424,atorvastatin,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0348,0.011,0.059,"[0.011,0.059]",0.005,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0019118,atorvastatin,retinal dystrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0307,0.003,0.058,"[0.003,0.058]",0.029,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0002046,atorvastatin,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0246,-0.018,0.068,"[-0.018,0.068]",0.261,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0006694,atorvastatin,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0225,0.016,0.03,"[0.016,0.03]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0019350,atorvastatin,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0186,-0.012,0.05,"[-0.012,0.05]",0.24,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0007827,atorvastatin,inclusion body myositis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0178,-0.034,0.07,"[-0.034,0.07]",0.503,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0007843,atorvastatin,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.017,-0.07,0.103,"[-0.07,0.103]",0.701,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0011122,atorvastatin,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0161,0.006,0.026,"[0.006,0.026]",0.001,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0010602,atorvastatin,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0133,0.007,0.019,"[0.007,0.019]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0018177,atorvastatin,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0132,0.008,0.019,"[0.008,0.019]",1.00E-04,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0008394,atorvastatin,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0113,-0.05,0.072,"[-0.05,0.072]",0.717,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005011,atorvastatin,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.008,-0.043,0.059,"[-0.043,0.059]",0.758,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0000153,atorvastatin,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0072,-0.065,0.08,"[-0.065,0.08]",0.847,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005101,atorvastatin,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0055,-0.059,0.07,"[-0.059,0.07]",0.868,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005146,atorvastatin,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0055,-0.081,0.092,"[-0.081,0.092]",0.901,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0019499,atorvastatin,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0053,-0.043,0.054,"[-0.043,0.054]",0.83,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0011786,atorvastatin,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0037,-0.153,0.16,"[-0.153,0.16]",0.963,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0002316,atorvastatin,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0037,-0.203,0.211,"[-0.203,0.211]",0.972,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0020066,atorvastatin,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0036,-0.027,0.034,"[-0.027,0.034]",0.818,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,atorvastatin,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0035,-0.085,0.092,"[-0.085,0.092]",0.939,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0002406,atorvastatin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0025,-0.078,0.083,"[-0.078,0.083]",0.952,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0005364,atorvastatin,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0021,-0.079,0.083,"[-0.079,0.083]",0.959,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,atorvastatin,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,0.0011,-0.157,0.159,"[-0.157,0.159]",0.989,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0015564,atorvastatin,castleman disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,5.00E-04,-0.46,0.461,"[-0.46,0.461]",0.998,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0019180,atorvastatin,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,4.00E-04,-0.792,0.793,"[-0.792,0.793]",0.999,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0016218,atorvastatin,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,4.00E-04,-0.229,0.23,"[-0.229,0.23]",0.997,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0021187,atorvastatin,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,3.00E-04,-0.271,0.272,"[-0.271,0.272]",0.998,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0007947,atorvastatin,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,3.00E-04,-0.304,0.305,"[-0.304,0.305]",0.998,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0018882,atorvastatin,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,3.00E-04,-0.508,0.509,"[-0.508,0.509]",0.999,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0004609,atorvastatin,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,2.00E-04,-0.359,0.359,"[-0.359,0.359]",0.999,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0007739,atorvastatin,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,7.53E-05,-0.912,0.912,"[-0.912,0.912]",1,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60823,biolink:associated_with_increased_likelihood_of,MONDO:0015924,atorvastatin,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.939739441,2.94E-05,-0.537,0.537,"[-0.537,0.537]",1,9070100,17515700,26585800,"Sample size with atorvastatin, approximately: 9070100","Sample size without atorvastatin, approximately: 17515700",All patients number is approximately: 26585800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,atenolol,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.9225,0.911,0.934,"[0.911,0.934]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0019369,atenolol,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.8711,0.864,0.878,"[0.864,0.878]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005302,atenolol,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.8256,0.819,0.832,"[0.819,0.832]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005072,atenolol,neuroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.5215,0.516,0.527,"[0.516,0.527]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0003620,atenolol,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.4445,0.439,0.45,"[0.439,0.45]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005147,atenolol,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.3335,0.327,0.34,"[0.327,0.34]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0009891,atenolol,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.3041,0.292,0.316,"[0.292,0.316]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0010383,atenolol,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.2883,0.282,0.295,"[0.282,0.295]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005011,atenolol,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.2404,0.227,0.254,"[0.227,0.254]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0018975,atenolol,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.2044,0.196,0.213,"[0.196,0.213]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005178,atenolol,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.2037,0.193,0.214,"[0.193,0.214]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,atenolol,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.1989,0.19,0.208,"[0.19,0.208]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005149,atenolol,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.1653,0.156,0.175,"[0.156,0.175]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0002406,atenolol,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.158,0.151,0.165,"[0.151,0.165]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0021107,atenolol,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.1169,0.107,0.127,"[0.107,0.127]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0013282,atenolol,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.1117,0.092,0.131,"[0.092,0.131]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005101,atenolol,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.1022,0.091,0.113,"[0.091,0.113]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005180,atenolol,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0977,0.092,0.103,"[0.092,0.103]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0004975,atenolol,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0806,0.058,0.103,"[0.058,0.103]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0008399,atenolol,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0645,0.051,0.078,"[0.051,0.078]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0800026,atenolol,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0598,0.037,0.083,"[0.037,0.083]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0000424,atenolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0586,0.05,0.067,"[0.05,0.067]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0002909,atenolol,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0577,0.041,0.075,"[0.041,0.075]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0010602,atenolol,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0571,0.034,0.08,"[0.034,0.08]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0016532,atenolol,lennox gastaut syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0567,0.045,0.068,"[0.045,0.068]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005009,atenolol,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0552,0.044,0.066,"[0.044,0.066]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005364,atenolol,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0297,-0.036,0.095,"[-0.036,0.095]",0.376,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0011786,atenolol,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0278,-0.029,0.085,"[-0.029,0.085]",0.339,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0006694,atenolol,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0276,0.013,0.042,"[0.013,0.042]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0002046,atenolol,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.022,-0.026,0.07,"[-0.026,0.07]",0.372,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005133,atenolol,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0183,-0.049,0.086,"[-0.049,0.086]",0.593,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005010,atenolol,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0168,-0.063,0.097,"[-0.063,0.097]",0.679,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0019499,atenolol,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0136,0.007,0.02,"[0.007,0.02]",1.00E-04,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0004979,atenolol,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0121,-0.081,0.105,"[-0.081,0.105]",0.799,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0002277,atenolol,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0117,-0.053,0.077,"[-0.053,0.077]",0.723,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005404,atenolol,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0103,-0.092,0.113,"[-0.092,0.113]",0.843,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005146,atenolol,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.01,-0.04,0.059,"[-0.04,0.059]",0.693,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0043693,atenolol,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0052,-0.043,0.054,"[-0.043,0.054]",0.833,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0011429,atenolol,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0038,-0.162,0.17,"[-0.162,0.17]",0.965,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0005388,atenolol,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,0.0037,-0.189,0.197,"[-0.189,0.197]",0.97,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0000153,atenolol,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,9.00E-04,-26.27,26.271,"[-26.27,26.271]",1,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0008542,atenolol,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,6.00E-04,-0.585,0.586,"[-0.585,0.586]",0.998,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0020066,atenolol,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,5.00E-04,-0.08,0.081,"[-0.08,0.081]",0.99,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:180559,biolink:associated_with_increased_likelihood_of,MONDO:0007739,atenolol,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.903784659,2.00E-04,-0.824,0.824,"[-0.824,0.824]",1,1873500,20827100,22700600,"Sample size with atenolol, approximately: 1873500","Sample size without atenolol, approximately: 20827100",All patients number is approximately: 22700600,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:148192,biolink:associated_with_increased_likelihood_of,MONDO:0003620,atazanavir,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994199963,0.2038,-0.213,0.62,"[-0.213,0.62]",0.338,6200,21788100,21794300,"Sample size with atazanavir, approximately: 6200","Sample size without atazanavir, approximately: 21788100",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:148192,biolink:associated_with_increased_likelihood_of,MONDO:0005149,atazanavir,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994199963,0.1351,-0.561,0.831,"[-0.561,0.831]",0.703,6200,21788100,21794300,"Sample size with atazanavir, approximately: 6200","Sample size without atazanavir, approximately: 21788100",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:148192,biolink:associated_with_increased_likelihood_of,MONDO:0000424,atazanavir,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994199963,0.072,-0.958,1.102,"[-0.958,1.102]",0.891,6200,21788100,21794300,"Sample size with atazanavir, approximately: 6200","Sample size without atazanavir, approximately: 21788100",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:148192,biolink:associated_with_increased_likelihood_of,MONDO:0005180,atazanavir,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994199963,0.0236,-0.501,0.548,"[-0.501,0.548]",0.93,6200,21788100,21794300,"Sample size with atazanavir, approximately: 6200","Sample size without atazanavir, approximately: 21788100",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:148192,biolink:associated_with_increased_likelihood_of,MONDO:0009693,atazanavir,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.994199963,0.0143,-2.373,2.401,"[-2.373,2.401]",0.991,6200,21788100,21794300,"Sample size with atazanavir, approximately: 6200","Sample size without atazanavir, approximately: 21788100",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0002406,asenapine,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.5426,0.465,0.62,"[0.465,0.62]",1.00E-04,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0005147,asenapine,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.2646,0.121,0.408,"[0.121,0.408]",1.00E-04,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0002909,asenapine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.1758,0.066,0.286,"[0.066,0.286]",0.002,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0004975,asenapine,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.1264,-0.652,0.904,"[-0.652,0.904]",0.75,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0005294,asenapine,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.1216,0.051,0.192,"[0.051,0.192]",0.001,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0005546,asenapine,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.0566,-0.291,0.404,"[-0.291,0.404]",0.749,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0005302,asenapine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.0226,-0.207,0.252,"[-0.207,0.252]",0.847,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,asenapine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.0106,-0.245,0.266,"[-0.245,0.266]",0.935,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0242748,biolink:associated_with_increased_likelihood_of,MONDO:0005180,asenapine,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.92974412,0.0094,-0.171,0.19,"[-0.171,0.19]",0.918,16900,21784400,21801300,"Sample size with asenapine, approximately: 16900","Sample size without asenapine, approximately: 21784400",All patients number is approximately: 21801300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004425,aripiprazole,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,1.1673,1.159,1.176,"[1.159,1.176]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004952,aripiprazole,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,1.0743,1.063,1.086,"[1.063,1.086]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0008300,aripiprazole,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.6908,0.678,0.704,"[0.678,0.704]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005298,aripiprazole,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.5368,0.524,0.55,"[0.524,0.55]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0011429,aripiprazole,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.5098,0.498,0.521,"[0.498,0.521]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0018882,aripiprazole,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.5083,0.496,0.521,"[0.496,0.521]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007972,aripiprazole,menieres disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.4212,0.408,0.435,"[0.408,0.435]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005180,aripiprazole,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.3285,0.311,0.346,"[0.311,0.346]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005002,aripiprazole,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.2926,0.276,0.309,"[0.276,0.309]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005147,aripiprazole,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.2625,0.249,0.277,"[0.249,0.277]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005178,aripiprazole,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.2462,0.229,0.263,"[0.229,0.263]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005101,aripiprazole,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.2338,0.202,0.266,"[0.202,0.266]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,aripiprazole,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.2261,0.186,0.266,"[0.186,0.266]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005711,aripiprazole,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.1928,0.162,0.223,"[0.162,0.223]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0010602,aripiprazole,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.1492,0.135,0.163,"[0.135,0.163]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007843,aripiprazole,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.1434,0.121,0.166,"[0.121,0.166]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0009693,aripiprazole,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.143,0.128,0.158,"[0.128,0.158]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005148,aripiprazole,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.1362,0.123,0.149,"[0.123,0.149]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005133,aripiprazole,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.1251,0.11,0.14,"[0.11,0.14]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005083,aripiprazole,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0747,0.03,0.12,"[0.03,0.12]",0.001,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,aripiprazole,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0558,0.031,0.081,"[0.031,0.081]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004981,aripiprazole,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0496,-0.033,0.132,"[-0.033,0.132]",0.241,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0018177,aripiprazole,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0433,-0.02,0.107,"[-0.02,0.107]",0.18,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0008644,aripiprazole,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0359,0.01,0.061,"[0.01,0.061]",0.006,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0019499,aripiprazole,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0323,0.018,0.046,"[0.018,0.046]",1.00E-04,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007947,aripiprazole,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0312,-0.007,0.07,"[-0.007,0.07]",0.114,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004975,aripiprazole,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0299,-0.125,0.184,"[-0.125,0.184]",0.705,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005404,aripiprazole,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0293,-0.019,0.078,"[-0.019,0.078]",0.233,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0010789,aripiprazole,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.028,0.008,0.048,"[0.008,0.048]",0.006,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005146,aripiprazole,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0241,-0.008,0.056,"[-0.008,0.056]",0.14,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005301,aripiprazole,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0235,-0.044,0.091,"[-0.044,0.091]",0.494,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0013282,aripiprazole,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0212,-0.04,0.083,"[-0.04,0.083]",0.498,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007915,aripiprazole,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0187,-0.008,0.046,"[-0.008,0.046]",0.177,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0009891,aripiprazole,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0162,-0.082,0.114,"[-0.082,0.114]",0.745,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004648,aripiprazole,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0155,-0.112,0.143,"[-0.112,0.143]",0.812,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0004979,aripiprazole,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0116,-0.164,0.188,"[-0.164,0.188]",0.897,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,aripiprazole,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0113,-0.249,0.271,"[-0.249,0.271]",0.932,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005364,aripiprazole,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.007,-0.408,0.422,"[-0.408,0.422]",0.974,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005011,aripiprazole,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0061,-0.132,0.144,"[-0.132,0.144]",0.931,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007027,aripiprazole,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.004,-0.013,0.02,"[-0.013,0.02]",0.638,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,aripiprazole,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0033,-0.203,0.209,"[-0.203,0.209]",0.975,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0010383,aripiprazole,fragile x syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0028,-0.176,0.181,"[-0.176,0.181]",0.975,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0019369,aripiprazole,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0027,-0.391,0.397,"[-0.391,0.397]",0.989,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0011786,aripiprazole,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0026,-0.266,0.272,"[-0.266,0.272]",0.985,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005546,aripiprazole,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0021,-0.429,0.433,"[-0.429,0.433]",0.992,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0007186,aripiprazole,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0017,-0.202,0.205,"[-0.202,0.205]",0.987,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0008487,aripiprazole,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0016,-0.88,0.883,"[-0.88,0.883]",0.997,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0002046,aripiprazole,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.0011,-0.444,0.446,"[-0.444,0.446]",0.996,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0003620,aripiprazole,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,0.001,-0.138,0.14,"[-0.138,0.14]",0.989,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0002909,aripiprazole,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,8.00E-04,-0.236,0.238,"[-0.236,0.238]",0.995,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0005388,aripiprazole,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,4.00E-04,-0.503,0.504,"[-0.503,0.504]",0.999,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0002316,aripiprazole,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,3.00E-04,-0.489,0.489,"[-0.489,0.489]",0.999,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:60795,biolink:associated_with_increased_likelihood_of,MONDO:0019565,aripiprazole,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.893310153,2.00E-04,-0.359,0.36,"[-0.359,0.36]",0.999,532100,21514200,22046300,"Sample size with aripiprazole, approximately: 532100","Sample size without aripiprazole, approximately: 21514200",All patients number is approximately: 22046300,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0009693,apremilast,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,1.0349,0.976,1.094,"[0.976,1.094]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0002406,apremilast,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.8345,0.796,0.873,"[0.796,0.873]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0021187,apremilast,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.8146,0.773,0.856,"[0.773,0.856]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0007186,apremilast,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.7111,0.661,0.761,"[0.661,0.761]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005147,apremilast,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.5302,0.493,0.568,"[0.493,0.568]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005010,apremilast,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.4412,0.402,0.481,"[0.402,0.481]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0004979,apremilast,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.4211,0.382,0.46,"[0.382,0.46]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0007027,apremilast,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.3329,0.28,0.386,"[0.28,0.386]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0011122,apremilast,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.2894,0.24,0.339,"[0.24,0.339]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0008399,apremilast,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.2825,0.232,0.333,"[0.232,0.333]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,apremilast,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.1741,0.111,0.237,"[0.111,0.237]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0003620,apremilast,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.1327,0.095,0.17,"[0.095,0.17]",1.00E-04,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0043693,apremilast,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.1024,-0.127,0.332,"[-0.127,0.332]",0.382,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005178,apremilast,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0882,0.038,0.138,"[0.038,0.138]",0.001,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005083,apremilast,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0683,-0.103,0.24,"[-0.103,0.24]",0.435,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0007915,apremilast,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0621,-0.012,0.137,"[-0.012,0.137]",0.102,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0002909,apremilast,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0596,-0.07,0.189,"[-0.07,0.189]",0.368,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0002046,apremilast,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0458,-0.054,0.146,"[-0.054,0.146]",0.368,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,apremilast,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0239,-0.137,0.185,"[-0.137,0.185]",0.771,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005002,apremilast,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0232,-0.152,0.198,"[-0.152,0.198]",0.795,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005298,apremilast,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0207,-0.892,0.934,"[-0.892,0.934]",0.964,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005101,apremilast,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0136,-0.088,0.115,"[-0.088,0.115]",0.793,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005130,apremilast,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0065,-0.549,0.562,"[-0.549,0.562]",0.982,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005393,apremilast,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0039,-0.047,0.055,"[-0.047,0.055]",0.881,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0002277,apremilast,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,0.0036,-0.824,0.831,"[-0.824,0.831]",0.993,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248531,biolink:associated_with_increased_likelihood_of,MONDO:0005392,apremilast,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.905015207,5.00E-04,-0.434,0.435,"[-0.434,0.435]",0.998,36400,21772100,21808500,"Sample size with apremilast, approximately: 36400","Sample size without apremilast, approximately: 21772100",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005302,amlodipine,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.7775,0.772,0.783,"[0.772,0.783]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005101,amlodipine,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.5696,0.566,0.573,"[0.566,0.573]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008383,amlodipine,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.484,0.478,0.49,"[0.478,0.49]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0010561,amlodipine,coffin lowry syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.3837,0.378,0.389,"[0.378,0.389]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0004609,amlodipine,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.319,0.313,0.325,"[0.313,0.325]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0000153,amlodipine,discordant ventriculoarterial connection,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.2671,0.254,0.28,"[0.254,0.28]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005392,amlodipine,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.23,0.22,0.24,"[0.22,0.24]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008542,amlodipine,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.2197,0.208,0.231,"[0.208,0.231]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007186,amlodipine,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1863,0.168,0.205,"[0.168,0.205]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0018882,amlodipine,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1806,0.173,0.188,"[0.173,0.188]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0004425,amlodipine,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1789,0.156,0.202,"[0.156,0.202]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008644,amlodipine,22q11 2 deletion syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1738,0.166,0.181,"[0.166,0.181]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0043693,amlodipine,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1468,0.137,0.157,"[0.137,0.157]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0018975,amlodipine,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1388,0.127,0.151,"[0.127,0.151]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007160,amlodipine,stickler syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1328,0.114,0.152,"[0.114,0.152]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005002,amlodipine,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1245,0.116,0.132,"[0.116,0.132]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005133,amlodipine,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1084,0.1,0.117,"[0.1,0.117]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008678,amlodipine,williams syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1057,0.098,0.113,"[0.098,0.113]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005083,amlodipine,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1015,0.083,0.12,"[0.083,0.12]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005178,amlodipine,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.1014,0.094,0.108,"[0.094,0.108]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0010526,amlodipine,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0853,0.065,0.105,"[0.065,0.105]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008377,amlodipine,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.08,0.063,0.097,"[0.063,0.097]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0011429,amlodipine,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0777,0.053,0.102,"[0.053,0.102]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,amlodipine,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0676,0.025,0.111,"[0.025,0.111]",0.002,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0001516,amlodipine,spinal muscular atrophy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0639,0.059,0.068,"[0.059,0.068]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0020066,amlodipine,ehlers danlos syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0633,0.034,0.092,"[0.034,0.092]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0009061,amlodipine,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0619,0.055,0.069,"[0.055,0.069]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007027,amlodipine,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0589,0.053,0.064,"[0.053,0.064]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007540,amlodipine,multiple endocrine neoplasia type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0485,0.038,0.059,"[0.038,0.059]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0006694,amlodipine,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0477,0.037,0.058,"[0.037,0.058]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0006058,amlodipine,nephroblastoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0406,0.036,0.045,"[0.036,0.045]",1.00E-04,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005010,amlodipine,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0379,-0.002,0.078,"[-0.002,0.078]",0.062,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0010789,amlodipine,melas,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.024,-0.019,0.067,"[-0.019,0.067]",0.274,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,amlodipine,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0219,-0.065,0.109,"[-0.065,0.109]",0.62,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008394,amlodipine,russell silver syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0217,-0.039,0.082,"[-0.039,0.082]",0.484,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,amlodipine,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0181,-0.039,0.076,"[-0.039,0.076]",0.536,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005011,amlodipine,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0157,-0.039,0.071,"[-0.039,0.071]",0.575,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008487,amlodipine,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0142,0.005,0.023,"[0.005,0.023]",0.003,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0011122,amlodipine,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.014,-0.001,0.029,"[-0.001,0.029]",0.067,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,amlodipine,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0104,-0.024,0.044,"[-0.024,0.044]",0.551,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0019565,amlodipine,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.008,-0.08,0.096,"[-0.08,0.096]",0.858,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005364,amlodipine,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0074,-0.054,0.068,"[-0.054,0.068]",0.812,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008642,amlodipine,vater association,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0065,-0.055,0.068,"[-0.055,0.068]",0.837,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0002909,amlodipine,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0064,-0.027,0.04,"[-0.027,0.04]",0.704,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005711,amlodipine,congenital diaphragmatic hernia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0056,-0.096,0.107,"[-0.096,0.107]",0.913,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005149,amlodipine,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0053,-0.019,0.03,"[-0.019,0.03]",0.673,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007947,amlodipine,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0048,-0.114,0.124,"[-0.114,0.124]",0.937,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0011786,amlodipine,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.004,-0.109,0.117,"[-0.109,0.117]",0.945,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005301,amlodipine,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0027,-0.101,0.106,"[-0.101,0.106]",0.96,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0002277,amlodipine,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0026,-0.105,0.11,"[-0.105,0.11]",0.963,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005148,amlodipine,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0018,-0.087,0.09,"[-0.087,0.09]",0.968,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007843,amlodipine,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,0.0017,-0.131,0.135,"[-0.131,0.135]",0.98,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0800026,amlodipine,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,8.00E-04,-0.411,0.413,"[-0.411,0.413]",0.997,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005298,amlodipine,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,7.00E-04,-1.895,1.896,"[-1.895,1.896]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0004648,amlodipine,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,7.00E-04,-0.149,0.15,"[-0.149,0.15]",0.993,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0019499,amlodipine,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,6.00E-04,-0.043,0.045,"[-0.043,0.045]",0.978,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0008300,amlodipine,prader willi syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,6.00E-04,-0.232,0.233,"[-0.232,0.233]",0.996,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0007739,amlodipine,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,3.00E-04,-0.667,0.668,"[-0.667,0.668]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0004979,amlodipine,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,3.00E-04,-0.676,0.676,"[-0.676,0.676]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0002046,amlodipine,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,2.00E-04,-0.316,0.316,"[-0.316,0.316]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0015924,amlodipine,pulmonary hypertensive arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,2.00E-04,-0.242,0.242,"[-0.242,0.242]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0019350,amlodipine,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,2.00E-04,-0.645,0.645,"[-0.645,0.645]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0002316,amlodipine,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,1.00E-04,-0.302,0.302,"[-0.302,0.302]",0.999,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2162,biolink:associated_with_increased_likelihood_of,MONDO:0005306,amlodipine,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.913739941,8.12E-05,-0.485,0.485,"[-0.485,0.485]",1,5546100,19116100,24662200,"Sample size with amlodipine, approximately: 5546100","Sample size without amlodipine, approximately: 19116100",All patients number is approximately: 24662200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004648,amitriptyline,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.3831,0.375,0.392,"[0.375,0.392]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004952,amitriptyline,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.3241,0.311,0.337,"[0.311,0.337]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0019180,amitriptyline,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.2821,0.262,0.303,"[0.262,0.303]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005147,amitriptyline,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.2805,0.269,0.292,"[0.269,0.292]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005364,amitriptyline,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.2571,0.242,0.272,"[0.242,0.272]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005178,amitriptyline,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.2364,0.221,0.252,"[0.221,0.252]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0019369,amitriptyline,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.226,0.215,0.237,"[0.215,0.237]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005392,amitriptyline,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.2178,0.203,0.233,"[0.203,0.233]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0009693,amitriptyline,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.1767,0.16,0.193,"[0.16,0.193]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005148,amitriptyline,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.1507,0.14,0.161,"[0.14,0.161]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0008599,amitriptyline,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.1372,0.127,0.147,"[0.127,0.147]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0013282,amitriptyline,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.134,0.086,0.181,"[0.086,0.181]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0010602,amitriptyline,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0978,0.086,0.11,"[0.086,0.11]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002869,amitriptyline,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0825,0.048,0.117,"[0.048,0.117]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005101,amitriptyline,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0798,0.05,0.109,"[0.05,0.109]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002909,amitriptyline,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.079,0.057,0.101,"[0.057,0.101]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0021187,amitriptyline,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0765,0.034,0.119,"[0.034,0.119]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0008487,amitriptyline,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0627,0.017,0.109,"[0.017,0.109]",0.008,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002316,amitriptyline,hereditary motor and sensory neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0504,0.035,0.066,"[0.035,0.066]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0000424,amitriptyline,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0473,0.012,0.082,"[0.012,0.082]",0.008,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002406,amitriptyline,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0447,0.013,0.076,"[0.013,0.076]",0.005,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005146,amitriptyline,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0369,-0.04,0.114,"[-0.04,0.114]",0.349,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0009891,amitriptyline,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0331,0.021,0.045,"[0.021,0.045]",1.00E-04,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005388,amitriptyline,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0278,-0.024,0.079,"[-0.024,0.079]",0.29,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004975,amitriptyline,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0258,-0.036,0.088,"[-0.036,0.088]",0.413,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005133,amitriptyline,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0236,-0.065,0.112,"[-0.065,0.112]",0.601,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0007915,amitriptyline,systemic lupus erythematosus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0233,-0.006,0.053,"[-0.006,0.053]",0.119,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0019565,amitriptyline,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0227,-0.116,0.161,"[-0.116,0.161]",0.749,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004981,amitriptyline,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0157,-0.037,0.068,"[-0.037,0.068]",0.558,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004425,amitriptyline,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0131,-0.115,0.142,"[-0.115,0.142]",0.841,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005404,amitriptyline,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0113,-0.145,0.167,"[-0.145,0.167]",0.887,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0018975,amitriptyline,neurofibromatosis type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0097,-0.004,0.023,"[-0.004,0.023]",0.156,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005294,amitriptyline,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0078,-0.123,0.139,"[-0.123,0.139]",0.907,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0003620,amitriptyline,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0048,-0.116,0.126,"[-0.116,0.126]",0.939,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0043693,amitriptyline,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0044,-0.044,0.053,"[-0.044,0.053]",0.857,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,amitriptyline,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0026,-0.716,0.721,"[-0.716,0.721]",0.994,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,amitriptyline,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0025,-0.125,0.13,"[-0.125,0.13]",0.969,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005010,amitriptyline,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0021,-0.2,0.204,"[-0.2,0.204]",0.984,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005002,amitriptyline,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0018,-1.205,1.209,"[-1.205,1.209]",0.998,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005302,amitriptyline,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.0012,-0.403,0.405,"[-0.403,0.405]",0.995,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002046,amitriptyline,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,0.001,-0.306,0.308,"[-0.306,0.308]",0.995,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0004609,amitriptyline,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,9.00E-04,-0.064,0.066,"[-0.064,0.066]",0.978,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0007739,amitriptyline,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,8.00E-04,-6.983,6.985,"[-6.983,6.985]",1,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0007186,amitriptyline,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,8.00E-04,-0.358,0.36,"[-0.358,0.36]",0.996,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0002277,amitriptyline,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,6.00E-04,-0.367,0.368,"[-0.367,0.368]",0.998,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0011429,amitriptyline,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,3.00E-04,-0.424,0.424,"[-0.424,0.424]",0.999,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2160,biolink:associated_with_increased_likelihood_of,MONDO:0005546,amitriptyline,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.81791441,8.21E-05,-0.273,0.274,"[-0.273,0.274]",1,625400,21436400,22061800,"Sample size with amitriptyline, approximately: 625400","Sample size without amitriptyline, approximately: 21436400",All patients number is approximately: 22061800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0002277,amiloride,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.8603,0.823,0.897,"[0.823,0.897]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0005148,amiloride,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.7013,0.662,0.741,"[0.662,0.741]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0007186,amiloride,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.5328,0.502,0.564,"[0.502,0.564]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0005180,amiloride,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.4778,0.445,0.51,"[0.445,0.51]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0021187,amiloride,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.4499,0.419,0.481,"[0.419,0.481]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0009061,amiloride,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.2108,0.177,0.245,"[0.177,0.245]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,amiloride,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.1304,0.099,0.162,"[0.099,0.162]",1.00E-04,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0002046,amiloride,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.1015,0.013,0.19,"[0.013,0.19]",0.024,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0004648,amiloride,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0902,0.03,0.15,"[0.03,0.15]",0.003,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0002869,amiloride,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0799,0.003,0.156,"[0.003,0.156]",0.041,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0019565,amiloride,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0419,-0.131,0.215,"[-0.131,0.215]",0.635,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0004981,amiloride,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.025,-0.151,0.201,"[-0.151,0.201]",0.78,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0004609,amiloride,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0163,-0.75,0.783,"[-0.75,0.783]",0.967,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0005298,amiloride,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0076,-0.245,0.261,"[-0.245,0.261]",0.953,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0000424,amiloride,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0067,-0.049,0.062,"[-0.049,0.062]",0.813,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0007739,amiloride,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0042,-0.192,0.2,"[-0.192,0.2]",0.967,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,MONDO:0011786,amiloride,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.002,-0.355,0.359,"[-0.355,0.359]",0.991,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:16231,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,amiloride,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.924100594,0.0017,-0.443,0.447,"[-0.443,0.447]",0.994,34100,21776000,21810100,"Sample size with amiloride, approximately: 34100","Sample size without amiloride, approximately: 21776000",All patients number is approximately: 21810100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0002909,alteplase,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.7409,0.736,0.746,"[0.736,0.746]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0007843,alteplase,kabuki make up syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.6341,0.628,0.64,"[0.628,0.64]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005180,alteplase,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.4254,0.414,0.437,"[0.414,0.437]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0000914,alteplase,cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.39,0.378,0.402,"[0.378,0.402]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008377,alteplase,retinitis pigmentosa,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.3792,0.372,0.387,"[0.372,0.387]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008383,alteplase,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.3439,0.332,0.356,"[0.332,0.356]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0018177,alteplase,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.2792,0.273,0.286,"[0.273,0.286]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0007818,alteplase,job syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.2498,0.239,0.261,"[0.239,0.261]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008399,alteplase,sarcoidosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.2372,0.231,0.243,"[0.231,0.243]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008738,alteplase,congenital aganglionic megacolon,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.2057,0.199,0.213,"[0.199,0.213]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0009891,alteplase,polycythemia vera,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.2003,0.193,0.207,"[0.193,0.207]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005011,alteplase,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.1674,0.154,0.18,"[0.154,0.18]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0006694,alteplase,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.1438,0.133,0.154,"[0.133,0.154]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0001044,alteplase,congenital atresia of esophagus,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.1385,0.131,0.146,"[0.131,0.146]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0000424,alteplase,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.1345,0.129,0.14,"[0.129,0.14]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0007739,alteplase,huntingtons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.074,0.047,0.101,"[0.047,0.101]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005002,alteplase,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0667,0.054,0.079,"[0.054,0.079]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0015263,alteplase,brugada syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0407,0.032,0.049,"[0.032,0.049]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0010602,alteplase,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0343,0.015,0.053,"[0.015,0.053]",1.00E-04,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0001676,alteplase,erythropoietic protoporphyria,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0253,-0.051,0.101,"[-0.051,0.101]",0.514,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005130,alteplase,celiac disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0111,0.004,0.018,"[0.004,0.018]",0.002,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005146,alteplase,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0108,-0.091,0.113,"[-0.091,0.113]",0.835,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,UMLS:C0577631,alteplase,carotid atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0089,-0.083,0.101,"[-0.083,0.101]",0.85,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0010526,alteplase,fabry disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0089,-0.121,0.139,"[-0.121,0.139]",0.893,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0013282,alteplase,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0065,-0.034,0.047,"[-0.034,0.047]",0.751,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005101,alteplase,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0044,-0.172,0.181,"[-0.172,0.181]",0.961,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0002277,alteplase,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0036,-0.521,0.528,"[-0.521,0.528]",0.989,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008487,alteplase,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0034,-0.11,0.117,"[-0.11,0.117]",0.953,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0800026,alteplase,ondine curse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0032,-0.109,0.115,"[-0.109,0.115]",0.956,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0008721,alteplase,medium chain acyl coenzyme a dehydrogenase deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.003,-0.155,0.161,"[-0.155,0.161]",0.97,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0002406,alteplase,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.0022,-0.202,0.206,"[-0.202,0.206]",0.983,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0019350,alteplase,hereditary spherocytosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.001,-0.35,0.352,"[-0.35,0.352]",0.996,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0011786,alteplase,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,0.001,-0.248,0.25,"[-0.248,0.25]",0.994,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0004609,alteplase,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,9.00E-04,-0.412,0.414,"[-0.412,0.414]",0.997,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0018882,alteplase,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,8.00E-04,-0.245,0.246,"[-0.245,0.246]",0.995,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0002046,alteplase,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,7.00E-04,-0.426,0.427,"[-0.426,0.427]",0.997,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0004979,alteplase,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,6.00E-04,-0.84,0.842,"[-0.84,0.842]",0.999,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005009,alteplase,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,6.00E-04,-0.542,0.543,"[-0.542,0.543]",0.998,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005392,alteplase,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,4.00E-04,-0.31,0.311,"[-0.31,0.311]",0.998,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0002869,alteplase,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,4.00E-04,-0.312,0.313,"[-0.312,0.313]",0.998,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0019499,alteplase,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,3.00E-04,-0.38,0.381,"[-0.38,0.381]",0.999,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0019015,alteplase,congenital omphalocele,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,3.00E-04,-0.294,0.295,"[-0.294,0.295]",0.998,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0259314,biolink:associated_with_increased_likelihood_of,MONDO:0005300,alteplase,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.972437965,1.00E-04,-0.592,0.592,"[-0.592,0.592]",1,2629300,21168800,23798100,"Sample size with alteplase, approximately: 2629300","Sample size without alteplase, approximately: 21168800",All patients number is approximately: 23798100,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0002277,alogliptin,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.6971,0.659,0.735,"[0.659,0.735]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,alogliptin,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.4992,0.436,0.562,"[0.436,0.562]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005180,alogliptin,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.4483,0.404,0.493,"[0.404,0.493]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0004425,alogliptin,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.4044,0.363,0.446,"[0.363,0.446]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005148,alogliptin,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.388,0.342,0.434,"[0.342,0.434]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0002909,alogliptin,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.2888,0.254,0.324,"[0.254,0.324]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005300,alogliptin,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.2731,0.241,0.305,"[0.241,0.305]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,alogliptin,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.2011,0.17,0.232,"[0.17,0.232]",1.00E-04,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0004975,alogliptin,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0925,-0.014,0.199,"[-0.014,0.199]",0.089,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005010,alogliptin,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0891,0.005,0.173,"[0.005,0.173]",0.038,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0008383,alogliptin,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0528,-0.138,0.244,"[-0.138,0.244]",0.587,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0004981,alogliptin,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0316,-0.096,0.159,"[-0.096,0.159]",0.628,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005083,alogliptin,psoriasis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0252,-0.312,0.362,"[-0.312,0.362]",0.884,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005298,alogliptin,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.025,-0.143,0.192,"[-0.143,0.192]",0.77,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0003620,alogliptin,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0242,-0.39,0.438,"[-0.39,0.438]",0.909,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0002406,alogliptin,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0204,-0.018,0.059,"[-0.018,0.059]",0.302,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0008487,alogliptin,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0109,-0.315,0.337,"[-0.315,0.337]",0.948,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0011429,alogliptin,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0092,-0.197,0.215,"[-0.197,0.215]",0.93,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005404,alogliptin,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,0.0064,-0.438,0.451,"[-0.438,0.451]",0.977,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0248177,biolink:associated_with_increased_likelihood_of,MONDO:0005002,alogliptin,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.951714363,8.00E-04,-0.563,0.564,"[-0.563,0.564]",0.998,36900,21771600,21808500,"Sample size with alogliptin, approximately: 36900","Sample size without alogliptin, approximately: 21771600",All patients number is approximately: 21808500,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005010,alirocumab,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,1.0131,0.936,1.09,"[0.936,1.09]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005148,alirocumab,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.5877,0.509,0.667,"[0.509,0.667]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005101,alirocumab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.4826,0.41,0.555,"[0.41,0.555]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0043693,alirocumab,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.4764,0.402,0.551,"[0.402,0.551]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005011,alirocumab,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.3151,0.203,0.427,"[0.203,0.427]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0002406,alirocumab,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.2354,0.17,0.301,"[0.17,0.301]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0007186,alirocumab,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.1844,0.074,0.295,"[0.074,0.295]",0.001,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005178,alirocumab,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.1621,0.087,0.237,"[0.087,0.237]",1.00E-04,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0008383,alirocumab,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.111,0.023,0.199,"[0.023,0.199]",0.014,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005298,alirocumab,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0774,-0.075,0.23,"[-0.075,0.23]",0.319,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0004981,alirocumab,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0523,-0.552,0.657,"[-0.552,0.657]",0.865,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0000424,alirocumab,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0328,-0.659,0.724,"[-0.659,0.724]",0.926,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0005146,alirocumab,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0138,-0.387,0.415,"[-0.387,0.415]",0.946,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0004609,alirocumab,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0076,-0.637,0.652,"[-0.637,0.652]",0.982,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0003620,alirocumab,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,0.0014,-1.299,1.302,"[-1.299,1.302]",0.998,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0004979,alirocumab,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,7.00E-04,-0.083,0.085,"[-0.083,0.085]",0.987,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:6744,biolink:associated_with_increased_likelihood_of,MONDO:0011122,alirocumab,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918028537,2.00E-04,-0.38,0.381,"[-0.38,0.381]",0.999,25900,21776300,21802200,"Sample size with alirocumab, approximately: 25900","Sample size without alirocumab, approximately: 21776300",All patients number is approximately: 21802200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005301,alendronate,multiple sclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,2.8444,2.834,2.855,"[2.834,2.855]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005364,alendronate,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.3923,0.383,0.401,"[0.383,0.401]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0019499,alendronate,turner syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.2847,0.272,0.297,"[0.272,0.297]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005178,alendronate,osteoarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.2586,0.245,0.272,"[0.245,0.272]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,alendronate,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.242,0.228,0.256,"[0.228,0.256]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0019369,alendronate,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.2098,0.199,0.221,"[0.199,0.221]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0018882,alendronate,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.1692,0.158,0.18,"[0.158,0.18]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0002406,alendronate,eczema,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.1339,0.093,0.175,"[0.093,0.175]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0010602,alendronate,hemophilia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.127,0.113,0.141,"[0.113,0.141]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0009693,alendronate,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.1133,0.092,0.134,"[0.092,0.134]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0002909,alendronate,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.1055,0.08,0.131,"[0.08,0.131]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005388,alendronate,primary biliary cholangitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.073,0.063,0.083,"[0.063,0.083]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005302,alendronate,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0602,0.031,0.089,"[0.031,0.089]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0009061,alendronate,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.057,0.035,0.079,"[0.035,0.079]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005101,alendronate,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0493,-0.003,0.101,"[-0.003,0.101]",0.063,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004981,alendronate,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0354,0,0.071,"[0,0.071]",0.053,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0008599,alendronate,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0322,0.021,0.044,"[0.021,0.044]",1.00E-04,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,alendronate,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0305,-0.04,0.101,"[-0.04,0.101]",0.397,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0018177,alendronate,glioblastoma multiforme,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0298,-0.048,0.107,"[-0.048,0.107]",0.452,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0021107,alendronate,narcolepsy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0287,-0.012,0.07,"[-0.012,0.07]",0.169,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004952,alendronate,hodgkin disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0209,-0.029,0.071,"[-0.029,0.071]",0.414,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0002046,alendronate,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0165,-0.027,0.06,"[-0.027,0.06]",0.454,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005300,alendronate,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0159,-0.112,0.144,"[-0.112,0.144]",0.808,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0008542,alendronate,tetralogy of fallot,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0147,-0.05,0.079,"[-0.05,0.079]",0.657,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0007027,alendronate,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0146,-0.016,0.045,"[-0.016,0.045]",0.353,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0013282,alendronate,alpha 1 antitrypsin deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0144,-0.129,0.157,"[-0.129,0.157]",0.843,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0007947,alendronate,marfan syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.013,-0.076,0.103,"[-0.076,0.103]",0.775,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004648,alendronate,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0099,-0.112,0.132,"[-0.112,0.132]",0.874,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005404,alendronate,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0084,-0.261,0.278,"[-0.261,0.278]",0.952,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005298,alendronate,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.008,-0.1,0.116,"[-0.1,0.116]",0.885,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0016218,alendronate,guillain barre syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0079,-0.173,0.189,"[-0.173,0.189]",0.932,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0019180,alendronate,osler hemorrhagic telangiectasia syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0066,-0.066,0.079,"[-0.066,0.079]",0.859,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005392,alendronate,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0056,-0.081,0.092,"[-0.081,0.092]",0.898,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0000424,alendronate,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0046,-1.144,1.153,"[-1.144,1.153]",0.994,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0011429,alendronate,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0036,-0.171,0.178,"[-0.171,0.178]",0.967,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0002277,alendronate,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.003,-0.088,0.094,"[-0.088,0.094]",0.948,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005002,alendronate,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.002,-0.181,0.185,"[-0.181,0.185]",0.983,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005546,alendronate,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0019,-0.249,0.252,"[-0.249,0.252]",0.988,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0007186,alendronate,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0017,-0.226,0.23,"[-0.226,0.23]",0.989,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004609,alendronate,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,0.0014,-1.094,1.097,"[-1.094,1.097]",0.998,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0011786,alendronate,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,8.00E-04,-0.284,0.285,"[-0.284,0.285]",0.996,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004425,alendronate,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,5.00E-04,-0.623,0.624,"[-0.623,0.624]",0.999,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0005133,alendronate,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,5.00E-04,-0.806,0.807,"[-0.806,0.807]",0.999,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:2088,biolink:associated_with_increased_likelihood_of,MONDO:0004979,alendronate,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.918636254,5.00E-04,-0.397,0.398,"[-0.397,0.398]",0.998,597700,21417600,22015300,"Sample size with alendronate, approximately: 597700","Sample size without alendronate, approximately: 21417600",All patients number is approximately: 22015300,,infores:isb-EHRMLA-data,prediction,computational_model
GTOPDB:7386,biolink:associated_with_increased_likelihood_of,MONDO:0005148,albiglutide,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.960287135,0.047,-0.918,1.012,"[-0.918,1.012]",0.924,4100,21790200,21794300,"Sample size with albiglutide, approximately: 4100","Sample size without albiglutide, approximately: 21790200",All patients number is approximately: 21794300,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:29413698,biolink:associated_with_increased_likelihood_of,MONDO:0005148,adefovir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.928368978,0.0122,-0.837,0.862,"[-0.837,0.862]",0.978,600,21792000,21792600,"Sample size with adefovir, approximately: 600","Sample size without adefovir, approximately: 21792000",All patients number is approximately: 21792600,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0003620,adalimumab,peripheral neuropathy,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.5778,0.557,0.598,"[0.557,0.598]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005147,adalimumab,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.4952,0.456,0.534,"[0.456,0.534]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005302,adalimumab,attention deficit hyperactivity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.3642,0.262,0.466,"[0.262,0.466]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0019565,adalimumab,von willebrand disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.3475,0.322,0.373,"[0.322,0.373]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0006694,adalimumab,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.3243,0.276,0.373,"[0.276,0.373]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005546,adalimumab,fibromyalgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.315,0.287,0.343,"[0.287,0.343]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0008599,adalimumab,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.2724,0.226,0.318,"[0.226,0.318]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0007027,adalimumab,nonalcoholic steatohepatitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.2228,0.173,0.272,"[0.173,0.272]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005300,adalimumab,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.1986,0.144,0.253,"[0.144,0.253]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0021187,adalimumab,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.1874,0.152,0.223,"[0.152,0.223]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005133,adalimumab,endometriosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.1725,0.129,0.216,"[0.129,0.216]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005180,adalimumab,parkinsons disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.1209,0.082,0.16,"[0.082,0.16]",1.00E-04,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0019369,adalimumab,complex regional pain syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.1097,-0.045,0.265,"[-0.045,0.265]",0.166,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0004975,adalimumab,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.063,0.002,0.124,"[0.002,0.124]",0.044,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0004425,adalimumab,hyperthyroidism,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0589,-0.082,0.199,"[-0.082,0.199]",0.412,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0004979,adalimumab,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0502,-0.101,0.202,"[-0.101,0.202]",0.516,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005101,adalimumab,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.047,-0.126,0.22,"[-0.126,0.22]",0.594,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0043693,adalimumab,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0383,0.004,0.072,"[0.004,0.072]",0.028,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,adalimumab,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0336,-0.068,0.136,"[-0.068,0.136]",0.519,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005010,adalimumab,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.032,-0.025,0.089,"[-0.025,0.089]",0.268,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005392,adalimumab,scoliosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0318,-0.04,0.104,"[-0.04,0.104]",0.386,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0011786,adalimumab,allergic rhinitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0288,-0.032,0.09,"[-0.032,0.09]",0.353,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0002909,adalimumab,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0146,-0.035,0.064,"[-0.035,0.064]",0.566,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0008383,adalimumab,rheumatoid arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0124,-0.158,0.183,"[-0.158,0.183]",0.886,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0011508,adalimumab,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0073,-0.267,0.282,"[-0.267,0.282]",0.958,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005404,adalimumab,chronic fatigue syndrome,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0063,-0.223,0.236,"[-0.223,0.236]",0.957,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0004609,adalimumab,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0056,-2.244,2.256,"[-2.244,2.256]",0.996,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005149,adalimumab,pulmonary hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0045,-0.28,0.289,"[-0.28,0.289]",0.975,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005364,adalimumab,graves disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0032,-0.351,0.358,"[-0.351,0.358]",0.986,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0007186,adalimumab,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.003,-0.318,0.324,"[-0.318,0.324]",0.985,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005002,adalimumab,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,0.0014,-0.413,0.416,"[-0.413,0.416]",0.995,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0005294,adalimumab,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,4.00E-04,-0.602,0.603,"[-0.602,0.603]",0.999,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
MESH:D000068879,biolink:associated_with_increased_likelihood_of,MONDO:0004981,adalimumab,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.882762771,1.00E-04,-0.31,0.31,"[-0.31,0.31]",0.999,114500,21724900,21839400,"Sample size with adalimumab, approximately: 114500","Sample size without adalimumab, approximately: 21724900",All patients number is approximately: 21839400,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0002909,aclidinium,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.566,0.523,0.609,"[0.523,0.609]",1.00E-04,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0005147,aclidinium,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.2613,0.161,0.361,"[0.161,0.361]",1.00E-04,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0002046,aclidinium,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.1584,-0.071,0.388,"[-0.071,0.388]",0.176,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0005009,aclidinium,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.1377,0.055,0.22,"[0.055,0.22]",0.001,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0005002,aclidinium,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.0386,-0.237,0.314,"[-0.237,0.314]",0.783,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0009693,aclidinium,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.018,-0.087,0.123,"[-0.087,0.123]",0.737,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0002277,aclidinium,arteriosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.0145,-2.67,2.699,"[-2.67,2.699]",0.992,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0004975,aclidinium,alzheimers disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.0127,-0.652,0.678,"[-0.652,0.678]",0.97,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0005101,aclidinium,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.0096,-0.724,0.743,"[-0.724,0.743]",0.979,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0011508,aclidinium,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,0.006,-0.757,0.769,"[-0.757,0.769]",0.988,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:11434515,biolink:associated_with_increased_likelihood_of,MONDO:0002869,aclidinium,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.956187971,1.63E-05,-0.425,0.425,"[-0.425,0.425]",1,18500,21780300,21798800,"Sample size with aclidinium, approximately: 18500","Sample size without aclidinium, approximately: 21780300",All patients number is approximately: 21798800,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:1978,biolink:associated_with_increased_likelihood_of,MONDO:0000424,acebutolol,vitamin b12 deficiency,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.897673965,0.0075,-0.497,0.512,"[-0.497,0.512]",0.977,4600,21789400,21794000,"Sample size with acebutolol, approximately: 4600","Sample size without acebutolol, approximately: 21789400",All patients number is approximately: 21794000,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0005300,acarbose,chronic kidney disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.6376,0.6,0.675,"[0.6,0.675]",1.00E-04,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0008599,acarbose,trigeminal neuralgia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.2603,0.188,0.333,"[0.188,0.333]",1.00E-04,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0011122,acarbose,obesity disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.1999,0.133,0.267,"[0.133,0.267]",1.00E-04,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0005010,acarbose,chronic ischemic heart disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.1547,0.068,0.241,"[0.068,0.241]",1.00E-04,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0009693,acarbose,multiple myeloma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.1546,0.077,0.232,"[0.077,0.232]",1.00E-04,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0007186,acarbose,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.1221,0.047,0.197,"[0.047,0.197]",0.001,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,UMLS:C0745114,acarbose,chronic hypertension,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.037,-0.301,0.375,"[-0.301,0.375]",0.83,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0005294,acarbose,peripheral arterial disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0166,-0.496,0.53,"[-0.496,0.53]",0.949,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,FB:FBgn0001201,acarbose,hiv,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0139,-0.081,0.109,"[-0.081,0.109]",0.774,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0011849,acarbose,psoriatic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0135,-0.421,0.448,"[-0.421,0.448]",0.951,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0008487,acarbose,polycystic ovarian disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0079,-0.536,0.551,"[-0.536,0.551]",0.977,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0004981,acarbose,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0067,-0.608,0.622,"[-0.608,0.622]",0.983,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0005146,acarbose,posttraumatic stress disorder,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0046,-0.941,0.95,"[-0.941,0.95]",0.992,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0005393,acarbose,gout,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0043,-0.042,0.051,"[-0.042,0.051]",0.856,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0043693,acarbose,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,0.0025,-0.199,0.204,"[-0.199,0.204]",0.98,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
PUBCHEM.COMPOUND:41774,biolink:associated_with_increased_likelihood_of,MONDO:0006694,acarbose,cerebral atherosclerosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.930731344,5.00E-04,-0.045,0.046,"[-0.045,0.046]",0.983,25600,21777600,21803200,"Sample size with acarbose, approximately: 25600","Sample size without acarbose, approximately: 21777600",All patients number is approximately: 21803200,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0005298,abatacept,osteoporosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.5197,0.425,0.615,"[0.425,0.615]",1.00E-04,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0002909,abatacept,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.4931,0.446,0.54,"[0.446,0.54]",1.00E-04,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0018882,abatacept,vasculitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.208,0.093,0.323,"[0.093,0.323]",1.00E-04,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0007186,abatacept,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.139,-0.081,0.359,"[-0.081,0.359]",0.215,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0004609,abatacept,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.133,-0.456,0.722,"[-0.456,0.722]",0.658,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0004981,abatacept,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0636,-0.028,0.156,"[-0.028,0.156]",0.175,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0011429,abatacept,juvenile idiopathic arthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0595,-0.361,0.48,"[-0.361,0.48]",0.782,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0043693,abatacept,alcoholic liver disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0571,-0.206,0.32,"[-0.206,0.32]",0.671,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0005009,abatacept,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0553,-0.093,0.203,"[-0.093,0.203]",0.464,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0011508,abatacept,non hodgkin lymphoma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0175,-0.722,0.757,"[-0.722,0.757]",0.963,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,abatacept,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0076,-0.461,0.476,"[-0.461,0.476]",0.975,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0005002,abatacept,chronic obstructive pulmonary disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,0.0025,-0.644,0.649,"[-0.644,0.649]",0.994,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0005306,abatacept,ankylosing spondyloarthritis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,2.00E-04,-0.437,0.438,"[-0.437,0.438]",0.999,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL1201823,biolink:associated_with_increased_likelihood_of,MONDO:0004648,abatacept,vascular dementia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.949473753,3.57E-06,-0.278,0.278,"[-0.278,0.278]",1,21800,21779000,21800800,"Sample size with abatacept, approximately: 21800","Sample size without abatacept, approximately: 21779000",All patients number is approximately: 21800800,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL3301581,biolink:associated_with_increased_likelihood_of,MONDO:0007186,abaloparatide,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942958335,0.0528,-0.967,1.073,"[-0.967,1.073]",0.919,7300,21787300,21794600,"Sample size with abaloparatide, approximately: 7300","Sample size without abaloparatide, approximately: 21787300",All patients number is approximately: 21794600,,infores:isb-EHRMLA-data,prediction,computational_model
CHEMBL.COMPOUND:CHEMBL3301581,biolink:associated_with_increased_likelihood_of,MONDO:0002869,abaloparatide,heart valve disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.942958335,9.00E-04,-0.674,0.676,"[-0.674,0.676]",0.998,7300,21787300,21794600,"Sample size with abaloparatide, approximately: 7300","Sample size without abaloparatide, approximately: 21787300",All patients number is approximately: 21794600,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0005101,abacavir,ulcerative colitis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,3.1929,2.851,3.535,"[2.851,3.535]",1.00E-04,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0021187,abacavir,hyperlipidemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,1.3007,1.23,1.371,"[1.23,1.371]",1.00E-04,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0004609,abacavir,herpes simplex,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.4637,0.337,0.591,"[0.337,0.591]",1.00E-04,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0009061,abacavir,cystic fibrosis,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.3886,0.335,0.442,"[0.335,0.442]",1.00E-04,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0004979,abacavir,asthma,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.2311,0.18,0.283,"[0.18,0.283]",1.00E-04,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0005148,abacavir,diabetes mellitus type 2,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.1059,-0.157,0.369,"[-0.157,0.369]",0.429,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0004981,abacavir,atrial fibrillation,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0901,-1.867,2.047,"[-1.867,2.047]",0.928,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0007186,abacavir,gerd,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.066,-0.191,0.323,"[-0.191,0.323]",0.614,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0002046,abacavir,alcohol abuse,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0251,-0.427,0.478,"[-0.427,0.478]",0.913,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,UMLS:C1561642,abacavir,chronic kidney disease v,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0243,-0.521,0.57,"[-0.521,0.57]",0.93,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0002909,abacavir,hyperglycemia,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0162,-0.325,0.357,"[-0.325,0.357]",0.926,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0005009,abacavir,heart failure,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0059,-0.948,0.959,"[-0.948,0.959]",0.99,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0005147,abacavir,diabetes type 1,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0043,-0.099,0.108,"[-0.099,0.108]",0.934,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
HMDB:HMDB0251820,biolink:associated_with_increased_likelihood_of,MONDO:0005011,abacavir,crohns disease,May Treat KG,RO:0003308,biolink:Association,Logistic Regression,0.998544968,0.0032,-0.488,0.494,"[-0.488,0.494]",0.99,17300,21782500,21799800,"Sample size with abacavir, approximately: 17300","Sample size without abacavir, approximately: 21782500",All patients number is approximately: 21799800,,infores:isb-EHRMLA-data,prediction,computational_model
